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ABSTRACT
The present investigation was undertaken to experimentally 
test the Williams hypothesis (1980) for the metabolic 
basis of cancer cachexia. The hypothesis proposed a 
sequence of events which accounted for neoplasm induced 
body wasting, muscle weakness, and associated whole body 
negative nitrogen balance. It was claimed that the 
events, if proven, fitted the phenomenon of cancer 
cachexia into a clinically manageable situation.
A primary investigation of quantitative intermediary, 
enzyme and endocrine metabolic study indicated a 
connection between the proposed sequence of events and led 
to the further exploration of specific metabolic 
alterations of carbohydrate, lipid and protein metabolism 
in tumour bearing animals.
The rate and extent of hepatic gluconeogenesis from 
alanine were significantly reduced in tumour bearing rats. 
These derangements were attributed to the notably 
suppressed activity of alanine aminotransferase, which 
occurred as a result of tumour-induced foetalistic 
retrodifferentiation of enzymes in the host liver.
A distortion in the fatty acid (FA) metabolism of tumour 
bearing rats involving enhanced FA esterification and 
suppressed FA oxidation and ketone body formation was 
noted. The results indicated that an inhibition may have 
occurred at the entry site of fatty acyl CoA from the 
cytoplasm to the mitochondria. These changes were 
attributed to the elevated levels of plasma vasopressin in 
tumour bearing rats. A role for tumour-induced 
retrodifferentiation of acyl carnitine transferase-I was 
also suggested.
Experiments in vitro and _in vivo demonstrated an enhanced 
oxidation of branched chain amino acids in the muscle of 
tumour bearing animals. This effect was attributed to the 
increased activity of the muscle branched chain keto acid 
dehydrogenase. Low circulating ketone bodies and elevated 
levels of prostaglandin E 2 were suggested as instigating 
these changes which led to the loss of a notable quantity 
of muscle mass.
It was concluded from the investigations presented in this 
thesis that the hypothesis had correctly predicted the 
sequence of metabolic events that are frequently 
associated with various neoplastic situations and which 
when taken together now unravel the metabolism of cancer 
cachexia.
The complete investigation has identified the existence of 
toxohormones and suggested that the following are the
significant contributors in the initiation and maintenance 
of cancer cachexia; namely, cachectin, vasopressin and 
prostaglandin E 2 . These mediators are suspected of 
channelling a network of communication between neoplastic 
and non-neoplastic tissues of the host. This results in 
cancer-induced body tissue wastage, muscle weakness, 
negative nitrogen balance and ultimately death. Based on 
current understanding of perturbed whole-body biochemistry 
in cancer cachexia and the putative effects of 
toxohormones on host metabolism, the hypothesis of cancer 
cachexia is comprehensively reviewed. The information was 
used to suggest a protocol for the clinical management of 
cancer cachexia and a therapeutic measure was proposed to 
impart a total or chronic delay in the development of 
cachectic symptoms in tumour bearing subjects.
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3 0HBA
2PG
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a KG
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ACTH
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GLY
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antidiuretic hormone 
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bovine serum albumin
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oxadizole
ceric sulphate 
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dihydroxy acetone phosphate
dihydroxy acetone phosphate acyl transferase
enzyme commission
free fatty acid
fructose 6-phosphate
fructose 1,6-bisphosphatase
fructose 2,6-bisphosphatase
fructose 1,6-bisphosphate
fructose 2,6-bisphosphate
fumarate
glycerol 3-phosphate
glucose 6-phosphatase
goat anti-rabbit gamma-globulin
glucokinase
glucose
glucose 6-phosphate
glycerol
glycogen
glutamate
glycine
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3- hydroxy 3-methyl glutary1 CoA 
perchloric acid 
interleukin
intratumoural macrophages
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LAC lactate
LDL low density lipoprotein
LPL lipoprotein lipase
MAL malate
NS not significant
NTB non-tumour bearing
OAA oxaloacetate
osci oscillations
PC pyruvate carboxylase
PDH pyruvate dehydrogenase complex
PEP phosphoenol pyruvate
PEPCK phosphoenol pyruvate carboxykinase
PFK-I phosphofructokinase-I
PFK-2 phosphofructokinase-2
PGE 2 prostaglandin E 2
PI post implantation
PK pyruvate kinase
RIA radioimmunoassay
SEM standard error of the mean
SER serine
SIADH syndrome of inappropriate
antidiuretic hormone
s u e succinate
TG triglyceride
THR threonine
TNF tumour necrosis factor
v/v volume/volume
VLDLP very low density lipoprotein
w/v weight/volume
w/w wet weight
secretion
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CHAPTER ONE
INTRODUCTION
1.1 Cancer Cachexia j_ An Introduction
The term 'cachexia' is derived from the Greek word 
'kakos' and 'hexis' meaning 'bad condition'. Clinically cancer 
cachexia is characterised by drastic loss of weight, anorexia, 
nausea, anaemia. asthenia and progressive weakness (Strain, 
1979). Metabolically, cancer cachexia is characterised by 
depletion and redistribution of host components, intestinal 
malabsorption, diarrhoea, electrolyte and water abnormalities, 
increased breakdown of tissue protein and lipids, negative 
nitrogen balance and progressive fading of vital functions, 
including the regulation of the intermediary metabolism of the 
organs and tissues of the host (Lawson et al., 1982; Strain,
1979) .
Almost all cancer patients suffer from cancer cachexia 
at various stages of their disease, which is often reported as a 
frequent cause of death (Table 1.1; Costa, 1977; Lawrence and 
Terz, 1977; Morrison, 1976; Robbins, 1974; Shapot, 1972). The 
severity of this condition depends upon the degree of muscle 
wastage. It was established that the muscle fibres from severe 
cancer cachectic patients, showed a 50% increase in protein 
degradation over those of normal subjects (Strain, 1979). Other 
studies have revealed increased protein degradation and decreased 
protein synthesis in cancer patients, tumour bearing animals and 
cultured tissue specimens from cancer patients (Clark and 
Goodlad, 1975; Emery et al., 1984; Lundholm et al., 1978a, 1981).
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Table 1.1: The reported incidence of death due to the 
effects of cancer
Site of Tumour No. of Patients %Incidence Reference
(In Study) (With Cachexia)
Breast 87 29 33 Warren (1932)
Cervix 64 10 16 Warren (1932)
Colon 90 20 22 Warren (1932)
Kidney 979 338 35 Chisholm and
Roy (1971)
Liver 53 18 34 Al-Sharaf et
al., (1974)
Lung 221 65 30 Bignall (1955)n 129 51 40 Costa (1977)
Lymph Node ** 31 DeWys et al., 
(1980)
Oesophagus 60 5 8 Lindsay (1941)
Pancreas 449 327 73 Gray et al.,
(1973)
Stomach 1112 934 84 La Due et al., 
(1950)it 87 DeWys et al., 
1980)
It has been suggested that a body weight loss of 30% is almost 
invariably fatal; however the occasional patient may survive a 
weight loss as extensive as 50% of the total body weight 
(Brennan, 1977). The frequency of’ weight loss in cancer patients 
with cachexia ranged from 16% for patients with cervical cancer 
to 87% for patients with gastric carcinoma (Table 1.1).
Defects in the functional integrity of -the 
gastrointestinal tract in patients with malignant disease are 
well documented and may result in notable loss of weight. This 
is due to inadequate nutrition based on organic pathology that 
prevents either the ingestion or digestion of food. Patients 
with carcinoma of the small bowel may have structural 
abnormalities of the jujenual mucosa, thus reducing the total 
absorptive surface area (Blackwell, 1961; Kelley et al., 1961). 
Further involvement of the intestinal tract, especially in the 
case of lymphoma, can lead to malabsorption syndrome with 
flattening of intestinal villi and steatorrhoea (Eidelman et al., 
1966). However a large number of patients die from cachexia 
without the involvement of the gastrointestinal tract or other 
vital organs, without well progressed neoplasms or space 
occupying metastasis and with tumours whose total mass is only a 
small fraction of the total body mass (Nathanson and Hall, 1974; 
Robbins, 1974). Furthermore, it has been repeatedly observed
that the degree of cachexia bears no simple correlation to the
tumour burden, tumour cell type or the anatomical site of
involvement, unless a vital organ is being impaired in situ
(Strain, 1979). This type of anatomical obstructive lesion must 
clearly be treated (if possible) by surgery and does not concern
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the issues being considered here. This thesis addresses the 
question 'how does the presence of a malignant neoplasm produce a 
chronic wasting of the host?'
1.2 Theories of Cancer Cachexia z_ A Review
Weight loss is listed in earlier literature as one of 
the initial and most common manifestations of cancer (Hornberger 
and Fishman, 1953). This condition is called the cachexia and 
anorexia syndrome. This syndrome has been recognised probably 
for as long as the natural history of the development of cancer 
has been described (Ewing, 1940) but has only recently received 
detailed study. Some attempts were made to investigate this 
syndrome during the past fifty years and in recent years a small 
number of investigators have tried to explain the biochemical 
basis of cancer cachexia.
1.2.1 Theories of the Pre - 1980 Period
The various theories described in this section are 
taken (with author's permission) from a review on cancer cachexia 
(Williams et al., 1980).
1.2.1.1 'Nitrogen Trap'
Mider et al., (1948) proposed the 'nitrogen trap' 
theory as being of major importance in the aetiology of the 
cachexia of malignancy. Mider and coworkers demonstrated that 
the nitrogen content of a large Walker 256 carcinosarcoma 
exceeded the amount of nitrogen that was supplied in the diet and 
stored by the host body during the period of tumour bearing. It 
was therefore concluded that the excess nitrogen component of the
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tumour must have been derived from the host body. Their data 
(Fenninger and Mider, 1954; Mider, 1951; Mider et al., 1948,
1951) indicated that cancerous rats degraded 'normal protoplasm1 
and supplied the nitrogen in the form of amino acid precursors to 
the tumour. The tumour therefore, acted as a 'trap' for the 
available amino acids and its growth consequently led to the 
depletion of the host tissue protein.
The concept of the 'nitrogen trap' theory was further
developed by other investigators. Sherman et al., (1950) studied
the nitrogen content of various tissues of rats bearing the
Walker 256 carcinosarcoma and found that muscle was the tissue
that contributed most to the nitrogen content of the tumour.
This was demonstrated, by investigations in vivo and in vitro
showing that neoplastic cells possessed an increased ability for
amino acid uptake (Christenson and Henderson, 1952; Wiseman and
Ghadially, 1955). In comparison with normal mouse liver
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preparations, increased incorporation of C-labelled glycine 
into the protein of tumour homogenates (Winnick, 1950), tumour 
slices (Zamecnik et al., 1948) and tumour cells (Lepage, 1953)
were reported. There were even demonstrations that rat hepatoma 
cells and cells of other types of primary and transplantable 
tumours possessed the ability to take up intact serum albumin and 
globulin (Bapson and Winnick, 1954; Cohen et al., 1961; Ghose et 
al., 1962). The 'nitrogen trap' theory is now a well accepted
phenomenon for cancer patients and tumour bearing animals. This 
theory may account for the terminal loss of carcass weight in 
some laboratory animals bearing massive and rapidly proliferating
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tumours which attained more than 40% of host body weight 
(Carruthers and Kim, 1968; Mider et al., 1948). However there is 
reason to doubt that the theory that tumours act as a 'nitrogen 
trap' is applicable to human neoplasia, since the average size of 
human neoplasms are usually 5% (approx.) of the total body weight 
(Costa, 1977; Waterhouse, 1974a).
1.2.1.2 Host Energy Depletion
A mechanism concerning tumour induced weight loss in 
the host was advanced by Gold (1968, 1974). He suggested that a 
progressive and significant energy loss from the host tissues 
could occur by the establishment of a systemic 'energy-depletion' 
cycle dependent on the interplay of tumour glycolysis and host 
gluconeogenesis. This was mechanistically achieved by an 
increase in the activity of the Cori Cycle (Cori, 1931) i.e. the 
breakdown of glucose to lactate via glycolysis in the tumour and 
reformation of glucose from lactate via gluconeogenesis in the 
host liver and kidney cortex. Many tumours show a high rate of 
aerobic glycolysis and produce large amounts of lactate (Gold, 
1966, 1974; Shapot, 1972, 1974; Warburg, 1956). Essentially all 
or most of the lactate that enters the blood in tumour bearing 
animals (Hiatt, 1957) or patients (Reichard, 1963) is converted 
back to glucose. However tumour tissue possesses a low rate of 
gluconeogenesis (Knox, 1976; Morris, 1975; Weber, 1974) and 
therefore this resynthesis must occur in the host liver and 
kidney. Thus for each turn of the Cori Cycle the tumour has a 
nett gain of two ATP molecules from glycolysis, while the host 
tissues loose the energy of the six ATP molecules required for
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the reconversion of lactate to glucose by gluconeogenesis as well 
as the provision of thirty six ATP molecules that could have been 
obtained in host tissues from the complete aerobic respiration of 
one mole of glucose. Thus the tumour derived a relatively low 
energy yield from the catabolism of glucose, but the host 
expended considerably more on glucose resynthesis. As the tumour 
enlarged, consuming ever increasing amounts of glucose the energy 
resources of the host were hypothesised to become increasingly 
depleted by the futile efforts to maintain the normal blood 
glucose levels. The result was an inital rapid depletion of 
adipose tissue followed by subsequent loss of tissue protein, 
ultimately leading to weight loss and eventual death (Fig. 1.1).
In support of the theory, Gold (1973, 1974) described 
tumour regression in experimental rats induced by the 
administration of compounds known to inhibit biochemical 
reactions unique to the pathway of gluconeogenesis. Reichard et 
'al., (1963) and Waterhouse (1974b) noted elevated Cori Cycle 
activity in patients with a wide variety of neoplasms. This 
theory is therefore supported by some experimental evidence, but 
the work of later investigators failed to support the main tenets 
of the theory. Although Cori Cycle activity in patients with 
cancer is an energy costly process, it probably only accounts for 
10% or less of the daily metabolic energy expenditure (Young, 
1977). There are some conflicting reports about gluconeogenesis 
from amino acids in tumour bearing subjects (see section 4.1.4). 
However it was estimated, in cancer patients with elevated rates 
of gluconeogenesis from alanine, that the nett contribution of 
alanine to glucose formation was still relatively small i.e., 4-
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Figure 1.1: Schematic representation of the systemic 
metabolic circuit responsible for energy loss in 
cancer cachexia
The diagram illustrates the progressive loss of 
energy from host tissues by virtue of the 
establishment of a systemic energy depletion 
cycle (Cori Cycle), dependent on the interplay of 
tumour glycolysis and host gluconeogenesis. For 
each turn of the Cori Cycle the tumour has a nett 
gain of two ATP molecules while the host tissue 
looses six ATP molecules. The rapidly growing 
tumour consumes an increasing amount of glucose 
and derives a relatively low energy yield from 
the catabolism of glucose, whereas the host 
expends considerably more energy on glucose 
resynthesis in order to maintain normal blood 
glucose levels. A continuation of this process 
results in depletion of tissue fat and protein, 
ultimately leading to weight loss and eventual 
death (for details see the text).
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5% of the total new glucose formed - probably not significant in 
terms of energy expenditure (Waterhouse et al., 1979) and the 
substrate economy (Arbeit et al., 1982) of cancer subjects. For 
these reasons it is difficult to accept that linked changes in 
Cori Cycle activity and gluconeogenesis from amino acids are the 
significant cause of the marked and often acute body wasting 
noted in patients with progressive neoplasia. It was also 
reported that some Morris minimum deviation hepatomas, although 
exhibiting normal rates of glycolysis (Ainseberg and Morris, 
1961; Weber et al., 1961) also caused marked terminal cachexia 
when growing in experimental animals. Moreover, small primary 
neoplastic lesions could produce notable cachexia (Costa, 1977; 
Nathanson and Hall, 1974; Robbins, 1974) and therefore these 
tumours of small mass would not be expected to produce an 
extensive energy depleting futile substrate Cori Cycle.
Thus, we conclude that Gold's theory of an increased 
futile substrate Cori Cycle alone offers a poor and unconvincing 
explanation of the pathogenesis of cancer cachexia.
1.2.1.3 Metabolic - Chaos
Theologides (1972, 1974, 1976, 1978) proposed that the 
bearing of a malignant neoplasm produced as yet unspecified 
metabolites which allosterically activated and inactivated 
various enzymes in the tissues of the host. This resulted in 
alterations in the metabolic pattern of the host due to changes 
(all unspecified) in various metabolic equilibria and created a 
metabolic 'chaotic' state. This metabolic chaos resulted in the 
release of essential metabolites by the host which were
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preferentially trapped by the tumour due to its growth potential. 
Therefore the tumour was able to grow while the host was wasted.
Theologides further proposed that in conjunction with 
the production of the allosteric enzyme modifiers, the tumour 
also produced anorectic peptides, which were interpreted by the 
hypothalamus as signalling satiety. Consequently, the host food 
intake-was suppressed. This suppression occured at a time when 
there was an increased energy expenditure because of the systemic 
derangement of the host metabolism. Thus, the suppression of 
food in conjunction with 'metabolic chaos' resulted in cancer 
cachexia (Fig. 1.2).
The metabolic chaos theory of Theologides has not been 
supported by the work of many investigators. The changes in the 
activities of selected enzymes of the host liver in response to 
the implantation of tumours are not chaotic. On the contrary, 
the selected enzyme changes are orderly and highly predictable 
because the susceptible enzymes are directed towards activities 
which are more characteristic of the 'foetal state' of the tissue 
origin (Herzfeld and Greengard, 1972; Longenecker and Williams, 
1977; Williams et al., 1980). It has been demonstrated 
(Matthaei, 1979) that the activities of the host tissue enzymes 
were not altered allosterically in the host liver or kidney, but 
rather the rate of the synthesis of enzymes was altered as a 
consequence of tumour bearing. There is no evidence that tumour 
bearing induced allosteric modification of the activity of host 
tissue enzymes.
The primary mechanism of cancer cachexia proposed by
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Figure 1.2: Schematic representation of the "Metabolic Chaos 
Theory" of cancer cachexia
The diagram illustrates that the tumour releases 
metabolites (yet unidentified) in the host 
circulation which results in the alteration of 
metabolic equilibria, due to changes in the 
activities of allosteric enzymes by these 
metabolites (metabolic chaos). The tumour also 
produces anorectic peptides which are interpreted 
by the hypothalamus as signalling satiety and 
consequently food intake is suppressed in cancer 
subjects (anorexia). Metabolic chaos in 
conjunction with anorexia induces host body 
wasting and thus cachexia (for details see the 
text).
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Theologides is anorexia. He claimed that it was caused by the 
production in the tumour of anorectic peptides which were 
interpreted by the subject with the neoplasm as signalling 
satiety and hence the food intake was decreased by the tumour 
bearing organism. Other workers (Liebelt et al., 1971; Nathanson 
and Hall, 1974) have suggested that the tumour directly or 
indirectly produced as yet unknown substances which reduced food 
intake in the same manner. To date however, no such substance 
have been identified. Moreover if this was the case then it 
should be possible to block such an effect by destroying the 
central loci that respond to satiety signals. The destructive 
ablation of the ventromedial hypothalamus, a procedure which 
blocks some satiety signals, does not prevent the cachectic 
hypophagea of tumour bearing animals (Baillie et al., 1965; 
Liebelt et al., 1971; Morrison, 1968). However it must be
pointed out that the mechanisms of the regulation of food intake 
and satiety are not clearly understood (Novin et al., 1976) and
they may not be entirely regulated by the endocrine physiology of 
the ventromedial hypothalamus (Booth et al., 1976; Harper, 1976;
Rogers and Leung, 1973). The possibility that neoplasms produce 
substances or cause substances to be produced by the host that 
are- interpreted as signalling satiety can therefore not be 
entirely discounted. Furthermore a number of investigators have 
demonstrated that anorexia alone cannot account entirely for 
progressive cachexia (Garattini et al., 1980; Lundholm et al., 
1980; Mider et al., 1951) and that the decreased energy intake 
due to anorexia was insufficient to cause the tissue depletion 
experienced by the tumour bearing host (Lundholm et al., 1980).
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Therefore, the 'metabolic chaos' theory as it presently 
stands does not provide an adequate explanation for the notable 
tissue wasting in the tumour bearing host.
1.2.1.4 Amino Acid Imbalance
Stein (1978) attempted to explain this enigma in the 
following way. He proposed that the host and the tumour required 
more nutrients than the host alone. During the early stages of 
tumour growth the host was unaware of this increased demand and 
thus the nutritional input was not increased. Eventually a 
competition for metabolites developed between the tumour and the 
host, with the tumour's need being met preferentially, 
particularly with respect to certain unspecified amino acids. 
This resulted in an amino acid imbalance, which caused the tumour 
associated anorexia. Stein further proposed that the removal of 
one or more amino acids from the host's amino acid pool by the 
tumour, left the host with the problem of disposing of the 
remainder of the amino acids. This situation occurred because 
normal protein synthesis requires a full complement of amino 
acids; if one amino acid is lacking the rate of protein synthesis 
may be notably depressed. Therefore, as the body has no means of 
sorting amino acids it must dispose of excess and thus enters a 
phase of negative nitrogen balance. Stein proposed that the 
regulatory processes of the cachectic cancer patient with 
progressive weight loss were distorted to favour gluconeogenesis. 
He attributed this to the stress induced lipid mobilisation, 
which in the tumour bearing host resulted in increased levels of 
acetyl coenzyme A (acetyl CoA). Elevated acetyl CoA levels in
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turn inhibited the pyruvate dehydrogenase complex and thus
blocked the oxidation of the carbon skeletons of many amino acids
and hence their utilisation for energy production by the host.
He further proposed that these amino acids were directed to the
formation of carbohydrate via gluconeogenesis, which is an energy
requiring process, whereas the oxidation of the amino acids to
CO would have produced energy. The host thus degenerated into 
2
an energy deficient state as a result of uncontrolled
gluconeogenesis. Thus, Stein stated that the host achieved an
energy depleting negative nitrogen balance and was unable or 
unwilling to increase the food intake and clinically exhibited 
the symptoms of the cachectic state (Fig. 1.3).
The above hypothesis was unlikely to explain the 
mechanism of cancer cachexia, since overt cachexia can occur in 
patients with remarkably small tumours (Nathanson and Hall, 1974 ; 
Robbins, 1974; Costa, 1977). It is therefore unlikely, that a 
chronic amino acid imbalance of notable dimension would result 
from the metabolic demands of a small neoplasm. Furthermore the 
proposal that uncontrolled gluconeogenesis from amino acids 
resulted in the depletion of host energy, has not been supported 
by experimental evidence (see section 4.1.4). It is also known 
that normal animals adapt to a dietary amino acid imbalance by 
increasing the activity of key amino acid metabolising enzymes, 
resulting in a return to normal food intake (Harper et al., 1970; 
Harper, 1976). Stein offered no explanation as to why a 
compensatory mechanism should not occur in cancer patients. 
However, an amino acid imbalance in the blood of tumour bearing
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Figure 1.3: Schematic representation of the Stein Theory of 
negative nitrogen balance, amino acid imbalance 
and energy depletion in cancer cachexia
The diagram illustrates that anorexia and 
selective extraction of amino acids by tumour 
growth results in host amino acid imbalance. 
Tumour associated stress induces fat mobilisation 
from the host and conseguently results in 
elevated levels of acetyl CoA. Acetyl CoA is an 
inhibitor of the pyruvate dehydrogenase complex 
and thus blocks the oxidation of amino acids via 
the citric acid cycle and hence their utilisation 
for energy production. The metabolism of amino 
acids is then directed towards glucose formation 
and disposal in urine. The overall effect 
results in energy depletion and negative nitrogen 
balance (for details see the text).
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animals may well be a cause of or a contributor to cancer 
cachexia and anorexia. Food intake by animals has been shown to 
be depressed as a result of feeding an amino acid imbalanced 
diet, a high protein diet (Anderson et al., 1968), an amino acid 
deficient diet (Frazier et al., 1947) and a diet containing an
excess of a single amino acid (Harper et al., 1970). These
observations led to the proposal that overall food intake and 
selection were regulated by plasma amino acid levels (Rogers and 
Leung, 1973; Harper et al., 1970).
1.2.2 The 1980 Period
1.2.2.1 Metabolic Basis of Cancer Cachexia
Williams et al., (1980) proposed the following sequence
of events which accompany tumour bearing. Further that these 
events are responsible for the initiation and maintenance of the 
cachectic state. These events in order are
(i) Tumour induced retrodifferentiating changes in 
the liver resulting in a large decrease in the 
activity of alanine aminotransferase in that 
organ.
(ii) The presence of high concentrations of alanine 
in the blood, which arise from muscle, and whose 
blood concentration is stoicheiometrically 
dependent on the oxidation in muscle of branched 
chain amino acids.
(iii) Initial increases in gluconeogenesis from 
lactate and glycerol, but not from the carbon 
chains of the gluconeogenic amino acids.
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(iv) Specific tumour associated stress resulting from
the above imbalanced metabolism and
characterised by increased secretions of 
vasopressin.
(v) Suppression by vasopressin of long chain fatty 
acid oxidation and the synthesis of ketone 
bodies.
(vi) Insufficient blood concentration of ketone 
bodies to regulate muscle proteolysis and 
branched chain amino acid oxidation.
The above postulates of the hypothesis are consistent 
with the clinical history of cancer patients and are supported by 
investigations carried out in cancer patients and tumour bearing 
animals by various investigators. The evidence supporting the 
elements of the hypothesis and their temporal sequence follows.
1.2.2.1.1 Postulate I - Retrodifferentiation of Alanine
Aminotransferase
Postulate I concerns the retrodifferentiation of 
alanine aminotransferase activity (EC 2.6.1.2) in the host liver 
as a consequence of tumour bearing at a site distant to the 
liver.
The data of Herzfeld and Greengard (1977), de Rosa and 
Pitot (1978), Herzfeld et al., (1978) and Williams et al., (1980)
indicated that a number of activites of host liver enzymes had 
changed as a consequence of tumour bearing. In particular, it 
was noted that the quantitative pattern of enzymes in the host 
liver had diverged, during tumour bearing, from the pattern 
observed in the normal liver towards that of the immature liver
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and supported the proposition that the liver of tumour bearing 
rats resembled an immature liver in enzyme profile and therefore 
appeared to be retrodifferentiated.
The enzyme alanine aminotransferase does not present in 
late foetal and neonatal enzyme clusters, rather it appears in 
the rat liver in the late suckling cluster and is essentially 
referred to as an 'adult type' enzyme (Greengard, 1971). The 
retrodifferentiation of this enzyme in the host liver is an 
established phenomenon and has already been reported in animals 
bearing the Walker 256 carcinosarcoma (Goodlad and Clark, 1962; 
Herzfeld and Greengard, 1972), Lymphoma RNC 290 (Herzfeld and 
Greengard, 1977), Morris hepatoma 5123C, Morris hepatoma 7777, 
R3230AC adenocarcinoma, MDAB induced hepatocarcinoma (Williams et 
al., 1980) and Novikoff hepatoma (Beaton et al., 1957).
1.2.2.1.2 Postulate II - Alanine Synthesis and Branched Chain
Amino Acid Oxidation in Muscle
Depletion in muscle protein, due to both an increase in 
its rate of degradation and a decrease in its rate of synthesis 
is a common systemic effect of a growing tumour (Clark and 
Goodlad, 1971, 1975; Goodlad and Clark, 1973; Lundholm et al., 
1976; Sherman et al., 1950). Amino acids derived from the 
degradation of muscle protein may be called upon to play an 
important role in the energy metabolism of the tumour bearing 
subject. Amino acids are released in large amounts from muscle 
during starvation (Goldberg and Odessey, 1972; Huston and Harper, 
1981), uncontrolled diabetes (Buse et al., 1976) and tumour 
bearing (Chung and Bauer, 1969; Clark et al., 1978; DeWys,
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1970). The release of alanine is predominant in the outflow of 
amino acids from muscle and cannot be explained on the basis of 
its availability in constituent cellular proteins (Felig, 1975). 
Alanine comprises no more than 7-10% of muscle proteins (Kominz 
et al. , 1954 ; Odessey et al., 1974) and yet it accounts for 30% 
or more of the nett flow of alpha amino nitrogen from muscle. 
This discrepancy led to the suggestion that alanine was 
synthesised de novo in muscle tissue by the transamination of 
pyruvate (Felig et al., 1970; Pozefsky, 1969).
The branched chain amino acids were suggested as major 
contributors to the origin of the amino group for muscle alanine 
synthesis (Pozefsky, 1969). Muscle is unique in being the 
specific site for the oxidation of branched chain amino acids 
(Harper and Zapalowski, 1981; Miller et al., 1962). It is of 
note that in skeletal muscle the synthesis of one mole of alanine 
requires the oxidation of one mole of either leucine, isoleucine 
or valine. These are essential amino acids since humans have no 
metabolic capacity to synthesise them in adequate dietary 
quantities. Therefore the loss of branched chain amino acids 
from muscle is an irreversible loss and can only be corrected by 
the supplementation of these amino acids in the diet.
1.2.2.1.3 Postulate III - Gluconeogenesis from Lactate and
Amino Acids
As previously discussed (Postulate I), the livers of 
tumour bearing animals possessed an enzyme profile characteristic 
of livers of one to two week old neonatal rats (with 'immature' 
livers). The neonatal rats possess an increased ability (in 
comparison with adult rats) to utilise lactate and pyruvate for
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gluconeogenesis, however an impaired ability to utilise high 
concentrations of alanine for the production of glucose was also 
observed (Snell, 1975, 1982). This decreased gluconeogenesis
from alanine was proposed (Snell, 1975) to be due to a deficiency 
of the enzymatic capacity to convert alanine to pyruvate because 
of the low activity of alanine aminotransferase in the neonatal 
rat liver (Greengard, 1971). These observations are similar to 
the situation that is present in the liver of tumour bearing 
rats. Gluconeogenesis from lactate (Gold, 1968, 1974; Reichard 
et al., 1963; Shearer et a L , 1983; Waterhouse, 1974b) and
pyruvate (Shearer et al., 1984) was increased in tumour bearing
animals. However, the activity of alanine aminotransferase was 
low in the host liver (Beaton et al., 1957; Goodlad and Clark,
1962; Herzfeld and Greengard, 1972, 1977; Williams et al., 1980). 
Therefore, a low rate of gluconeogenesis from plasma alanine was 
proposed in the livers of tumour bearing subjects.
1.2.2.1.4 Postulate IV - Vasopressin and Stress
Elevated levels of vasopressin have been demonstrated
in a number of stress situations (see section 7.1.1). The rapid
growth of a tumour (physical stress) and accompanying adrenal
hypertrophy (metabolic stress), are sufficently convincing
symptoms to indicate that a growing neoplasm represents a
physiological stress to the host (Selye, 1946; Tepperman et al.,
1943) Fifteen different kinds of neoplasm have individually been shown to 
raise vasopressin levels in human patients."
n
(Table 1.2); such patients are commonly referred to as exhibiting 
the syndrome of inappropriate secretion of the antidiuretic
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Table 1.2: Inappropriate production of vasopressin in human 
cancer
Human Cancer References
Adenocarcinoma of lung 
Carcinoma of adrenal gland 
Carcinoma of bladder 
Carcinoma of duodenum 
Carcinoma of oesophagus
Carcinoma of pancreas
Carcinoma of prostate 
Carcinoma of ureter 
Ewing's sarcoma 
Hodgkin's disease 
Leukaemia 
Lymphoma
Mediastinal reticulosarcoma 
Mesothelioma
Oat cell carcinoma of lung
Squamous cell carcinoma of
Tongue
Thymoma
Schwartz et al., (1962)
Falchuk (1973)
Kaye and Ross (1977)
LeBacq and Delaere (1965)
De Troyer and Demanet (1976), 
Hamilton et al., (1972)
DeSousa and Jenny (1964),
Marks et al., (1968), Vorherr
et al., (1968)
Sacks et al., (1975)
Zerbe et al., (1980)
Zimbler et al., (1975)
Cassileth and Tortman (1973) 
Susan (1984)
Susan (1984)
Honoune et al., (1965)
Perks et al., (1978)
Hirata et al., (1976), Kaye
(1966), Marks et al., (1968),
Schwartz et al., (1957, 1960,
1962), Vorherr et al., (1978)
Hamilton et al., (1972)
Bartter and Schwartz (1967), 
Haas et al., (1975)
hormone (SIADH). The clinical histories of patients with SIADH 
show that cachexia was reported to be common in these patients 
(see section 7.1.1). Thus the hypothesis proposed that 
vasopressin played an important role in the initiation and 
maintenance of cancer cachexia.
1.2.2.1.5 Postulate V - Vasopressin, Fatty Acid Esterification
and Ketone Body Synthesis
Hyperlipidemia, in particular the elevation of serum 
triglyceride rich low density lipoprotein (LDLP), is associated 
with tumour growth in cancer patients and experimental animals 
(see section 5.1.4). Moreover, cancer subjects frequently have a 
poor appetite and are often too ill to eat (Brennan, 1977). In 
spite of their apparent starvation, ketosis is reported to be an 
uncommon phenomenon in cancer patients (Conyers et al., 1979 a,b; 
Williams et al., 1980) and tumour bearing animals (Mider et al., 
1951). Ketonuria has not been reported, nor has an increase in 
the titratable acidity of urine been demonstrated in tumour 
bearing animals (Mider et al., 1951).
The role of vasopressin in stimulating long chain fatty 
acid esterification and suppressing ketone body synthesis is now 
well established (Rofe and Williamson, 1983 a,b; Williamson et 
al., 1980). The consistencies in the observations of elevated 
levels of vasopressin in cancer patients, hypertriglyceridaemia 
and impaired ketosis in cancer patients and tumour bearing 
animals suggest that vasopressin is an agent responsible for 
directing fatty acid esterification and the suppression of ketone 
body synthesis in cancer patients and tumour bearing animals.
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1.2.2.1.6 Postulate VI - Ketone Bodies and the Regulation of
Branched Chain Amino Acid Oxidation
During starvation of normal subjects there are notably 
elevated levels of ketone bodies in the blood. These compounds 
act not only to replace glucose as the major fuel of the central 
nervous system, but they also contribute to protein conservation 
(Owen et al., 1967, 1969; Ruderman and Berger, 1974). The 
infusion of ketone bodies resulted in protein conservation in 
fasted human subjects (Sherwin et al., 1975). Hyperketonaemia 
has also been associated with decreased protein catabolism in 
traumatised man (Smith et al., 1975) and postoperative patients 
(Hoover et al., 1975). The decline in alanine release is 
suggested as an index of protein conservation (Smith and Aoki,
1981) . Inhibition of alanine release by ketone bodies has been 
observed in vitro using diaphragm (Palaiologos and Felig, 1976), 
soleus and extensor digitorum longus muscles (Snell and Duff,
1982) from starved rats. Considerable interest has been shown in 
the possible role of ketone bodies in inhibiting muscle 
proteolysis (Palaiologos and Felig, 1976), alanine release from 
extrahepatic tissues (Sherwin et al., 1975) and branched chain 
amino acid breakdown in muscle (Landaas, 1977). Inhibition of 
alanine release was suggested to be a consequence of the 
inhibition of protein catabolism and/or glycolytic flux and 
pyruvate oxidation (Maizels et al., 1977; Palaiologos and Felig, 
1976). An alternative proposal was that the ketone bodies 
inhibited the branched chain keto acid dehydrogenase complex 
(Snell and Duff, 1982; Zapalowski et al., 1981).
It was demonstrated that addition of sodium DL-3-
18
hydroxybutyrate decreased the tissue content of several amino
acids, among which were tyrosine and phenylalanine. This
suggests that proteolysis was decreased by ketone bodies
(Palaiologos and Felig, 1976). Other studies (Turinsky and
Shangraw, 1981) showed that decreases in alanine release by
injured and uninjured muscle was always associated with a
depression of glucose uptake. Conversely, the failure of 3-
hydroxybutyrate to appreciably depress alanine release by
thermally injured muscle was coupled to the absence of
significant effects on glucose uptake by the burned limb muscle.
These results seemed to indicate that the alanine inhibiting
action of ketone bodies is at least in part mediated by their
action on glycolysis and the production of pyruvate (Turinsky and
Shangraw, 1981). It is of further interest that ketone bodies
14 14
appeared to inhibit CO production from [1- C] leucine and [1- 
14 2
C] valine and decreased alanine release in parallel (Palmer et 
14 14
al., 1985a). CO production from [1- C] labelled branched
2
chain amino acids is a specific measure of their oxidative 
decarboxylation and therefore it was concluded that ketone bodies 
inhibited the release of alanine by acting at the branched chain 
keto acid dehydrogenase reaction. Alanine production was not, in 
theory, likely to be influenced by modulation of the flux in the 
branched chain keto acid dehydrogenase reaction (Snell and Duff, 
1982). Therefore, the specific inhibition of alanine formation 
may result from the inhibition, by ketone bodies, of branched 
chain amino acid uptake or transamination. However it is clear 
from these experiments that the hypoalaninaemic action of ketone
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bodies in vivo may be mediated in part via inhibition of branched 
chain amino acid metabolism (Palmer et al., 1985a).
It can be concluded from the above brief review of 
experimental evidence that the level of ketone bodies in the 
blood conserves body protein by acting at multiple sites i.e., 
inhibiting protein catabolism, limiting pyruvate availability for 
transamination by inhibiting glycolytic flux, acting on branched 
chain amino acid uptake, transamination and decarboxylation.
An integration of events of the above six postulates is 
illustrated in Fig. 1.4. It is clear that the hypermetabolic 
cachectic state is both characterised by and locked into a 
situation where there is chronic protein breakdown and alanine 
release from muscle, an inhibited capacity of the liver to rescue 
the alanine for gluconeogenesis, irreversible loss of muscle 
nitrogen (in urine) and the establishment of a new and different 
type of stress distinguished by low ketone body synthesis by the 
liver and thus insufficient or no regulation of alanine release 
from the muscle bed. This situation, when unchecked, can quickly 
lead to a loss of one-third to one-half of the mass of muscle 
protein, a situation itself sufficient to cause death.
1.2.3 Theories of the Post - 1980 Period 
1.2.3.1 Brown Adipose Tissue Activation
Brooks and coworkers (1981) have demonstrated a 40% 
increase in energy expenditure in mice bearing an implanted human 
nephroma. They proposed that the rapid weight loss of tumour 
bearing animals may be due to a high metabolic rate, which 
resulted from sympathetic stimulation of brown adipose tissue
20
Figure 1.4: Schematic representation of the hypothesis for 
the "Metabolic Basis of Cancer Cachexia"
The diagram illustrates that a tumour releases 
agent(s) (unidentified) which cause foetalistic 
changes in the host liver enzymes, in particular 
suppression of the activity of alanine 
aminotransferase. The stress induced by tumour 
bearing resulted in increased secretion of 
vasopressin in the host circulation from the 
posterior pituitary. Increased vasopressin 
levels resulted in enhanced esterification of 
long chain fatty acids and suppressed fatty acid 
oxidation and ketone body fromation. Low 
circulating levels of ketone bodies deregulate 
the muscle protein degradation, which is
charaterised by increased BCAA oxidation and 
excess alanine formation. The utilisation of 
alanine for glucose synthesis is suppressed
because of a notable reduction in alanine 
aminotransferase activity in the host liver, thus 
results in hyperalaninaemia and hyperalaninuria. 
The overall effect of this metabolic state is 
tumour induced uncontrolled breakdown of muscle 
protein, body wasting and negative nitrogen 
balance.
The diagram is taken (with author's permission) 
from Asean. J. Clin. Sei. (1981) 2, 158-166.
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metabolism. Their studies in tumour bearing cachectic mice 
showed remarkable similarities to those reported in cold adapted 
and hyperphagic animals.
In normal animals, high metabolic rates are observed in 
response to cold exposure, arousal from hibernation (Himms-Hagen, 
1976; Jansky, 1973) and elevated energy intake (Rothwell and 
Stock, 1979, 1980; Tulp et al., 1980). These phenomenon involve 
the nervous system and brown adipose tissue activation. Cold 
adapted and hyperphagic rats exhibit high metabolic rates which 
can be blocked by $-adrenergic blockade, enhanced thermogenic 
response to noradrenaline (Himms-Hagen, 1976; Jansky, 1973; 
Rothwell and Stock, 1979, 1980), increased noradrenaline turnover 
(Landsberg et al., 1981) and hyperplasia and hypertrophy of brown 
adipose tissue (Rothwell and Stock, 1979). Nicholls (1979) 
suggested that the high rates of heat production in brown adipose 
tissue were due to the presence of a proton conductance pathway 
in the inner mitochondrial membrane. This pathway dissipated the 
proton gradient generated by respiration and therefore permitted 
uncoupled respiration, which was responsible for the elevated 
energy expenditure. The activity of this pathway was estimated 
from the binding of purine nucleotides to mitochondria; such 
measurements revealed a high activity of the pathway in brown fat 
from cold adapted (Nicholls, 1979; Sundin and Cannon, 1980) and 
hyperphagic (Brooks et al., 1980) rats.
Brooks et al., (1980) demonstrated that the structural
alterations in the mitochondria of brown adipose tissue from 
tumour bearing cachectic mice resemble those seen in tissue taken
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from cold adapted animals. These alterations were not present in 
the mitochondria of starved normal mice. Increased mitochondrial 
guanine nucleotide diphosphate (GDP) binding in brown adipose 
tissue was also reminiscent of data from cold adapted (Sundin and 
Cannon, 1980) and hyperphagic (Brooks et al., 1980) rats. These 
results showed an increased activity of the proton conductance 
pathway in brown adipose tissue of tumour bearing mice, which was 
responsible for the uncoupled respiration and elevated energy 
expenditure.
This theory was further supported by the work of 
Shellock and coworkers (1986). These investigators have 
demonstrated a high prevalence of brown adipose tissue in 
patients who had died with cancer cachexia and suggested that 
this tissue may be partially responsible for an accelerated rate 
of energy expenditure and resultant weight loss.
Increased metabolic rates and elevated energy 
expenditure are commonly observed in cancer patients (Dempsey et 
al., 1984; Strain, 1979; Theologides, 1979; Warnold et al., 1978) 
and tumour bearing animals (Mider, 1951; Morrison, 1971). A wide 
range of factors are known to influence metabolic rate and energy 
expenditure including age, nutritional stress, temperature, 
levels of various hormones and pathological variables in studies 
of energy expenditure in cancer patients. Patients with evidence 
of sepsis have elevated energy expenditure, 35% to 80% above that 
predicted for the normal subjects (Long et al., 1979). Major 
abdominal surgery can be expected to increase energy expenditure 
by about 10% during the first few postoperative days (Elwyn et 
al., 1981). Other possibilities for increased energy wastage in
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cancer patients include an increase in futile cycling of
carbohydrate intermediates (Holroyde and Reichard, 1981; 
Waterhouse, 1981), changes in the coupling efficiency of 
oxidative phosphorylation, increased channelling of glucose into 
lipogenic pathways, (Hegsted, 1974) high energy cost of protein 
turnover (Young et al., 1975) and ion pumping (Rothwell and 
Stock, 1981). Therefore it is difficult to draw a satisfying 
conclusion about the relative contributions of brown tissue 
activation to elevated energy expenditure. Increased energy 
expenditure due to impairmant of mitochondrial function is still 
both possible and questionable. It was demonstrated that the 
25,000xg supernatant fraction of a homogenate from a Novikoff 
hepatoma of the rat (Devlin and Pruss, 1958) and serum from a 
sarcoma bearing rat (Nanni and Casu, 1961) could uncouple the 
oxidative phosphorylation of freshly isolated normal liver 
mitochondria. In contrast to these findings, no impairment in 
oxidative phosphorylation was detected in liver mitochondria from 
Walker 256 carcinosarcoma bearing rats (Greene, 1960) or from 
Krebs-2-carcinoma bearing mice (Devlin and Costa, 1964). The 
theory of brown adipose tissue activation, although supported by 
some experimental work is not sufficiently developed to explain a 
mechanism by which tumour induced activation of brown adipose 
tissue metabolism leads to cachexia.
Brown adipose tissue is typically located in definite 
anatomical sites in humans primarily during the early stages of 
life and it generally diminishes with age (Hassi, 1977). It is 
therefore of interest to note that a high incidence of brown
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adipose tissue was encountered in a relatively old population (72 
+ llyears) of patients with cancer and cachexia (Shellock et al., 
1986). This observation may be accepted as further confirmation 
of the re-differentiating and foetalistic effects of tumour 
growth on host tissue metabolism (section 1.2.2.1 - postulate I).
1.2.3.2 Immunologic Response
Rivarola (1985) proposed that the mechanism for the 
initiation of cancer cachexia was essentially immunologic in 
nature. Many neoplasms elicit in the host a reaction that is 
similar to that produced by a tuberculous infection, which is the 
paradigm of cell mediated, delayed type or type IV 
hypersensitivity. In this condition the sensitised host becomes 
susceptible to a 'toxic' action by tuberculin which is otherwise 
totally inocuous to the virgin subject. Rivarola proposed that 
an immune response was elicited by some (unidentified) noxious 
agent (s) from the tumour resulting in a. di sab l ed  or ineffective 
response to eliminate the source of the antigen, which keeps on 
producing and exerting its 'toxic' capabilities. He concluded 
therefore, that an intrinsically innocent tumour antigen is a 
true antigen only to virgin subjects and that it has a second 
role as pathogen to the sensitised subjects and that it is 
responsible for the general debilitating symptoms noted in tumour 
bearing patients, including the acute loss of weight that may 
develop into cachexia.
This theory has been supported by the observation of 
Koch (1891) who demonstrated that an animal sensitised through a 
previous contact with a bacilli was killed by the injection of a
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small amount of tuberculin (the tuberculin shock), whereas a 
nonsensitised animal was able to withstand a dose many thousand 
times higher wihout showing any harmful effects. Furthermore, it 
is known that the presence of a neoplasm in the body elicits a 
host response with predominant involvement of macrophages and 
mononuclear phagocytic cells (Nathan et al., 1980). However no 
factor(s) has been convincingly isolated from tumours which 
initiate an immune response in the host. Moreover the theory 
doesn't explain why an elicited response in the host was 
ineffective and/or unable to eliminate or neutralise the source 
of the antigen. The theory also failed to explain how the 
antigen from the tumour acted as a pathogen in sensitised 
subjects and induced cachexia.
It is of interest to note that the Williams hypothesis 
proposed an as yet unidentified agent(s) for the initiation of 
the sequence of events which leads to body wasting i.e, cachexia. 
It is possible that the initiation of the sequence of events is 
triggered by an immune response which is elicited by some 
agent(s) from the tumour. The Williams theory is still at the 
first stages of its development. It has proposed steps (capable 
of being experimentally investigated) in the metabolic sequelae 
which follow the whole body reception of a neoplasm and the 
accompanying stress of its growth (Fig. 1.4 and later sections of 
this thesis - chapter seven).
1.2.3.3 Host Tumour Metabolic Interaction
Lazo (1985) proposed that the requirement for essential 
amino acids for the growth of a neoplasm can be used as a
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unifying principle that links the tumour to the two main 
components of cachexia: muscle wastage and anorexia. He proposed 
that there were two types of amino acid pool: a fast reacting
pool formed by free amino acids of intracellular and 
extracellular locations, and a slow reacting pool formed by 
proteins with skeletal muscle as its main component. The 
interaction between the slow and fast reacting pool was 
represented by a plasma pool which operated as a bridge pool 
among different cell and tissue populations. It was proposed 
that the growing tumour made its demands for nutrients e.g, 
essential amino acids, from the plasma pool. This plasma pool 
could be depleted in a short time because of its limited size, 
but before this happened the muscle free amino acids would 
respond to the extracellular changes. This response would 
involve the release of amino acids from the muscle free 
intracellular pool and thus would be reflected in muscle 
metabolism; first as a decrease in its ability to synthesise 
protein, resulting in a nett loss without increased degradation, 
at later stages degradation would also increase. Lazo (1985) 
also proposed that while essential amino acids have a specific 
destination, the non-essential amino acids were mobilised at the 
same time and contributed to the host metabolic derangements e.g, 
altered amino acid ratios and negative nitrogen balance(Fig. 1.5) 
The host metabolic interaction theory of Lazo (1985) is 
another version of the amino acid imbalance theory of Stein 
(1978) which was reviewed in section 1.2.1.4. Moreover it does 
not seem reasonable to ascribe cancer cachexia simply to the 
nutritional demands of the tumour. This point is most easily
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Figure 1.5: Flux of essential amino acids among different 
pools in cancer patients
The diagram illustrates that the tumour growth 
makes a demand of nutrients e.g, essential amino 
acids which alters the muscle metabolism.
Initially synthesis of protein is suppressed but 
later this results in increased protein
degradation and thus the host exhibits altered 
amino acid ratios, negative nitrogen balance and 
cachexia (for details see the text)
The diagram is taken (with author's permission) 
from FEBS Lett. 187, 189-192 (1985)
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demonstrated when the metabolic requirements of the tumour are
compared with those of the conceptus during pregnancy. In both 
of these instances there is rapid growth made possible by a 
supply of nutrients from the host. Overt cachexia, can appear in 
patients with tumours which are less than 0.01% of total body 
weight (Nathanson and Hall, 1974). It was also reported that the 
total mass of the tumour in the majority of terminal cancer 
patients (without obstruction of vital organs) seldom exceeded 
500g (Costa, 1977). Neoplasms therefore, are often lethal while 
still only being a small fraction of the total biomass of the 
host (Morrison, 1976; Shapot, 1972; Robbins, 1974; Williams et 
al., 1980). On the other hand the mean birth weight of the human 
foetus is 3.5kg (Widdowson, 1968). In addition, a tumour does 
not grow as rapidly as the foetus (Robbins, 1974), yet the 
pregnant human subject does not become cachectic, on the contrary 
she often gains body weight (Llewellyn-Jones, 1971) . The human 
body therefore, is able to compensate for, and support a much 
larger and more rapidly growing 'parasitic' mass of tissue than 
is the case for bearing a neoplasm. Similarly, studies with 
experimental animals have shown that the maternal organism has an 
increased intake of food and is therefore not calorically 
depleted (Blaxter, 1957; Naismith, 1969). Parasitisation of 
nutrients via the tumour per se is therefore unlikely to be an 
important cause of cancer cachexia.
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1.3 Pathophysiology of Monokines in the Development of
Cachexia
Microbial invasion, tissue injury, immunologic 
infections and inflammatory processes induce a set of host 
responses collectively referred to as the 'acute phase response' 
(Dinarello, 1984). The response is characterised by changes in 
neurologic, immunologic, metabolic and endocrinologic functions. 
The presence of acute phase changes can also serve as an 
indicator of silent diseases and of some cancers, particularly 
renal cell carcinoma and Hodgkin's disease (Dinarello, 1984). 
The most potent substance which induces acute phase response is 
the lipopolysaccharide of Gram negative bacteria. This
polysaccharide is also called an endotoxin (Dinarello and Wolff, 
1978). The most fundamental event in the initiation of the acute 
phase response is the production of hormone like mediators from 
activated macrophages to signal distant tissues (Beisei, 1983; 
Dinarello, 1984). A number of mediators have been reported in 
fever, inflammation, infectious diseases and some forms of 
cancers (Dinarello, 1984; Kawakami et al., 1982) and have been
given different names by different investigators. The following 
are a selection granulocytic pyrogens (Beeson, 1948),
leukocytic pyrogens and endogenous pyrogens (Atkin and Wood, 
1955), lymphocyte activating factor (Gery and Waksman, 1972), 
leukocytic endogenous mediator (Wannemacher et al., 1972, 1975),
mononuclear cell factor (Krane et al., 1982) and catabolin
(Saklatvala et al., 1984). Wood et al., (1976) introduced the
term 'monokine' for the macrophage secretory products. Later the 
immune regulators from lymphocytes and macrophages were unified
28
under a common name - 'interleukin* (Aarden et al., 1980) i.e., 
interleukin-I (IL-I) for the monokine that effects lymphocyte 
activation or maturation and interleukin-II (IL-II) for the 
lymphokine that initiates lymphocyte proliferation and growth. 
Considerable evidence now supports the concept that these 
substances, which are collectively called IL-I, are physically 
related and thought to be either a polypeptide derived from a 
single gene or a group of related peptides produced by a family 
of closely related genes (Dinarello, 1984). The primary source 
of IL-I are blood monocytes, the phagocytic lining of the liver, 
spleen and other tissues with fixed macrophages. Specialised 
cells such as keratinocytes, gingival and corneal epithelial 
cell, renal mesangial cells and brain astrocytes also produce IL- 
I like molecules (Dinarello, 1984).
More recently activated macrophages were shown to 
release 'tumour necrosis factor' (TNF) which has been found in 
the sera of endotoxin-treated mice and rabbits previously 
infected with BCG (Bacillus Calmette-qeurin) - an attenuated 
strain of Mycobacterium tuberculosis which is used as a vaccine 
against tuberculosis and leprosy (Carswell et al., 1975; Mannel 
et al♦, 1980, 1981). The TNF displays cytostatic and cytocidal 
activities against transformed cell lines in culture but has no 
effect on the normal cell culture derived from human, rabbit, 
chicken and mouse sources (Carswell et al., 1975; Helson et al., 
1975; Matthews, 1978; Matthews and Watkins, 1978; Ostrove and 
Gifford, 1979; Ruff and Gifford, 1981a, 1981b). Mouse and human 
TNF show approximately 80% amino acid homology (Fransen et al.,
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1985; Pennica et al., 1985).
Another monokine, 'cachectin' (produced by macrophages 
stimulated with endotoxin), has been isolated and characterised 
(Beutler et al♦, 1934, 1985a; Mahoney et al., 1985). Cachectin 
completely suppressed the synthesis of lipoprotein lipase (LPL) 
in adipocytes in vitro and in vivo (Beutler et al., 1984, 1985a; 
Mahoney et al., 1985).
Comparison of the amino acid composition of mouse 
cachectin and human tumour necrosis factor revealed striking 
similarities. Both proteins were hydrophobic, acidic and 
contained identical numbers of threonine, valine, alanine, 
histidine, arginine and cysteine residues (Beutler et al., 
1985b). Cachectin was also found to have cytotoxic effects on L- 
929 cells (Beutler et al., 1985b). Experiments with recombinant 
human TNF showed that the morphological effects of this substance 
on adipocyte differentiation and lipid mobilisation were similar 
to those of cachectin (Martin et al., 1986; Muller et al., 1986; 
Torti et al., 1985). These observations suggested that a single 
protein was responsible for cachetin and TNF activity (Beutler et 
al., 1985b). Recent investigations showed that cachectin/TNF was 
secreted by the peripheral blood mononuclear cells of patients 
with colorectal, breast, pancreatic, renal, stomach, ovarian and 
lung cancer (Aderka et al., 1985). Furthermore, a high affinity 
receptor for cachectin/TNF had previously been identified and 
characterised in liver, kidney, skin, lung and the 
gastrointestinal tract of normal mice (Beutler et al., 1985c). 
Cachectin/TNF possess similar molecular weights and isoelectric 
points to those described for interleukin-I, but have no
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characteristic leukocyte activating factor activity (Beutler et 
al., 1985a)
1.3.1 Metabolic Alterations Induced by Monokines
It is known that mammals, in response to invasion by 
bacteria, viruses, parasites and neoplasms, display a number of 
metabolic changes which are believed to be mediated by monokines 
(Beisei, 1975; Dinarello, 1984, 1985; Filkins, 1979, 1980, 1981). 
Some of these changes involve the production of insulin, 
glucagon, growth hormone, thyroid stimulating hormone and 
vasopressin as an acute phase response (Dinarello, 1985).
1.3.1.1 Lipid Metabolism
Interleukin-I (monokine) induced complex alterations 
in fat metabolism (Beisei and Wannemacher, 1980; Beisei, 1983) 
which included hypertriglyceridaemia and elevated levels of free 
fatty acids, reduction of adipose tissue lipolytic activity in 
vivo, decreased fatty acid uptake and oxidation, decreased 
ketogenesis and decreased fatty acid synthesis.
Hypertriglyceridemia was also reported in cancer 
patients and tumour bearing animals (see section 5.1.4). Several 
investigators (Barclay et al., 1962; Beisei and Wannamacher, 
1980) suggested that the hypertriglyceridaemia in infected and 
tumour bearing animals was caused by a deficiency in the activity 
of the removal enzyme lipoprotein lipase (LPL; EC 3.1.1.34) in 
peripheral tissues. In support of this, Thompson et al., (1981) 
observed that the activity of LPL was lower in the adipose tissue 
of mice bearing a preputial gland tumour than in control mice. A
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similar situation was encountered in endotoxin treated mice, 
where LPL activity was markedly suppressed in adipocytes and 
resulted in a 2.6 fold elevation in serum triglyceride levels 
(Kawakami and Cerami, 1981). A mediator which was produced by 
the macrophages of endotoxin treated mice was suggested as being 
responsible for the suppression of LPL activity in adipocytes 
(Kawakami et al., 1982) . It was demonstrated that treatment of
adipocytes with cachectin prevented the accumulation of adipose 
tissue-inducible mRNA and the complete inhibition of lipid 
accumulation (Beutler et al., 1985d). After 4-6 days of exposure 
to cachectin most adipocytes lost the neutral lipid (Beutler et 
al., 1985d). The mechanism presumably involved the suppression
of the biosynthesis of LPL by cachectin/TNF apparently acting at 
the level of transcription of protein synthesis. Recent 
investigations demonstrated the production of cachectin/TNF by 
peripheral blood mononuclear cells of patients with solid tumours 
(Aderka et al., 1985).
The other major derangement of lipid metabolism was 
diminished hepatic ketogenesis during inflammatory/infectious 
episodes despite the availability of excess exogenous free fatty 
acids supplied to the liver (Pace et al., 1977). The direct
application of the leukocytic endogenous mediator into the rat 
produced a reduction in the fasting ketonaemia (Keenan et al., 
1981) and increased the synthesis of acute phase proteins 
(Wannemacher et al., 1975).
Investigations have demonstrated that basic defect in 
inflamed and infected subjects appears to lie at the entry site 
of the fatty acid from the cytoplasm to the mitochondria (see
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section 5.1.3). This may result in the diversion of fatty acids 
away from the oxidative pathway to the esterification pathway and 
hence hypertriglyceridaemia which is a common syndrome in 
infectious and cancer subjects.
1.3.1.2 Carbohydrate Metabolism
Monokine induced alterations in carbohydrate metabolism
involved increased glycogenolysis, decreased glycogen synthesis,
decreased gluconeogenesis and a markedly enhanced peripheral
glucose utilisation (Beisei and Wannemacher, 1980; Filkins, 1984
14
a,b). In endotoxin treated mice, the incorporation of [U- C] 
alanine into glucose was reduced by 50% of the amount seen in 
control animals, together with a significant inhibition of 
phosphoenolpyruvate carboxylase (PEPCK) activity (McCollum and 
Berry, 1973; McCollum, 1981). McCollum (1981) demonstrated that 
endotoxin stimulated the Kupffer cells of the liver to release 
mediator from macrophages, which then inhibited the activity of 
PEPCK in hepatocytes and thus the conversion of gluconeogenic 
amino acids into glucose.
1.3.1.3 Protein Metabolism
Skeletal muscle provides a metabolically dynamic
protein bulk and serves as the potential source of free amino
acids for the synthesis of acute phase reactants (Beisei and
Wannemacher, 1980; Munro, 1979). Catabolism in vivo of
contractile proteins in man can be estimated by the measurement
of 3-methyl histidine in urine (Young, 1973). 3-methyl histidine
is subjected to little, if any, degradation to CO or
2
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reutilisation in man. Its excretion in the urine serves to
quantify the daily catabolism of contractile proteins 
(Wannemacher et al., 1974; Young, 1973). Young and coworkers
(1983) demonstrated that there was an increased breakdown of 
myofibrillar proteins and connective tissues as shown by a 30% 
higher excretion of 3-methyl histidine and a 40% increase in the 
excretion of hydroxyproline in the urine. Creatinine excretion 
also rose significantly by 50% in these animals.
Recent investigations have criticised the use of 3- 
methyl histidine as a measure of skeletal muscle degradation, 
after it was demonstrated that skeletal muscle contributed only 
about 25% of the total daily urinary excretion of 3-methyl 
histidine (Millward et al., 1980), whereas the gastrointestinal
tract accounts for as much as 41% of this excretion (Wassner and 
Li, 1982) in adult rats. Whether such differences occur in 
humans, in whom skeletal muscle mass/gut mass ratio is
significantly larger than in adult rats, is currently not known 
(Landle et al., 1985).
The direct action of interleukin-I on muscle tissue
resulted in dramatic increases in prostaglandin E production and
2
protein degradation (Baracos et al., 1983; Beisei, 1983). It was
already known that muscle -synthesised and released prostaglandin
E (Rodemann and Goldberg, 1982). Thus the enhancement of 
2
protein degradation by interleukin-I appeared to be mediated by
prostaglandin E (Baracos et al., 1983; Beisei, 1983). Moreover,
2
an increased body temperature may in itself promote nett protein
degradation independent of prostaglandin E (Baracos, 1983).
2
Fever was often accompanied by muscle pain and because
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prostaglandin E is a potent stimulator of peripheral pain
2
receptors and hyperalgia (Baracos, 1983) these events have been
linked. Thus the increased prostaglandin E production induced
2
by interleukin-I in muscle, especially at higher temperatures 
(39 C) accounted in part for the myalgia that accompanied many 
infectious episodes.
Infusion of prostaglandin of the E series into hydrated
animals increased urinary sodium excretion (Beck et al., 1981)
and plasma vasopressin levels (Sklar and Schrier, 1983). The
elevated levels of vasopressin are known to inhibit hepatic
ketone body synthesis (Rofe and Williamson, 1983 a,b). It has
been demonstrated that ketone bodies are regulators of protein
synthesis in muscle (Palaiologos and Felig, 1976; Palmer et al.,
1985a; Smith and Aoki, 1981). Thus by lowering the levels of
ketone bodies in plasma via vasopressin, prostaglandin E may
2
further enhance protein degradation. Elevated levels of
prostaglandin E have been reported in cancer patients and tumour
2
bearing animals (Karmali, 1980). It is therefore possible that
prostaglandin E may play an important role in the muscle wasting
2
of patients with cancer cachexia.
1.4 Animal Tumour Models
The rat transplantable Walker 256 carcinosarcoma and 
R3230AC adenocarcinoma were selected as models for tumour bearing 
and for the induction of cancer cachexia in the present 
investigations. These tumour lines have several advantages over 
these of other animal neoplasms. These advantages involve 
induction, transplantability, superficial location and
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similarities to human mammary tumours in their hormone 
sensitivity and histology.
The Walker 256 carcinosarcoma was derived from a 
spontaneously appearing tumour in the region of the mammary gland 
of a pregnant albino rat (Dunham and Stewart, 1953). It consists 
of transformed epithelium and stroma. Microscopic appearance 
shows a field of elongated cells and spindle-shaped nuclei in 
bundles that run in irregular directions. This is a fast growing 
tumour that attains up to 30-40% of body weight of the host 
within two to three weeks of implantation (see section 3.2.4). 
The Walker 256 carcinosarcoma has been studied extensively and is 
an established model animal tumour for the study of tumour 
induced cachexia and anorexia (Guaitani et al., 1982).
The R3230AC adenocarcinoma is a slow growing variant 
neoplastic line which arose spontaneously from a fast growing 
transplantable mammary adenocarcinoma, R3230AB (Hilf et al., 
1965) . This subline is autonomous, responsive and composed 
primarily of epithelial cell elements. It possesses the ability 
to induce lactation in response to oestrogen treatment. The 
R3230AC adenocarcinoma has certain biochemical and morphological 
similarities to normal breast tissue and is regarded as a most 
valuable experimental tumour model (Hilf et al., 1965). The 
effects of this tumour on host metabolism have been studied and 
symptoms of cachexia were demonstrated in the host (Matthaei, 
1979) .
The applicability and value of experimental results, 
obtained from animal tumour models, to human neoplasia, have been
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pointed out (Strain, 1979). The tumour lines which were selected 
for the present investigation cannot exactly represent the 
cachexia of human neoplasia, but considering their functional and 
structural resemblance to hormone sensitive human breast 
carcinomas and their reproducible effects on host metabolism to 
induce cachexia, it is difficult to think of any other animal 
tumour model of comparable importance. Moreover, the 
experimental systems were designed to represent a physiological 
situation close to the system encountered in vivo. Therefore, 
the results obtained from the present investigations are of value 
for basic science and closely, if not exactly, align with 
situations encountered with human patients bearing a tumour of 
the breast.
Unfortunately, at the last stages of the present 
investigations the R3230AC adenocarcinoma tumour line was lost. 
Time did not permit us to reestablish the line, thus a small 
number of experiments were performed using the Walker 256 
carcinosarcoma bearing animals only.
1.5 The Aim of the Present Investigations
The present investigation was undertaken to test 
experimentally the overall proposition and subpostulates of the 
Williams et al., (1980) hypothesis for the metabolic basis of 
cancer cachexia (section 1.2.2) using two different animal tumour 
systems which are close to human neoplasia and represent cancer 
induced cachexia and anorexia (section 1.4). The study is 
comprised of investigations aimed at answering the following 
questions.
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(a) What are the effects of tumour bearing on the 
growth characteristic of the host, various host 
organs and the levels of selected metabolites in 
the plasma, liver, tumour and urine of tumour 
bearing animals during the development of 
cachexia?
(b) Does tumour growth communicate to the distant 
non-involved organs of the host and induce 
retrodifferentiatiated changes in these organs?
(c) Does the tumour bearing animal exhibit an 
impaired ability to synthesise glucose from 
amino acids?
(d) What are the changes in fatty acid metabolism in 
tumour bearing animals?
(e) Does tumour growth induce a 'stress’ in the host 
system which is characterised by the release of 
vasopressin?
(f) Does the tumour growth induce enhanced
proteolysis by stimulating the synthesis of
prostaglandin E ?
2
(g) Do tumour bearing animals have deregulated 
oxidation of branched chain amino acids?
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CHAPTER TWO
EXPERIMENTAL
2.1 Enzymes and Chemicals
Unless stated otherwise, all enzymes, coenzymes,
substrates and buffers were obtained from either Boehringer,
Mannheim (West Germany), Calbiochem (Australia) Pty. Ltd.,
N.S.W., Australia or Sigma Chemical Co., St. Louis, Mo., U.S.A.
Inorganic chemicals and organic solvents were of analytical grade
and were obtained from either E. Merck, Darmstadt (West Germany),
The British Drug House, Poole, England, May and Baker, Ltd.,
Degenham, England or Ajax Chemicals, N.S.W., Australia.
Phloridzin was obtained from ICN Pharmaceuticals Inc, Life
Sciences Group, Plain View, N.Y., U.S.A. Nembutal was obtained
from Ceva Chemicals (Australia) Pty. Ltd., N.S.W., Australia.
Glass distilled water was used to prepare all solutions.
All gases were supplied by Commonwealth Industrial
Gases Pty. Ltd., N.S.W., Australia.
Anion exchange resin AGlx4 (OH form) was obtained from
+
Bio-Rad Laboratories, Richmond, California, U.S.A. Dowex 50W (H 
form) and Florisil were obtained from Sigma Chemical Co., St. 
Louis, Mo., U.S.A. Sep Pak (C18) columns and Sep Pak (Silica) 
columns were purchased from Waters Associates Inc., Milford, 
M.A., U.S.A.
14 14
L-[U- C] Alanine, D-(-)-3hydroxy [3- C] butyric acid 
14
(sodium salt) and L-[l- C] leucine were obtained from Amersham
14 125
International, Amersham, Bucks, U.K. [U- C] Oleate and [ I]-
Prostaglandin E radioimmunoassay (RIA) kit were obtained from
2
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New England Nuclear, Boston, U.S.A. [ I] Arginine Vasopressin 
RIA kit was kindly supplied by Professor C.I. Johnston, 
Department .of Medicine, Prince Henry's Hospital, Monash 
University, Melbourne, Australia.
2.2 Animal Housing and Diet
Male rats of the Sprague Pawley strain, weighing 
between 200-300g were .used as host animals for the Walker 256 
carcinosarcoma. Female rats of the Fischer 344 strain, weighing 
between 200-300g were used as host animals for the R3230AC 
adenocarcinoma. Animals were bred and housed (not more than 
three per cage) in perspex cages (size 26x42cm), kept in an 
animal house maintained at 22 + 2°C and 60-65% humidity. The 
animal house was fitted with automatic lighting equipment 
programmed for a 12/12 light and dark cycle which commenced at 
8am (light cycle). Control and tumour bearing animals were 
allowed access ad libitum to water and laboratory chow (YSF 
Feeds, Young, N.S.W, Australia). A group of animals of the same 
strain and same weight range served as 'pair fed' controls. 
These animals were allowed access to the same amount of food and 
water (isocaloric maintenance) as that consumed by tumour bearing 
animals.
Metabolic studies were performed in metabolic cages (E. 
Sieper and Co. Pty. Ltd., Strathfield, N.S.W., Australia) each 
housing one animal. Animals were kept in these cages for 5-7 
days prior to the commencement of experiments. Body weight, 
tumour weight (section 2.4), food and water consumption were 
recorded during all metabolic studies.
125 '
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2 .3 Tumour Transplantation
2.3.1 Walker 256 Carcinosarcoma
The Walker 256 carcinosarcoma cells (see section 1.4) 
were obtained from C.S.I.R.O., Division of Molecular Biology, 
North Ryde, N.S.W, Australia. Cells were frozen in sterile 
isotonic saline and stored in liquid nitrogen until used.
The cells were thawed and 0.2ml of cell suspension 
6
which contained 2x10 Walker 256 carcinosarcoma cells were 
injected into the right hind limb of an animal as the primary 
transplantation in vivo. Further transplantation was made (Dill 
et al., 1984) by harvesting tissues from the solid growing tumour 
on day 10 post implantation (PI). 2.5-3.0g of tumour fragments 
were taken and placed into 1.0ml of sterile isotonic saline at 
22 °C. The fragments were minced with a domestic onion chopper 
(Zyliss, Switzerland) and passed through a fine stainless steel 
mesh (diameter 40cm; pore size 140 micron). The tumour tissue 
entrapped on the mesh was washed with 3.0ml of sterile isotonic 
saline and the final cell suspension was made up to 15.0ml. The 
cell suspension (0.5ml) contained 70-100mg of minced tissue and 
was injected into the right hind limb of each recipient animal 
using 1.0ml tuberculin syringes fitted with 19-G needles. The 
entire procedure was performed at room temperature. The maximum 
time from harvesting the cells to injection was 15-20 min. This 
procedure was used in all subsequent passages of the Walker 256 
carcinosarcoma. The rapidly growing tumour was visible by day 5- 
6 PI, reaching a mass of 7 0+6g which caused the death of the host 
animal at 14+2 days PI.
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2.3.2 R3230AC Adenocarcinoma
The R3230AC adenocarcinoma (section 1.4) was obtained
from the Mason Research Institute, Breast Cancer - Animal and
Human Tumour Bank, Worcester, Massachusetts, U.S.A. as an
implanted tumour in female Fischer rats. The subsequent
transplantation was carried out (Technical Bulletin, Mason
3
Research Institute) by harvesting approximately 1mm tumour 
fragment at day 20-22 PI and implanting it subsequently into the 
right hind limb of female Fischer rats using a trochar (Size No. 
12). There was visible tumour growth by day 10-14 PI which was 
maintained at a moderate rate reaching a mass of 25+5g which 
caused the death of the host animal at 35+5 days PI.
2.4 Tumour Weight Determination
The tumour weight was calculated from the measurement 
of external dimensions of the tumour using a plastic tape measure 
and fitting the data to the following equation (Guaitani et al. ,
1982) .
2
T.W = (a/TT) .b 
2
where
T.W. = Tumour weight 
a = Circumference 
b = Length of tumour 
tt = 3 . 1 4
Values were computed in programme PI (Appendix A) for 
the calculation of tumour weight.
2.5 Growth Pattern of Host Body and Selected Organs
The growth patterns (changes in mass) of the host, 
tumour, gastrocnemius muscle, adipose tissue, adrenal glands,
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spleen and liver were determined by gravimetric analysis.
For the determination of the wet weight and dry 
weight of the host body and tumour, the animals were preweighed 
and killed by cervical dislocation. The abdomen was opened and 
the complete neoplastic tissue mass of the tumour bearing animal 
was excised, from the hind limb. The carcass (minus tumour) was 
then dried at 80 in a vacuum oven (500mBar) for approximately 
sixty hours to constant weight.
For the determination of the wet and dry weight of the 
tumour, gastrocnemius muscle, adrenal glands, spleen and liver, 
the animals were killed by cervical dislocation. The organs were 
removed, blotted free from excess blood and weighed. The
remainder of the carcass was then discarded. The organs (except 
the adrenal glands) were dried at 80°C in a vacuum oven to 
constant weight.
The dry weight of the carcass, tumour and the above 
organs were recorded and moisture content calculated.
2.6 Collection and Processing of Tissue Specimens
2.6.1 Blood
Animals were killed by guillotine. The blood was
collected from the neck wound into heparinised tubes. 5.0ml of
blood was mixed with an equal volume of 0.6M perchloric acid
(HC10 ). Following the removal of precipitated proteins by 
4
centrifugation (5000xg, 10 min. at 4 C), the supernatant fluid was
then neutralised to pH 6.8 with saturated potassium hydrogen
carbonate (KHCO ) and after removal of KC10 by centrifugation
3 4
was used for the determination of selected metabolites (section
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2.7). In cases where the plasma fraction was required for 
analysis, the heparinised blood was subjected to centrifugation 
at 2000xg for 5 min. and the plasma was processed as above.
2.6.2 Liver
Animals were killed by cervical dislocation.
Approximately l.Og of liver was removed from the left lateral
lobe and immediately homogenised in 5.0ml of ice cold 0.6M HC10 .
4
The acid insoluble residue was removed by centrifugation at
5000xg for 10 min. at 4 °C. The supernatant fraction was
neutralised to pH 6.8 with saturated KHCO and used for the
3
determination of selected metabolites (section 2.7).
2.6.3 Tumour
The tumour was removed from killed animals by careful
dissection to ensure it was free from necrotic tissue. l.Og of
minced tumour was homogenised in 5.0ml of ice cold 0.6M HC10 .
4The homogenate was further processed as described in section
2.6.2 for the preparation of an acid soluble extract.
2.6.4 Gastrocnemius Muscle
The gastrocnemius muscle (from the left hind limb) was 
removed, weighed and homogenised in 20% (v/v) trichloroacetic 
acid (1:4 w/v). The protein precipitate was removed by
centrifugation at 5000xg for 10 min. at 4 °C. The supernatant 
fluid was discarded and the residue was dissolved in 1.0ml of 1M 
NaOH. Samples (0.1ml) were taken for the determination of
protein as described in section 2.7.
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2.6.5 Urine
Animals were placed in metabolic cages for the
collection of the 24 hour urine specimen. Urine was filtered to
remove food particles and then mixed with an equal volume of 30%
HC10 . The precipitate was removed by centrifugation (5000xg,
4
10 min. at 4°C). The supernatant was neutralised to pH 6.8 with
saturated KHCO and used for the determination of a-lanine as
3
described in section 2.7.
2.7 Determination of Selected Metabolites
The perchloric acid extracts of tissue samples (section
2.6) were analysed spectrophotometrically using specific enzyme
+
coupled reactions and the oxidation-reduction of NAD(P) /NAD(P)H 
couple was followed. A change in the extinction at 340nm was 
used for the quantitative estimation of specific metabolites 
using programme P2 (Appendix A).
Alanine was determined with alanine dehydrogenase (EC 
1.4.1.1). Pyruvate and lactate were determined with lactate 
dehydrogenase (EC 1.1.1.27). Acetoacetate and D-(-)-3
hydroxybutyrate were determined with D-(-)-3 hydroxybutyrate (EC 
1.1.1.30). Glucose was determined with hexokinase (EC 2.7.1.1) 
and glucose 6-phosphate dehydrogenase (EC 1.1.1.49). 
Triglyceride was determined after alkaline hydrolysis as 
glycerol, with glycerokinase (EC 2.7.1.30), pyruvate kinase (EC 
2.7.1.40) and lactate dehydrogenase. The above enzymatic 
determinations were adapted from Methods of Enzymatic Analysis, 
ed. H. Bergmeyer (2nd edition, 1974). The recoveries of known 
amounts of specific substrates were in the range of 95.5% to
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104%.
Free fatty acids were determined as described by
Falholt et al., (1973). The method was based upon the reduction
2 +
of the Cu -complex of fatty acid with 1,5-diphenylcarbazide. 
The extinction of colour yielding reaction product was measured 
at 550nm after 15 min. of reaction. Assays were performed in 
triplicate and were accompanied by freshly prepared reagent 
blanks and a set of standards of precisely known concentration. 
The concentration of fatty acids in samples were estimated using 
data from the calibration curve. The recovery of known amounts 
of authentic oleic acid was >87%.
Proteins were determined either by the Biuret method 
(Gornall et al., 1949) or the Lowry method (Lowry et al., 1951).
Samples containing 0.1-10mg of protein were determined by the 
Biuret method whereas samples containing 10-200 g of protein were 
determined by the Lowry method.
2.8 Measurement of Gluconeogenesis from Alanine using the
Isolated Liver Perfusion Technique
2.8.1 Perfusion Apparatus
The perfusion apparatus was originally based on the
design of Miller et al., (1951) and Schimassek (1963). The
apparatus illustrated diagramatically in Fig. 2.1, was housed in
a Perspex cabinet of size 86cm high x 83cm wide x 55cm deep, with
a hinged perspex front opening. It consisted of a gas humidifier
(B), a reservoir for the bulk of the perfusion fluid (D),
membrane oxygenators (Cl, C2), an LKB Broma 2115 peristaltic pump
(L: LKB - produkter AB, S 161 25 Broma, Sweden), a 25mm Millipore
filter (F), a bubble trap (G), a hydrostatic pressure head (S),
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Figure 2.1: Isolated liver perfusion apparatus
A = (5%C02/95%02) 
gas cylinder
C = Membrane oxygenator
E = Multiways tap
G = Bubble trap
I = Organ chamber
K = Recirculation flask
M = Thermometer
0 = Water Bath (37°C)
Q = Glass syringe
S = Hydrostatic reservoir
(for details see the text)
B = Gas humidifier
D = Buffer reservoir 
F = Filter 
H = Out flow tube 
J = Oxygen electrode 
L = Peristaltic pump 
N = Thermostatic fan heater 
P = Constant infusion pump 
R = Collection vessel

an organ chamber (I), Clark type Ag.-Pt. oxygen electrodes (Jl,
J2: Rank Brothers, Cambridge, England) and a glass flask (K) for
recirculation of buffer. Samples were taken from the glass flask
by means of a glass syringe (Q) and the substrate were added to
the flask by a Braun perfusor (P: Type 871104, B. Braun,
Melsungen A.G., West Germany). The cabinet was heated by a
thermostatically controlled fan heater (N). The temperature of
the circulatory air in the cabinet was 37 + 1°C.
The components of the apparatus were held in position
by clamps attached to rods which were freely moveable in the
horizontal or vertical plane.
The perfusion medium was Krebs-Henseleit bicarbonate
buffer (Krebs and Henseleit, 1932), pH 7.4, modified to contain
1.3mM CaCl .2H 0. It was placed in the reservoir flask (D) at 37 
o 2 2C in a thermostatically controlled water bath (0). The medium
was equilbrated with CO /0 (5%:95%) in a membrane oxygenator
2 2
(Cl). The membrane oxygenator was used as recommended by Berry
et al., (1973), and was constructed in the Departmental workshop.
The membrane oxygenator consisted of a perspex cylinder and a
perspex lid. The lid was attached to a perspex support for the
coils of silastic tubing (0.132"ID x 0.182"OD). Enough space was
provided between the coiled silatic tubing and the walls of the
cylinder to circulate the CO /0 (5%:95%) . The oxygenation was
2 2
carried out via the diffusion of gases across the silastic 
tubing. The perfusion medium from the membrane oxygenator was 
pumped into the bubble trap (G) through a 25mm Millipore filter 
(F). The bubble trap was fitted with a glass column (70cm high)
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to provide the desired constant hydrostatic pressure. The 
constant perfusion pressure was regulated by the height of the 
perfusion medium above the liver in the hydrostatic reservoir 
(S). The hydrostatic pressure varied 30-40cm of perfusate from 
the point of perfusate delivery to the liver and return of 
perfusate back to the liver to maintain a flow rate of 30ml/min. 
The perfusion medium was then passed through an oxygen electrode 
(Jl) (in order to continuously monitor the arterial oxygen 
concentration) into the liver, supported in the organ chamber 
(I), via the portal vein.
The organ chamber was constructed from two 13.5cm 
diameter hemispheres. The top hemisphere was fitted with three 
B/10 sockets. One of which received a thermometer, another one 
received the portal vein cannula and the third was used to 
conduct the bile duct cannula into a small collection flask. In 
the present experiments, the bile duct was not cannulated, thus 
this entry socket was sealed. The1 bottom hemisphere was 
connected with a small collection vessel (R) of 2.0ml volume. A 
perspex plate (11cm in diameter) was fitted in the organ chamber 
(Fig. 2.2). The upper surface of this plate was convex shaped 
and the holes in the plate allowed free drainage of perfusate 
from the vena cava into the small collection vessel (R). A thin 
stainless steel plate was attached to one side of the liver 
support plate. This plate served to hold the liver lobes in 
position with respect to one another and to prevent them twisting 
and sliding on the liver support plate and thus limit perfusion 
fluid flow.
From the collection vessel (R) the perfusate flowed
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Figure 2.2: Liver support plate
A perspex plate (11cm in diameter) was fitted in 
the organ chamber. The upper surface of this 
plate was convex shaped and the holes in the 
plate allowed free drainage of perfusate from the 
vena cava into the small collection vessel (R: 
Fig. 2.1). A thin stainless steel plate was 
attached to one side of the liver support plate. 
This plate served to hold the liver lobes in 
position with respect to one another and to 
prevent them twisting and sliding on the liver 
support plate and thus permit perfusion fluid 
flow.
STAINLESS STEEL PLATE 
fo r  a t t a c h m e n t  o f  d ia p h r a g m
PERSPEX
LIVER SUPPORT PLATE
through a second Clark type Ag.-Pt. oxygen electrode (J2) in
order to monitor the venous oxygen concentration. The fluid was
then pumped into the second membrane oxygenator (C2). When the
volume of the perfusate exceeded 2.0ml in the small collection
vessel (R) it overflowed and pumped directly into the second
membrane oxygenator (C2) by passing the oxygen electrode (J2).
The construction of the membrane oxygenator was as discussed
above. The previously used system in which a thin film of
perfusate was spread over a large surface and exposed to a stream
of CO /O (5%:95%) was avoided as this system may cause 
2 2
evaporation of medium, loss of volatile reaction products and
also damage to cellular and proteinaceous components of blood
(Ekert et al., 1971; Kolobow et al., 1968; Lande et al., 1967;
Miller, 1973; Mortimore, 1961; Vervloet et al., 1970).
When non-recirculation perfusion was performed the
perfusate from the outlet tube of the membrane oxygenator (C2)
was collected and used for analysis. During recirculation the
perfusate fluid was collected in a glass flask (K) and
recirculated from this flask through the liver.
The glass flask (K) was specially designed for this
purpose and it was provided with water jackets to maintain
constant temperature (37°C). Five B/10 sockets were attached to
the top lid of the flask. One was used to collect the perfusate
from the membrane oxygenator into the flask. Another was used to
pump the perfusate fluid into the liver via the portal vein. The
third was used to bubble the CO /0 (5%:95%) into the perfusion
2 2
medium. The fourth was used to supplement the perfusion medium
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with substrates and the fifth contained a glass syringe (Q) for 
the withdrawal of samples from the flask for analysis.
The capacity of the flask was 100ml. The void volume 
of the apparatus was 70ml. These volumes (as well as any change 
in volume due to the addition of substrate or removal of samples) 
were taken into account during the calculation of results of 
experiments.
Before and after each experiment the oxygen electrode
was calibrated at 37°C against: 1) CO /O (5%:95%) saturated
2 2
Krebs-Henseleit bicarbonate buffer (100%), 2) air (21%) and 3)
0.002% aq. dithionite solution (0%).
Silastic tubing (Dow Corning Corporation, Midland, 
Michigan, U.S.A.) was used for the LKB Bromma 2115 peristaltic 
pump (0.104"ID x 0.192MOD) and for the membrane oxygenator 
(0.132"ID x 0.183"OD). Clear vinyl tubing (2.0mmID x 3.0mmOD, 
Dural Plastic and Engineering, Dural, N.S.W., Australia) was used 
to connect the bubble trap to the pre-liver positioned oxygen 
electrode, portal vein cannula and then from the collection 
vessel (R) to the post-liver positioned oxygen electrode and LKB 
Bromma peristaltic pump. The rest of the connections were made 
using clear vinyl tubing (3.0mmID x S.OmmOD).
2.8.2 Surgical Procedure
The surgical procedure was adopted as described by 
Miller et al., (1951) and Hems et al., (1966).
The rat was anaesthetised by intraperitoneal injection 
of Nembutal (5-6mg/100g body wt.). The rat was placed dorsally 
on a heated operating table and the four limbs were secured. The
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Figure 2.3: Operative preparation for liver perfusion
The surgical procedure adopted was that described 
by Hems et al., (1966). The portal vein was 
cannulated with a metal cannulae (No. 17G 
hypodermic needle) with buffer flowing through 
the cannulae. Ligature 2 was tied to secure the 
cannulae in position. Ligature 3 was tied to 
shut off the blood supply from the viscera to the 
portal vein. Ligature 1 was then tied and the 
liver was carefully dissected away from the 
animals body.
The diagram is taken from Perfusion Techniques in 
Biochemistry (Ross, B.D., ed.) (1972) Clarendon 
Press, Oxford
In fe rio r  
Vena C ava Liver
P o rta l
Vein
In flo w
C annulae
abdomen was opened through a midline incision and a midtransverse 
incision to the left and to the right of the midline was made, 
avoiding the large vessel. Blood loss was carefully controlled 
at all times. The intestines were placed to the animal's left 
and the connective tissue between the inferior vena cava and the 
right lateral lobe was cleared. The inferior vena cava and 
portal vein were located. A loose ligature (lig. 1) of silk 
(size 3/0, Cyanamid, Australia) was placed around the vena cava 
above the right renal vein. A second ligature (lig. 2) was 
placed around the portal vein below the point where the vein 
divides to enter the separate lobes of the liver. The third 
loose ligature (lig. 3) was placed around the portal vein at a 
point distal to the liver (Fig. 2.3).
The portal vein was cannulated with a metal cannula 
(No. 17-G Hypodermic needle) with buffer flowing through the 
cannula. The ligature (2) was tied to secure the cannula in 
position, ligature (3) was tied to shut off the blood supply from 
the viscera to the portal vein and then ligature (1) was tied. 
The thorax was opened and the inferior vena cava was divided. 
Once the perfusion had commenced the liver was carefully 
dissected away from the animal. The diaphragm was cut so that it 
formed a circular cuff around the vena cava. The right and left 
triangular ligaments and diaphragmatic crura were cut, the 
oesophagus divided and the liver dissected away from remaining 
peritoneal attachments. The position of the liver on the support 
plate was adjusted to ensure unobstructed ingress and egress to 
and from the lobes and to obtain optimal perfusate flow through 
the liver.
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The adequacy of the perfusion was judged by the 
appearance of the liver and the oxygen uptake by the liver. The 
whole operation takes approximately 10 min. The perfusion 
pressure was 30-40cm of perfusion fluid height above the liver 
and the flow rate was 30ml/min.
2.8.3 Removal of Liver Glycogen by Glucagon and Phloridzin
Treatment
l.Omg of glucagon was dissolved in 8.0ml of a solution 
of 1:1 (v/v) lmM NaOH and tricaprylin (Reinhart and Bygrave, 
1981). l.Og of phloridzin was made into 4.0ml of 50% aqueous 
solution with butane 2,3-diol as recommended by Ross et al. , 
(1967b).
The animals were starved prior to the injection of the 
phloridzin and glucagon. The tumour bearing animals were starved 
for a shorter period (20-24 hours) than control animals (36-40 
hours), because in early studies death resulted in tumour bearing 
animals when they were starved for a period equal to control 
rats. The main purpose of the starvation was to remove liver 
glycogen, therefore variation in the starvation period was 
considered unimportant. The animals were then lightly 
anaesthetised with ether, phloridzin (40-50mg/100g body wt.) was 
injected subcutaneously into the dorsal region and glucagon (15- 
20yg/100g body wt.) was injected intraperitoneally. The animals 
were left without food but water was supplied ad libitum for 
3.0+0.5 hours prior to commencement of the liver perfusion. 
During this interval much glucose was excreted in the urine. 
This treatment decreased liver glycogen by 94-97% in both control
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and tumour bearing animals.
The liver from rats bearing the Walker 256
carcinosarcoma was perfused at day 13-14 whereas the liver from 
R3230AC adenocarcinoma bearing rats was perfused at day 21-22, 
following the initiation of induction of the respective tumours, 
for the study of gluconeogenesis from physiological
concentrations of alanine as described below.
2.8.4 Perfusion Medium
The basic perfusion medium was Krebs-Henseleit
bicarbonate buffer, pH 7.4, consisting of 118mM NaCl, 4.6mM KC1,
1.3mM CaCl .2H 0, 1.16mM KH PO , 1.16mM MgSO .7H 0 and 24mM
2 2 2 4 4 2
NaHCO equilibrated with CO /0 (5%:95%) at 37°C. In the primary
3 2 2
(non-recirculation) perfusion study no addition of substrates was 
14
made. L-[U- C] alanine was used to initiate the perfusion
medium in order to study gluconeogenesis from this labelled 
substrate. This was then conducted as a recirculating perfusion 
system.
2.8.5 Liver Perfusion
Details of the perfusion apparatus, operative technique
and the basic perfusion medium were given in sections 2.8.1-
2.8.4. Initially a non-recirculation liver perfusion was
performed with Krebs-Henseleit bicarbonate buffer, pH 7.4, with
no added substrate, equilibrated with CO /0 (5%:95%) at 37°C for
2 2
a duration of 60 min. 2.0ml samples were collected every 10 
min., for the analysis of the endogenous release of glucose.
After this the recirculation of perfusate through the liver was 
made with Krebs-Henseleit bicarbonate buffer as described above.
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14
There was an addition to this buffer of C labelled (or
unlabelled) L-alanine at physiological concentration. This
concentration of alanine was then maintained throughout the
perfusion by constant infusion of stock alanine solution (80mM)
14
at a rate of 8.Oumol/min. L-[U- C] alanine was maintained at a
specific radioactivity of O.OlCi/mol when the alanine was given
as an isotopically labelled substrate. The .specific
radioactivity was maintained at a steady state value throughout
the course of the perfusion by constant infusion of a stock 
14
L-[U- C] alanine solution (O.SmCi) at a rate of 0.08 uCi/min. 
Samples were collected at 10 min. intervals throughout the course 
of the recirculatory perfusion (60 min.) for the analysis of 
metabolites.
2.8.6 Treatment of Perfusion Samples
After collection, the samples were immediately placed 
in a boiling water bath for 3.0 min. and the protein precipitates 
were removed by centrifugation. This method was found 
satisfactory since proteins were not detected in the supernatant 
solution using the Lowry method (section 2.7). The supernatant 
solution was used for enzymatic analysis of metabolites and the 
separation of metabolites by ion-exchange chromatography.
2.8.7 Treatment of Perfused Liver
At the end of each perfusion, with the pump still
running, about 2.Og of perfused liver (left lateral lobe) was
snipped off and immediately placed in ice cold 0.6M HC10 . This
4
was then homogenised quickly using an Ultra Turrax tissue
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homogeniser. The tissue residues were removed by centrifugation 
(5000xg for 10 min.)* The supernatant fraction was neutralised 
and applied to an ion exchange column for the separation of 
glucose, lactate and pyruvate. The supernatant fraction was also 
used for the enzymatic analysis of these metabolites (section 
2.7) .
2.8.8 Ion Exchange Chromatography for the Separation of Liver
Metabolites
Glucose, amino acids, lactate and pyruvate were
separated by ion exchange chromatography. 2.0ml syringes
(Terumo, Japan) were used as columns. The syringes were packed
to the 1.0ml mark with mixed bed (1:1 w/w) ion exchange resin
(Dowex 50W (100-200 mesh size) and AGlx4 (100-200 mesh size)) and
1.0ml of sample was loaded for resolution. The column was then
eluted serially with 3x3.0ml of deionised distilled water to
elute the components of uncharged molecules (principally
containing glucose) then 5x3.0ml of 2M NH OH was used to elute
4
the amino acid fraction, then 2x3.0ml of 0.5M formic acid was 
used to displace lactate and finally 2x3.0ml of 4.0M formic acid 
was used to release the pyruvate fraction.
An aliquot of 0.3ml from each fraction was dried on a 
rotary evaporator. The residues were mixed with 10ml of 
'scintillant fluid’ containing 6.Og of 2-(4'-ter-butylphenyl)-5- 
(4"-biphenyl)-1,3,4-oxadizole (butyl PBD) in a mixture of 600ml 
toluene and 400ml methoxyethanol. The radioactivity in the 
various fractions was counted as described in section 2.8.9. The 
d.p.m. in the glucose fractions were computed in programme P3 
(Appendix A). The rate of gluconeogenesis was calculated using
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the following equation -
-1 -1
Rate (umol glucose min g w/w)
Total d.p.m. at time t 1 1
--------------------------- x - x -
Alanine specific activity t 2
Glucose formation from alanine was corrected by 
subtracting the amount of endogenous glucose produced by the 
liver.
2.8.9 Counting of Radioactivity
14
Radioactivity in C-labelled metabolites was counted 
in a Beckman LS-5800 series liquid scintillation counter. Each 
vial was counted for five min. to 2 sigma (a) error. Efficiency 
of counting (80-90%) was determined using external 
standardisation of Beckman Quench Set Standards.
2.9 Measurement of Ketogenesis from Oleate using the 
Isolated Liver Perfusion Technique
2.9.1 Removal of Fatty Acids from Bovine Serum Albumin
The commercially obtained bovine serum albumin (BSA;
Cohn fraction IV; Sigma Chemical Co.) was rendered free from
fatty acid impurities (Chen, 1967). The BSA was put into
solution by adding approximately 300ml of distilled water to 50g
of BSA. The solution was kept overnight at 4 0 C with gentle
stirring, avoiding any froth formation. Activated charcoal (25g)
was mixed into the BSA solution and the pH was adjusted to 3.0
with 0.5M HC1. The solution was stirred at for one hour. The
charcoal was then removed from the solution by centrifugation at
20,200xg for 20 min. The supernatant fraction was found to
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contain a slight dark tint of charcoal, which was removed by
filtration through fat free filter paper (Whatman No.l). The
clear BSA solution was adjusted to pH 7.0 with 0.5M NaOH and
dialysed (Krebs et al., 1969) against 3 1  of Krebs-Henseleit
bicarbonate buffer modified to contain 1.3mM CaCl .2H 0 for 72h.
2 2
The buffer was changed after each 24h interval. All 
manipulations were carried out in an ice bath or in the cold room 
at 4 °C. The final volume of BSA was made up to 500ml with Krebs- 
Henseleit bicarbonate buffer and used in all experiments.
2.9.2 Binding of Oleate with BSA
A solution of stock BSA:oleate complex (12mM oleate
with 2.5% BSA) was prepared (Krebs et al., 1969) freshly by
mixing 95 ul of oleate (0.89g/ml) with approximately 8.0ml of 
2+ 2 +
calcium (Ca ) and magnesium (Mg ) free Krebs-Henseleit
bicarbonate buffer, pH7.4, in a water bath at 60 °C with
continuous stirring. 1ml of 1M NaOH was added to the solution
dropwise and left stirring at 60°C for 5 min. BSA (10% w/v) was
added to this solution dropwise to a final concentration of 2.5%
(w/v), while the contents of the tube were agitated on a vortex
mixer. The temperature of the mixture was brought to 60°C and
the- pH was adjusted to 7.4 with 0.2M HC1. The final volume of
2+ 2 +
the solution was made up to 25ml with Ca and Mg free Krebs-
Henseleit buffer.
14
[U- C] oleate:BSA complex (0.01Ci/mol) was prepared by
14
vigorously mixing 3uCi of [U- C] oleate into the above solution, 
while the solution was still warm.
The solution of oleate:BSA complex was brought to 37 °C
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before use and discarded if there was any sign of precipitation.
2.9.3 Perfusion Medium
The' basic perfusion medium was Krebs-Henseleit
bicarbonate buffer (see section 2.8.4). The perfusion medium was
used without any addition of substrate for the measurement of the
rate of endogenous ketogenesis in a • nonrecirculation liver
perfusion system. In order to measure ketogenesis from oleate,
the perfusion medium was supplemented with BSA to a final
concentration of 2.5% (w/v) and liver perfusion (with
14
recirculation of medium) was commenced by the addition of [U- C]
14
oleate:BSA complex ( [U- C] oleate, 0.01Ci/mol; BSA, 2.5% w/v).
14
The concentration of [U- C] oleate in the perfusion medium was
maintained at 0.75 + 0.06mM during the time course of the
14
perfusion by constant infusion of [U- C] oleate solution at a 
rate of 2.4umol/min (McGarry et al., 1973).
2.9.4 Liver Perfusion
Details of the perfusion apparatus and surgical 
technique were as described in sections 2.8.1 and 2.8.2.
Endogenous ketogenesis was measured by conducting a 
non-recirculation liver perfusion (section 2.9.3) without oleate 
for 60 min. The samples were collected at 15 min. intervals and 
assayed for acetoacetate and D-(-)-3-hydroxybutyrate as described 
in section 2.7. Ketogenesis from oleate was then initiated and 
measured by commencing a recirculation liver perfusion. Samples 
of perfusate (3.0ml) were collected at 15 min. intervals for the 
analysis of acetoacetate, D-(-)-3-hydroxybutyrate (section 2.7)
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14
and CO (section 2.9.6).
2
2.9.5 Treatment of Perfusion Samples
An aliquot of perfusate (1.0ml) was mixed with an equal
volume of HG10 (10% w/v) and left at 4°C for 15 min. The
4
protein precipitates were removed by centrifugation at 5000xg for
10 min. at 4°C. The supernatant solution was neutralised with
saturated KHCO and used for the determination of acetoacetate,
3 14
D-(-)-3-hydroxybutyrate (section 2.7) and [U- C] labelled ketone
bodies (section 2.9.11). Untreated perfusate samples were used
14
for the determination of CO (section 2.9 .6) and free fatty
acids (section 2.7). The
z
production of ketone bodies was
calculated by computing the perfusate concentration of
acetoacetate and 3-hydroxybutyrate in programme P4 (Appendix A)
14
2.9.6 Measurement of CO
14 2 14
CO formed from [U- C] oleate was assayed as 
2
described by McGarry and Foster (1971). 1.0ml of perfusate was
transferred to the main compartment of a flask fitted with a
centre well (25ml Erlenmeyer flask, well size 14x17mm). Hyamine
hydroxide (0.5ml of 1M) on a piece of Whatman No. 4 filter paper
was placed in the centre well and the flask was sealed with a
Suba Seal stopper (Scientific Supplies Ltd., London). 10.0ml of
air was withdrawn from the flask to create a partial vacuum.
0.5ml of HC10 (10% w/v) was injected into the main compartment 
4 14
of the flask through the stopper, to evolve CO . The flask was
2
placed on the platform of a metabolic shaker at 100 
oscillations/min for one hour. The hyamine hydroxide was removed 
from the centre well and the well was rinsed with 3x1.0ml washes
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of absolute ethanol. The contents were transferred
quantitatively into a scintillation vial containing 10ml of butyl
14
PBD scintillatant fluid (section 2.8.9). Radioactivity of CO
2was counted as described in section 2.8.9.
2.9.7 Treatment of Perfused Liver
At the end of each perfusion with the pump still 
delivering perfusion fluid, approximately 2.Og of liver (left 
lateral lobe) was snipped off and freeze clamped in aluminium 
tongs, precooled in liquid nitrogen (Wollenberger et al., 1960). 
The frozen liver was stored at -70°C for the later extraction of 
lipids.
2.9.8 Extraction of Lipids from Liver
Lipids were extracted from liver samples as described 
by Folch et al♦, (1957). An accurately weighed portion of frozen
liver (approximately l.Og) was homogenised in 10ml of chloroform- 
methanol mixture (2:1 v/v). The homogenate was kept overnight at 
room temperature and then filtered through fat free filter paper 
(Whatman No. 1) into a glass-stoppered vessel. The residues were 
reextracted and washed with 2x3.0ml of chloroform-methanol 
mixture (2:1 v/v), with further homogenisation. The total volume 
of the lipid extract was adjusted to achieve a final dilution 20 
fold the volume of the tissue sample (Folch et al., 1957). The
extract was shaken well with 0.2 volume of distilled water for 2 
min. on a vortex mixer. Two extraction fluid phases were 
separated by centrifugation at 2000xg for 20 min. at room 
temperature. The upper aqueous phase was removed by aspiration
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and discarded. The lower phase was readjusted to 20ml volume 
with chloroform-methanol mixture (2:1 v/v). This extract was 
divided into two 10ml portions and stored at 4°C.
2.9.9 Separation of Triglycerides and Free Fatty Acids
A 10ml fraction of the lipid extract (section 2.9.8) 
was evaporated to dryness on a rotary evaporator (Laboratorims, 
Technik, Switzerland). The residue was dissolved in a small 
quantity of diethyl ether (0.5-1.0ml) and applied to a column 
(1x15cm) of Florisil (5g; 60-100 mesh) in diethyl ether. Neutral 
lipids were eluted with 150ml of 2% (v/v) methanol in diethyl 
ether and free fatty acids with 150ml of 4% (v/v) acetic acid in 
diethyl ether (Enser et al., 1967). Phospholipids were not 
eluted from the Florisil column using these solvents.
2.9.10 Determination of Radioactivity in Total Lipid, Neutral
Lipid and Free Fatty Acid Fractions
Radioactivity was estimated in the various lipid 
fractions using the procedure of Weidemann and Krebs (1969). The 
second 10ml portion of the lipid extract (section 2.9.8) was 
evaporated to dryness on a rotary evaporator. The residue was 
dissolved in 3.0ml of heptane. Duplicate samples of 1.0ml were 
taken for liquid scintillation counting as described in section 
2.8.9. This measured the radioactivity in the total lipid 
fraction. The neutral lipid and free fatty acid eluates from the 
Florisil column (section 2.9.9) were prepared for the measurement 
of radioactivity using the procedure described for total lipids.
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2.9.11 Determination of C-labelled Ketone Bodies 
14
The C-labelled ketone bodies in the perfusate were
determined using the method described by Mayes and Feltz (1967a),
as modified by Mewes et al., (1979). The principle of the
determination was based on the enzymatic conversion of 
14 14
[U- C]-D-(-)-3-hydroxybutyrate to [U- C] acetoacetate. The
14 14
resulting [U- C] acetoacetate plus any preformed [U- C]
14 14
acetoacetate was then decarboxylated to [U- C] acetone and CO
2
by heating with acid. These volatile compounds were trapped by
differential diffusion in a sealed flask fitted with two wells,
one contained acid-hydrazine to trap acetone and the other
14
contained NaOH to trap CO . The content of each well was
14 2
counted for C radioactivity by the liquid scintillation 
technique.
14
2.9.11.1 Total Ketone Bodies
1.0ml of freshly prepared hydrazine-lactate solution
(prepared by mixing 10.0ml of 88% lactic acid with 2.0ml of 99-
100% hydrazine hydrate) was placed in the larger well of a double
well flask (50ml Erlenmeyer flask fitted with a B-19 quickfit
socket; the small well measured 10x11mm and the largerone was
14x17mm) and 0.05ml of 10N NaOH on a piece of folded filter paper
(3/4"x3/4") was placed in the other. 2.0ml of reaction mixture
was placed in the main compartment of the flask which contained
+
100UM Tris (pH8.5), lOOuM oxaloacetate, luM NAD , 2U D-(-)-3- 
hydroxybutyrate dehydrogenase and 10U of malate dehydrogenase. 
The flask was sealed with a Suba Seal stopper and the reaction 
was initiated by the injection of 1.0ml of the neutralised HC10
4
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acid extract of the perfusate through the Suba Seal. The flask
was placed on the mobile platform of a metabolic shaker at 25 °C
for two hours at 60 osci/min. The reaction was stopped by
freezing the contents of the flask in liquid nitrogen. 0.1ml of
HC10 (30% w/v) was injected into the main compartment of the 
4
flask and the flask contents allowed to come to room temperature.
The flask was then placed in a boiling water bath for 5 min. with
gentle shaking (60 osci/min) to quantitatively decompose the
acetoacetate into acetone and CO . The flask was then cooled to
2
room temperature and left for 35-40 hours to ensure the complete
trapping of the acetone and CO . Hydrazine-lactate was removed
2
from the well which was rinsed with 2-3ml of absolute ethanol.
The contents were transferred quantitatively into a scintillation
vial. 10ml of scintillation fluid was mixed into the vial
(section 2.8.9) and the radioactivity of the acetone determined.
This represented the radioactivity of free acetone and carbons 1-
3 of acetoacetate and 3-hydroxybutyrate.
The filter paper was removed from the small well of the
reaction flask and placed in the main compartment of a single
well flask which contained 5.0ml of distilled water and 3.0ml of
methanol. 0.5ml of hyamine hydroxide (1M) was placed in the
centre well and the flask sealed with a Suba Seal stopper. A
partial vacuum was created in the flask and 0.2ml of 5N H SO
2 4
injected into the main compartment of the flask. The flask was 
then agitated (100 osci/min) for 90 min. at room temperature. 
The hyamine hydroxide was removed from the well which was then 
rinsed with 2-3ml of absolute ethanol. The contents were 
transferred quantitatively into a counting vial containing 10ml
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of scintillation fluid (section 2.8.9). This measured the 
radioactivity in the carboxyl moiety of acetoacetate and 3- 
hydroxybutyrate. The radioactivity in the acetone and CO
2
fractions were summed together. Approximately 20-30% of the
total radioactivity was in the CO fraction. The recovery of
14 2
standard [3- C]-D-(-)-3-hydroxybutyrate was 93-96%.
14
Radioactivity contamination due to the presence of C-labelled 
oleate in samples was less than 1.0%.
2.9.11.2 Acetoacetate and Acetone and CO
2
1.0ml of deproteinised liver perfusion sample was
placed in the main compartment of a double well flask. The
volume of reaction mixture was made up to 3.0ml with distilled
water. The sample was processed as described in section 2.9.11.1
for measuring the radioactivity in the acetoacetate and acetone
and CO fraction.
2
2.9.11.3 Acetone and CO
2
1.0ml of deproteinised liver perfusion sample was
placed in the main compartment of a double well flask. The
solution was treated with 0.05ml of 4N NaOH to prevent the
decarboxylation of acetoacetate (Lopez-Soriäno and Argiles,
1985). The volume of reaction mixture was made up to 3.0ml with
distilled water. The flask was left standing at room temperature
for 35-40 hours to enable the diffusion of acetone and CO into
2
the respective trapping wells. The samples were then processed 
as described in section 2.9.11.2.
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2.9.11.4 D-(-)-3-hydroxybutyrate
The radioactivity in [U- C]-D-(-)-3-hydroxybutyrate
was obtained by subtracting the radioactivity in the acetoacetate
and acetone and CO fraction from the radioactivity in the total
2
ketone bodies fraction.
14
2.9.11.5 Acetoacetate
14
The radioactivity of [U- C] acetoacetate was 
by subtracting the radioactivity of the acetone and CO
2
from the radioactivity of the acetoacetate and acetone 
fraction.
obtained 
fraction 
and CO
2
It is of note that in practice radioactivity was not
found in the free acetone and CO fractions (section 2.9.11.3).
2
It is considered most unlikely that this could be attributed to
the losses of acetone and CO during the neutralisation and sample
2
processing, because control experiments involving the transfer of 
radioactively labelled gases and other volatile compounds were 
accomplished with loss of radioactivity.
2.10 Measurement of Leucine Oxidation by Muscle
2.10.1 Studies In Vitro
2.10.1.1 Tissue Preparation
Rats were killed by guillotine. Gastrocnemius muscle
and tumour fragments were rapidly excised and placed in ice cold
saline. Tissues were finely minced with scissors and homogenised
(l.Og in 4.5ml cold homogenising medium) using a dual glass
homogeniser. The homogenising medium was 0.025M potassium
phosphate buffer, pH 7.4, containing 2.OmM MgCl . Hand
2
homogenisation was considered necessary because more vigorous
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techniques have been demonstrated to lead to a decrease in 
branched chain keto acid dehydrogenase activity (Sketcher et al., 
1974). The homogenate was then filtered through 0.8mm nylon 
mesh. All procedures were carried out on ice and the homogenate 
was stored on ice until used.
2.10.1.2 Assay of Branched Chain Amino Acid Aminotransferase 
and Branched Chain Keto Acid Dehydrogenase Activities
The assay of branched chain amino acid aminotransferase
(BCAAT) and branched chain keto acid dehydrogenase (BCKDH)
activities was carried out as described by Ward et a l ., (1985a).
The principle of the assay was based on the following reactions -
L-[l- C] amino acid
14
L-[l- C]2-keto acid
'BCAAT:
2-keto acid1 ■L-amino acid
BCKDH
14
L-[l- C]-2-keto acid -►Fatty Acid +
The amount of CO plus any radioactively labelled
2
branched chain keto acids (BCKA) (not decarboxylated) were the
measure of the aminotransferase activity. BCKA undergo
quantitative decarboxylation in the presence of ceric sulphate
(Ce(S0 ) ). Therefore, at a given substrate concentration the 
4 2 14
enzymatically produced CO from the amino acid labelled in the
2
carboxyl group reflected the decarboxylase activity and the sum
14 14
of enzymatically liberated CO plus Ce(S0 ) liberated CO ,
2 4 2 2
the transferase activity. BCAAT activity is not rate limiting in
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supplying BCKA as substrate for BCKDH in a enzyme linked assay
system (Mason and Ward, 1981).
Enzyme assays were carried out using 25ml Erlenmeyer
flasks constructed with 15x7mm centre wells. A polythene
microfuge tube containing 0.5ml phenylethylamine absorbed on a
piece of Whatman No. 4 filter paper (20x20mm) was placed in the
centre well of the flask. The incubation medium, which consisted 
14
of luci L-[l- C] leucine, 20umol L-leucine, 0.15umol coenzyme A, 
+
1.5umol NAD , 3Umol ATP, O.öumol thiamine pyrophosphate, 0.3umol
pyridoxal phosphate, 0.3umol malate and 20Umol a-ketoglutarate
dissolved in a total volume of 2.0ml 0.025M potassium phosphate
buffer, pH 7.4, containing 2mM MgCl , was placed in the main
2
compartment. The flasks were stoppered with Suba Seal stoppers.
Flasks were preincubated for 5 min. in a metabolic
shaker/water bath at 37°C and 60 osci/min. The enzymatic
reaction was started by the addition of 1.0ml of homogenate to
the reaction mixture via injection through the Suba Seal. The
reaction mixture was incubated for a further 40 min. at 37°C (60
osci/min). The reaction was stopped by the injection of 0.2ml
trichloroacetic acid (20% w/v) into the incubation mixture
through the Suba Seal. The flask was agitated for a further 60
14
min. to ensure that all CO was released from the incubation
2
mixture and trapped in the phenylethylamine solution. The 
microfuge tube was then removed, washed with ethanol and placed 
in a 20ml scintillation vial containing 10ml scintillant (section 
2.8.9) .
A second microfuge tube containing 0.5ml
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phenylethylamine and filter paper, as previously described, was
placed in the centre well of the flask and the stopper replaced.
5.0ml of 0.2M Ce(SO ) in 2.0M H SO was injected into the
4 2 2 4
reaction flask via the Suba Seal. The flask was returned to the
water bath (37°C) for a further 60 min. to allow the collection
14 14
of nonenzymatically released CO from L-[l- C] BCKA. At the
2
end of this period the microfuge tube was removed, washed with
ethanol and prepared for counting, as previously described.
The concentration of proteins in the tissue homogenate
was estimated by Biuret's method (section 2.7) using bovine serum
albumin as a protein standard. BCAAT and BCKDH activities are
-1 -1 14
expressed as nmol BCKA formed hr mg protein and nmol CO 
-1 -1 2 
formed hr mg protein respectively. The rate of leucine
oxidation was calculated from the data of the enzymatically 
14
produced CO using the following equation (see programme P5 
2
(Appendix A) for calculations) -
14 -1 -1
nmol [1- C] leucine oxidised hr g muscle =
14 -1 -1 -1
nmol CO produced hr mg protein x mg protein g muscle 
2
2.10.2 Studies In Vivo
14
2.10.2.1 Administration of L-fl- C] Leucine
Animals were placed in a hot chamber (40 °C with 
adequate flow of air for 7-10 mins.), in order to dilate the body 
surface blood vessels, and were then gently wrapped in cloth in 
order to restrain them. The tip of a 26-G needle connected to 
15cm long medical grade silastic tubing (0.015"ID x 0.043"OD, 
Clay Adams, Becton Dickinson Co., NJ, U.S.A) was inserted into 
the lateral tail vein. The patency of the cannulation was judged
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by injecting 0.5ml of sterile saline and a bolus tracer dose of 
14
L-[l- C] leucine in saline (30uCi/kg body wt.) was administered. 
The animal was placed in a metabolic chamber, as rapidly as 
possible, which permitted the collection and analysis of the 
expired gas. Animals were not permitted access to food or water 
for the duration of the experiment (2 hours).
14
2.10.2.2 Collection of Expired CO
2
The animal was secured in a perspex metabolic chamber
(at 25°C), which possesed only one air inlet and outlet. The
volume of the the metabolic chamber was approximately 5 times
that of the animals body. The air outlet was connected to a gas
flow meter (GAP meter; Daff and Macintosh, Sydney, Australia), a 
14
CO trapping apparatus and an air pump (DYMAX-2; Charles Austen 
2
Pumps Ltd., Surrey, England) as shown in Fig. 2.4. The air flow 
through the metabolic chamber was maintained at a rate of 
500ml/min.
Gas leaving the metabolic chamber first passed through
a drying vessel containing silica gel, and then passed
successively through two bottles each containing 40ml of
methoxyethanol to saturate the air with this solvent. Absorption 
14
of CO was affected by sequential passage of gas through two 
2
glass scintillation vials, the first contained 5.0ml of hyamine
hydroxide indicating solution (0.1M hyamine hydroxide in methanol
containing 0.lmg thymol pthalein/ml, standardised with 0.IM HC1)
which trapped a stoicheoimetric quantity of CO (1:1), the second
2
vial contained 8.0ml ethanolamine:2methoxyethanol solution (4:5
14
v/v) which trapped any CO not absorbed by the hyamine
2
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Figure 2.4: Schematic representation of the apparatus for the 
collection of CO in vivo
2
A = Animal metabolic chamber
B = Drying vessel
C = Gas flow guage
D,E = 2-methoxyethanol containers
F, H = Hyamine hydroxide indicating solution traps
G, I = Ethanolamine:2-methoxyethanol traps 
J = Moisture trap
K = Air pump
<
hydroxide trap. In order to obtain quantitative CO absorption,
2
the gas inlet in each trap consisted of a scintered glass disc to
provide a stream of finely dispersed air bubbles. The time
required to trap a standard quantity (500 ymol) of CO was
2
recorded. In between collection periods the gas stream was
14
diverted to bypass one set of CO absorption traps at a time,
2
hence, the facility for continuous gas collection was available 
in this system.
14
2.10.2.3 Measurement of CO Radioactivity
2
The radioactivity present in the absorbing mixtures
14
after the collection of CO was determined by liquid
2
scintillation spectrometry using a Beckman LS-5800 series liquid
scintillation counter, as described by Ward et al., 1985b. 2.0ml
of the hyamine hydroxide absorption solution was added to 10ml of
scintillation fluid, which consisted of 0.lg of bis-2,4-(methyl-
5-phenoxyl)-benzene (POPOP) and 4.Og of 2,5-diphenyloxazole (PPO)
in one litre of redistilled toluene. Whereas 2.0ml of the
ethanolamine:2methoxyethanol absorption solution was added to
10ml of scintillation fluid, which consisted of 0.lg POPOP and
4.Og PPO in one litre of a mixture of 2methoxyethanol:toluene
(1:2 v/v). Efficiency of counting (between 80-90%) was
determined using automated external standards and all samples
were counted to two sigma error. The efficiency of CO trapping
14 2
was 95%. The d.p.m. of CO in hyamine hydroxide and
2
ethanolamine:2methoxyethanol solutions were computed in programme
14
P6 (Appendix A) to calculate the specific activity of 
exhaled air and the % dose of leucine oxidized.
CO
2
in
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2.11 Radioimmunoassay of Arginine Vasopressin
Several biologically active substances exist in
physiological fluids at extremely low levels. Most hormones
-12
perform their physiological actions between 1x10 to
-12
100x10 M. Bioassays and radioimmunoassays (RIA) have been used
to quantitate these substances. Bioassays are very time
consuming, require large quantities of specimen, are less
sensitive and specific than the RIA technique. RIA are less time
consuming, require small amounts of the sample specimen, are
highly sensitive and remarkably specific and accurate.
The RIA of arginine vasopressin (AVP) is based on the
competitive reaction mechanism where unlabelled vasopressin
(antigen) from standards or test samples and a fixed amount of
125
radioiodinated vasopressin ([ I]AVP; tracer) are allowed to 
react with a constant and limited amount of antibody binding 
sites. Decreasing amounts of the antibody are bound to the 
antibody as the amount of unlabelled antigen is increased. The 
separation of the antigen-antibody complex is achieved by 
precipitation with a secondary antibody. Results obtained for 
the standards are used to construct a standard curve from which 
the- amounts of vasopressin in test samples are determined.
RIA of vasopressin measures a sequence of amino acids 
which represent the antigenic site of the molecule and which do 
not necessarily correspond to that responsible for its biological 
activity. There is some evidence to suggest that provided the 
disulphide bond remains intact and no amino acid substitution has 
occurred, then the vasopressin-antibody complex is likely to be
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measuring biologically active vasopressin (Thomas and Lee, 1976).
2.11.1 Description of Reagents and their Preparation
The RIA kit for vasopressin was kindly supplied by 
Professor C.I. Johnston, Department of Medicine, Prince Henry's 
Hospital, Monash University, Melbourne, Victoria, Australia. The 
reagents were constituted as follows:
125
[ I]-AVP.
125
2.11.1.1 [ I]-AVP (Tracer)
The lyophilised powder contained lyCi of 
The contents of the vial were dissolved in 10ml assay buffer, 
pH 7.4 (section 2.11.1.4). The solution was stored at -20°C in 
1.0ml aliquots in sealed polypropylene microfuge tubes.
2.11.1.2 AVP-Antibody
The lyophilised rabbit anti-AVP was reconstituted in 
10ml assay buffer, pH 7.4. The solution was stored at -20°C in 
lml aliquots in sealed polypropylene microfuge tubes.
2.11.1.3 AVP Standard
The AVP standard concentrate contained 20ng/ml of AVP 
in 0.05M acetic acid. The aliquots of AVP standard were diluted 
serially with assay buffer, pH 7.4, to give concentrations of 
500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9, 1.9, 0.9 and 
0.5pg/10 Oyl.
2.11.1.4 Assay Buffer
The assay buffer was made by dissolving 0.78g
NaH PO .2H 0, 6.39g Na HPO (anhydrous), 3.72g Na EDTA, 1.00g
2 4 2 2 4 2
Neomycin and 9.00g NaCl in approximately 800ml of distilled
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water. The pH was adjusted to 7.4 and the final volume was made 
to one litre with distilled water. The buffer was made 0.25% 
(w/v) with respect to bovine serum albumin just prior to use.
2.11.1.5 Precipitation Reagent
The precipitation reagent consisted of Goat anti-rabbit 
gamma globulin. The lyophilised powder was reconstituted in 10ml 
assay buffer. The solution was stored at -20°C in 1.0ml aliguots 
in sealed polypropylene microfuge tubes.
2.11.2 Sample Handling
All samples were processed immediately after collection 
and assayed as soon as possible thereafter. The containers used 
for the assays were either siliconised glass or polypropylene 
test tubes.
2.11.3 Extraction of Vasopressin 
2.11.3.1 Plasma
Vasopressin was extracted from plasma as described by 
Hussain et al., (1973). Animals were killed by guillotine and 
blood was collected from the neck wound into heparinised and 
siliconised glass test tubes. The plasma was obtained by 
centrifugation at 2000xg for 5 min. at 4°C. 1.0ml of plasma was 
mixed with 2.0ml cold acetone (nanograde) to precipitate the 
plasma proteins. After centrifugation at 2000xg for 20 min. at 
4 °C, the precipitates were discarded and the supernatant fluid 
was thoroughly mixed with 3.0ml cold petroleum ether (nanograde). 
The two layers were separated by centrifugation at 2000xg for 20 
min. at 4°C. The top layer was aspirated and discarded. This
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step was repeated once to ensure the complete elimination of 
plasma lipids. The lower acetone-aqueous layer was evaporated to 
dryness using a stream of air at room temperature (25 °C). The 
dried residues were reconstituted in 125yl of assay buffer.
2.11.3.2 Liver and Tumour
Vasopressin from liver and tumour tissues was extracted
as described by Marks et al., (1968). Animals were killed by
guillotine and the liver and tumour were removed immediately.
Samples of tissue were placed in 200ml of cold acetone at 4°C for
three hours. The acetone was decanted and tissues were
homogenised in 30.0ml of fresh acetone using an Ultra Turrax
tissue homogeniser. The homogenate was allowed to stand for 5
min. at 4 °C and then centrifuged for 5 min. at 4 °C. The
supernatant fluid was decanted and residues were washed three
times by homogenisation in fresh acetone and centrifugation as
described above. The final residual fraction was transferred to
a container and placed in a P 0 dessicator. After being vacuum
2 5
dried, the acetone powder was stored at 4°C in a dessicator under 
vacuum. For the RIA 30mg of acetone powder was suspended in 1ml
glacial acetic acid and 1.0ml assay buffer, shaken and
centrifuged at 2000xg for 10 min. at 4°C. The supernatant fluid 
was diluted three times with assay buffer, the pH was adjusted 
and used for RIA.
2.11.3.3 Urine
Vasopressin from urine was extracted as described by 
Tausch et al., (1983). The urine was collected from animals for
74
24 hours in metabolic cages and acidified with IM HC1. 
Disposable Sep Pak columns packed with octadecasilyl-silica (Sep 
Pak C18, Water Associates Inc., Milford, M.A., U.S.A.) and 
attached with Sep Pak cartridge racks (Water Associates Inc.) 
were washed sequentially with 5.0ml 8M urea, 20.0ml deionised 
water, 5.0ml methanol and 20.0ml deionised water. 1.0ml of 
acidified urine sample was loaded on the column. This was 
followed by a 20.0ml wash with 4% acetic acid, followed by a 
4.0ml wash with 10% ethanol containing 4% acetic acid. The 
sample was eluted with 4.0ml of a solution of 75% acetonitrile, 
4% acetic acid and 21% water. The eluate was dried under a 
stream of nitrogen gas and reconstituted in 1.0ml of assay 
buffer.
2.11.4 Assay Procedure
2.11.4.1 Calibration Curve
The AVP standard (20ng/ml) was diluted serially, as 
described above with assay buffer.
125
2.10.4.2 Incubation with [ I]AVP and Antisera
Each assay was performed in duplicate. lOOUl of
diluted standards (section 2.11.4.1), extracts of plasma (section
2.11.3.1), tissues (section 2.11.3.2) and urine (section
125
2.11.3.3) were mixed with 100yl of [ I]AVP (tracer) and 100U1 
of AVP antibody. The reaction mixture was incubated at room 
temperature (25°C) for 24 hours.
A series of control experiments accompanied each RIA 
assay; these were -
1) Total radioisotope binding - 100U1 of assay buffer
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was mixed with 100ul of [ I]AVP and 100ul of AVP antibody. The 
mixture was further processed as above.
125
2) Non-specific binding - lOOul of [ I]AVP was mixed 
with 200ul of assay buffer. The mixture was further processed as 
described above.
125
3) Total radioactive counts - lOOjjl of [ I]AVP was 
incubated, in order to assess the total counts added per assay 
tube, as described above.
2.11.4.3 Separation of Antigen-Antibody Complex
100 pi °f reconstituted Goat anti rabbit gamma globulin
(section 2.11.1.5) and lOOul of 2% normal rabbit serum were added
to each assay tube, except for the total radioactivity control.
The mixture was incubated for a further 24 hours at 4°C. After
incubation the assay tubes were centrifuged using a microfuge
(Model 101M, Sigma Chemical Co.) at 6000rpm for 40 min. at 4°C.
The supernatant fractions were decanted and tubes were placed
upside down for several hours to ensure the removal of free 
125
[ I]AVP. The pellets were counted in a gamma counter (Packard 
Autogamma Spectrometer System, Model 5210) at 60% efficiency. 
The calibration curve was obtained by plotting linear and 
semilogarithmically the ratio of isotope binding (B) in each 
assay tube to total binding (Bo) expressed as % versus AVP 
concentrations (%B/Bo vs. [AVP]). The concentration of AVP in 
plasma, tissues and urine extracts were read from the calibration 
curve (Fig. 2.5).
125
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Figure 2.5: Calibration curve for the radioimmunoassay of 
arginine vasopressin (AVP)
The AVP standard (20ng/ml) was diluted serially 
with assay buffer from 500 to 0.5pg/100yl. Each 
dilution was incubated with lOOyl of [ i25I]AVP 
(tracer) and 100 yl anti-AVP as described in the 
text. The antigen-antibody complex was separated 
using 100 yl goat anti-rabbit gamma globulin 
solution (section 2.11.1.5). The calibration 
curve was constructed by plotting linear semi- 
logarithmically the ratio of [125I]AVP bound with 
anti-AVP in each assay tube (B) to total binding 
(Bo) expressed as a % versus AVP concentration (% 
B/Bo vs. [AVP])
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2.12 Radioimmunoassay of Prostaglandin E
The basic principle for the radioimmunoassay of
prostaglandin E (PGE ) was the same as that described for
2 2
arginine vasopressin, where unlabelled PGE from standards or
2
samples and fixed amounts of radioiodinated PGE (tracer) were
2
allowed to react with a constant and limited amount of antibody
binding sites. Decreased amounts of radioiodinated PGE were
• 2
bound to the antibody as the amounts of unlabelled antigen were 
increased. The separation of the antigen-antibody complex from 
free antigen was achieved by precipitation with 16% polyethylene 
glycol solution in the presence of carrier immunoglobulin. The 
pellet containing the antigen-antibody complex was counted in a 
gamma counter. Results obtained for the standards were used to 
construct a standard curve from which the unknown was read from.
2
2.12.1 Description of Reagents and their Preparation
125
Du Pont [ I]PGE RIA kit (New England Nuclear,
2
Boston, U.S.A.) was used for PGE estimation. The reagents were
2constituted as follows.
125
2-12.1.1 [ I1PGE (Tracer)
125 2 125
The [ I]PGE contained <2yCi of [ I]PGE in 0.75ml 
2 2
of acetonitrile. The contents of the vial were diluted to 15.0ml 
with the assay buffer, pH 6.8 (section 2.12.1.4). The solution 
was stored at -20°C in 1.0ml aliguots in sealed polypropylene 
microfuge tubes.
2.12.1.2 PGE -Antibody 
2
The lyophilised rabbit antiPGE was reconstituted with
2
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13.0ml of assay buffer, pH 6.8. The solution was stored at -20°C 
in 1.0ml aliquots in sealed polypropylene microfuge tubes.
2.12.1.3 PGE Standard
2
The PGE standard concentrate contained 100ng/ml of 
2
PGE in acetonitrile. Aliquots (0.1ml) of PGE standard were 
2 2 
diluted with assay buffer, pH 6.8, to give concentrations which
ranged from 25, 10, 2.5, 1.0, 0.5 and 0.25pg/100ul.
2.12.1.4 Assay Buffer
This solution contained 0.9% NaCl, 0.01M EDTA, 0.3%
Bovin-Y-globulin, 0.005% Triton X-100, 0.05% sodium azide,
0.0255M NaH PO .H 0 and 0.0245M Na HPO .7H 0 in distilled water.
2 4 2 2 4 2
The pH was adjusted to 6.8.
2.12.1.5 Precipitation Reagent
This solution consisted of 16% polyethylene glycol (PEG 
6000) and 0.05% sodium azide in 50mM phosphate buffer, pH 6.8.
2.12.2 Sample Handling
All samples were processed immediately after collection 
and assayed as soon as possible thereafter. The containers used 
in this assay were either siliconised glass or polypropylene test 
tubes. Blood and tissue samples were processed in the presence 
of prostaglandin synthetase inhibitor indomethacin, at a 
concentration of 10 yg/ml. All the solvents were doubly 
distilled, using long path distillation, before use.
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2.12.3 Extraction of PGE
2.12.3.1 Plasma
2
PGE from plasma was extracted using a procedure 
2
modified from that of Skrinska and Lucas (1981). Blood samples
were collected in prechilled siliconised glass test tubes, coated
with a solution of 4.5mM EDTA and 10 ug/ml indomethacin, and
subjected to 2000xg for 10 min. to obtain the plasma. 2.0ml of
plasma was acidified to pH 3.5-4.0 with 0.1ml of 2N HC1 and
centrifuged (2000xg for 10 min.) to remove denatured proteins.
Disposable Sep Pak columns packed with octadecasilyl-
silica (Sep Pak C18) and attached with Sep Pak cartridge racks
were washed sequentially with 2.0ml methanol and 2.0ml distilled
water, pH 3.5. This and all subsequent elutions were performed
under slight positive air pressure and the flow rate was adjusted
to 1.0ml/2.5 min. 1.0ml of plasma supernatant fluid was applied
to the column. This was followed by sequential washing with
2.0ml distilled water, pH 3.5, 2.0ml 15% methanol and 2.0ml
petroleum ether. The PGE was eluted of the Sep Pak C18 column
2
with 1.0ml ethylacetate directly onto and through a Sep Pak
silica column using an adaptor. The Sep Pak silica columns were
prepared by washing with 5.0ml of a mixture of benzene and
ethylacetate (80:20). The Sep Pak C18 column was removed and the
Sep Pak silica column was washed sequentially with 1.0ml of each
of the following mixtures - benzene and ethylacetate (80:20),
benzene and ethylacetate (60:40), benzene, ethylacetate and
methanol (60:40:2), benzene, ethylacetate and methanol
(60:40:10). All eluates were discarded. PGE was eluted off the
2
silica column with 5.0ml of a mixture of benzene, ethylacetate
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and methanol (60:40:30) into a polypropylene test tube. The
extract was dried under nitrogen gas and reconstituted with
10.0ml of assay buffer, pH 6.8. The recoveries of known amounts
of PGE standard using this method was 89%.
2
2.12.3.2 Muscle and Tumour
PGE from muscle and tumour tissues were extracted 
2
using a procedure modified from that of Tan et al., (1974).
Animals were killed by cervical dislocation. Gastrocnemius
muscle and tumour tissue were removed immediately. Tissues (0.5-
l.Og) were homogenised three times in 10.0ml absolute ethanol.
The ethanol extracts were pooled together and evaporated to
dryness on a rotary evaporator. The dried extracts were
reconstituted in 20.0ml ethylacetate and PGE was reextracted
2
twice in 10.0ml 0.2M phosphate buffer, pH 8.0. The pH of the
extract was adjusted to 3.0. A 1.0ml extract was applied to a
Sep Pak C18 column and PGE was eluted as described in section
2
2.12.3.1. The recoveries of known amounts of standard by this 
method was 90%.
2.12.3.3 Urine
The manufacturer's recommended method was used to
extract PGE from urine (Instruction Manual for the measurement 
2
of PGE in plasma and tissue samples, New England Nuclear, 
2
Boston, U.S.A.). Urine was acidified to pH 4.0 with IN HC1. 
1.0ml of the acidified urine was extracted twice with 2.0ml 
chloroform. Pooled extracts were evaporated to dryness under 
nitrogen gas and reconstituted in 20.0ml assay buffer. The 
recoveries of known amounts of standard was 105%.
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2.12.4 Assay Procedure
2.12.4.1 Calibration Curve
The PGE standard (100ng/ml) was diluted serially, as 
2
described above, with assay buffer.
125
I]PGE and Antisera 
2
Each assay was performed in- duplicate
2.12.4.2 Incubation with [
100 Ml of
diluted standards (section 2.12.4.1), extracts of plasma (section
2.12.3.1), tissues (section 2.12.3.2) and urine (section
125
2.12.3.3) were mixed with lOOul of [ I]PGE (tracer) and 100U1
2 0
of PGE antibody. The mixtures were incubated at 4 C for 18-24 
2
hours.
A series of control experiments accompanied each PGE -
2
RIA assay; these were -
1) Total radioisotope binding - lOOul of assay buffer
125
was mixed with lOOyl of [ I]PGE and lOOul of PGE antibody.
2 2
The mixture was further processed as above.
125
2) Non-specific binding - lOOul of [ I]PGE was
2
mixed with 200 ul of assay buffer. The mixture was further 
processed as described above.
125
3) Total radioactive counts - lOOul of [ I]PGE was
2
incubated, to assess total counts added per assay tube, and
processed as described above.
2.12.4.3 Separation of Antigen-Antibody Complex
1.0ml of cold precipitation reagent was added to all 
tubes, except for the total radioactivity control, and incubated 
for a further 3 0 min. at 4 °C. The antigen-antibody complex was
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removed down by centrifugation at 2000xg for 30 min. The
supernatant fluid was decanted and the residue precipitates were
counted in a gamma counter (Packard Autogamma Spectrometer, Model
5210) at 60% efficiency. A calibration curve was constructed by
125
plotting linear and semilogarithmically the ratio of [ I]PGE
2
bound with anti PGE in each assay tube (B) to total binding (Bo)
2
expressed as % versus PGE concentration (%B/Bo vs. [PGE ]). The
2 2
PGE concentration in plasma, tissue and urine specimens were 
2
estimated using the calibration curve (Fig. 2.5).
2.13 Statistical Analysis
Student's t test (paired or unpaired data) was used to 
calculate the statistical significance of the data. Programme P7 
was used to evaluate the statistical significance (Appendix A). 
The p values are related to control vaules except where otherwise 
mentioned.
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Figure 2.6: Calibration curve for the radioimmunoassay of 
prostaglandin E (PGE2 )
2
PGE2 standard (100ng/ml) was diluted with assay 
buffer from 25 to 0.25 pg/lOOul. Each dilution 
was incubated with lOOUl of [125I]PGE2 and lOOul 
anti-PGE2 , as described in the text. The 
antigen-antibody complex was separated by using 
100 ul 16% polyethylene glycol solution (section 
2.12.1.5). The calibration curve was constructed 
by plotting linear semi-logarithmically the ratio 
of [12 51]PGE2 bound with anti-PGE2 in each assay 
tube (B) to total binding (Bo) expressed as a % 
versus PGE2 concentration (% B/Bo vs. [PGE2 ]).
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CHAPTER THREE
NUTRITIONAL AND GROWTH STUDIES ON CACHECTIC ANIMALS 
3.1 Introduction
The English word 'cancer* is derived from the Latin 
word for 'crab', suggesting the condition to reach out and cling 
tenaciously (with associated pain) to adjacent tissues. All 
tumours fall into one of two categories: benign or malignant.
The word 'benign' refers only to a form of behaviour
characterised by non-invasiveness and the inability to
metastasise. However, a benign neoplasm may exhibit a variety of 
adverse effects relating to the progressive occupation of vital 
space (Robbins, 1974) and the production of biochemically active 
substances (Omenn, 1970) which may metabolically effect distant 
non-involved organs and in an occasional instance cause death 
(Vincent, 1985). The term 'malignant' more strictly refers to 
the metastatic behaviour and the spread of the neoplasm, by 
various routes, to distant discontinous sites where separate 
colonies may be established, colloquially called 'metastasis' or 
'secondaries'. The initial tumour mass is then known as the 
'primaries'. The outcome, without effective treatment, is nearly 
always the death of the host.
The growth of cancer leads to profound alterations of 
host organs and their functions and metabolism, as a consequence 
of multiple interactions, spanning destruction, attempted repair, 
homeostasis and production by the tumour of biochemical toxin 
(Costa, 1977; Dabbous et al., 1977; Recklies, 1980). For the
sake of simplicity, the changes in the host metabolism and other
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abnormalities associated with tumour bearing are discussed 
separately in the following sections.
3.1.1 Anorexia
Anorexia is a common phenomenon for most cancer 
patients at some time during their illness and is one of the 
possible causes of their notable weight loss (Costa, 1977). 
Force-feeding programmes e.g. , parenteral nutrition or enteral 
hyperalimentation were often required to overcome anorexia 
(Blackburn, 1977). The pathogenesis of anorexia is still 
unclear. A change in taste perception has been described by 
DeWys (1978). The postulation that lactate, known to be produced 
abundantly by tumours, could serve as an anorexigenic agent was 
attractive (Baile et al., 1970) but requires further
documentation in man. Pain, fever and anxiety also contributed 
to the lessening of food consumption (Costa, 1977). Many other 
substances including biogenic amines, steroid hormones, lipids, 
amino acids, peptides and oligonucleotides were reported to 
effect appetite (Costa, 1977; DeWys, 1977; Shils, 1979; 
Theologides, 1976, 1979). However, a number of investigators
demonstrated that anorexia could not account entirely for the 
progressive cachexia (Garattini et al., 1980; Lundholm et al.,
1980; Mider et al., 1951) and neither did the decreased energy
(food) intake, because of anorexia, account for the tissue 
depletion associated with tumour bearing (Lundholm et al., 1980) .
3.1.2 Carbohydrate Metabolism
Tumour growth depends greatly on available carbohydrate 
metabolism to meet its energy requirement (Costa, 1977). High
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rates of glucose utilisation (McKeehan, 1982) and enhanced 
aerobic glycolysis and lactate production (Aisenberg, 1961; Gold, 
1966, 1974; Hume et al., 1978; Kester et al., 1977; Shapot, 1974; 
Warburg, 1956) in tumour bearing tissue areas compared to normal 
control regions, were demonstrated for many experimental animals 
and human tumours. It was estimated that approximately 35% of 
the glucose consumed by the tumour was eliminated as lactate 
regardless of the tumour type (Gullino, 1967). Essentially all 
or most of the lactate that entered the blood of tumour bearing 
animals (Hiatt, 1957) or cancer patients (Reichard et al., 1963) 
was converted back to glucose by the host liver or kidney cortex. 
Energy loss associated with a high rate of gluconeogenesis from 
lactate was suggested as an explanation for the increased energy 
expenditure and the associated loss of adipose tissue by cancer 
patients (Gold, 1974; Holroyde et al., 1975). Other
abnormalities of carbohydrate metabolism induced by tumour growth 
included reduced pyruvate and/or acetyl CoA oxidation (Hepp et 
al., 1966; Lazo and Sols, 1980 a,b; Nakano et al., 1982; Young
and Nakano, 1980), low sensitivity to oxygen (Arany et al., 1981; 
Carroll et al., 1978; Simon et al., 1981), low liver glycogen
levels (Young, 1977), carbohydrate intolerance (Bishop and Marks, 
1959; Jasani et al., 1978; Waterhouse, 1974 a,b), decreased
sensitivity to insulin (Schein et al♦, 1979; Waterhouse, 1974
a,b) and failure of glucose loading to suppress fatty acid 
oxidation (Holroyde et al., 1979; Jasani et al., 1978; Waterhouse 
and Kemperman, 1971; Waterhouse, 1974, a,b).
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3.1.3 Protein Metabolism
An important aspect of tumour nutrition is the capacity 
of cancer cells to take up amino acids from biological fluids and 
to concentrate them to a greater extent than do some normal 
tissues (Christensen and Henderson, 1952; Wiseman and Ghadially, 
1955) . Incorporation of host tissue derived amino acids into the 
tumour for the synthesis of proteins was demonstrated in animal 
tumour models (Fenninger and Mider, 1954) and in human cancer 
patients (Norton et al., 1980) . Many studies of the varying
concentrations of individual amino acids in plasma and urine 
revealed differences between cancer patients and normal control 
subjects, but these measurements have not established the
existence of a consistent profile of abnormalities for any 
particular neoplastic condition. In patients with acute
leukaemia, elevated levels of glutamine, phenylalanine, tyrosine 
and threonine were reported (Kelley and Waisman, 1957). In 
contrast, Rudman et al., (1971) found that 60% of their leukaemic
patients had subnormal fasting plasma levels of total amino 
nitrogen during their disease, with decreases in alanine, 
glutamine, histidine, proline, threonine and methionine. While 
Clark and coworkers (1978) demonstrated increased plasma alanine, 
isoleucine and lysine levels in cancer patients. In one study 
(Young et al., 1967) of patients with advanced malignant
melanoma, where no abnormality was noted in the plasma 
aminograms, urinary aminograms revealed decreased excretion of 
phosphoserine, alanine, isoleucine, ornithine, ethanolamine and 
histidine. In contrast to this finding, Wisemann et al., (1976)
found elevated excretion of glycine, aspartate, methionine,
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serine, threonine, leucine, isoleucine, valine, alanine, 
tyrosine, phenylalanine, proline, cysteine and lysine in the 
urine of leukaemic patients (see chapter six for further details 
on this topic).
3.1.4 Lipid Metabolism
Profound alterations in host lipid metabolism occur 
during the growth of a variety of neoplasms in both animals and 
man (Begg and Dickenson, 1951; Copeland and Dudrick, 1976; Costa 
et al., 1976). The most consistent feature being the marked loss 
of adipose tissue in patients with advanced cancer (Bloor and 
Haven, 1955) and in tumour bearing animals (Guaitani et al., 
1982) .
It was demonstrated that blood taken from tumour 
bearing subjects was generally lipaemic (Bloor and Haven, 1955) 
with a significant increase in plasma free fatty acids (Carter et 
al., 1975; Feldman and Carter et al., 1971; Mueller and Watkin, 
1961) and triglycerides (Barclay and Skipski, 1975; Kitada et 
al., 1982; Kremmer and Holozinger, 1976; Lanza-Jacoby et al. , 
1982; Mays, 1971; Santer, 1969; Shearer et al., 1983).
Ketosis was reported to be a most uncommon phenomenon 
in cancer patients (Conyers et al., 1979 a,b; Williams et al., 
1980) and tumour bearing animals (Mider et al., 1951) . 
Furthermore, it was established that neoplasms also demanded an 
appropriate lipid supply in order that membrane synthesis could 
proceed at a rate consistent with their rapid growth rate 
(Spector and Brenneman, 1973). It was also demonstrated that 
although tumour cells in vitro utilised fatty acids as a source
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of energy, the contribution of fatty acids to energy production 
in vivo was probably small (Henderson and Lapage, 1959). A brief 
review of the regulation of fatty acid metabolism under normal 
and pathabolic states is given in chapter five.
3.1.5 Water and Mineral Metabolism
Water forms an essential part of all body cells and 
fluids. It enters into biochemical reactions, acts as a solvent 
for many ions and molecules, provides a medium of transport for 
the intra and extra cellular processes, serves as a lubricant and 
regulates body temperature (Martin, 1983). In normal healthy 
subjects water levels remain remarkably constant, but they 
fluctuate in disease states (Martin, 1983; Wolf, 1950). A number 
of investigators have demonstrated elevated water content in both 
the host body and in the neoplasm of cancer patients (Watson and 
Sammon, 1980) and tumour bearing animals (Aoki et al., 1938; 
Gullino, 1967; Lundholm et al., 1980; Recheigl et al., 1961). It 
has been suggested that the elevated water content of tumour 
bearing subjects resulted from the oxidation of a higher 
proportion of fats and proteins (Recheigl et al., 1961).
Body water retention is under the control of the 
antidiuretic hormone (ADH), vasopressin, which increases 
reabsorption of water by the renal distal tubules and collecting 
ducts (Lipsett et al., 1961). Cancer patients with the syndrome 
of an inappropriate secretion of vasopressin usually retain 2.5 
litres of excess water (Susan, 1984). It is therefore possible 
that retention of water by tumour bearing subjects may be 
attributed to the involvement of vasopressin in these animals.
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However, the exact mechanism accounting for the elevated water 
content of cancer subjects is still unknown.
Mineral elements, in ionic form, have well defined 
physiological functions. Their excess or deficiency lead to a 
wide variety of disorders (Martin, 1983). It is reported that 
growing neoplasms induce specific abnormalities in electrolyte 
and mineral metabolism which cannot be generalised for all types 
of cancers (Blackburn et al., 1977). Hypokalaemia often
accompanied mucin-secreting, potassium-depleting adenocarcinomas 
of the colon (Moore, 1959). Hypercalcaemia has been associated 
with parathyroid tumour, cancer metastasis to bone with primaries 
in the breast and thyroid and multiple endocrine adenomatosis 
(Blackburn et al., 1977). Hypocalcaemia occured as a sequelae of 
malnutrition associated with hypoalbuminaemia (Blackburn et al., 
1977). Breast cancer specimens contained high levels of 
magnesium, the significance of which has not been ascertained 
(Santoliquido et al., 1976). In areas of the world where
nutritional iron deficiency is common, the incidence of gastric 
carcinoma was high (Vitale, 1974). Elevated zinc levels were 
observed in bronchogenic and colonic cancer (Mulay et al., 1971) . 
Copper levels with oral cancer, arsenic levels with laryngeal 
cancer and lead levels with leukaemia, lymphomas and ovarian 
cancer were also found to be elevated (Mulay et al., 1971;
Schwartz, 1975).
It is evident from the brief introduction discussed 
above that tumour growth induced a variety of effects on the host 
body and its metabolism, including the loss of body lipids from
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adipose tissue and nitrogen from muscle. However, the metabolite 
and metabolic changes which often occur in other organs are 
neither consistent nor well defined. This chapter presents data 
which were gained to monitor and characterise cancer cachexia 
using selected clinical and biochemical parameters to define 
changes in various host organs. Comparisons of the clinical and 
biochemical changes in the tumour bearing host with those of well 
and malnourished control animals are reported.
3.2 Results
3.2.1 Prefatory Statement
The results presented in this section show the time 
course changes in selected metabolites and host organs of rats 
bearing either the Walker 256 carcinosarcoma or the R3230AC 
adenocarcinoma. However in some experiments, because of various 
experimental limitations, progressive time course studies were 
not performed, instead results were shown at the terminal stages 
(for the Walker 256 carcinosarcoma, day 10-14 PI and for the 
R3230AC adenocarcinoma, day 20-25 PI). Furthermore, for some of 
the studies, results are not presented for rats bearing the 
R3230AC adenocarcinoma because of the reasons given at the end of 
section 1.4.
During the time course studies on tumour bearing 
animals, the first observation was made when the tumour became 
palpable (i.e., day 5-6 PI - Walker 256 carcinosarcoma and day 
12-14 PI - R3230AC adenocarcinoma) otherwise various time periods 
were chosen for study.
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3.2.2 Growth Characteristics of Animals
Changes in the weight of rats after implanting the 
Walker 256. carcinosarcoma or the R3230AC adenocarcinoma were 
compared to control (fed ad libitum) and 'pair fed' - non-tumour 
bearing (NTB) rats. The results are shown in Figs. 3.1 a,b as 
the differences from the initial body weight of each group of 
rats at day 0 PI. The time course of the total body weight (host 
+ tumour) gain of rats bearing the Walker 256 carcinosarcoma was 
similar to pair fed - NTB rats. The total body weight gain of 
control rats commenced to stabilise at day 10 of the experiments 
and continued to gain, but at a significantly lower rate than the 
tumour bearing and pair fed - NTB animals. A sharp decline in 
carcass weight (host - tumour) of rats bearing the Walker 256 
carcinosarcoma occured between days 5-10 PI. The time course of 
the total body weight gain (host + tumour) of rats bearing the 
R3230AC adenocarcinoma was similar to the pair fed - NTB rats up 
to day 16 of the experiments, then the total body weight of pair 
fed - NTB rats continued to gain at a rate approximately similar 
to the control animals. The total body weight of tumour bearing 
animals did not increase to the extent of the pair fed - NTB or 
control rats. The slight gain in carcass weight (host - tumour) 
of the R3230AC adenocarcinoma bearing animals started to decline 
at day 8 PI and by the time of death (day 28 PI) had returned to 
the initial body weight of the animals.
3.2.3 Food and Water Consumption
The food and water consumption of rats bearing the 
Walker 256 carcinosarcoma or the R3230AC adenocarcinoma were
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Figure 3.1 (a): Time course changes in the body weight of control
rats, "pair fed" non-tumour bearing rats and rats 
bearing the Walker 256 carcinosarcoma
All experiments were performed in metabolic cages 
each housing one animal. Animals were caged 5-7 
days prior to commencement of experiments. 
Control and the Walker 256 carcinosarcoma bearing 
animals were allowed food and water ad libitum. 
Whereas "pair fed" non-tumour bearing animals 
were given a restricted food and water supply as 
described in section 2.2. The body weight of 
control and the Walker 256 carcinosarcoma bearing 
animals were recorded every alternate day between 
9.30 to 10.00 a.m. Whereas the body weight of 
"pair fed" non-tumour bearing animals was 
recorded at 0th, 6th, 10th and 14th day of study. 
The method of tumour implantation is described in 
section 2.3.1. The values show the mean for at 
least five animals in each experimental group. 
The SEM are represented by the vertical lines.
a : Control (fed ad libitum) rats
■ : Pair fed non tumour bearing rats
• : Walker 256 carcinosarcoma bearing rats
(carcass + tumour)
♦ : Walker 256 carcinosarcoma bearing
(carcass - tumour)
rats
5 + 3 0 -
0 2 10 12 14
Days Post Tumour Implantation.
Figure 3.1 (b): Time course changes in the body weight of control
rats, Mpair fed" non-tumour bearing rats and rats 
bearing the R3230AC adenocarcinoma
All experiments were performed in metabolic cages 
each housing one animal. Animals were caged 5-7 
days prior to commencement of experiments. 
Control and R3230AC adenocarcinoma bearing 
animals were allowed food and water ad libitum. 
Whereas "pair fed" non-tumour bearing animals 
were given a restricted food and water supply as 
described in section 2.2. The body weight of all 
animals were recorded every 4th day between 9.30 
and 10.00 a.m. The method of tumour implantation 
is described in section 2.3.2. The values show 
the mean for at least five animals in each 
experimental group. The SEM are represented by 
the vertical lines.
a : Control (fed ad libitum) rats
■ : Pair fed non tumour bearing rats
• : R3230AC adenocarcinoma bearing rats
(carcass + tumour)
♦ : R3 2 3 0AC adenocarcinoma bearing rats
(carcass - tumour)
Days Post Tumour Implanta t ion
Figure 3.2 (a,b): Daily food (a) and water consumption (b) of 
Sc 3.3 (a,b) control rats and rats bearing the Walker 256
carcinosarcoma (Fig. 3.2) or R3230AC 
adenocarcinoma (Fig. 3.3)
All experiments were performed in metabolic cages 
each housing one animal. Animals were caged 5-7 
days prior to commencement of experiments. The 
method of tumour implantation is described in 
section 2.3. Both control and tumour bearing 
animals were allowed food and water ad libitum. 
The values show the mean for five animals in each 
experimental group. The SEM are represented by 
the vertical lines.
■: Control (fed ad libitum) rats 
a : Walker 256 carcinosarcoma 
adenocarcinoma bearing rats
or R3230AC
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compared with their respective fed ad libitum controls. The 
initial food and water intake of rats bearing the Walker 256 
carcinosarcoma (Fig. 3.2 a,b) were similar to those of the 
control animals but after day 5 PI, when the tumour was palpable, 
food and water consumption declined and remained low throughout 
the remaining interval of tumour bearing. Similar effects on 
food and water consumption were also noted for rats bearing the 
R3230AC adenocarcinoma (Fig. 3.3 a,b). The intake of food and 
water in these rats was also reduced when the tumour was of 
palpable proportions (day 10-12 PI) and then continued 
throughout the remaining course of tumour bearing.
3.2.4 Tumour Growth Characteristics
Growth of the Walker 256 carcinosarcoma was visible •by 
day 6 PI (Fig. 3.4 a). Growth of the neoplasm increased with 
time at a rate of approximately 4-5g/day and reached 
approximately 1/4 of the host body weight at the time of the host 
death (day 12-14 PI). Growth of the R3230AC adenocarcinoma 
became visible at day 12 PI (Fig. 3.4 b). The tumour growth, 
after a short period, increased linearly with time at the 
moderate rate of 1.0-1.25g/day and reached l/10th to l/8th of the 
host body weight at the time of host death (day 2 0-3 0 PI) .
The calculated tumour weight, as determined from the 
external dimensions of the tumour (section 2.4), was compared to 
the measured tumour mass. There was no significant difference 
between the calculated and measured tumour weight (Fig. 3.4 a,b) 
for both tumour models.
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Figure 3.4 (a,b): Growth characteristics of the Walker 256
carcinosarcoma (a) and R3230AC adenocarcinoma 
(b) bearing rats
All experiments were performed in metabolic cages 
each housing one animal. Animals were caged 5-7 
days prior to the commencement of experiments. 
All animals were allowed access to food and water 
ad libitum. The method of tumour implantation is 
described in section 2.3. The measured tumour 
weight was determined by surgically isolating the 
tumour free from the animal body. The calculated 
tumour weight was determined from measurements of 
external dimensions of the tumour and fitting the 
data to the equation; T.W. = [ (a/rr )2 .b]/2, where 
T.W. = tumour weight, a = circumference of 
tumour, tt= 3.14, b = length of tumour mass 
(Guaitani et al., 1982). The values show the
mean for at least five animals in each 
experimental group. The SEM are represented by 
the vertical lines.
■: Measured tumour weight 
a : Calculated tumour weight
aDays p o s t  tumour im p la n ta t io n
Days Post Tum our Im p lan ta t ion
3.2.5 Changes in the Concentrations of Selected Metabolites
The time course changes in the concentrations of 
selected metabolites in the blood and liver of control and tumour 
bearing animals are shown in Table 3.1 and 3.2 respectively.
In rats bearing the Walker 256 carcinosarcoma blood 
alanine concentration was increased by 48% (pcO.OOl) at day 10 
PI, whereas in the liver a gradual accumulation of alanine was 
observed leading to a value equivalent to 276% of normal (p<0.01) 
at day 14 PI. In rats bearing the R3230AC adenocarcinoma blood 
alanine levels were increased by 25% (non-significant - NS) in 
blood and by 160% (pcO.OOl) in the liver at day 20 PI.
The level of ketone bodies in the blood were reduced 
from normal by 48-54% (pcO.OOl) between day 6-14 PI and reduced 
by 35% (p<0.005) at day 6 and 10 PI in the liver of Walker 256 
carcinosarcoma bearing animals. Ketone body levels were also 
decreased by 53% (p<0.05) in the blood but there was no 
significant change in the concentration of these compounds in the 
liver of animals bearing the R3230AC adenocarcinoma at day 20 PI.
A significant increase by 470% over normal (pcO.OOl) in 
blood lactate levels was found in rats bearing the Walker 256 
carcinosarcoma at day 14 PI. Lactate levels were increased by 
140% (p<0.1) in the livers of animals bearing this tumour for 14 
days. Similar results were observed for rats bearing the R3230AC 
adenocarcinoma where lactate levels were increased by 230% 
(pcO.OOl) and 50% (NS) in blood and liver respectively, at day 20 
PI.
Blood pyruvate levels were increased by 190% (pcO.OOl) 
in animals bearing the Walker 256 carcinosarcoma at day 14 PI and
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Changes in the concentration of selected 
metabolites in the whole blood of control rats 
and rats bearing the Walker 256 carcinosarcoma or 
R3230AC adenocarcinoma
Animals were killed by guillotine. The blood of 
each animal was collected separately from the 
neck wound and introduce into heparinised test 
tubes. 5.0ml of blood was mixed with an egual 
volume of 0.6M HCIO4 . Following the removal 
of protein by centrifugation (5000xg for 10 min.) 
and neutralisation with saturated KHC03 , the 
concentration of selected metabolites were 
determined as described in section 2.7. Total 
ketone bodies refers to a sum of acetoacetate and 
3-hydroxybutyrate. The values are the mean + 
SEM. The number of observations are shown in 
parentheses. "Student’s t test" was used for the 
statistical evaluation of the data. The p values 
are related to the results of the control 
experiments for the same estimation, *p<0.05,
**p<0. 01, ***p<0.001.
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Table 3.2: Changes in the concentration of selected 
metabolites in the liver of control rats and rats 
bearing the Walker 256 carcinosarcoma or R3230AC 
adenocarcinoma
Animals were killed by cervical dislocation. 
Approx. l.Og of liver was removed from the left 
lateral lobe and immediately homogenised in 5.0ml 
of ice cold 0.6M HCIO4. The tissue residues were 
removed by centrifugation (5000xg for 10 min.) 
and the supernatant fraction was neutralised with 
saturated KHCO3. The concentration of 
metabolites in the supernatant fluid were 
determined as described in section 2.7. Total 
ketone bodies refer to a sum of acetoacetate and 
3-hydroxybutyrate. The values are the mean + 
SEM. The number of observations are shown in 
parentheses. "Student’s t test" was used for the 
statistical evaluation of the data. The p values 
are related to the results of the control 
experiments, *p<0.05, **p<0.01, ***p<0.001
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120% (p<0.05) in animals bearing the R3230AC adenocarcinoma at 
day 20 PI. Pyruvate levels in the liver were reduced initially 
by 67% (p<0.01) at day 6 PI in rats bearing the Walker 256 
carcinosarcoma, but for later intervals there was no significant 
change in pyruvate concentration, when compared to normal values. 
There was also no change in the pyruvate concentration of the 
liver of rats bearing the R3230AC tumour at day 20 PI. Lactate 
and pyruvate ratios were significantly increased in the blood and 
liver of rats throughout the entire interval of tumour bearing. 
The highest increase of the [lactate]/[pyruvate] ratio - by 120% 
(p<0.001) and 90% (p<0.01) was noted in the blood and liver 
respectively for rats bearing the Walker 256 carcinosarcoma at 
day 6 PI. The [lactate]/[pyruvate] ratios were increased by 53% 
(p<0.01) and 64% (p<0.01) in blood and liver respectively, for 
rats bearing the R3230AC adenocarcinoma at day 20 PI.
Blood glucose levels remained within the normal levels 
for rats bearing the Walker 256 carcinosarcoma and the R3230AC 
adenocarcinoma (Table 3.1).
FFA and TG levels in the plasma of control (fed ad 
libitum), variously starved and tumour bearing animals are shown 
in Table 3.3. In comparison with control rats, plasma FFA levels 
were increased in all cases with a significant increase by 65% 
(p<0.05) to 335% (pco.001) in rats during the time course of 
Walker 256 carcinosarcoma bearing (days 6-14 PI). Plasma TG 
levels did not change significantly in pair fed - NTB, 12 and 
48hr starved rats in comparison with those of the control 
animals. An increase of 52% (NS) and 223% (p<0.01) was observed
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Table 3.3: Free fatty acid and triglyceride levels in the 
plasma of control, variously starved and tumour 
bearing rats
Free fatty acid Triglyceride
limol ml— 1
Control 0.23 + 0.06 1.55 + 0.11
(fed ad libitum)
"Pair fed" 0.25 + 0.11 1.85 + 0.43
(non-tumour bearing)
12 hour starved 0.31 + 0.05 1.14 + 0.44
48 hour starved 0.34 + 0.04 1.05 + 0.45
Walker 256 carcinosarcoma 0.38 + 0.07* 2.15 + 0.41
bearing (day 6 PI)
Walker 256 carcinosarcoma 0.84 + 0.22* 2.35 + 0.74
bearing (day 10 PI)
Walker 256 carcinosarcoma 1.00 + 0.14*** 5.01 + 0.41***
bearing (day 14 PI)
Animals were killed by guillotine. The blood of each animal was 
collected separately from the neck wound into heparinised test 
tubes and subjected to centrifugation at 3000xg for five min. A 
plasma fraction was prepared and used for the determination of 
free fatty acids and triglycerides as described in section 2.7. 
The values are the mean + SEM for five rats in each experimental 
group. "Student's t test" was used for the statistical 
evaluation of the data. The p values are related to the results 
of control experiments, *p<0.05, **p<0.01, ***p<0.001.
in plasma TG levels of rats bearing the Walker 256 carcinosarcoma 
at day 10 and 14 PI respectively. FFA and TG levels in the 
livers of control (fed ad libitum), variously starved and tumour 
bearing animals are shown in Table 3.4. There were no changes in 
the FFA levels in the livers of pair fed - NTB, 12 and 48 hr 
starved or Walker 256 carcinosarcoma bearing rats at day 6 and 10 
PI when compared to those of the control animals. FFA were 
increased by 60% (p<0.05) in Walker 256 carcinosarcoma bearing 
rats at day 14 PI. Hepatic TG levels were reduced by 37% 
(p<0.01) and 60% (p<0.001) in the livers of 12 and 48 hr starved 
rats respectively. TG levels did not change significantly in the 
livers of rats bearing the Walker 256 carcinosarcoma at day 6 and 
10 PI, but increased by 110% (p<0.001) at day 14 PI.
Time course changes in the concentration of selected 
metabolites in the Walker 256 carcinosarcomas implanted in the 
hind limb muscle of rats, are shown in Table 3.5. The results 
were compared to the data of the muscle of normal animals as the 
tumour was implanted in the hind limb muscle of rats.
Alanine levels in the tumour homogenate were 560% 
(p<0.001) greater at day 10 PI than alanine levels in the hind 
limb muscle of the non-tumour bearing animal (control). These 
values were later reduced to 250% (pcO.001) over control at day 
14 PI.
Ketone bodies could not be detected in the tumour 
homogenate of the Walker 256 carcinosarcoma.
Lactate levels in the tumour were initially increased 
by 100% (p<0.05) over control levels at day 6 PI but later 
increased by 35% only over control levels (NS) at day 10 PI and
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Table 3.4: Free fatty acid and triglyceride levels in the 
liver of control, variously starved and tumour 
bearing rats
Free fatty acid Triglyceride
umol g — i of frozen liver powder
Control
(fed ad libitum)
"Pair fed" 
(non-tumour bearing)
12 hour starved
48 hour starved
Walker 256 carcinosarcoma 
bearing (day 6 PI)
Walker 256 carcinosarcoma 
bearing (day 10 PI)
Walker 256 carcinosarcoma 
bearing (day 14 PI)
12.40 + 0.97 13.07 + 0.80
11.87 + 0.87 13.91 + 1.65
13.59 + 0.69 8.27 + 0.95**
14.97 + 1.08 5.46 + 0.78***
14.96 + 0.98 15.79 + 2.50
14.31 + 0.75 19.47 + 4.45
19.84 + 2.03* 27.39 + 2.46***
Animals were killed by cervical dislocation. Approx. l.Og of 
liver (left lateral lobe) was removed and freeze clamped in 
aluminium tongs, pre-cooled in liquid nitrogen. A precisely 
known quantity (0.5-0.7g) of frozen liver powder was used for the 
extraction of total lipids in a chloroform/methanol mixture (2:1 
v/v) as described in section 2.9.8. Free fatty acid and 
triglyceride were separated by chromatography using a column 
containing Florisil resin (60-100 mesh) as described in section 
2.9.9 and their concentrations were determined as described in 
section 2.7. The values are the mean + SEM for five animals in 
each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments, *p<0.05, **p<0.01,
***p<0.001.
Table 3.5: Changes in the concentration of selected 
metabolites in the tumour of rats bearing the 
Walker 256 carcinosarcoma
Animals were killed by cervical dislocation. 
Approx. l.Og of tumour was removed, accurately 
weighed and immediately homogenised in 5.0ml of 
ice cold 0.6M HC104. The acid insoluble residue 
was removed by centrifugation (5000xg for 10 
min.) and the supernatant fraction was 
neutralised with saturated KHC03 . The 
concentration of metabolites in the supernatant 
fraction were determined as described in section 
2.7. The values are the mean + SEM. Total 
ketone bodies refers to a sum of acetoacetate and 
3-hydroxybutyrate. The number of observations 
are shown in parentheses. "Student's t test" was 
used for the statistical evaluation of the data. 
The p values are related to the results of 
control experiments for the same estimation, 
*p<0.05, **p<0.01, ***p<0.001, ND: not 
detectable.
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by 65% over control levels (NS) at day 14 PI.
Pyruvate levels in the tumour homogenate declined by 
79% (p<0.05) of control at day 6 PI and by 48% (NS) of control at 
day 10 PI. Pyruvate could not be detected in the Walker 256 
carcinosarcoma at day 14 PI. [Lactate]/[pyruvate] ratios in this 
tumour were initially increased by 640% (p<0.01) over control 
values at day 6 PI, but the ratio then declined to 195% (p<0.05) 
at day 10 PI.
Glucose levels in the tumour homogenate of the Walker 
256 carcinosarcoma were gradually reduced by 29% (NS), 45% 
(p<0.05) and 85% (p<0.05) at day 6,10 and 14 PI respectively, in 
comparison with the control values.
The urinary excretion of alanine is reported in Table 
3.6. In animals bearing the Walker 256 carcinosarcoma the 
urinary excretion of alanine increased throughout the course of 
tumour bearing and reached the greatest output by 128% (pcO.001) 
over normal at day 6 PI. In animals bearing the R3230AC 
adenocarcinoma, alanine excretion increased significantly by 87% 
(p<0.05), 94% (p<0.05) and 87% (p<0.05) at days 4,10 and 18 PI 
respectively.
3.2.6 Changes in the Mass of Epididymal Adipose Tissue
The time course changes in the wet weight of epididymal 
adipose tissue of the control (fed ad libitum), pair fed - NTB 
and tumour bearing rats are shown in Tables 3.7 a,b. The weight 
of adipose tissue remained stable throughout the time course of 
the experiments for control rats and also did not change 
significantly for the pair fed - NTB rats (Tables 3.7 a,b). The
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Table 3.6: Changes in the concentration of alanine excreted 
in the urine of rats bearing the Walker 256 
carcinosarcoma or the R3230AC adenocarcinoma
Days
Post Implantation
Walker 256 
carcinosarcoma 
bearing
R3230AC
adenocarcinoma
bearing
jjmol ml — 1
0 1.12 + 0.07 1.00 + 0.25
2 1.76 + 0.10** -
4 1.76 + 0.27* 1.87 + 0.18*
6 2.55 + 0.16*** -
10 1.91 + 0.40 0.76 + 0.18
14 1.40 + 0.19 1.03 + 0.17
16 - 1.94 + 0.18*
18 _ 1.87 + 0.20*
Animals were placed in metabolic cages for the collection of 24 
hour urine specimens. Urine was filtered and then mixed with an 
egual volume of 30% of HC1CU. The precipitates were removed by 
centrifugation at 5000xg for 10 min. at 4°C. The supernatant 
fluid was neutralised with saturated KHCO 3 and used for the 
determination of alanine as described in section 2.7. The values 
are the mean + SEM for four animals in each experimental group. 
"Student's t test" was used for statistical evaluation of the 
data. The p values are related to the results of day 0 PI, 
*p<0.05
Table 3.7 (a,b): Changes in the mass of epididymal adipose
tissue of control rats, "pair fed1 non-tumour 
bearing rats and rats bearing the Walker 256 
carcinosarcoma (a) or R3230AC adenocarcinoma
m .
Animals were killed by cervical dislocation and 
the epididymal adipose tissue removed. Changes 
in the wet weight of adipose tissue were 
determined by gravimetric analysis. The values 
are the mean + SEM for four animals in each 
experimental group. "Student's t test" was used 
for the statistical evaluation of the data. The 
p values are related to the results of control 
experiments, *p<0.05, **p<0.01, ***p<0.001
(a)
Table 3.7
Post
Days Control
Implantation (fed ad­
lib i turn)
"Pair Fed" 
non tumour 
bearing
Walker 256 
carcinosarcoma 
bearing
g/100g carcass wet weight (body w t . - tumour w t .)
0 0.70 + 0.07 0.70 + 0.07 0.70 + 0.07
6 1.02 + 0.20 0.53 + 0.05 0.44 + 0.01*
8 - - 0.34 + 0.05**
10 0.77 + 0.08 0.57 + 0.04 0.28 + 0.01**
12 - - 0.28 + 0.01*
14 0.70 + 0.4 0.55 + 0.11 0.18 + 0.01***
16 - - 0.21 + 0.02***
(b)
Post
Days Control
Implantation (fed ad
libitum)
"Pair Fed" 
non tumour 
bearing
R3230AC
adenocarcinoma
bearing
g/100g carcass wet weight (body wt. - tumour w t . )
0 0.69 + 0.05 0.71 + 0.04 0.62 + 0.09
8 0.78 + 0.07 0.50 + 0.07 0.49 + 0.10
16 0.61 + 0.04 0.60 + 0.06 0.37 + 0.05**
24 0.82 + 0.05 0.48 + 0.06 0.26 + 0.05***
weight of adipose tissue declined significantly by 70% (pcO.OOl) 
at day 14 PI and 50% (p<0.001) at day 24 PI for animals bearing 
the Walker 256 carcinosarcoma and R3230AC adenocarcinoma 
respectively.
3.2.7 Changes in the Mass of Gastrocnemius Muscle
The time course changes in the wet weight of 
gastrocnemius muscle of control (fed ad libitum), pair fed - NTB 
and tumour bearing rats are shown in Table 3.8 a,b. The mass of 
the gastrocnemius muscle remained very stable in the control and 
pair fed - NTB animals throughout the duration of the 
experiments. The growth of the Walker 256 carcinosarcoma and 
R3230AC adenocarcinoma induced a reduction of the wet weight of 
the muscle by 50% (p<0.01) at day 14 PI and 30% (p<0.05) at day 
24 PI respectively.
3.2.8 Changes in Body Weight (Anhydrous) and Water Content 
The time course changes in the anhydrous body weight
and the water content of rats bearing the two tumour lines were 
similar and are shown in Table 3.9 a,b. Tumour bearing animals 
contained more water than the control animals. The water content 
of total host body (host + tumour) of animals bearing either the 
Walker 256 carcinosarcoma or R3230AC adenocarcinoma was increased 
by 10% (p<0.01) at the terminal stages of their disease in 
comparison with the water content of the normal control animals. 
The carcasses of these animals also contained significantly more 
water, ranging from 8-10% greater than normal (p<0.01). Tumour 
tissues from both tumour bearing animals contained approximately
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Table 3.8 (a,b): Changes in the wet weight of gastrocnemius
muscle of control rats, "pair fed" non-tumour 
bearing rats and rats bearing the Walker 256 
carcinosarcoma (a) or R3230AC adenocarcinoma
m.
Animals were killed by cervical dislocation and 
the gastrocnemius muscle were carefully dissected 
from the left hind limb. Changes in the wet 
weight of gastrocnemius muscle were determined by 
gravimetric analysis. The values are the mean + 
SEM for four animals in each experimental group. 
"Student's t test" was used for the statistical 
evaluation of the data. The p values are related 
to the results of control experiments, *p<0.05,
**p<0.01, ***p<0.001.
Table 3.8
(a)
Post
Days Control
Implantation (fed ad
libitum)
"Pair Fed" 
non tumour 
bearing
Walker 256 
carcinosarcoma 
bearing
g/100g carcass wet weight (body w t . -tumour w t .)
0 0.25 + 0.02 0.23 + 0.01 0.28 + 0.02
6 0.23 + 0.01 0.25 + 0.01 0.28 + 0.01
8 - - 0.13 + 0.01***
10 0.26 + 0.02 0.26 + 0.01 0.18 + 0.01*
12 - - 0.16 + 0.01**
14 0.27 + 0.01 0.25 + 0.002 0.14 + 0.04**
16 - - 0.20 + 0.02*
(b)
Post
Days Control
Implantation (fed ad
libitum)
"Pair Fed" 
non tumour 
bearing
R3230AC
adenocarcinoma
bearing
g/100g carcass wet weight (body w t . - tumour w t .)
0 0.22 + 0.02 0.21 + 0.01 0.20 + 0.01
8 0.23 + 0.02 0.25 + 0.02 0.16 + 0.01*
16 0.22 + 0*03 0.25 + 0.01 0.18 + 0.01
24 0.20 + 0.02 0.23 + 0.01 0.14 + 0.01*
Table 3.9 (a,b) : Changes in the water content and dry body
weight of rats bearing the Walker 256
carcinosarcoma (a) or R3230AC adenocarcinomam
Animals were preweighed and killed by cervical 
dislocation. The abdomen of each animal was 
opened to expose the viscera and the tumour was 
carefully excised from hind limb. Both the 
tumour and the respective carcass were dried at 
80 + 1.0 °C in a vaccuum oven (500mBar) to 
constant weight (30-40 hours). The dry weight of 
the carcass and tumour were recorded and the 
water content calculated. The values are the 
mean + SEM for four animals in each experimental 
group. "Student's t test" was used for 
statistical evaluation of the data. The p values 
are related to the results of control
experiments, *p<0.05, **p<0.01, ***p<0.001.
TABLE 3.9
(a)
Days
(PI) Water content {%)
Dry body wt. 
g/100g Carcass wet; wt.
Total Carcass Tumour Total Carcass
(BW+TW) (BW-TW) (BW+TW) (BW-TW)
G 67.08 £ 0.85 67.08 ± 0.85 - 32.90 £ 0.85 32.90 £ 0.85
0 70.45 r 0.13** 69.93 ± 0.04* 79.82 £ 0.70** 29.54 £ 0.12** 30.06 £ 0.04
10 69.75 £ 0.86 68.81 £ 0.85 80.62 £ 0.50*** 30.24 £ 0.92 31.25 £ 0.80
16 75.20 t 0.81*** 73.03 £ 0.62*** 80.66 £ 0.23*** 24.80 £ 0.80*** 26.92 £ 0.60**
13 74.75 £ 0.91*** 73.90 £ 1.18** 81.00 £ 0.14*** 25.24 £ 1.10** 26.24 £ 1 .32*
20 73.08 - 0.97** - - 26.91 £ 0.95** -
(b)
Days Dry body wt.
(PI) Water content (%) g/100g Carcass wet; wt.
Total Carcass Tumour Total Carcass(BW+TW) (BW-TW) (BW+TW) (BW-TW)
0 67.55 ± 1 .17 67.55 £ 1.17 - 32.45 £ 0.91 32.45 £ 0.91
4 70.09 t 0.44** - - 29.90 £ 0.40 -
3 69.87 t 1 .07 - - 30.13 £ 0.98 -
12 71.76 — 0.59* 68.00 £ 1.17 80.57 £ 0.30*** 28.24 £ 0.51** 32.00 £ 1.12
16 72.65 i 0.45** 70.68 £ 0.63 80.89 £ 0.32*** 27.35 £ 0.44** 29.31 £ 0.59*
20 73.80 ± 0.58** 72.18 £ 0.79* 80.82 £ 0.37*** 26.20 £ 0.51*** 27.84 + 0.74**
24 74.29 £ 0.97** 73.16 £ 0.93* 80.63 £ 0.16*** 25.71 i 1.04** 26.84 £ 0.98**
28 74.18 t 0.65** 73.02 £ 0.45** 81.03 £ 0.12*** 25.82 £ 0.64*** 26.98 ± 0.44**
20% (p<0.001) more water than the normal control animal body. A 
decline of approximately 20% (p<0.01) in the dry weight of the 
total host body and the carcasses of tumour bearing rats was also 
observed.
3.2.9 Changes in the Mass of the Liver, Spleen and Adrenal
Glands
Table 3.10 a,b shows the time course changes in the 
mass of the liver, spleen and adrenal glands of control and 
tumour bearing rats. The wet weight of livers from Walker 256 
carcinosarcoma bearing animals increased gradually during the 
time course of tumour bearing, reaching a maximum increase of 37% 
(p<0.01) over normal at day 10 PI. The increased weight of the 
liver was confirmed by the increased dry liver weight (20% 
(pcO.001) greater than normal) and increased water content of the 
hydrous liver (5% (p<0.01) greater than normal). The wet weight 
of livers from rats bearing the R3230AC adenocarcinoma were 
increased by 17% (p<0.05) at day 18 PI. No other changes were 
noted for the wet weight, dry weight or water content of livers 
from animals bearing this neoplasm. The spleens of tumour 
bearing animals were both heavier and enlarged in comparison with 
those of control animals. The weight of the spleen was increased 
by 165% (pcO.001) over normal at day 14 PI and 78% (p<0.01) at 
day 24 PI in rats bearing the Walker 256 carcinosarcoma and 
R3230AC adenocarcinoma respectively. A 100% (p<0.01) increase in 
anhydrous weight and a 5% (p<0.01) increase in the water content 
was found for the spleen of the Walker 256 carcinosarcoma bearing 
animals at day 14 PI in comparison with control animals. Whereas 
no significant change was found in the anhydrous weight of
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Table 3.10 (a,b); Changes in the wet and dry weight of organs of
rats bearing the Walker 256 carcinosarcoma (a) 
or R3230AC adenocarcinoma (b)
Animals were preweighed and killed by cervical 
dislocation. The liver, spleen and adrenal 
glands were surgically removed, blotted free from 
any excess blood and weighed. The remainder of 
the carcass was discarded. The organs (except 
adrenal glands) were dried at 80.0 + 1.0°C in the 
vaccuum oven (500mBar) to constant weight (30-40 
hours). The anhydrous weights of the organs were 
recorded and the water content calculated. The 
size of the spleen was determined from its 
length. The values are the mean + SEM. 
"Student's t test" was used for the statistical 
evaluation of the data. The p values are related 
to the results of control experiments, *p<0.05,
**p<0.01, ***p<0.001.
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R3230AC adenocarcinoma bearing animals. However a 4% (p<0.05) 
increase in water content was found at day 24 PI. Measurements 
of the size (length) of the spleen revealed an increase of 80% 
(p<0.01) over normal at day 14 PI and 50% (pcO.OOl) over normal 
at day 24 PI for animals bearing the Walker 256 carcinosarcoma 
and R3230AC adenocarcinoma, respectively. The wet weight of the 
adrenal glands increased by 117% (p<0.001) over normal at day 14 
PI and 70% (p<0.001) at day 24 PI for animals bearing the Walker 
256 carcinosarcoma and R3230AC adenocarcinoma, respectively.
3.2.10 Changes in the Activity of Alanine Aminotransferase
The time course changes induced by the 
retrodifferentiating effect of tumour bearing, on the activity of 
alanine aminotransferase were measured and are shown in Fig. 3.5. 
The growth of the Walker 256 carcinosarcoma induced a significant 
reduction in the activity of this enzyme as early as day 6 PI, 
which reached its maximum decline of 80% (p<0.001) over normal 
(day 0 PI) by day 12 PI and then remained at this level until the 
death of the animal.
3.3 Discussion
The total body weight (host + tumour) gains of rats 
bearing the Walker 256 carcinosarcoma were similar to the weight 
gains of the control non-tumour bearing counterpart (Fig. 3.1a) 
but were reduced in animals bearing the R3230AC adenocarcinoma 
(Fig. 3.1b). The increase in total body weight in animals with 
the Walker 256 tumour occurred in spite of the reduced food 
intake and can undoubtedly by attributed to the very rapid growth
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Figure 3.5: Changes in the activity of alanine 
aminotransferase in the liver of animals bearing 
the Walker 256 carcinosarcoma
Animals were killed by cervical dislocation. The 
liver was removed quickly and placed in ice cold 
0.25M sucrose. The liver was homogenised in the 
sucrose solution in a volume equal to 9 times the 
weight of the liver. Alanine aminotransferase 
activity was assayed in the 104,000xg supernatant 
fraction as described in section 2.7. One unit 
of enzyme activity is expressed as 1 umol of 
pyruvate formed/min./g liver wet wt. at 25 °C. 
The values show the mean for four animals in each 
experimental group. The SEM are represented by 
the vertical lines. "Student's t test" was used 
to evaluate the statistical significance of the 
data. The p values are related to the enzyme 
activity at day 0 PI, ***p<0.001.
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of this tumour. Subtraction of the tumour mass from the total
body weight of the respective hosts showed there was a notable 
reduction in the carcass weights of tumour bearing animals. The 
loss in weight of the carcasses of the tumour bearing animals is 
not explained by the reduced food intake (Fig. 3.2 a,b) since the 
managed restriction of food and water intake in the pair fed 
NTB control animals, did not result in any body wasting effects.
The data of Table 3.1 and those of several others 
(Chung and Bauer, 1969; Clark et al., 1978; DeWys, 1970; Shearer 
et al., 1984) have demonstrated that there are increased levels
of alanine in the blood of tumour bearing animals. The elevated 
levels of alanine in the blood were found to be associated with 
elevated alanine levels in liver (Table 3.2) and urine (Table 
3.6). It is proposed that the levels of alanine in the blood 
were elevated because of its excessive release by muscle 
proteolysis (Garber et al., 1976a), de novo synthesis from the
carbon skeletons of other amino acids in muscle (Chang and 
Goldberg, 1978a) and from the transamination of amino acids with 
pyruvate produced via glycolysis in muscle (Caldecourt et al., 
1985). The observation that tumours concentrate amino acids to 
greater extent than control tissues (Christensen and Henderson, 
1952; Wiseman and Ghadially, 1955) were further supported by 
results shown in Table 3.5 where a 560% (p<0.001) increase in 
alanine levels was observed in the Walker 256 carcinosarcoma in 
comparison with the muscle of the non-tumour bearing hind limb.
The low hepatic and blood concentrations of ketone 
bodies in both the Walker 256 carcinosarcoma and the R3230AC 
adenocarcinoma (Table 3.1 and 3.2) bearing animals has further
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confirmed the absence of ketosis in cancer patients (Conyers et 
al., 1979 a,b; Williams et al., 1980) and tumour bearing animals
(Mider et al., 1951). The absence of ketone bodies in the tumour 
extracts (Table 3.5) suggests the absence of ketone body 
synthetic capacity by these neoplasms. Moreover, it was also 
reported that ketone bodies are not utilised to any significant 
amount by the Walker 256 carcinosarcoma because of the absence of 
the enzyme 3-keto acid CoA transferase (Fearon et al., 1985).
Elevated concentrations of lactate and negligably small levels of 
glucose in the tumour (Table 3.5) clearly demonstrated that there 
were high rates of aerobic glycolysis in these tumours. Elevated 
glycolysis in the tumours no doubt caused the elevation in 
lactate in the blood and liver of the tumour bearing animals 
(Table 3.1 and 3.2). Elevated levels of pyruvate in the blood of 
tumour bearing animals were also noted, however low 
concentrations or no significant changes were found in the 
concentration of pyruvate in the liver (Table 3.2). This is 
attributed to the high rates of gluconeogenesis (from lactate) 
which operate to maintain normoglycaemia in tumour bearing 
animals (Table 3.1). The elevated [lactate]/ [pyruvate] ratios in 
the blood and liver illustrated the ’reduced' redox states of 
these tissues. [Lactate]/[pyruvate] ratios in the liver were 
used as a measure of the free [NAD]/[NADH] ratios in the 
cytoplasm of liver cells (Krebs, 1967); a decrease in this ratio 
favouring the formation of glucose from lactate (Struck et al., 
1965; Williamson et al., 1966). The reduced redox state of the 
liver was repeatedly demonstrated in tumour bearing animals and
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cancer patients (section 3.1.2). The high [lactate]/[pyruvate] 
ratios in tumours further support the proposal that neoplasms 
have a low sensitivity to oxygen (Arany et al., 1981; Carroll et 
al., 1975; Simon et al., 1981).
The maintenance of body water balance is regulated by 
the hypothalamus (Chord, 1975). The antidiuretic hormone 
vasopressin, increased the retention of body water by increasing 
its reabsorption by the renal distal tubules and collecting ducts 
(Lipsett et al., 1961). It is therefore possible that retention 
of water by tumour bearing animals (Tables 3.9 a,b) may be 
attributed to the involvement of an inappropriate secretion or 
ectopic production of vasopressin by these neoplastic animals.
The elevated levels of TG and FFA in the plasma and 
liver of rats bearing the Walker 256 carcinosarcoma are shown in 
Table 3.3 and 3.4 respectively. The TG and FFA levels in the 
plasma and blood of rats bearing the R3230AC adenocarcinoma were 
regrettably not determined for reaons given in section 1.4. 
However hyperlipidaemia, particularly hypertriglyceridaemia and 
hyperfattyacidaemia are well documented phenomena in cancer 
patients and tumour bearing animals (section 3.1.4). The 
profound alterations of lipid metabolism in cancer subjects are 
further investigated and discussed in chapter five.
The depletion of host body lipids and proteins were 
investigated by studying the changes in the mass of epididymal 
adipose tissue and gastrocnemius muscle as appropriate 
representative test sites (Guaitani et al., 1982). The results 
clearly demonstrated that lipids (Table 3.6 a,b) and proteins 
(Table 3.7 a,b) were depleted in tumour bearing animals. A
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decline in the content of fat and protein is frequently noted in 
cachectic cancer subjects but the exact mechanism of these losses 
is still unknown. In chapter one various hypothetical mechanisms 
were reviewed, which attempted inter alia to explain the 
depletion of lipids and proteins in cancer patients and tumour 
bearing animals.
The results of the present study (Table 3.10a) and 
others (Ichinoe et al., 1965) have demonstrated that the growth 
of the Walker 256 carcinosarcoma resulted in increases in the 
weights of the liver, spleen and adrenal glands of the host. The 
increased liver, spleen and adrenal glands weights were also 
noted for the host animal bearing the R3230AC adenocarcinoma 
(Table 3.10b). The increased liver weight in the tumour bearing 
animals was most likely due to the increased protein synthesis in 
that organ (Clark and Goodlad, 1981; Dusck and Hradec, 1978; 
Lundholm et al., 1980). The total nitrogen content of the liver 
increased during tumour bearing (Clark and Goodlad, 1960). 
Furthermore, it was also demonstrated that there was a tumour 
induced proliferation of hepatocytes and reticuloendothelial 
cells in the liver (Baserga and Ksielski, 1961; Morgan and 
Cameron, 1973). This phenomenon may also be judged to contribute 
to the increased weight of the liver. The enlargement of the 
spleen in tumour bearing animals is attributed to an antigenic 
response to tumour growth (Lundholm et al., 1980). Adrenal 
hypertrophy in tumour bearing animals is also consistent with the 
proposal that tumour growth is a stressing agent to the host 
(Selye, 1946; Tepperman et al., 1943) resulting in the frequently
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encountered enlargement of these glands.
Following the implantation of the Walker 256 
carcinosarcoma the activity of alanine aminotransferase was 
measured at day 6 PI when the tumour became palpable (Goodlad and 
Clark, 1962; Herzfeld and Greengard, 1972). A significant 
decline in the activity of this enzyme was observed at day 6 PI 
with a notable maximum decline by 80% (pcO.OOl) by days 12-16 PI. 
It appears that by six days following the tumour implantation, 
tumour growth had been able to communicate its presence to 
distant non-involved organs, particularly the liver, and induced 
a foetalistic retrodifferentiating change causing the activity of 
alanine aminotransferase to move towards the levels of enzyme 
activity encountered in the foetal liver (Williams et al., 1980) . 
The retrodifferentiating effects of tumour growth on the activity 
of alanine aminotransferase has already been reported in rats 
bearing the R3230AC adenocarcinoma (Williams et al., 1980) or 
other neoplasms (section 1.2.2.1.1).
The body wasting, anorexia, loss of muscle and negative 
nitrogen balance are generally regarded as the main symptoms of 
cancer cachexia. However, it has been demonstrated that these 
symptoms may in part be reproduced by implanting an inert mass 
comparable in size to many experimental neoplasms (Morrison et 
al., 1984) . These symptoms are therefore not unique features of 
cancer. It is concluded from the above study that cancer 
cachexia is characterised by a wide variety of well characterised 
clinical symptoms which include body wasting, weakness, anorexia, 
depletion of tissue proteins and lipids, increases in circulating 
alanine, lactate, pyruvate, FFA and TG and decreased ketone body
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levels, water retention and the enlargement of the liver, spleen 
and adrenal glands of cancer subjects.
In the quantitative, intermediary and endocrine 
metabolic study of cancer cachexia which follows all the above 
symptoms are encountered and connected in the unifying hypothesis 
of Williams et al., 1980. The sub-statements of the original 
hypothesis have been confirmed during the investigation and 
extended by the results of this study and show that the 
phenomenon of cancer cachexia are natural sequelae of a new 
metabolic state induced by the bearing of certain neoplasms. A 
provisional explanation of the mechanism of cancer cachexia has 
also opened up the possibility that the symptoms of this 
condition may perhaps be managed in spite of continued neoplastic 
growth. The prospect of a blockade of cachectic symptoms may 
have interesting repercussions on the metabolism and extent of 
the growth of the neoplasm.
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CHAPTER FOUR
GLUCONEOGENESIS FROM ALANINE IN THE LIVER 
OF TUMOUR REARING RATS
4.1 Introduction
Gluconeogenesis comprises the synthesis of glucose from 
compounds with five carbon atoms or less; physiologically the 
substrates are lactate, pyruvate, glycerol and certain amino 
acids (Fig. 4.1). Cahill and coworkers (1970) quantified the 
relative contribution made by the various precursors to hepatic 
glucose production in man using arteriovenous differences across 
the tissue bed. They estimated that in the postabsorptive state 
approximately 30% of total glucose produced by the liver was 
derived from gluconeogenesis, half of which originated from 
lactate, pyruvate and glycerol and the remaining half from the 
appropriate gluconeogenic amino acids. However under unusual or 
abnormal body conditions, gluconeogenesis can represent a major 
biosynthetic pathway capable of synthesising up to 200g or more 
of glucose/day in adult man (Krebs, 1964a). In these conditions 
skeletal muscle , the greatest metabolic reservoir of amino acids 
precursors for gluconeogenesis (Snell, 1979) serves to contribute 
alanine to hepatic gluconeogenesis in quantitatively the most 
significant amount (Exton and Park, 1967; Ross et al., 1967a).
Two groups of investigators (Felig et al., 1970; Mallette et
al., 1969a) proposed that glucose formation from alanine
represents a metabolic cycle which is mechanistically analagous 
to that proposed by Cori for lactate (Cori, 1931). These workers 
proposed that alanine would serve to carry amino groups and 
carbon substrates from muscle to liver for conversion to urea and
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Figure 4.1: Gluconeoqenesis in the liver cell
The diagram illustrates the cytoplasmic and 
mitochondrial interactions for the conversion of 
lactate, pyruvate and amino acids into glucose. 
The plasma membrane is represented by a 
rectangle; the mitochondrion by a circle. 
Abbreviations are: LAC, lactate; PYR, pyruvate;
ALA, alanine; SER, serine; GLY, glycine; FA fatty 
acids; AcCoA, acetyl CoA; CIT, citrate; a-KG, a- 
ketoglutarate; SUC, succinate; FUM, fumarate; 
MAL, malate; OAA, oxaloacetate; ASP, aspartate; 
GLUT, glutamate; THR, threonine; PEP, phosphoenol 
pyruvate; 2PG 2-phospho.gly cerate; 3 PG, 3-
phosphoglycerate; G3P, glyceraldehyde 3- 
phosphate; DHAP, dihydroxyacetone phosphate;
GLYP, glycerol 1-phosphate; GLL, glycerol; FDP, 
fructose 1,6-bisphosphate; F6P, fructose 6- 
phosphate; G6P, glucose 6-phosphate; GLU,
glucose; G1P, glucose 1-phosphate; GLN, glycogen. 
Numbers are: 1, alanine aminotranferase; 2,
lactate dehydrogenase; 3, pyruvate dehydrogenase; 
4, pyruvate decarboxylase; 5, phosphoenolpyruvate 
carboxykinase; 6, fructose 1,6-bisphosphatase; 7, 
phosphofructokinase; 8, glucose 6-phosphatase; 9, 
glucokinase.
The diagram is taken (with author's permission) 
from Metabolism (1972) 2, 945-990.
P
Y
R
 
A
L
A
 
G
L
L
D
0
♦ 
P
E
P
glucose respectively. It was further proposed that alanine would 
be resynthesised in muscle from transamination of the pyruvate 
derived from glucose or other amino acids. This operation 
permitted the catabolism of muscle protein without the release of 
ammonia (Fig. 4.2; section 6.1.2). The glucose alanine cycle is 
itself quantitatively unimportant and does not contribute to nett 
glucose flux (Caldecourt et al., 1985), but energetically its
contribution to the transamination of branched chain amino acids 
into branched chain keto acids and their subsequent oxidation 
provides 4-5 fold more ATP than glycolysis (Krebs, 1964b).
4.1.1 Regulation of Gluconeogenesis
Glycolysis and gluconeogenesis have most of their
enzymes in common. These enzymes catalyse reversible reaction,
the rates of which are essentially controlled by the
concentration of their respective substrates and products. The
irreversibility of the two pathways is maintained by energy
barriers imposed by a few reactions, the so called 'key' steps.
These reactions are catalysed by pyruvate carboxylase (PC; EC
6.4.1.1), phosphoenolpyruvate carboxykinase (PEPCK; EC 4.1.1.32),
fructose 1,6-bisphosphatase (F 1,6-P ase; EC 3.1.3.11) and
2
glucose 6-phosphatase (G 6-Pase; EC 3.1.3.9) and thus break the 
energy barriers. If these antagonistic reactions were to operate 
simultaneously, then there would be no nett flux of metabolites, 
only a futile recycling. These futile cycles are identified as;
1) glucose/glucose 6-phosphate cycle
2) fructose 6-phosphate/fructose 1,6-bisphosphate cycle
3) pyruvate/phosphoenolpyruvate cycle
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Figure 4.2: Glucose-alanine cycle
The diagram illustrates the synthesis of alanine 
in muscle. The carbons of alanine are derived 
from the oxidation of glucose, whereas the amino 
group is supplied by the catabolism of amino 
acids. Alanine, when released from muscle, 
serves as a precursor for hepatic glucose 
formation. The establishment of this cycle 
provides energy for muscular work and removes the 
toxic ammonia from muscle to the liver for 
disposal as urea. For other details see the 
text.
The diagram is adapted from the publications of 
Felig et al., (1970) and Mallette et al., (1969a).
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The nett balance of these cycles can involve the 
apparent wasteful hydrolysis of ATP. It therefore appears that 
the enzymes involved in these cycles are regulated to channel the 
flow of metabolites in one direction or the other. This section 
provides a summary review of the regulation of these enzymes. It 
is realised that this topic is larger than the other sections in 
this chapter. The pathways of gluconeogenesis/glycolysis are 
highly complicated processes. The irreversibility of these 
pathways are regulated at multiple sites by the interplay of 
gluconeogenic/glycolytic enzymes, substrate/product modulators, 
and a wide variety of hormones and by intracellular 
compartmentation. They are regarded as being among the richest 
areas of biochemical knowledge on carbohydrate metabolism, thus 
this short summary of necessity represents a bulky contribution 
to the chapter. The key regulatory steps of gluconeogenesis are 
summarised in Fig. 4.3.
4.1.1.1 Substrate and Enzyme Regulation
The pathway of gluconeogenesis involves three 
compartments; the cytoplasm, mitochondria and microsomes derived 
from the endoplasmic reticulum. This intracellular 
compartmentation offers a mechanism for the regulation of the 
gluconeogenic pathway (Utter and Chuang, 1978). The first step 
is the transportation of the substrates across the plasma 
membrane into the cytoplasm (access control). The precursors 
lactate, pyruvate and glycerol enter through the hepatic cell 
membrane by specific carriers (Christenson, 1969), but in the 
case of the amino acids, a membrane controlled transport has been
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Figure 4.3: Control of hepatic gluconeogenesis
The diagram illustrates the key regulatory steps 
of glycolysis, glycogenolysis and 
gluconeogenesis. Solid lines denote pathways or 
enzyme catalysed reactions. Broken lines denote 
effect of substrates or hormones. Symbols^ or 
Q a r e  used for activation or inhibition 
respectively.
Abbreviations are: c'AMP, cyclic adenosine 
3 5 ' -monophosphate; IP 3 , inositol 1,4,5- 
triphosphate; DAG, diacylglycerol; FRU 2,6-P, 
fructose 2,6-bisphosphate; FRU 6-P, fructose 6- 
phosphate; FRU 1,6-Pz, fructose 1,6-bisphosphate; 
PEP, phosphoenolpyruvate; PYR, pyruvate; OAA, 
oxaloacetate; GLC 6-P, glucose 6-phosphate; 
F 1,6-P2 ase, fructose 1,6-bisphosphatase; 
F 2,6-P2 ase, fructose 2,6-bisphosphatase; 
PFK-I, phosphofructokinase-I; PFK-II, 
phosphofructokinase-II; G 6-Pase, glucose 6- 
phosphatase; GK, glucokinase; PK, pyruvate 
kinase; PD, pyruvate dehydrogenase; PC, pyruvate 
carboxylase; PEPCK, phosphoenolpyruvate 
carboxykinase.
The diagram is taken (with author's permission) 
from Ann. Rev. Biochem. (1983) 52, 617-653.
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demonstrated (Mallette et al., 1969a). Further investigations
(Groen et al., 1982; McGiven et al., 1981; Sips et al., 1980)
showed that in the range of the plasma physiological 
concentration of alanine (0.2-0.5mM), the transport of the amino 
acid across the plasma membrane was the only process controlling 
the rate of its metabolism. However when the alanine 
concentration was higher than ImM, transport was not rate 
limiting, rather transamination was the rate determining process 
for alanine metabolism (McGiven et al., 1981). Upon entry into
the cytoplasm, the substrates lactate and alanine were first 
converted to pyruvate and then to phosphoenolpyruvate (PEP). 
Since the direct conversion of pyruvate to PEP is a 
thermodynamically formidable step (Krebs, 1954; Topper and 
Hasting, 1949), pyruvate is directed to PEP by the sequential 
actions of PC and PEPCK. In rat liver, PC is a mitochondrial 
enzyme (Siess et al., 1976; Weiss et al., 1974) requiring
pyruvate entry from the cytoplasm into the mitochondria. The
mitochondrial membrane is probably an important site for the 
control of gluconeogenesis in liver because the transport of many 
metabolites across the inner mitochondrial membrane is carrier 
mediated (Klingenberg, 1970) .
Recent investigations using 4-hydroxycyanocinnamate, an 
inhibitor of the pyruvate translocator (Thomas and Halestrap, 
1981), oxamate, a structural analog of pyruvate (Martin-Requero 
et al., 1986) and the determination of the elasticity coefficient 
of pyruvate carboxylase to pyruvate (Groen et al., 1986) , have
demonstrated that the first rate controlling step for
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gluconeogenesis from physiological concentrations of pyruvate or 
substances yielding this precursor was the transport across the 
inner mitochondrial membrane. However at saturating
concentrations of pyruvate, the gluconeogenic flux was regulated 
by PC rather than its mitochondrial transport (Groen et al., 
1986; Halestrap and Armston, 1984).
The activity of PC is highly stimulated by acetyl CoA
(Barrit et al., 1976; McClure and Lardy, 1971; Utter et al.,
2 +
1964) and Mg (Keech and Barritt, 1967; McClure and Lardy, 1971) 
but is inhibited by glutamate (Barritt et al., 1976). Pyruvate
dehydrogenase (PDH; EC 1.2.2.2) competes with PC for pyruvate. 
The regulation of PDH activity is directed by a phosphorylation - 
dephosphorylation reaction sequence (Bantenburg and Olson, 1976; 
Denton and McCormack, 1980; Hansford, 1981; Siess and Wieland, 
1978; Reed, 1969).
PC catalyses the conversion of pyruvate into 
oxaloacetate (OAA). Since mitochondrial membranes are not 
permeable to OAA, it is reduced to malate or is transaminated to 
aspartate for its transport out of the mitochondria (Krebs et 
al., 1967; Lardy et al., 1965), where by the action of malic
enzyme (EC 1.1.1.37) or aspartate transaminase (EC 2.6.1.1) and 
cytoplasmic PEPCK it is converted to PEP.
PEPCK is also a key regulatory enzyme of gluconeogenic 
flux, where cyclic adenosine 3'-5 * monophosphate (c'AMP) acts 
directly or indirectly to activate gluconeogenesis (Exton and 
Park, 1966). The intracellular distribution of PEPCK varies 
between species: in rat and mouse liver, it is almost exclusively 
cytoplasmic and in pigeon and rabbit liver it is almost totally
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mitochondrial, whereas in guinea pig and man it is equally
distributed between the cytoplasm and mitochondria (Soling and
Kleineke, 1976; Tilghman et al♦, 1974, 1976). However only the
cytoplasmic enzyme is responsive to hormonal and dietary
regulation (Ballard and Hopgood, 1973; Tilghman, 1976). PEPCK 
2 +
requires Mg for full activity (Foster et al♦, 1967). Other
2+  24- 2+  24-
metal ions, Fe , Ca , Cd and Mn can also appreciably
24-
increase the activity of this enzyme, of these only Fe appeared
to be involved in the regulation of PEPCK under physiological
24-
conditions (Lardy and Merryfield, 1981). The action of Fe on 
PEPCK activity required the presence of a protein called PEPCK- 
ferroactivator (Lardy and Merryfield, 1981; Merryfield and Lardy, 
1982) .
PEPCK is also an important site for the hormonal
regulation of gluconeogenesis (section 4.1.1.2). Five hormones 
have been shown to regulate the transcription of the gene for 
PEPCK. Three of these hormones, insulin (Granner et al♦, 1983) , 
glucagon (Lamers et al♦, 1982) and epinephrine (Cimbala et al.,
1980) act via plasma membrane receptors. The remaining two, 
glucocorticoids (Lamers et al., 1982) and thyroid hormone
(Sibrowski et al., 1982; Muller et al., 1982; Loose et al., 1985) 
act via cytoplasmic and nuclear receptors.
PEP can be converted to pyruvate by pyruvate kinase 
(PK; EC 2.7.1.40), thereby creating a futile cycle (Friedmann et 
al., 1971). At least three different isoenzymes of pyruvate
kinase have been identified in mammalian tissues. Muscle and 
brain contain the type M isoenzyme; the type L is the major
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isoenzyme in liver but minor in kidney. The type A is present in
most other tissues except liver, including kidney, adipose tissue
and lung (Kayne, 1973). Type A and L, but not M are
allosterically regulated. The most active conformation is
favoured by PEP, fructose 1,6-bisphosphate (fru 1,6-P ) and low
2
pH. The less active conformation is favoured by ATP, alkaline
pH, alanine and several other amino acids (Kayne, 1973; Seubert
and Schoner, 1971). The enzyme activity is also regulated by
phosphorylation catalysed by c’AMP dependent protein kinase (EC
2.7.1.37) (Engstrom, 1978; Ljungstrom et al., 1974).
The concentration of PEP in the cytoplasm is most
critical for the regulation of gluconeogenesis. Recent studies
showed that all steps which are able to influence PEP
concentration would exert control on gluconeogenesis (Groen et
al., 1983, 1986). The reactions between PEP and fru 1,6-P are
2
catalysed by enzymes of the Embden-Meyerhof pathway which
maintain the reactants in a near equilibrium state. Under fed
conditions these enzymes exert a fine control on the
concentration of PEP and are effective regulators of PK flux and
thus gluconeogenic flux (Groen et al., 1983, 1986).
Fru 1,6-P is the principle substrate of F 1,6-P ase 
2 2 
which catalyses its conversion into fructose 6-phosphate and Pi.
The intervention of phosphofructokinase-I (PFK-I; EC 2.7.1.11) at
this step creates the possibility of a futile cycle (Hers and
Hue, 1983). It has been suggested that the regulation of
glycolysis and gluconeogenesis can occur at least partially at
the levels of this enzyme (Start and Newsholme, 1970). The
activity of F 1,6-P ase is regulated by its substrate and its two
2
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Theinhibitors AMP and fructose 2, 6-bisphosphate (fru 2,6-P ).
2
inhibition by AMP is cooperative - noncompetitive (Taketa and
Pogell, 1965) and is less important at low than at high substrate
concentration (Pilkis et al., 1981a). Fru 2,6-P , despite its
2
obvious structural similarities with the substrate, does not act
primarily by competing for the active site (Gottschalk et al.,
1982). It was proposed that fru 2,6-P binds to a specific
2
allosteric site, thereby initiating a mechanism that decreases
the occupancy of the active site for the substrate (Francois et
al., 1984). The enzyme PFK-I catalyses the phosphorylation of
fructose 6-phosphate into fru 1,6-P . It is regulated by its
2
substrates, ATP and fructose 6-phosphate (Scrutton and Utter,
+
1968) and has a relatively large series of negative [citrate, H
(Kemp, 1971) and glycerol 3-phosphate (Claus et al., 1982)] and
+  —
positive [AMP, ADP, Pi, NH , OH (Kemp, 1971; Scrutton and
4
Utter, 1968), fru 1,6-P , glucose 1,6-bisphosphate (glc 1,6-P ),
2 2 
fru 2,6-P (Sener et al., 1982; Uyeda et al., 1981; Van
2
Schaftingen et al., 1981) and 6-phosphogluconate (Sommercorn and
Freedland, 1982)] effectors. The efficiency of fru 2,6-P is 2-
2
3.5 fold greater than that of its isomeric ester fru 1,6-P and
2
glc 1,6-P (Sener et al., 1982; Uyeda et al., 1981; Van
2
Schaftingen et al., 1981a).
The next important step in the gluconeogenic pathway is 
the isomerisation of fructose 6-phosphate into glucose 6- 
phosphate by glucose 6-phosphate isomerase (EC 5.3.1.9), which is 
reported to maintain a near equilibrium reaction. This is 
followed by the final step of the pathway involving the
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conversion of glucose 6-phosphate to glucose and Pi catalysed by
G 6-Pase. However the presence of hexokinase (HK; EC 2.7.1.1) 
and glucokinase (GK; EC 2.7.1.2) in liver creates the potential 
for a third futile cycle (Hers and Hue, 1983). No mechanism 
other than that involving the concentrations of substrates and 
products is known to effect the activity of G 6-Pase (Nordlie,
1971, 1976) and GK (Ureta et al., 1970). It was demonstrated
that the infusion of glucose into normal humans suppressed 
endogenous glucose production independently of the insulin 
response (Wolfe et al., 1986) . Similar results were previously
reported in humans (Robert et al., 1982) and dogs (Shulman et
al., 1980). From this, it was reasoned that increasing the
concentration of the substrate of the reaction accelerated its 
conversion to the product, a higher level of which should then 
favour the reverse reaction. However this phenomenon did not 
occur for the following reasons:
1) When glucose concentration was high, it not only 
activated glucokinase but it also inactivated glycogen 
phosphorylase (EC 2.4.1.1) and activated glycogen 
synthase (EC 2.4.1.11), two effects that cooperated to 
maintain low levels of glucose 6-phosphate (Hers, 1976; 
Stalmans, 1976).
2) An increase in glucose 6-phosphate secondarily induced
the formation of fru 2,6-P , resulting in a higher rate
2
of glycolysis (Hers and Van Schaftingen, 1982; Pilkis et 
al., 1981a) .
3) When the concentration of glucose 6-phosphate was high, 
glucose was formed at a proportional rate, but because it
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diffuses out of the liver and was diluted in the body 
fluids, its intracellular concentration was only 
moderately increased (Hue, 1981).
The details of the exit of glucose from the liver cell 
and its regulation are still unknown. It is not clear whether 
the glucose produced is directly released from the endoplasmic 
reticulum to the interstitial space or whether it has to cross 
the plasma membrane. These questions require more investigations 
(Kraus-Friedmann, 1984).
4.1.1.2 Hormonal Regulation
Regulation of gluconeogenesis also involves interplay 
between the hepatic and peripheral effects of several 
glucoregulatory hormones, which include glucagon, epinephrine, 
glucocorticoids, vasopressin, angiotensin-II and insulin.
4.1.1.2.1 Glucagon
The inital action of glucagon is its encounter with the
cell membrane receptor, which leads to the activation of membrane
bound adenylate cyclase (EC 4.6.1.1) (Krug et al., 1971). The
activation of adenylate cyclase then generated a second
messenger, c'AMP (Robinson et al., 1971) which mediates the
intracellular effects of glucagon (Exton et al., 1971). The
effects of c ’AMP are attributed to the activation of c'AMP
dependent protein kinase (Glass and Krebs, 1980; Greengard, 1978;
Pilkis et al., 1975b), which catalyses the phosphorylation of the
following five regulatory enzymes; PFK-I (Claus et al., 1980),
F 1,6-P ase (Claus et al., 1981; Riou et al., 1977), PFK-2 (El-
2
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Maghrabi et al., 1982 a,b; Furuya et al., 1982b; Van Schaftingen
et al., 1981), F 2,6-P ase (El-Maghrabi et al., 1982 a,c; Furuya
2
et al., 1982a; Van Schaftingen et al., 1982) and PK (Engstrom,
1978; Ljungstrome et al., 1974, 1976). Thus it appears that the
phosphorylation of these enzymes which regulates gluconeogenesis
by glucagon occured at the levels of fructose 6-phosphate/fru
1,6-P and pyruvate/PEP interconversions. Furthermore these two 
2
glucagon regulated steps of gluconeogenesis may also be connected
by metabolites, which reinforce the hormonal effect. The
inactivation of PK causes a several fold increase in the
concentration of PEP which further inhibits PFK-2 (Van
Schaftingen and Hers, 1981) and stimulates F 1,6-P ase (Hers and
2
Hue, 1983). Through this feed forward mechanism glucagon
decreased the concentration of fru 2,6-P and hence
2
gluconeogenesis was stimulated. Fru 2,6-P by itself has no
2
effect on pyruvate kinase (Hers and Van Schaftingen, 1982; Soling
et al. , 1981), however decreased levels of fru 2,6-P can
2decrease the levels of fru 1,6-P (Pilkis et al., 1981b) which is
2
a potent stimulator of pyruvate kinase (Kayne, 1973; Seubert and 
Schoner, 1971) and hence the utilisation of PEP for 
gluconeogenesis is stimulated (Hers and Hue, 1983) (Fig. 4.3). 
However glucagon also has other effects which may lead to the 
stimulation of gluconeogenesis. It activates PC (Chan et al., 
1979), PDH (Adam and Haynes, 1969), PEPCK (Shargo et al., 1963) 
and the transport of pyruvate across the mitochondrial membrane 
(Halestrap, 1978; Titheradge and Coore, 1976).
116
4.1.1.2.2 Epinephrine
Epinephrine was the first hormone for which the 
hyperglycaemia effect was recognised and studied. These studies 
led to the discovery of c'AMP (Rail et al., 1957) and the 
development of the second messenger concept (Robinson et al.,
1971) . Accordingly, until recently the gluconeogenic and 
glycogenolytic effects were attributed to its stimulation of 
adenylate cyclase and subsequent increase in c'AMP levels (Exton,
1972) . However recent studies demonstrated that the effects of 
epinephrine, norepinephrine, phenylephrine and isoproterenol on 
the activation of glycogen phosphorylase , inactivation of PK and 
stimulation of gluconeogenesis were blocked by a-antagonist (Kemp 
and Clark, 1978; Sherline et al., 1972). Furthermore, the 
calcium channel blockers were shown to inhibit the a -adrenergic 
activation of glycogenolysis (Kimura et al., 1981) and a - 
adrenergic antagonists act as calcium channel inhibitors (Atlas 
and Adler, 1981). It was therefore concluded that there are two 
independent mechanisms whereby catecholamines activate 
glycogenolysis and gluconeogenesis: a 3-receptor mediated effect, 
arising from the activation of c'AMP dependent protein kinase and 
an öl -receptor mediated effect arising from the increased 
cytosolic calcium content (Berthon et al., 1981; Blackmore et 
al., 1982; Garrison et al., 1979).
Recently diacylglycerol and inositol 1,4,5-triphosphate 
were also proposed to be putative mediators of the a-adrenergic 
mechanism (Berridge, 1983; Creba et al., 1983; Exton, 1985; 
Joseph et al., 1984). More recently Garcia-Sainz and Hernandez- 
Sotomayer (1985) showed that the effects of a-adrenergic agents
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on glycogenolysis and gluconeogenesis involved two mechanisms: 
1) a calcium dependent insulin insensitive process that was 
modulated by thyroid hormone and was shared by vasopressin and 
angiotensin-II (see section 4.1.1.2.4) and 2) a calcium 
independent-insulin sensitive process that is modulated by 
glucocorticoids. These workers also proposed a role for c'AMP in 
the & -adrenergic action, but this idea has not been supported by 
the work of Lardy et al., (1983).
4.1.1.2.3 Glucocorticoids
The role of glucocorticoids in maintaining the ability 
of an organism to carry out gluconeogenesis and glycogen 
synthesis was first recognised by the classic studies of Long and 
coworkers (1940). The effects of glucocorticoids are genrally 
grouped into two categories: the direct and the permissive 
(Kraus-Friedmann, 1984). Direct effects of steroids appear to be 
mediated by specific hormone-receptor proteins via a two step 
mechanism involving the formation of hormone receptor complexes 
in the cytoplasm followed by their interaction with nuclear 
components (Jensen and DeSombre, 1972; O ’Malley and Means, 1974). 
Whereas the permissive effects permitted the generation of a 
secondary stimulus such as glucagon to effect the biochemical 
changes (Ingle, 1952).
The best understood direct effect of the 
glucocorticoids is the induction of enzyme synthesis (Voigt et 
al., 1978). The most studied enzyme in the gluconeogenic pathway 
is PEPCK, whose synthesis was increased many fold following the 
interaction of glucocorticoids with cytoplasmic receptors and the
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induction of the transcription of the gene for PEPCK (Lamers et 
ah, 1982) .
The role of glucocorticoids in skeletal muscle 
mobilisation to supply gluconeogenic precursors to the liver 
(Bondy et al., 1954) probably constitutes a major part of their 
permissive effects on gluconeogenesis. Glucocorticoids raise the 
plasma levels of nearly all amino acids (Kaplan and Shimizu, 
1963), both by inhibiting the synthesis of protein (Shoji and 
Pennington, 1977; Steel, 1975; Tomas et a L , 1979) probably 
acting at the translational level (Rannels et al., 1978) and by 
their nett protein catabolic effects on peripheral tissues 
(Kostyo, 1965; Smith and Long, 1967). The exact mechanism of the 
permissive effect of glucocorticoids is still unknown.
4.1.1.2.4 Vasopressin and Angiotensin-II
Vasopressin and angiotensin-II stimulate 
gluconeogenesis in the presence of gluconeogenic substrates (Hems 
and Whitton, 1973 ; Whitton et al., 1978) . It was demonstrated 
that both hormones stimulated the phosphorylation of some hepatic 
proteins in much the same fashion as glucagon (Garrison et al., 
1979) (Fig. 4.3; section 4.11.2.1). Vasopressin actions in the 
kidney involve binding to a cellular receptor, activation of 
adenylate cyclase and c'AMP dependent protein kinase (Schlondroff 
et al., 1980). However the hepatic actions of vasopressin do not 
involve a change in c'AMP dependent protein kinase (Kirk and 
Hems, 1974) but they are related to ion fluxes and especially to 
the uptake of calcium (Chen et al., 1978). The action of both 
hormones were completely abolished in calcium free incubation
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medium (Garrison et al., 1979). These studies indicated that the 
effect of vasopressin and angiotensin-II on the cytoplasmic step 
of the gluconeogenic pathway may be similar to those of glucagon 
and epinephrine (Kraus-Friedmann et al., 1984; Hers and Hue,
1983). It was also shown that, in addition to the inhibition of 
PK activity, these hormones may activate gluconeogenesis by 
stimulating the activity of PDH (Hems et al., 1978a; Hue, 1981).
Moreover, vasopressin stimulated the accumulation of fru 2,6-P
2
in hepatocytes from fed rats but not from starved rats or from 
2 +
Ca depleted hepatocytes from fed rats (Hue et al., 1981 a,b) .
This further indicated the involvement of vasopressin in the
PFK-I/F 1,6-P ase cycle. However, angiotensin-II did not cause 
2
any change in the cellular levels of fru 2,6-P (Sistare and
2
Haynes, 1985).
4.1.1.2.5 Insulin
Insulin generally opposes the effects of the
gluconeogenic stimulatory hormones in the liver for most of the 
parameters that are conventionally examined. Several studies 
have shown that, following the administration of insulin to whole 
animals, the perfused liver or hepatic tissue culture
preparations, the activities of PC and PEPCK were diminished 
(Gunn et al., 1975; Veneziale et al., 1983; Wienberg and Utter,
1980) whereas the activities of PK (Blair et al., 1976; Feliu et
al., 1976; Miyanaga et al., 1982) and PDH (Czech, 1981; Larner et 
al., 1979; Parker and Jarnett, 1985; Seals and Czech, 1980) were
increased. Several explanations have been proposed about the 
mechanism by which insulin diminished hepatic gluconeogenesis.
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One explanation was the increased degradation of pyruvate (Kraus- 
Friedmann, 1984; Patel et al♦, 1984; Weinberg and Utter, 1980) 
because of the enhanced activities of PK and PDH. Other 
explanations involved argument that the anabolic effects of 
insulin counterbalanced the catabolic effects of glucagon, 
epinephrine and other stress hormones (Bessman and Runner, 1982; 
Zaidise and Bessman, 1984) . This concept was supported by the 
evidence that insulin inhibited gluconeogenesis in diabetic 
rabbits, enhanced Krebs cycle activity and stimulated muscle 
protein synthesis (Mohan and Bessman, 1981). Recent developments 
showed that the major role of insulin in the regulation of 
gluconeogenesis was its ability to limit the availability of 
substrates for gluconeogenesis by apparently enhancing protein 
(Inculet et al., 1986; Mohan and Bessman, 1981) and fatty acid
synthesis (Gomez-Coronado et al., 1985) from gluconeogenic
substrates rather than inhibiting the activities of gluconeogenic 
enzymes or stimulating the oxidation of pyruvate to acetyl CoA.
Another mechanism of insulin action involved inhibition
2 +
of a-adrenergic activation of hepatic phosphorylase and Ca 
output (Blackmore et al., 1979). It was proposed that insulin
either inhibited the binding of a-agonists to their specific 
plasma membrane receptors or altered the generation and/or 
degradation of putative a-adrenergic second messengers (Dehaye et 
al., 1981).
Further studies demonstrated the generation of an acid 
and heat stable substance in rat skeletal muscle by insulin 
(Larner et al., 1979). This factor inhibited the c'AMP dependent
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protein kinase and stimulated glycogen synthase phosphorylase
(Cheng et al., 1980; Larner et al., 1979). The same kind of 
mediator was also shown to activate PDH in adipocyte mitochondria 
(Jarett and Seals, 1979) by activating phosphatase rather than 
inhibitng kinase (Kiechle et al., 1981). Moreover it was 
demonstrated that the adipocytes and skeletal muscle sensitive 
materials were indistingiushable and were regarded as the 
chemical mediators of insulin action (Kiechle et al., 1981).
4.1.2 Gluconeogenesis in the Foetus
Hepatic gluconeogenesis was negligible in the foetal 
rat liver but increased very rapidly after birth, especially 
during the first week of extrauterine life (Ballard and Oliver, 
1963; Jones and Ashton, 1976). Lactate and pyruvate were the 
major substrates for early gluconeogenesis but later amino acids 
and glycerol were also utilised for glucose formation (Snell, 
1975). Blood lactate levels were elevated in the foetus because 
of the relative hypoxia and because glucose was the principal 
fuel (Snell, 1975). The highly reduced cytoplasmic redox state 
of foetal liver had been used as the explanation for the low 
rates of gluconeogenesis (Ballard, 1971) and was attributed to 
the low levels of pyruvate and oxaloacetate (Philippidis and 
Ballard, 1969). This explanation was not supported by others 
(Girard et al., 1977). Another possible factor that was used to 
explain the absence of gluconeogenesis in foetal rat liver was 
the high insulin/glucagon ratio in foetal plasma (Girard et al. , 
1977) but this explanation proved to be inadequate for other 
animal species (Jones et al., 1981).
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The activity of alanine aminotransferase in 10 day old
neonatal rat liver was 1/10 of the enzyme activity present in the
adult rat (Snell, 1975). PEPCK activity was detected prior to
the appearance of other gluconeogenic enzymes (Kirby and Hahn,
1973). The enzymes, PC, F 1,6-P ase and asprtate transaminase
2
were present in relatively high activity in foetal liver (Adam, 
1971). PK, citrate lyase (EC 4.1.3.6), glucose 6-phosphate 
dehydrogenase and malic enzyme were also present in foetal liver 
but increased many fold after weaning (Vernon and Walker, 1968). 
It was apparent that the low activity of alanine aminotransferase 
relative to the other gluconeogenic enzymes in foetal liver 
restricted the conversion of alanine into glucose despite an 
enhanced gluconeogenic capacity from lactate and pyruvate (Snell, 
1975, 1982). Furthermore it was also demonstrated that when the
activity of alanine aminotransferase was blocked by L-cycloserine 
in neonatal liver, the plasma concentrations of glucose and 
alanine were unchanged, which indicated that alanine was not a 
significant substrate for neonatal gluconeogenesis (Snell, 1982).
4.1.3 Gluconeogenesis in Infectious and Inflammatory Diseases
Failure of gluconeogenesis is recognised as a major 
determinant of endotoxic hypoglycaemia (Agarwal, 1975; Agarwal 
and Lazer, 1977; Berry, 1971, 1975, 1977; Filkins, 1978).
Isolated parenchymal cells from rats, treated with lead (Pb) 
salts to depress the liver reticuloendothelial system, manifested 
depressed gluconeogenesis from alanine, pyruvate and lactate 
(Filkins and Yelich, 1980). Isolated hepatocytes from septic 
rats were reported to show depressed gluconeogenesis from alanine
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(Wannemacher et al., 1980). Similar depressions of hepatic
gluconeogenesis have been observed in humans (Wilmore et al.,
1980) and in guinea pig liver (Wolfe and Burke, 1978). In
14
endotoxin treated mice, the incorporation of [U- C] alanine into 
glucose was reduced by 50% of the amount seen in control animals 
(McCollum, 1981; McCollum and Berry, 1973). The failure of
gluconeogenesis in infectious animals may be explained in part by 
changes in enzyme levels. The activity of PEPCK declined 
significantly following the treatment of hepatocytes from mice 
with endotoxin (McCollum, 1981). Berry et al., (1968) showed
that endotoxin prevented the induction by cortisone of PEPCK 
activity. McCollum (1981) demonstrated that endotoxin stimulated 
Kupffer cells of liver to release mediator(s) from macrophages 
which then inhibited the activities of PEPCK in hepatocytes and 
thus conversion of pyruvate into glucose. However, whatever 
changes occur in the activity of alanine aminotransferase and 
other gluconeogenic enzymes during infection/inflammation are 
still issues on which there is little or no data.
It can be concluded from these studies that an immune 
response due to infection or inflammation in animals was inter 
alia characterised by suppressed gluconeogenesis.
4.1.4 Gluconeogenesis in Neoplastic Disease
Tumour growth depends largely on glycolysis and 
glutaminolysis for the provision of energy (Reitzer et al♦, 
1979). It has been shown that the activities of key glycolytic 
enzymes in neoplasms increase in parallel with the increasing 
growth rate of the tumour and with associated loss of
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differentiation (Weber, 1966). A number of tumours show high 
rates of aerobic glycolysis and produce large amounts of lactate 
(Gold, 1966; Shapot, 1972, 1974). Measurement by arteriovenous 
differences across many neoplasms shows that 50% of the glucose 
carbon taken up by the tumour appears as lactate in the venous 
blood (Gullino et al., 1967; Singh et al., 1978). Lactic 
acidosis has been reported•in some patients with uncontrolled 
solid tumours such as bronchogenic carcinomas and hepatocarcinoma 
(Spechler et al., 1978). It has been suggested that an increase 
in the process of gluconeogenesis may be present in cancer 
subjects to maintain normoglycaemia (Gold, 1974). Increased 
gluconeogenesis from lactate (Gold, 1968, 1974; Holroyde et al., 
1975; Shearer et al., 1983; Reichard et al., 1963; Waterhouse, 
1974b) and pyruvate (Shearer et al., 1984) has been reported for 
tumour bearing subjects. However it was demonstrated that basal 
alanine metabolism, glucose turnover and gluconeogenesis from 
alanine in vivo were not significantly different in cachectic 
tumour bearing animals in comparison with non tumour bearing 
animals (Arbeit et al., 1982; Lowry et al., 1979). Furthermore, 
a smaller than normal conversion of alanine into glucose was 
demonstrated in vivo in tumour bearing mice (Shapot and Blinov, 
1974). In contrast to these studies, increased glucose synthesis 
from alanine in hepatocytes of tumour bearing rats (Roh et al., 
1984) and in rats (Singh et al., 1978), mice (Lundholm et al., 
1980) and cancer patients (Waterhouse et al., 1979) in vivo has 
been reported. However it was estimated that the nett 
contribution of alanine to glucose formation in patients with 
elevated levels of gluconeogenesis from alanine was still
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relatively small i.e., 4-5% of total new glucose formed and
probably not significant in terms of energy expenditure
(Waterhouse et al., 1979) and substrate economy (Arbeit et al.,
1982) in cancer subjects. A small number of investigators have 
tried to explain the impairment of gluconeogenesis in tumour 
bearing subjects. Singh et al., (1980) demonstrated that the key
gluconeogenic enzymes in the livers of tumour bearing rats were 
similar to those of the livers of overnight starved rats and were 
insufficient to explain the high rates of gluconeogenesis from 
lactate and alanine in vivo. It was therefore suggested that a 
hormonal response may be important for the regulation of 
gluconeogenesis in cancer subjects (Lundholm et al., 1980; Singh
et al., 1980). It is of interest to note that the levels of
insulin (Burt et al., 1981; Shapot and Blinov, 1974) and glucagon 
(Burt et al., 1981) were found to be similar in both control and
tumour bearing animals. Although insulin resistance (Lundholm et 
al., 1978b) and abnormal glucose tolerance (Marks and Bishop,
1957) have been described in cancer bearing subjects. The basal 
cortisol levels in cancer patients were found to be normal 
(Carter et al♦, 1975; Goodman et al., 1978). Furthermore, when
mice with Ehrlich carcinoma were subjected to stress or given 
cortisol, less endogenous glucose was formed from amino acids 
than in healthy control animals under identical conditions 
(Shapot and Blinov, 1974). This reduced responsiveness of the 
host tissues to glucocorticoids was regarded as a manifestation 
of the systemic actions of the tumour (Shapot and Blinov, 1974) . 
A recent study (Roh et al., 1984) demonstrated that increased
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glucose formation from alanine was associated with the increased 
transport of alanine in hepatocytes of tumour bearing rats. To 
date, no other source has reported the increased transport of 
alanine in the liver of tumour bearing animals. No explanation 
has been provided for the unimpaired (Arbeit et al., 1982; Lowry 
et al., 1972) or decreased gluconeogenesis (Shapot and Blinov, 
1974) from alanine in tumour bearing animals.
It is apparent from the above investigations that there 
are conflicting reports of gluconeogenesis from alanine in tumour 
bearing rats. The reported changes in the levels of substrates, 
enzymes and hormones are insufficiently catalogued to resolve 
this conflict. Bearing in mind the controversial nature of 
existing data, the present study, using the isolated perfused 
liver of normal and tumour bearing rats was most carefully 
performed. The rate and extent of gluconeogenesis from alanine 
at the physiological blood concentrations were measured in order 
to attempt to resolve the conflicting reports of glucose 
formation from amino acids in cachectic tumour bearing animals. 
The results are used to point out the possible impairments in the 
process of gluconeogenesis in these animals, in the light of the 
abnormalities of other physiological processes commonly 
encountered as systemic effects of tumour bearing.
4.2 Results
4.2.1 Oxygen Consumption by the Perfused Livers
The oxygen consumption of livers during perfusion was 
measured in the presence and absence of the gluconeogenic 
substrate, alanine. The results are shown in Table 4.1. The
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Table 4.1: Oxygen consumption during the course of liver 
perfusion of control rats and rats bearing the 
Walker 256 carcinosarcoma or R3230AC 
adenocarcinoma
No added substrate 
(ymol min— i g — i w/w)
Alanine
(limol min— i g— i w/w)
Control rats 2.22 + 0.06 
(n=18)
2.90 + 0.43***° 
(n=12)
Walker 256 
carcinosarcoma 
bearing rats
1.33 + 0.09 ***a 
(n=7)
1.53 + 0.09***° 
(n=7)
R3230AC
adenocarcinoma 
bearing rats
1.60 + 0.17 ***a 
(n=4)
1.84 + 0.20***° 
(n=4)
Livers were perfused as described in section 2.8.5. The 
concentration of alanine in the perfusion fluid is shown in Fig. 
4.4. The oxygen consumption was determined by the difference of 
efferent and afferent oxygen concentration during the course of 
the perfusion (0-60 min). Values are the mean + SEM. The number 
of observations in each group are shown in parenthesis. 
"Student’s t test" was used for the statistical evaluation of the 
data. The p values are related to: a) the results of control
experiments (unpaired data)and b) the results of the respective 
groups in the absence of added substrate(paired data), ***p<0.001.
oxygen consumption of the livers of control rats was 
approximately 30% (pcO.OOl) greater when perfused with alanine 
than in the absence of added substrate. The livers of the tumour 
bearing rats consumed significantly less oxygen in the absence of 
alanine in comparison with the oxygen consumption of the livers 
of control rats. Perfusion with alanine stimulated the oxygen 
consumption by approximately 15% (p<0.001) in the livers of the 
tumour bearing animals.
4.2.2 Alanine Concentration in the Perfusion Medium
The concentration of alanine in the perfusion medium 
was assessed during the time course of each liver perfusion. The 
results are shown in Fig. 4.4. The concentration of alanine in 
the perfusion medium during the perfusion of the livers of 
control rats did not vary significantly and was maintained at 
0.45 + O.OlmM to 0.54 + 0.04mM. In the case of livers of rats
bearing the Walker 256 carcinosarcoma and R3230AC adenocarcinoma, 
the concentration of alanine varied significantly from 0.45 +
0.04mM to 0.7 + 0.033mM (pcO.OOl) and 0.44 + 0.02mM to 0.88 +
0.04mM (p<0.001) respectively.
4.2.3 Endogenous Glucose Formation
The rate of endogenous glucose formation in the absence 
of substrate alanine was determined for a period of 60 min. (Fig. 
4.5). The rate of endogenous release of glucose into the 
perfusion medium from the livers of control, Walker 256
carcinosarcoma and R3230AC adenocarcinoma bearing rats was found
-1 -1
to be 0.06 + 0.00.4, 0.042 + 0.003 and 0.02 + 0.002 Umol min g 
liver wet weight respectively. These rates were used to correct
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Figure 4.4: Concentration of alanine in the perfusate
Livers were perfused as described in the 
experimental section (section 2.8.5). The livers 
of animals bearing the Walker 256 carcinosarcoma 
were perfused at day 13-14 post implantation (PI) 
and the livers of animals bearing the R3230AC 
adenocarcinoma were perfused at day 21-22 PI. 
Glycogen from livers was depleted, prior to the 
perfusion by glucagon and phloridzin treatment as 
described in the experimental section (section 
2.8.3). The livers were first perfused using a 
non-recirculating fluid consisting of Krebs- 
Henseleit bicarbonate buffer, pH 7.4, 
equilibrated with 5%C02/95%02 at 37 C with no 
added substrate for a duration of 60 min. to 
determine the endogenous glucose formation. The 
perfusion (recirculation) was then conducted from 
a second reservoir containing alanine at 
physiological blood concentration (0.45mM) in the 
above buffer. In order to maintain this 
concentration at a steady state value, a constant 
infusion of stock alanine solution (80mM) was 
made at a rate of 8.0 umol/min. Samples (2.0ml) 
of perfusate were taken at 10 min intervals and 
analysed for their alanine concentration. The 
values show the mean for six perfusions in each 
experimental group. The SEM are represented by 
the vertical lines. "Student's t test" was used 
for the statistical evaluation of the data. The 
p values are related to the alanine concentration 
at 0 min. of perfusion, *p<0.05, **p<0.01,***p<0.001.
▲: Control rats
■: Walker 256 carcinosarcoma bearing rats 
♦: R3230AC adenocarcinoma rats
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Figure 4.5: Endogenous glucose production
Livers were perfused, as described in the legend 
of Fig. 4.4, using a non-recirculating fluid 
consisting of Krebs-Henseleit bicarbonate buffer, 
pH 7.4, equilibrated with 5%C02/95%02 at 37°C with 
no added substrate for a duration of 60 min. and 
glucose released from the livers was measured. 
The rate of endogenous glucose formation was 
determined from the average rate of glucose 
release into the perfusion fluid during the last 
30 min. of the perfusion. The values show the 
mean for at least five perfusions in each 
experimental group. The SEM are represented by 
vertical lines.
a : Control rats
■: Walker 256 carcinosarcoma bearing rats
♦: R3230AC adenocarcinoma bearing rats
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the values for glucose formation in the presence of alanine.
4.2.4 Glucose Formation from Alanine
The hepatic capacity of the control and tumour bearing
rats to form glucose from the physiological blood concentration
of alanine (0.45mM) were assessed using enzymatic assay and
radioisotopic methods as described in section 2.8.8. The results
are shown in Figs. 4.6 and 4.7. The results obtained by these
two methods showed consistent trends but the magnitude of the
measured quantities were different. The results obtained using
the enzymatic assay method may be expected to be more accurate as
such methods are highly specific for the detection of glucose.
In the radioisotopic assay method there is always a chance that 
14
C-label measured in a certain metabolite may escape (by
undergoing a biochemical reaction) to other metabolites causing 
anticipated levels of radioactivity to decline and therefore the 
assessed levels of the metabolite to decline. However it is 
evident from both sets of results that there was a 45% (p<0.001) 
decrease in the rate of glucose formation from alanine in the 
livers of rats bearing the Walker 256 carcinosarcoma and a 65%
(p<0.001) decrease in the livers of rats bearing the R3230AC
adenocarcinoma (Table 4.2). These rates were significantly lower 
than the rates of gluconeogenesis from alanine by the livers
from control animals. Furthermore, Figs. 4.6 and 4.7 also 
indicated that the extent of glucose formation from alanine after 
60 min. of liver perfusion by tumour bearing rats were 
significantly lower than the extent of glucose formation by the 
livers of control animals. The extent of glucose formation was
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Figure 4.6: Glucose formation from alanine
Livers were perfused as described in the legend 
of Fig. 4.4. The perfusion was conducted using 
recirculating fluid containing alanine at 
physiological blood concentration (0.45mM) in the 
Krebs-Henseleit buffer. In order to maintain 
this concentration at a steady state value, a 
constant infusion of stock alanine solution 
(80mM) was made at a rate of 8.0 umol/min. The 
concentration of alanine in the circulation at 
various stages of the perfusion was shown in Fig. 
4.4. The glucose formation from alanine was 
followed for a further 60 min. Glucose formation 
was determined by subtracting the amount of 
endogenous glucose produced. The values shown 
are the mean for at least five animals in each 
experimental group. The SEM are represented by 
the vertical lines.
a : Control rats
■: Walker 256 carcinosarcoma bearing rats
♦: R3230AC adenocarcinoma bearing rats
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Figure 4.7: Glucose formation from L-fU- C] alanine
Livers were perfused as described in the legend 
of Fig. 4.4. The specific activity of L-[U-14C] 
alanine in the recirculation perfusion fluid was 
0.01Ci/mol. This activity was maintained by 
constant infusion of stock alanine solution 
(0.8mCi) at a rate of 0.08 UCi/min. Samples 
(2.0ml) of perfusate were taken at 10 min. 
intervals. 1ml of sample was passed through a 
column containing mixed bed resin (Dowex 50W 
(100-200) and AGlx4 (100-200) in 1:1 ratio 
(w/w)). Glucose was quantitatively recovered in 
deionised water eluted fractions and measured 
using liquid scintillation spectrometry as
described in section 2.8.9. The concentration of 
14C-glucose synthesised from [U-14C] alanine was 
determined from the relationship that two
molecules of alanine form one molecule of
glucose. The values show the mean for at least 
four animals in each experimental group. The SEM 
are represented by the vertical lines.
14
a : Control rats
■ : Walker 256 carcinosarcoma bearing rats 
♦ : R3 2 3 0AC adenocarcinoma bearing rats
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Table 4.2: Rates of gluconeogenesis from alanine 
perfused livers of control rats and rats 
the Walker 256 carcinosarcoma or 
adenocarcinoma
by the 
bearing 
R3230AC
Umol min— :g — i(w/w) 
by enzyme assays
Umol min— 1g— 1 (w/w) 
[U-14C] alanine 
incorporation
Control rats 0.11 + 0.005 
(n=5)
0.074 + 0.006 
(n=4)
Walker 256 
carcinosarcoma 
bearing rats
0.063 + 0.007*** 
(n=6)
0.044 + 0.003*** 
(n=4)
R3230AC
adenocarcinoma 
bearing rats
0.043 + 0.003*** 
(n=5)
0.025 + 0.001*** 
(n=5)
Livers were perfused as described in section 2.8.5. All control 
and tumour bearing animals were starved for 24-36 hours prior to 
the liver perfusion, to remove liver glycogen, as described in 
section 2.8.5. For further details see the legends of Figs. 4.4- 
4.7. The values are the mean + SEM. The number of observations 
in each group are shown in parenthesis. "Student's t test" was 
used for the statistical evaluation of the data. The p values 
are related to the results for control experiments, ***p<0.001.
reduced by 48% (p<0.01) and 56% (p<0.05) of control rats as 
assayed by specific enzymatic and radioisotopic methods 
respectively, by the livers of rats bearing the Walker 256 
carcinosarcoma. Similarly the extent of glucose formation was 
reduced by 76% (p<0.01) and 81% (p<0.01) of control rats as 
assayed by specific enzymatic and radioistopic methods 
respectively, by the livers of rats bearing the R3230AC 
adenocarcinoma.
4.3 Discussion
The livers of control rats and rats bearing the Walker 
256 carcinosarcoma and R3230AC adenocarcinoma were isolated and 
perfused in order to study the rate of formation of glucose from 
alanine, when given at its physiological concentration. The 
results are most useful in that they can be used to help resolve 
the conflict concerning the varying reports of the rates of 
gluconeogenesis from alanine in tumour bearing cachectic subjects 
(see section 4.1.4). The data are also an important test of the 
central hypothesis of the present investigation. Alanine was 
chosen because of its participation in the glucose-alanine cycle 
(Felig, 1973) and because of its proposed role as the predominant 
amino acid released from muscle during starvation (Pozefsky et 
al., 1976) , uncontrolled diabetes (Buse, 1976) and tumour bearing 
(Chung and Bauer, 1969; Clarke et al., 1978; DeWys, 1970; 
Williams et al. , 1980) . Alanine is also the most important 
gluconeogenic amino acid taken up by the liver in the 
postabsorptive state (Ross et al., 1967a).
The perfused liver technique was used for this study
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because of its obvious experimental advantages over the intact 
animal (in vivo) system or isolated hepatocytes. Gluconeogenesis 
is known to occur not only in the liver bed but also in the 
kidney cortex (Krebs et al., 1963) . Under normal basal 
conditions renal gluconeogenesis contributes a minor part to the 
maintenance of blood glucose levels (Kida et al., 1978). However 
in conditions such as chronic fasting and diabetes, renal 
gluconeogenesis increases with the result that kidney and liver 
contribute equally to glucose formation (Kida et al., 1978; Owen 
et al. , 1969) . Therefore, studies using the intact animals (in 
vivo) system do not convincingly permit the accurate measurement 
of hepatic gluconeogenesis in pathological conditions. On the 
other hand the isolated perfused liver system also has advantages 
over isolated hepatocytes in that it preserves the control 
systems associated with intact cells and provides a milieu 
similar to that of the intact animal while retaining the 
advantages of an in vitro system (Exton and Park, 1967). The 
physiological adequacy of each liver perfusion was judged by the 
oxygen uptake and the normal appearance of the liver. The 
uniform, well oxygenated, fully perfused colour of all of the 
livers after two hours of perfusion was considered normal.
The process of gluconeogenesis involves the 
interactions of the cytoplasmic and mitochondrial compartments. 
It is an energy utilising process and results in the increased 
consumption of oxygen (Scholz and Nohl, 1976; Soboll et al., 
1978). Thus fully functional mitochondria are essential for 
gluconeogenesis. The lower consumption of oxygen by the livers
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of tumour bearing rats, in the absence of alanine, in comparison 
with the values of control rats, raised the issue of impairment 
of mitochondrial respiration. Furthermore, the lower stimulation 
of oxygen consumption by alanine during gluconeogenesis by the 
livers from tumour bearing animals strengthened this suspicion 
and indicated that the reason for the low rate of gluconeogenesis 
may be found in abnormal mitochondrial function. However, in 
this investigation no attempt was made to investigate the status 
of liver mitochondrial function in tumour bearing animals. To 
date, there is still controversy about the uncoupling of 
oxidative phosphorylation in the livers of tumour bearing rats 
(see section 1.2.3.1).
The concentration of alanine in the perfusion medium
was maintained by constant infusion as described in section
2.8.5. The rate of infusion of alanine was the same as the rate
of utilisation of alanine by the livers of control rats. The
rate of alanine utilisation was established by a number of
14
experiments on control rats using unlabelled and [U- C] alanine. 
Using this approach the concentration of alanine was maintained 
in the range of 0.45 + O.OlmM to 0.54 + 0.04mM during the entire 
course of the perfusion of the livers of control rats (Fig. 4.4). 
In the case of perfusion of livers of tumour bearing rats, the 
concentration of alanine in the perfusate increased significantly 
above physiological levels, indicating that the utilisation of 
alanine by these livers was not the same as that of control 
animals (Fig. 4.4). A number of investigators have demonstrated 
that the transport of alanine (below ImM) across the plasma 
membrane is the only rate controlling step for its metabolism
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(Sips et al., 1980; Mallette et al., 1969 a,b; McGiven et al.,
1981; Groen et al., 1982). Intrinsic membrane alterations may 
occur in disease states and thus effect the transport of alanine 
across the plasma membrane of the liver (Rosenthal et al., 1985). 
On the other hand, in one study (Roh et al., 1984) , increased 
gluconeogenesis from alanine was attributed to increased rates of 
its transport in the isolated hepatocytes of tumour bearing rats. 
No other investigation has demonstrated such changes in tumour 
bearing rats. However, this finding does not look attractive 
because the integrity of the hepatic plasma membrane and its 
permeability to small molecules during isolated hepatocyte 
preparation is questionable. Moreover, investigations of the 
functional biochemistry, kinetics mechanism and thermodynamic 
properties of the transport of alanine across the plasma membrane 
of parenchymal cells are not yet well studied (Groen et al., 
1982) .
Glucose formation from alanine was determined using two 
different analytical techniques as mentioned in section 2.8.6. 
The pattern of results obtained by the two different analytical 
methods was consistent. The rate of gluconeogenesis from alanine 
by the livers of rats bearing the Walker 256 carcinosarcoma was 
45% lower, while livers of rats bearing the R3230AC 
adenocarcinoma had a rate which was 60% lower in comparison with 
the normal rate of gluconeogenesis from alanine delivered at 
physiological concentrations (Figs. 4.6, 4.7, Table 4.2). The 
extent of hepatic glucose formation from alanine was also 48%-56% 
and 76%-81% lower in rats bearing the Walker 256 carcinosarcoma
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and R3230AC adenocarcinoma respectively, in comaprison with that 
of control rats.
The very first key enzyme in the pathway of 
gluconeogenesis from alanine is alanine aminotransferase (Groen 
et al., 1982; Krebs et al., 1964b). Results shown in Fig. 3.5 
indicated that the growth of the Walker 256 carcinosarcoma at a 
site distant to the liver induced a retrodifferentiating change 
in the activity of this enzyme causing a shift of enzyme activity 
to the level found in the foetal liver (Herzfeld and Greengard, 
1972) . The retrodifferentiation of hepatic alanine 
aminotransferase has already been reported in animals bearing 
various neoplasms (see section 1.2.2.1.1).
It is therefore concluded from the above investigations 
that the decrease in the rate and extent of glucose formation 
from alanine in the livers of tumour bearing rats may be due to 
an impairment of mitochondrial function and/or.less utilisation 
of alanine due to changes in membrane permeability for alanine 
and/or suppression of hepatic alanine aminotransferase activity 
due to the retrodifferentiated changes induced by tumour bearing 
and/or a combination of these processes.
Suppression of gluconeogenesis from alanine has been 
reported in septic and infected rats (McCollum, 1980, 1981; 
McCollum and Berry, 1973; Wannemacher et al., 1980; Wilmore et 
al., 1980; Wolfe and Burke, 1978). This inhibition was 
attributed to the notable suppression of PEPCK activity by 
mediator(s) released from the Kupffer cells of the liver on 
stimulation with endotoxin (McCollum, 1981). It is known that 
cancer growth in the body elicits a host response with prominent
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involvement of macrophages and blood mononuclear phagocytic cells
(Nathan et al., 1980). It was demonstrated that tumour growth 
communicated its presence to distant non-involved organs of the 
body, particularly the liver (see section 3.3). It is possible 
that the Kupffer cells of the liver are involved and release 
mediators to inhibit gluconeogenesis from alanine in parenchymal 
cells. Moreover, a role for cachectin in the development of 
cachexia was proposed (Beutler et al., 1985a) but its involvement 
in the suppression of gluconeogenesis is not yet established, 
although the data presented in this and other chapters (see 
chapters five, six and seven) are consistent with it having a 
role in the initiation and maintenance of the cancer cachectic 
state (see Fig. 8.1).
The impaired ability of the foetal rat liver to utilise 
alanine for the production of glucose (see section 4.1.2) was 
attributed to a deficiency of the enzymatic capacity to convert 
alanine to pyruvate because of the low activity of alanine 
aminotransferase. These observations are similar to the 
situation that is present in the liver of tumour bearing rats 
(see section 1.2.2.1.3) and consistent with the proposal that the 
host liver of tumour bearing animals are enzymatically similar to 
the livers of 1-2 week old neonatal liver (Matthaei, 1979).
It is of interest that in a few studies (Singh et al., 
1978; Waterhouse et al., 1979) increased rates of gluconeogenesis 
from alanine were demonstrated in tumour bearing subjects but no 
sign of cachexia or anorexia was reported. Burt et al., (1981) 
have demonstrated increased glucose recycling and rates of
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gluconeogenesis from alanine in noncachectic tumour bearing 
animal models. The present investigation of gluconeogenesis from 
alanine in tumour bearing rats was carried out near the terminal 
stages of their disease, when the symptoms of cachexia were the 
prominent feature of tumour bearing. It is therefore, suggested 
that the noncachectic tumour bearing animals may have metabolic 
alterations different to those of cachectic tumour bearing 
animals. They thus may not exhibit a reduced rate of 
gluconeogenesis from alanine. Furthermore, as pointed out 
earlier, the contributions of renal gluconeogenesis should not be 
neglected in interpreting the increased rates of gluconeogenesis 
from alanine in tumour bearing subjects in vivo (Lundholm et al., 
1980; Singh et al., 1978; Waterhouse et al., 1979).
As discussed in section 4.1.1, hepatic gluconeogenesis 
is regulated at various steps by multiple interactions of 
gluconeogenic enzymes, substrate/product modulators, a vast 
variety of hormones and intracellular compartmentation. The 
growth of a neoplasm induced foetalistic retrodifferentiating 
changes in the various organs of tumour bearing animals involving 
changes in the activity of many enzymes, appearance of new 
isoenzymes, ectopic and inappropriate production of hormones and 
foetal proteins, alterations in the number and structure of cell 
membrane receptors for hormones and changes in the concentration 
of various metabolites (Knox, 1976; Longenecker and Williams, 
1977; Matthaei, 1979). Furthermore, the tumour itself secretes a 
number of metabolites and peptides/proteins in the host 
circulation. These changes and their interplay in the regulation 
of hepatic gluconeogenesis in tumour bearing subjects are still
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not fully known.
The main concern of the current investigation of 
gluconeogenesis from alanine was to measure the tumour induced 
changes which were seen to be part of a sequence of the 
pathabolism of cancer. This sequence of events (Fig. 1.4) was 
proposed to be responsible for the initiation and maintenance of 
the cachectic state in cancer subjects (section 1.2.2.1). 
Therefore, attempts were not made to study gluconeogenesis per se 
from other substrates nor the regulation of this process in 
tumour bearing animals. It is stressed that the outcome of this 
enquiry supports postulate III of the Williams hypothesis 
(section 1.2.2.1) for the metabolic basis of cancer cachexia.
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CHAPTER FIVE
FATTY ACID METABOLISM IN TUMOUR BEARING RATS 
5.1 Introduction
Ketone bodies (acetoacetate and D-(-)-3-
hydroxybutyrate) are water soluble metabolites that are produced 
from the oxidation of fatty acids, derived from fat. The 
principle fate of ketone bodies is oxidation, but in addition to 
this, ketone bodies inhibit discrete reactions that are involved 
in glycolysis (Potezny et al., 1981; Robinson and Williamson,
1980; Shambaugh, 1985; Turinsky and Shangraw, 1981), proteolysis 
(Sherwin et al., 1975; Smith and Aoki, 1981), lipolysis
(Binkiewicz et al., 1974; Senior and Loriden, 1968), branched
chain amino acid metabolism (Palmer et al., 1985a; Shambaugh, 
1985; Shambaugh and Koehler, 1981; Snell and Duff, 1982; 
Zapalowski et al., 1981) and purine and pyrimidine biosynthesis
(Shambaugh, 1985).
The rate of ketogenesis varies greatly. In fed 
animals, the rate is low but increases when less carbohydrate is 
available, for example in starvation, diabetes, late pregnancy 
(when the metabolic demands of the foetus are high) and early 
lactation (when glucose is required for the synthesis of milk 
components by mammary gland) (McGarry and Foster, 1980; Robinson 
and Williamson, 1980; Zammit, 1981). Different rates of 
ketogenesis are associated with (i) changes in the availability 
of respective substrates (Lund et al., 1980; Robles-Valdes et
al., 1976) (ii) changes in the activity of enzymes in the
pathways of fatty acid oxidation and esterification (Bates and
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Saggerson, 1979; Van Tol, 1974). These variations are attributed 
to changes in the level of a number of appropriate hormones under 
physiological and pathological conditions (Alberti et al., 1981; 
McGarry and Foster, 1980; Mooney and Lane, 1981; Rofe and 
Williamson, 1983 a,b).
5.1.1 Regulation of Ketogenesis
The regulation of ketogenesis is a multisite and 
consequently highly integrated process and like gluconeogenesis, 
a simple list of regulatory mechanisms can not explain all of the 
investigational observations.
5.1.1.1 Substrate and Enzymatic Regulation
The following aspects of the substrate and enzymatic 
regulation of ketogenesis are summarised in Fig. 5.1.
The intrahepatic control of ketogenesis from long chain 
fatty acids can occur at the stage of partitioning of acyl CoA 
between triacylglycerol synthesis and 3 -oxidation (Mayes and 
Feltz, 1967b; McGarry and Foster, 1972; Ontko, 1972; Zammit, 
1981) or later at the stage of partitioning of acetyl CoA between 
citrate synthesis and ketone body formation (Mooney and Lane, 
1982; Wieland, 1968; Williamson, 1979; Zammit, 1981).
The distribution of fatty acids between triacylglycerol 
synthesis and the oxidation pathway may be effected through a 
decrease in the activity of the esterification pathway or through 
an increase in the formation of acyl carnitine esters and their 
uptake into mitochondria (Zammit, 1981). The activity of 
mitochondrial glycerol-3-phosphate acyl tranferase (GPAT; EC 
2.3.1.15) which catalyses the first reaction in the formation of
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Figure 5.1: The substrate and enzymatic regulation of 
ketogenesis
The diagram illustrates the regulatory steps 
between the pathways of fatty acid 
esterification, oxidation and ketone body 
formation.
Symbols @  and Q are used to denote activation and 
inhibition respectively. The abbreviations are, 
AT, acetyl CoA transferase; HMG CoA synthase, 
hydroxy methyl glutaryl CoA synthase ; ACT-I and 
II, acyl carnitine transferase I and II; GPAT, 
glycerol 3-phosphate acyl transferase; DHAPAT, 
dihydroxyacetone phosphate acyl transferase; PFK, 
phosphofructokinase; F 1,6-P2ase, fructose 1,6 
bisphosphatase; OAA, oxaloacetate; HMG CoA, 
hydroxy methyl glutaryl CoA; Fru 1,6-P2 , fructose 
1,6 bisphosphate; Fru 6-P, fructose 6-phosphate; 
Glc 6-P, glucose 6-phosphate. See the text for 
further details.
The diagram is taken (with author's permission) 
from Trends Biochem. Soc. (1981) 6, 46-49.
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triglyceride from glycerol-3-phosphate and acyl CoA decreased in 
rats by 40% after 24 hours of starvation (Bates and Saggerson, 
1979). Consequently the activity increased during refeeding 
(Bates and Saggerson, 1979) and during peak lactation (Zammit, 
1981). GPAT activity in liver also increased after perfusion 
with insulin (Bates et al., 1977). Whereas adrenalectomy caused 
a decrease in mitochondrial GPAT activity (Bates and Saggerson,
1979) . The activities of other enzymes of the esterification 
pathway (e.g. dihydroxy acetone phosphate acyl transferase 
(DHAPAT; EC 2.3.1.42) and phosphatidate phosphohydrolase (EC 
3.1.3.27)) also changed under different physiological conditions 
in the same direction as changes in the direction of triglyceride 
synthesis (Bates and Saggerson, 1979; Bates et al., 1977; 
Brindley, 1978). However it was also shown that the availability 
of glycerol-3-phosphate and nonesterified carnitine in the liver 
could effect the rate of long chain acyl CoA esterification and 
oxidation (Lund et al., 1980; McGarry et al♦, 1975; Zammit,
1980) .
The first reaction of the oxidative pathway of fatty 
acids is the formation of acyl carnitine from fatty acyl CoA and 
free carnitine. This reaction is catalysed by acyl carnitine 
transferase-I (ACT-I; EC 2.3.1.21), which is located on the 
outerside of the inner mitochondrial membrane and its activity is 
two to three fold higher in hepatic mitochondria of starved rats 
than those isolated from fed rats (Harper and Saggerson, 1975; 
Harano et al., 1972) . The activity of ACT-I is strongly 
inhibited in vitro by micromolar concentrations of malonyl CoA
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(McGarry et al., 1977; McGarry and Foster, 1980). This
inhibition leads in turn to a greater availability of fatty acyl 
CoA for esterification to form triglyceride.
The second branching point in the pathway of fatty acid 
oxidation and ketone body formation is the disposal of
mitochondrial acetyl CoA (Demaugre et al., 1982; Mooney and Lane, 
1982). It may be used to synthesise either acetoacetyl CoA (via 
the ketogenic pathway) or citrate (tricarboxylic cycle) inside 
the mitochondria. Acetyl CoA acetyl tranferase (EC 2.3.1.9)
cataylses the formation of acetoacetyl CoA from two molecules of 
acetyl CoA (Lynen, 1953), whereas citrate synthase (EC 4.1.3.7) 
catalyses the formation of citrate from acetyl CoA and
oxaloacetate (Ochoa, 1954; Stern and Miller, 1959). The activity 
of acetyl CoA acetyl transferase may control the flux through the 
subsequent reactions of the 3-hydroxy 3-methyl glutary1 CoA (HMG-
CoA) pathway. This enzyme is inhibited by low concentrations
-7 -6
(10 -10 M) of acetoacetyl CoA and by CoA (Huth et al., 1978).
The acetoacetyl CoA also inhibits the next enzyme of the HMG-CoA 
pathway, HMG-CoA synthase (EC 4.1.3.5) (Reed et al., 1975). 
Therefore, changes in the concentration of acetoacetyl CoA also 
determine the extent of the flux through the HMG-CoA pathway 
(Reed et al., 1975).
Citrate synthase diverts acetyl CoA away from the
synthesis of ketone bodies (HMG-CoA pathway). The strength of
the competition of citrate synthase for acetyl CoA depends on the
availability of oxaloacetate (Demaugre et al♦, 1978; Mooney and
Lane, 1982; Nosadini et al., 1980; O'Donnel and Freedland, 1980;
+
Siess et al., 1982). The ratio of [NAD ]/[NADH] in the
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mitochondrial matrix influences the concentration of
oxaloacetate, through the reaction catalysed by malate
dehydrogenase (EC 1.1.1.37) (Wieland et al., 1964). An increase
+
in the formation of NAD favours the reduction of oxaloacetate to
malate. The amount of oxaloacetate in the mitochondria also
depends on its formation (through carboxylation of pyruvate) and
utilisation (in the synthesis of phosphoenolpyruvate) for
gluconeogenesis (Krebs, 1966). However, it was recently
demonstrated that dibutyryl c'AMP, which activates ketogenesis
and inhibits fatty acid synthesis from acetate, drastically
lowered the cellular levels of oxaloacetate and malate (Mooney
and Lane, 1982), concomitantly inhibiting the conversion of
glucose to pyruvate via the glycolytic pathway (Lane and Mooney,
1981). These results showed that decreased levels of
oxaloacetate and malate were the result of decreased production,
rather than utilisation (Mooney and Lane, 1982). The site of
inhibition of glycolysis was found to be at the
PFK-I reaction step (Lane et al., 1979). More recent
investigations, revealed that levels of the modulator fru 2,6-P ,
2
which activated PFK-I and inhibited F 1,6-P ase were decreased by
2
90% during starvation or diabetes (Neely et al♦, 1981) and
therefore inhibited glycolysis and stimulated gluconeogenesis 
i.e., limited the oxaloacetate availability by decreasing its 
production and increasing its utilisation. It was therefore, 
suggested that the mitochondrial oxaloacetate concentration 
controls the metabolic fate of acetyl CoA by the following two 
mechanisms (Demaugre et al., 1982) -
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(a) at low levels it directed mitochondrial acetyl CoA 
towards ketone body synthesis (HMG-CoA pathway) whereas 
at high levels it diverts acetyl CoA towards citrate 
synthesis,
(b) it also determined via citrate, the cytosolic malonyl 
CoA concentration which in turn regulated the entry of 
long chain fatty acids into the mitochondria.
5.1.1.2 Hormonal Regulation
The following aspects of the hormonal regulation of 
ketogenesis are summarised in Fig. 5.2.
The hormones most widely associated with the regulation 
of ketogenesis are glucagon and insulin (McGarry and Foster, 
1980; Reed et al., 1984; Weinstein et al♦, 1973). The role of
insulin is to control the delivery of free fatty acid to the 
liver. The elevation of plasma insulin inhibits lipolysis in 
adipose tissue and thereby diminishes the free fatty acid 
turnover such that the liver is deprived of substrate for ketone 
body synthesis (McGarry et al., 1975). The enhancement of
hepatic fatty acid oxidation and ketogenesis in fed animals can 
be induced acutely by the infusion of anti insulin serum (McGarry 
et al., 1975). This suggests that the depletion of insulin from
the animal converts the non-ketotic liver into the ketotic state 
(McGarry et al., 1975). Glucagon acts primarily to enhance the
liver ketogenic machinery (McGarry and Foster, 1980). It 
increases ketogenesis by decreasing the concentration of malonyl 
CoA through inactivation of acetyl CoA carboxylase (EC 6.4.1.2) 
as a result the transport of acyl CoA into the mitochondria is
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Figure 5.2: The hormonal regulation of ketogenesis
The hormonal regulation of fatty acid 
mobilisation, oxidation, esterification and ketone 
body synthesis are shown. The solid lines denote 
the metabolic pathways or the carrier mediated 
transport across the plasma and mitochondrial 
membranes. The broken lines denote the effects of 
the hormones. The symbols (+) and Q  denote 
activation or inhibition respectively. The 
abbreviations are, FA, free fatty acid; TG, 
triglyceride; VLDL, very low density lipoprotein; 
KB, ketone bodies; ACT-I, acyl carnitine 
transferase-I and AC, acetyl CoA carboxylase.
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enhanced (McGarry and Foster, 1980; Malewiak et al., 1985; 
Saggerson and Carpenter, 1982a; Singh et al., 1982). Thus in the 
fed state (low [glucagon]/[insulin] ratio) the direction of fatty 
acid metabolism is primarily towards its synthesis. Under these 
conditions fatty acid oxidation and ketone body synthesis are 
shut down due to the high hepatic levels of malonyl CoA. In the 
ketotic state (diabetes, starvation; high [glucagon]/[insulin]) 
the synthesis of malonyl CoA and therefore, lipogenesis are 
supressed, with the concomitant activation of fatty acid 
oxidation and ketogenesis (McGarry and Foster, 1980; Neufeld et 
al., 1983; Reed et al., 1984).
Insulin and glucagon are not the only hormones that 
effect ketogenesis, others including catecholamines (Basso and 
Havel, 1970, Clutter et al., 1980; Pernet et al., 1983), 
vasopressin (Almas et al., 1983; Edwards et al♦, 1981; Rofe and 
Williamson, 1983), glucocorticoids (Fain and Czeck, 1975; Alberti 
et al., 1981), thyroxin and growth hormone (Alberti et al., T978) 
have all been reported to be involved in the regulation of 
ketogenesis.
Epinephrine and norepinephrine are both considered to 
be lipolytic and ketogenic hormones based on their abilities to 
cause an increase in the levels of circulating fatty acids and 
ketone bodies (Basso and Havel, 1970; Clutter et al., 1980; 
Pernet et al., 1983). It was suggested that the ketogenic effect 
of these hormones may be mediated at least partially by their 
simultaneous suppression of plasma insulin concentration, which 
has known antiketogenic activities (Heimberg et al., 1969) and/or 
an elevation of plasma glucagon (Gray et al., 1980; Iverson,
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1973; Lerner and Porte, 1971; Ribes et al., 1983; Robertson and
Porte, 1973), which has ketogenic activity independent of its
lipolytic effect (McGarry et al., 1975; Schade and Eaton, 1975;
Woodside and Heimberg, 1976). Moreover it was found that
epinephrine and norepinephrine stimulated ketogenesis in a way
that was mechanistically different to that of glucagon, which is
c'AMP independent (Kosugi et al., 1983). This was concluded from
observation that epinephrine raised c ’AMP levels approximately
two fold, while glucagon increased c'AMP levels thirty fold in
rat hepatocytes (Pilkis et al., 1975b). Furthermore,
14
norepinephrine effected [1- C] palmitate oxidation and
ketogenesis was inhibited by the ai blocker, prazosine but not by
the a2 blocker, yohimbine or by the 3 blocker, propranolol in rat
hepatocytes (Oberhaensli et al., 1985). Similarly epinephrine
14
induced stimulation of ketogenesis from [U- C] palmitate was
almost totally inhibited by phentolamine (an a blocker) but was
not effected by propranolol ( 3blocker) or by isoproterenol, an
adrenergic 3 stimulator (Kosugi et al., 1983). Trifluoperazine,
which was reported to antagonise the a adrenergic stimulation of
the perfused rat liver (Reinhart et al., 1980), almost completely
antagonised the stimulatory effect of epinephrine or
14
norepinephrine on ketogenesis from [U- C] palmitate in isolated 
rat hepatocytes (Kosugi et al., 1983). These results indicate
that epinephrine and norepinephrine, unlike glucagon, have a 
direct stimulatory effect on ketogenesis mainly via the a - 
adrenergic receptors. Moreover, it was also demonstrated that 
epinephrine was a more potent stimulator of ketogenesis than
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norepinephrine or phenylephrine (Kosugi et al., 1983). This is
consistent with the fact that a receptors are more sensitive to
epinephrine than to other catecholamines (Exton, 1980). The
mechanism by which trifluoperazine blocked ol adrenergic
2 +
stimulants was thought to be via the inhibition of the Ca
calmodulin system (Weiss and Levine, 1978) by interference with
the binding of the agonist to the a adrenergic receptor (Gray et
al. , 1980; Iverson, 1973). In any case the fact that
trifluoperazine inhibited the stimulative effects of epinephrine
or norepinephrine suggested that these catecholamines stimulated
ketogenesis mainly via an otadrenergic system by the activation
of the calcium dependent protein kinase (Exton, 1980). Moreover
epinephrine was reported to inactivate acetyl CoA carboxylase
(Lee et al., 1973). A similar mechanism to that of glucagon
might also be operative, which stimulated ketogenesis by
decreasing the concentration of malonyl CoA through the
inactivation of acetyl CoA carboxylase (McGarry et al., 1977).
In addition epinephrine action inhibited hepatic
PFK-I by decreasing the concentration of fru 2,6-P (Richards et
2
al., 1981) thereby decreasing glycolytic flux and the ultimate
production malonyl CoA (Demaugre et al., 1982)
Another hormone which notably effects hepatic fatty 
acid metabolism and ketogenesis is vasopressin. Vasopressin 
inhibited ketogenesis from added fatty acid and stimulated its 
esterification in hepatocytes from fed rats (Williamson et al., 
1980). The inhibitory effect of vasopressin on ketogenesis was 
also observed in hepatocytes from fed lean mice without any 
effect on esterification (Edwards et al., 1981). However
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Vasopressin failed to inhibit ketogenesis and fatty acid 
esterification in heptocytes from starved rats (Almas et al., 
1983; Siess et al., 1978; Williamson et al., 1980) and obese
(ob/ob) mice (Edwards et al., 1981). Infusion of vasopressin in
vivo caused an immediate decrease in the concentration of ketone 
bodies in the blood and liver with an associated decrease in 
plasma levels of unesterified fatty acid in starved (12-16 hour) 
anaesthetised rats (Rofe and Williamson, 1983a) and increased 
serum triglyceride levels in both fed lean or obese (ob/ob) mice 
(Triscari and Sullivan, 1981).
The exact mechanism by which vasopressin regulates 
hepatic fatty acid metabolism is not clear. It was reported that 
vasopressin stimulated glycogen breakdown in the perfused liver 
of fed rats (Hems and Whitton, 1973; Kirk and Hems, 1974) and 
mice (Ma and Hems, 1975) and in isolated hepatocytes from fed 
rats (Almas et al., 1983) and lean mice (Edwards et al., 1981).
There was also increased glycolytic flux (Hems and Whitton, 
1973), together with the activation of the pyruvate dehydrogenase 
complex (Hems et al., 1978a). These processes were expected to
stimulate lipogenesis at the level of acetyl CoA carboxylase 
(Jeannet et al., 1981) and consequently the increased formation
of malonyl CoA was expected to inhibit fatty acid oxidation and 
ketone body formation. However, the regulation of malonyl CoA 
synthesis by vasopressin remains uncertain, since vasopressin was 
reported to inhibit lipogenesis from glucose and lactate in 
perfused mouse liver (Ma and Hems, 1975). On the other hand, 
Kirk and Hems (1979) reported that vasopressin did not modify
147
lipogenesis from these substrates in perfused rat liver.
Moreover a recent study (Jeannet et al., 1981) showed that the
dose response for vasopressin stimulation of acetyl CoA
carboxylase in isolated rat hepatocytes was identical to the dose
response for vasopressin stimulated lipogenesis and was in the
range of its actions on glycogenolysis. Clearly, more work is
needed to decide the role of malonyl CoA in the mechanism of
vasopressin action. Meanwhile, stimulated esterification was
suggested as the cause of the decreased rate of ketogenesis
(Sugden et al., 1980 a,b; Williamson et al♦, 1980a).
The activities of the fatty acid esterification enzymes
GPAT and DHAPAT were found to be increased in rat liver
homogenate and in subcellular fractions (mitochondrial and
microsomal) when isolated hepatocytes from fed rats were
incubated with vasopressin (Sugden et al., 1980b). It was also
14 14
reported that vasopressin increased CO production from [U- C]
2
oleate in isoated hepatocytes from fed rats (Sugden et al.,
1980a; Sugden and Watts, 1983) and lean mice (Edwards et al.,
1981) but not from starved rats (Sugden and Watts, 1983) and
obese mice (Edwards et al., 1981). These effects of vasopressin
were not mediated by c'AMP (Hems and Whitton, 1980; Sugden et
al., 1980a), rather the increased oxidation to CO and
2
antiketogenic effects of hormone were shown to be dependent on
calcium (Almas et al., 1983; Hems and Whitton, 1980; Sugden et
al., 1980a; Sugden and Watts, 1983). In contrast, esterification
was stimulated by vasopressin both in the presence and absence of 
2 +
Ca (Sugden et al., 1980a). Furthermore, it is known that
2 +
certain enzymes of the citric acid cycle are activated by Ca
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(Denton et al., 1978; McCormack and Benten, 1979). However,
vasopressin did not increase the oxidation of oleate to CO in
2+ 2 
the absence of Ca . It is therefore, possible that the hormone
2 +
exerts its effect by increasing the mitochondrial Ca
concentration (Sugden et al., 1980a). From these studies, it is
suggested that in addition to an extramitochondrial effect,
vasopressin has an intramitochondrial action, which plays a role
in the antiketogenic effect of the hormone and stimulates flux
2 +
through the citric acid cycle as a result of the Ca dependent
+
activation of NAD -linked isocitrate dehydrogenase (EC 1.1.1.41),
aketo glutarate dehydrogenase (EC 1.2.4.2) and/or electron
24-
transport. It was also shown that increasing Ca levels had a
biphasic effect. Most of the hormones mentioned above brought
2 +
about changes in cytoplasmic Ca in the range of 0.1-10 M (Almas
et al., 1983). It was demonstrated that incubation of a
mitochondrial suspension or liver homogenate with 0.3 M free
calcium caused the formation of labelled oxidation product to
be maximal and labelled glycerophosphate formation was minimal,
2 +
but when the concentration of Ca was further increased within 
the above range, the fatty acid oxidation was inhibited and 
esterification was stimulated (Almas et al., 1983).
Little is known about other hormone actions in the 
regulation of ketogenesis. Cortisol enhanced lipolysis and fatty 
acid supply to the liver (Fain and Czeck, 1975). If insulin was 
present, fatty acids were diverted to triacylglycerol formation 
in the liver; however when insulin levels were suppressed as in 
somatostatin administration or in insulin-deprived diabetic man,
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cortisol administration caused significant synthesis of ketone 
bodies (Alberti et al., 1981). Similarly somatotropin and
triiodothyronine caused a rise in ketone body concentration when 
insulin levels were low or suppressed (Alberti et al., 1981).
5.1.2 Fatty Acid Oxidation in the Foetal Liver
The capacity for the hepatic oxidation of long chain
fatty acids is low during foetal life. It increases sharply
after birth, remains high during suckling and then declines after
weaning and thereafter remains unchanged (adult level) (Bailey
and Lockwood, 1973). Using liver preparations from foetal rats,
14 14
the rate of [1- C] palmitate oxidation to CO was
2
approximately l/10th of that found with adult liver homogenate,
and the rate of incorporation of labelled palmitate into
acetoacetate was approximately l/100th and l/20th of the
corresponding rate of liver preparations from neonatal and adult
rats (Augenfeld and Fritz, 1970). Similarly, the conversion of 
14 14 14
C-palmitate to C-acetacetate and C-3-hydroxybutyrate by rat
liver mitochondrial preparation increased rapidly after birth,
remained high during suckling and declined to the adult level by
30 days of age (Lockwood and Bailey, 1970). Moreover, it was
shown that hepatocytes from the premature rabbit only had l/10th
of the ketogenic rate from oleate to that of hepatocytes from 48
hour starved adult rabbits (Carrington et al., 1981).
Furthermore, the change in the concentration of ketone bodies in
blood followed the pattern of hepatic oxidation of fatty acid
during development (Lockwood and Bailey, 1971; Page et al. ,
1971) .
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It was also established that the hepatic fatty acid 
oxidation capacity of foetal, neonatal and adult rats was 
influenced by the level of carnitine palmitoyl transferase-I 
since changes in the activity of this enzyme in hepatic 
mitochondria from foetal, neonatal and adult rats were nearly 
parallel to the changes in fatty acid oxidation (Augenfeld and 
Fritz, 1970; Girard et al., 1981; Lee and Fritz, 1971). The 
activity of this enzyme in foetal mitochondria was approximately 
l/10th that observed in the liver mitochondria of adult rats (Lee 
and Fritz, 1971) while the activites were slightly greater in the 
liver mitochondria of neonates (Augenfeld and Fritz, 1970).
It was also shown that the hepatic carnitine levels 
limited the entry of long chain fatty acids into the mitochondria 
since foetal blood carnitine levels were lower than post-natal 
ones (Barger-Lockner et al., 1981). The limited capacity of 
foetal liver to synthesise carnitine was due to the low 
activities of the enzymes required for its synthesis (Rebouche, 
1980). It may be concluded from these changing developmental 
patterns of hepatic fatty acid oxidation, carnitine palmitoyl 
transferase-I and hepatic carnitine levels, that the fatty acid 
entry site into the mitochondria is also the rate limiting site 
during foetal development as is the case with adult metabolism 
(McGarry and Foster, 1980). This proposal is supported by the 
observation that, during suckling 75-80% of ketogenesis is 
derived from medium chain fatty acid oxidation (fatty acids with 
12 or less carbon atoms) which bypass the mitochondrial entry 
site controlled by ACT-I (Wells, 1985) .
Although there is little doubt that the regulation of
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long chain acyl CoA entry into mitochondria is the primary site
for the control of ketogenesis, changes in the rate of disposal
of acetyl CoA between its oxidation to CO and ketone body
2
formation may occur (Augenfeld and Fritz, 1970). The major 
pathway of acetoacetate formation (HMG-CoA pathway) involves the 
conversion of acetoacetyl CoA and acetyl CoA into HMG-CoA by HMG- 
CoA synthase, which is then converted to acetacetate and acetyl 
CoA by HMG-CoA lyase (EC 4.1.3.4) (Lynen et al., 1958). HMG-CoA
synthase is thought to be the rate limiting enzyme for this 
pathway (Williamson et al., 1968). A low activity of HMG-CoA
synthase (10-40% of adult activity) was found in the foetal liver 
(Hipolito-Reis et al., 1974; Lockwood and Bailey, 1971; Shah and
Bailey, 1977). However the activity of this enzyme increased 
sixteen fold during the 24 hours following birth and remained 
high during the suckling period declining to the adult value 
after weaning (Bailey and Lockwood, 1973; Hipolito-Reis et al., 
1974; Lockwood and Bailey, 1971). The liver mitochondrial HMG- 
CoA lyase exhibited a similar developmental pattern to that of 
mitochondrial hydroxyglutaryl synthase. The activity of this 
enzyme in foetal liver was found to be approximately 10-25% of 
the enzyme activity of the adult liver (Hipolito-Reis et al♦, 
1974; Shah and Bailey, 1977). In addition to carnitine palmitoyl 
transferase-I, HMG-CoA synthase and HMG-CoA lyase, the
mitochondrial acetoacetyl CoA thiolase (Lockwood and Bailey, 
1971) and D-(-)-3-hydroxybutyrate dehydrogenase (Bailey and 
Lockwood, 1973) activities showed a similar developmental pattern 
(Fig. 5.3).
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Figure 5.3: Changes in the activities of the enzymes of 
ketogenesis in developing rats
Results are expressed in proportionate units 
relative to the enzyme activity of foetal liver. 
The results show data for
a : hydroxy methyl glutaryl CoA synthase (Bailey 
and Lockwood, 1973)
■: hydroxy methyl glutaryl CoA lyase (Shah and 
Bailey, 1977)
♦ : acetoacetyl CoA thiolase (Lockwood and 
Bailey, 1971)
•: 3-hydroxybutyrate dehydrogenase (Bailey and 
Lockwood, 1973)
▼: carnitine palmitoyl transferase-I
(Augenfeld and Fritz, 1970)
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Greengard (1970, 1971) proposed the following three
stages of development that classified the sudden accumulation 
and/or decline of a significant number of enzymes in rat liver
(1) Late foetal period (the I6th-20th days of 
gestation)
(2) Postnatal or neonatal period
(3) Late suckling period
The developmental pattern of enzymes of ketogenesis 
(carnitine palmitoyl transferase-I, HMG-CoA synthase, KMG-CoA 
lyase, acetoacetyl CoA thiolase, 3-hydroxybutyrate dehydrogenase) 
show that they fall into the third category and they are 
therefore essentially of the adult type (Lee and Fritz, 1971). 
The assignment to this third category is important since there is 
evidence that these enzymes retrodifferentiate to the foetal
period during tumour bearing by an animal (Herzfeld and
Greengard, 1972).
5.1.3 Fatty Acid Metabolism in Infectious and Inflammatory
Disease
Profound changes in fatty acid metabolism occurred 
during Gram negative (G-ve) bacterial endotoxaemia and sepsis, 
which resulted in the alteration of serum levels of triglyceride 
(TG), free fatty acids (FFA) and ketone bodies (Blackburn, 1977). 
Plasma levels of TG increased two to eleven fold in animals
infected with Serratia marcescens, Escherichia coli (Hirsch et 
al., 1964), Bacillus anthracis, Francisella tularensis and
Diplococcus pneumoniae (Farshtchi and Lewis 1968, Canonico et 
al., 1977). The concentration of plasma TG is primarily
dependent on the activity of adipose tissue lipoprotein lipase
153
(LPL) which preserves the maintenance of normal plasma values 
through the uptake of TG into adipose sites (Kaufmann et al., 
1976 a,b) and secondarily to the increased production of TG by 
the liver (Blackburn, 1977). Kawakami and Cerami (1977) 
demonstrated that in endotoxin treated mice the adipose tissue 
LPL activity was markedly suppressed resulting in a nearly three 
fold elevation in serum triglyceride levels. More recently, a 
factor 'cachectin' (tumour necrosis factor) was isolated and 
purified from macrophages which were stimulated with endotoxin 
(Beutler et al., 1984, 1985 a,e; Mahoney et al., 1985). 
Cachectin completely suppressed the synthesis of LPL in 
adipocytes in vivo and in vitro (Beutler et al., 1984, 1985 a,e; 
Mahoney et al., 1985).
The other major derangement of fatty acid metabolism 
during inflammatory and infectious diseases was diminished 
hepatic ketogenesis which occured despite the availability of 
excess exogenous FFA supplied to the liver (Pace et al., 1977). 
Ryan et al♦, (1974) showed that when rats were subjected to 
experimental peritonitis, there was a marked depression in the 
blood ketone body levels. Furthermore, it was also observed that 
the ‘fasting induced' elevation of ketone bodies was abolished 
during the progress of infection by Streptococcus pneumoniae or 
Francisella tularensis (Neufeld et al., 1976). Moreover, a 
direct action of endotoxin in rats reduced fasting induced 
ketonaemia (Keenan et al., 1981). Livers from rats infected with 
Streptococcus pneumoniae when perfused with oleate exhibited a 
notable inability for ketone body synthesis. However, when
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perfused with octanoate there was no impairment of ketone body-
synthesis (Neufeld et al., 1977). These results strongly
suggested that the basic defect lay at the entry site of the 
fatty acids from the cytoplasm into the mitochondria. However, 
it was not clear whether this defect could be attributed to low 
levels of hepatic carnitine or reduced activity of ACT-I. 
Further work is needed on the topic of impaired ketogenesis in 
infectious and inflammatory disease.
5.1.4 Fatty Acid Metabolism in Neoplastic Disease
The metabolic abnormalities observed in the tumour 
bearing animal resemble those of semistarved animals as well as 
those encountered in sepsis and trauma (Brennan, 1977). As 
previously discussed (section 5.1.3), hyperlipidaemia, 
particularly the elevation of serum TG, is a characteristic of 
neoplastic growth in the cancer patient and in tumour bearing 
animals. Hypertriglyceridaemia was reported in patients with 
breast cancer (Barclay and Skipski, 1975; Mays, 1971), liver 
cancer (Santer et al., 1967; Viallet et al., 1962), melanoma
(Mays, 1971) and cancer of the colon (Eridani et al., 1970; Mays, 
1971) . In animals, the growth of the Walker 256 carcinosarcoma 
(Barclay et al., 1962); Ehrlich ascites tumour (Kremmer and
Holozinger, 1976); Lymphoma (Beaumont and Beaumont, 1974; Kitada 
et al., 1982); AC-33 adenocarcinoma (Lanza-Jacoby et al., 1982)
and dimethyl-a-aziridinopropionamide induced adenocarcinoma 
(Shearer et al., 1983) have all been associated with elevated
blood TG levels. Several investigators have (Barclay et al., 
1962; Beissel and Wannemacher, 1980; Posner, 1960) suggested that
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the hypertriglyceridaemia of the tumour bearing animal was caused
by a deficiency of the TG removal enzyme, LPL in the peripheral
tissues. In support of this it was demonstrated that the
activity of adipose tissue LPL declined during the early stage of
tumour growth and remained low throughout the course of tumour
bearing (Lanza-Jacoby et al., 1982, 1984; Thompson et al., 1981).
This situation was similar to that encountered with endotoxin
treated mice where the LPL was markedly suppressed in adipocytes
and resulted in a nearly three fold elevation of the TG levels
(Kawakami and Cerami, 1981; section 5.1.3).
In some patients with malignant tumours, there are
elevated levels of plasma FFA with no apparent cause (Carter et
al., 1975; Feldman and Carter, 1971; Mueller and Watkin, 1961).
14 14
Fatty acid ([U- C] palmitate) oxidation to CO was also found
2
to be impaired in the livers of tumour bearing animals (Lundholm
14
et al. , 1980) . This was also noted when C-tripalmitin was the
substrate (Costa et al., 1976). Ketosis has been reported to be
an uncommon phenomenon in cancer patients who are frequently poor 
eaters or because of their illness are frequently voluntarily 
starving (Conyers et al., 1979 a,b; Williams et al♦, 1980).
Neither ketonuria, nor titratable acidity of the urine were 
reported for tumour bearing animals (Mider et al., 1951). 
Furthermore, lower than normal ketonaemic responses to fasting 
were observed in some cancer patients (Rich and Wright, 1979) and 
tumour bearing animals (Sauer and Dauchy, 1983). To date, no 
attempt appears to have been made to study the impaired
regulation of fatty acid metabolism in cancer patients or tumour 
bearing animals.
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It is clear from the above introduction that major
derangements in fatty acid metabolism during the pathogensis of
disease are characterised by impaired fatty acid oxidation,
esterification and ketone body metabolism. The studies of this
chapter were designed to study the fatty acid metabolism of the
cachectic tumour bearing animal. Emphasis was placed on an
investigation of fatty acid esterification, oxidation to CO and
14 2
ketone body formation, when [U- C] oleate was metabolised at 
physiologically elevated levels (0.69-0.81mM) by the isolated 
perfused liver. A range of control experiments were conducted 
using fed (ad libitum), "pair fed" non tumour bearing and 
variously starved rats to study the expression of normal
regulation of fatty acid metabolism and for its comparison with 
data from tumour bearing animals.
5.2 Results
5.2.1 Prefatory Statement
The characteristic ketogenic response to reduced food 
intake was not demonstrated in tumour bearing animals as it was 
in "pair fed" non tumour bearing animals. Taking into account 
this lack of response of tumour bearing animals towards 
semistarvation, the results in the proceeding sections are 
compared to control (fed ad libitum) animals. This is done with 
caution to avoid exaggeration of differences between tumour 
bearing and "pair fed" non tumour-bearing animals.
5.2.2 Endogenous Ketone Body Formation
The time course of ketone body synthesis from
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Figure 5.4: Endogenous ketone body formation
Ketone body production was measured by commencing 
the liver perfusion (non-recirculation) with 
Krebs-Henseleit bicarbonate buffer (pH 7.4, 
equilibrated with 95%02:5%C02 at 37 °C) without 
any added substrate for 60 min. as described in 
section 2.9. Total ketone bodies defines the sum 
of acetoacetate and D-(-)-3-hydroxybutyrate which 
were assayed in the neutralised perchloric acid 
extract of the perfusate as described in section 
2.7. Each point represents the mean value in 
each experimental group. The SEM are represented 
by the vertical lines.
•: Control (fed ad libitum) rats (n=4)
a : "Pair fed" non-tumour bearing rats (n=6)
■: 12 hours starved rats (n=5)
▼: 48 hours starved rats (n=5)
O: Walker 256 carcinosarcoma bearing rats (day 
6 PI) (n=4)
a : Walker 256 carcinosarcoma bearing rats (day 
10 PI) (n=5)
□: Walker 256 carcinosarcoma bearing rats (day 
14 PI) (n=5)
v: R3230AC adenocarcinoma bearing rats (day 23 
PI) (n=4)
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endogenous substrates by isolated perfused rat livers of control, 
variously starved and tumour bearing rats are shown in Fig. 5.4 
and Tables 5.1 to 5.3. The rates of total ketone body synthesis 
after 1 hour of liver perfusion were compared to those of control 
(fed ad libitum) rats. The results demonstrated that the rate of 
endogenous ketogenesis was increased by 20% (NS), 90% (p<0.05) 
and 125% (p<0.001) in the perfused livers of "pair fed" NTB, 12 
and 48 hour starved rats respectively, whereas the rate of 
endogenous ketogenesis was decreased by 24%(NS), 33% (p<0.05) and 
35% (p<0.05) in the perfused livers of rats bearing the Walker 
256 carcinosarcoma at days 6, 10 and 14 PI respectively. The 
rate of endogenous ketogenesis was also decreased by 39% (p<0.05) 
in the liver of rats bearing the R3230AC adenocarcinoma at day 23 
PI.
5.2.3 Ketone Body Formation from Oleate
Ketone body formation from elevated levels of oleate 
(0.75 + 0.06mM) by the perfused livers of control, "pair fed" 
NTB, variously starved and tumour bearing rats are shown in Fig. 
5.5 and Tables 5.1 to 5.8. The rates of ketone body production, 
after one hour of liver perfusion, are compared with those of the 
control animals. The results demonstrated that the rate of 
ketogenesis from oleate was increased by 5% (NS), 15% (NS) and 
125% (p<0.001) in the livers of pair fed NTB, 12 and 48 hour 
starved rats respectively, wherease the rate of ketone body 
formation was decreased by 45% (p<0.01), 40% (p<0.01) and 37% 
(p<0.01) in the livers of rats bearing the Walker 256 
carcinosarcoma at day 6, 10 and 14 PI. The rate of ketogenesis
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Figure 5.5: Ketogenesis from oleate
Ketone body formation from oleate 7mM) was
studied by commencing the liver perfusion 
(recirculation) with Krebs-Henseleit bicarbonate 
buffer (pH 7.4, equilibrated with 95%02:5%C02 at 
37 °C) containing oleate (0.75 + 0.06mM) as
described in section 2.9. Ketone body formation 
was followed for 60 min. Total ketone bodies are 
defined in the legend of Fig. 5.4 and were 
assayed in the neutralised perchloric acid 
extract of the perfusate as described in section 
2.7. Each point represents the mean value in 
each experimental group. The SEM are represented 
by the vertical lines.
•: Control (fed ad libitum) rats (n=4)
a : "Pair fed" non-tumour bearing rats (n=6)
■: 12 hours starved rats (n=5)
▼: 48 hours starved rats (n=6)
o: Walker 256 carcinosarcoma bearing rats (day 
6 PI) (n=4)
a : Walker 256 carcinosarcoma bearing rats (day 
10 PI) (n=5)
□: Walker 256 carcinosarcoma bearing rats (day 
14 PI) (n=5)
v: R3230AC adenocarcinoma bearing rats (day 23 
PI) (n=4)
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from oleate was also decreased by only 8.3% (NS) in the livers of 
rats bearing the R3230AC adenocarcinoma at day 23 PI.
145.2.4 Ketone Body Formation from [U- C] Oleate
14
The rate of ketone body formation from [U- C] oleate
(0.01Ci/mol) showed the same trend as the data obtained using
unlabelled oleate (0.75 + 0.06mM). The absolute differences in
the results are explained 'in section 4.2.4. The results are
shown in Fig. 5.6 and Table 5.9 to 5.13. The rate of total
ketone body production after 1 hour perfusion are compared with
14
the control data. The rates of [U- C] ketone body formation
were increased by 45%(p<0.05), 43% (p<0.05) and 200% (pcO.OOl) in
the livers of pair fed NTB, 12 and 48 hour starved rats,
14
respectively. Whereas the rates of ketogenesis from [U- C] 
oleate were decreased by 32% (p<0.05), 42% (p<0.05) and 45%
(p<0.05) in the livers of rats bearing the Walker 256 
carcinosarcoma at day 6, 10 and 14 PI. The rate of ketogenesis
was also decreased by 30% (p<0.05) in the livers of rats bearing 
the R3230AC adenocarcinoma at day 23 PI.
5.2.5
14
Hepatic Production of C02 from the Metabolism of [U 
14C] Oleate
14
The oxidation of [U- C] oleate via the fatty acid
oxidation pathway was studied by monitoring the time course of 
14
CO production in the perfused livers of control (fed ad 
2
libitum), pair fed NTB, variously starved and tumour bearing
14
rats. The results are shown in Fig. 5.7. CO production did
2
not change significantly in the liver of the 12 hour starved rats 
but was decreased by 20% (p<0.05) and 35% (NS) in the livers of
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Figure 5.6: Ketone body formation from [U- C] oleate
Ketone body formation from [U-14C] oleate was 
studied by commencing the liver perfusion 
(recirculation) with Krebs-Henseleit bicarbonate 
buffer (pH 7.4, equilibrated with 95%02:5%C02 at 
37 °C) containing [U-14C] oleate (0.75 + 0.06mM;
specific activity 0.01Ci/mol) as described in 
section 2.9. Ketone body formation was followed 
for 60 min. [U-14C] acetoacetate and [U-14C] 
D-(-)-3-hydroxybutyrate were collectively assayed 
in the neutralised perchloric acid extract of the 
perfusate as described in section 2.9.11. Each 
point represents the mean value in each 
experimental group. The SEM are represented by 
the vertical lines.
•: Control (fed ad libitum) rats (n=4)
a : "Pair fed" non-tumour bearing rats (n=4)
■: 12 hours starved rats (n=2)
▼: 48 hours starved rats (n=2)
o: Walker 256 carcinosarcoma bearing rats (day 
6 PI) (n=2)
a : Walker 256 carcinosarcoma bearing rats (day 
10 PI) (n=2)
□: Walker 256 carcinosarcoma bearing rats (day 
14 PI) (n=4)
v: R3230AC adenocarcinoma bearing rats (day 23 
PI) (n=4)
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Figure 5.7:
14 14
Hepatic CO formation from [U- C] oleate 
2
The oxidation of [U-14C] oleate to 1 4C02 was 
studied by commencing the liver perfusion 
(recirculation) with Krebs-Henseleit bicarbonate 
buffer (pH 7.4, equilibrated with 95%02:5%C02 at 
37 °C) containing [U-14C] oleate (0.75 + 0.06mM;
specific activity 0.01Ci/mol) as described in 
section 2.9. Production of 14C02 was followed 
for 60 min. 14C02 was recovered by treating the 
perfusate with 10% perchloric acid and was 
collected quantitatively in hyamine solution (1M 
in methanol). The hyamine solution was counted 
for radioactivity using the liquid scintillation 
method (section 2.9.6). Each point represents 
the mean value in each experimental group. The 
SEM are represented by the vertical lines.
•: Control (fed ad libitum) rats (n=4)
■: "Pair fed" non-tumour bearing rats (n=4) 
a : 12 hours starved rats (n=2)
▼: 48 hours starved rats (n=2)
o: Walker 256 carcinosarcoma bearing rats (day 
6 PI) (n=2)
a : Walker 256 carcinosarcoma bearing rats (day 
14 PI) (n=4)
v: R3230AC adenocarcinoma bearing rats (day 23 
PI) (n=4)
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pair fed NTB and 48 hour starved rats (comparisons were made with
14
control rats). Similarly, CO production was notably decreased
2
by 75% (p<0.05) in the livers of rats bearing the Walker 256
carcinosarcoma during the time course of tumour bearing. A 
14
decrease in CO by 60% (p<0.05) was also noted for the livers
2
of rats bearing the R3230AC adenocarcinoma at day 23 PI.
5.2.6 The Ratio of 3-Hydroxybutyrate/Acetoacetate
(30HBA/AcAc) in the Liver Perfusate
The ratios of 30HBA/AcAc in the perfusate during the 
time course of ketone body formation from endogenous substrates 
are shown in Tables 5.1 to 5.8. In comparison with the values 
for control rats, the ratio of 30HBA/AcAc during .endogenous 
ketogenesis was decreased in all cases. The data from the liver 
perfusions of pair fed NTB, 12 and 48 hours starved, showed 
decreases of 63% (pcO.OOl), 78% (pcO.OOl) and 73% (pcO.OOl) in 
the ratio. Whereas there were decreases of 15% (NS), 34% (NS)
and 22% (NS) for rats bearing the Walker 256 carcinosarcoma at 
day 6, 10 and 14 PI. For rats bearing the R3230AC adenocarcinoma 
the ratio of 30HBA/AcAc was decreased by 75% (p<0.001).
The ratios of 30HBA/AcAc in liver perfusate during 
the time course of ketone body formation from oleate are shown in 
Tables 5.1 to 5.8. In comparison with the control rats there was 
no significant change in the ratio of 30HBA/AcAc in the 12 and 48 
hours starved rats and rats bearing the R3230AC adenocarcinoma 
(day 23 PI). However the ratio of 30HBA/AcAc was increased by 
60% (p<0.05) in the pair fed NTB rats and by 37% (NS), 67% 
(p<0.05) and 74%(p<0.05) for the Walker 256 carcinosarcoma 
bearing rats at day 6, 10 and 14 PI.
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Table 5.1: Ketone body formation by the perfused livers of 
control (fed ad libitum]_ rats in the presence or 
absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
umol g— i liver (w/w)
Condition: ENDOGENOUS
15 4 0.78 + 0.30 0.68 + 0.51 2.30 + 0.54 0.87 + 0.21
30 4 1.68 + 0.47 1.25 + 0.29 3.79 + 0.37 0.74 + 0.19
45 4 2.48 + 0.50 1.81 + 0.32 5.21 + 0.52 0.73 + 0.21
60 4 3.26 + 1.00 2.61 + 0.33 7.25 + 0.31 0.80 + 0.30
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 4 3.25 + 0.35 5.15 + 0.64 8.40 + 0.80 1.63 + 0.22
30 4 4.88 + 0.66 7.48 + 0.55 12.35 + 0.96 1.61 + 0.20
45 4 6.38 + 0.70 8.61 + 0.72 14.98 + 0.79 1.41 + 0.20
60 4 8.27 + 1.03 10.42 + 0.52 18.69 + 1.13 1.32 + 0.17
For endogenous (absence of substrate i. e. , oleate) ketone body
formation, the livers were perfused (non-recirculation) with 
Krebs-Henseleit bicarbonate buffer (pH 7.4, equilibrated with 
95%02 :5%C02) for 60 min. For ketone body formation from oleate 
at elevated levels (0.75 + 0.06mM) the livers were perfused with 
the above buffer supplemented with oleate (section 2.9). 2.0ml 
samples were taken at 15 min. intervals and mixed with an equal 
volume of 0.6% HC10i+ and left to stand in an ice bath for 5 min. 
The protein precipitates were removed by centrifugation at 5000xg 
for 10 min. and the supernatant was neutralised with saturated 
KHCO 3 solution. The concentration of acetoacetate (AcAc) and D- 
(-)-3-hydroxybutyrate (30HBA) were determined in the neutralised 
perchloric acid extract as described in section 2.7. The values 
are the mean + SEM; n = number of observations.
Table 5.2: Ketone body formation by the perfused livers of 
"pair fed" non-tumour bearing rats in the presence 
or absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
umol g-1 liver (w/w)
Condition: ENDOGENOUS
15 6 0.69 + 0.20 0.17 + 0.01 0.81 + 0.17* 0.35 + 0.10*
30 6 2.73 + 0.60 0.48 + 0.07** 3.00 + 0.60 0.27 + 0.03**
45 6 3.69 + 1.30 0.88+ 0.16* 4.29 + 1.16 0.33 + 0.05*
60 6 8.40 + 1.51 1.09 + 0.28* 8.57 + 1.64 0.20 + 0.03***
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 6 2.32 + 0.38 5.51 + 1.01 7.82 + 1.12 2.31 + 0.46
30 6 3.26 + 0.51 8.68 + 1.27 12.43 + 1.76 2.58 + 0.54
45 6 4.47 + 1.01 12.44 + 2.20 16.89 + 2.58 2.57 + 0.42*
60 6 5.98 + 1.28 15.41 + 1.86 21.40 + 2.18 2.27 + 0.45
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.3: Ketone body formation by the perfused livers of 
12 hours starved rats in the presence or absence 
of oleate
Time n Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
_______________________________________  AcAc
umol g— i liver (w/w)
Condition: ENDOGENOUS
15 5 4.00 + 0.86* 0.44 + 0.05 4.44 + 0.95 0.17 + 0.04***
30 5 7.47 + 1.30** 1.43 + 0.15 8.91 + 1.60 0.18 + 0.01***
45 5 10.16 + 1.79** 1.76 + 0.29 11.95 + 2.00* 0.17 + 0.02***
60 5 7.28 + 2.14 2.53 + 0.42 13.81 + 2.70* 0.17 + 0.03**
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 5 2.91 + 0.19 5.50 + 0.69 8.54 + 0.70 1.85 + 0.27
30 5 5.15 + 0.63 7.84 + 1.08 13.27 + 1.66 1.47 + 0.18
45 5 8.38 + 1.04 9.84 + 1.38 18.14 + 2.28 1.18 + 0.08
60 5 9.10 + 1.29 10.45 + 1.11 19.53 + 2.21 1.19 + 0.11
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student’s 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.4: Ketone body formation by the perfused livers of 
48 hours starved rats in the presence or absence 
of oleate
Time
(min)
n Acetoacetate 3-Hydroxy Total Ketone
Butyrate Bodies 3 0HBA 
AcAc
ymol g— i liver (w/w)
Condition: ENDOGENOUS
15 5 3.52 + 0.96* 0.79 + 0.17 4.03 + 1.01 0.13 + 0.01**
30 5 4.8 + 0.83* 2.06 + 0.32 6.54 + 0.89* 0.28 + 0.07
45 5 12.26 + 2.18** 2.77 + 0.32 14.76 + 2.31** 0.22 + 0.04*
60 5 13.47 + 1.3*** 3.30 + 0.5 16.36 + 1.5*** 0.22 + 0.03***
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 6 5.09 + 0.67 9.79 + 1.25 14.87 + 1.86* 1.97 + 0.17
30 6 10.0 + 0.97** 17.3 + 2.19** 27.2 + 3.01** 1.75 + 0.15
45 6 12.9 + 0.9*** 20.3 + 2.31** 33.3 + 2.9** 1.59 + 0.16
60 6 16.7 + 0 .8*** 25.7 + 2.88** 42.4 + 3.3*** 1.54 + 0.17
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test” was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.5: Ketone body formation by the perfused livers of 
rats bearing the Walker 256 carcinosarcoma (day (5 
PI) in the presence or absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
ymol g — i liver (w/w)
Condition: ENDOGENOUS
15 4 0.69 + 0.09 0.44 + 0.17 0.92 + 0.21 0.56 + 0.18
30 4 1.44 + 0.28 1.05 + 0.4 2.4 + 0.5 0.61 + 0.21
45 4 2.18 + 0.57 1.9 + 0.63 4.08 + 0.92 0.73 + 0.12
60 4 3.12 + 0.91 2.46 + 0.94 5.54 + 1.05 0.76 + 0.37
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 4 1.29 + 0.15** 2.64 + 0.49** 3.92 + 0.45** 2.24 + 0.65
30 4 2.15 + 0.6* 4.0 + 0.41** 6.15 + 0.9** 2.2 + 0.45
45 4 3.11 + 0.81* 5.17 + 0.51** 8.28 + 1.08 2.0 + 0.42
60 4 3.98 + 0.91* 6.23 + 0.48** 10.2 + 1.3** 1.8 + 0.33
For experimental details see the legend of table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.6: Ketone body formation by the perfused livers of 
rats bearing the Walker 256 carcinosarcoma (day 
10 PI) in the presence or absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
umol g— i liver (w/w)
Condition: ENDOGENOUS
15 5 0.63 + 0.07 0.39 + 0.05 1.55 + 0.5 0.52 + 0.84
30 5 1.4 + 0.18 1.06 + 0.21 2.19 + 0.3* 0.51 + 0.15
45 5 2.32 + 0.37 1.51 + 0.25 3.54 + 0.73 0.53 + 0.11
60 5 3.19 + 0.67 1.8 + 0.3 4.86 + 0.91* 0.49 + 0.08
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 5 0.98 + 0.23** 2.9 + 0.48* 4.14 + 0.68** 2.47 + 0.57
30 5 1.63 + 0.43** 3.7 + 0.65** 5.33 + 0.7*** 2.55 + 0.53
45 5 1.98 + 0.42** 5.78 + 1.15 7.0 + 1.0*** 2.78 + 0.76
60 5 2.85 + 0.69** 7.94 + 1.6 10.13 + 1.49** 2.25 + 0.66
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.7: Ketone body formation by the perfused livers of 
rats bearing the Walker 256 carcinosarcoma (day 14 
PI) in the presence or absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total ‘Ketone 
Bodies 3 0HBA 
AcAc
umol g— i liver (w/w)
Condition: ENDOGENOUS
15 5 0.74 + 0.19 0.49 + 0.12 1.41 + 0.27 0.77 + 0.26
30 5 1.27 + 0.24 0.65 + 0.17 2.1 + 0.36* 0.49 + 0.07
45 5 1.98 + 0.35 0.91 + 0.18* 3.21 + 0.5* 0.47 + 0.07
60 5 2.96 + 0.92 1.81 + 0.51 4.72 + 1.1* 0.71 + 0.15
Condition: WITH ADDED OLEATE (0.75 + 0,.06mM)
15 5 1.5 + 0.36* 3.1 + 0.36* 4.41 + 0.88* 2.39 + 0.48
30 5 2.24 + 0.79* 4.64 + 0.61* 7.3 + 0.99** 2.85 + 0.52'
45 5 2.9 + 1.02* 6.2 + 0.75 9.61 + 1.27* 2.75 + 0.67
60 5 3.81 + 1.21** 7.44 + 1.07* 11.74 + 1.52** 2.45 + 0.51
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
Table 5.8: Ketone body formation by the perfused livers of
PI) in the presence or absence of oleate
Time
(min)
n Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
umol g — 1 liver (w/w)
Condition: ENDOGENOUS
15 4 0.82 + 0.09 0.12 + 0.02* 0.94 + 0.1* 0.16 + 0.03***
30 4 1.55 + 0.28 0.2 + 0.06** 1.75 + 0.27* 0.14 + 0.05***
45 4 2.19 + 0.98 0.55 + 0.27** 2.86 + 1.34** 0.2 + 0.03***
60 4 3.67 + 1.36 0.83 + 0.6** 4.5 + 1.91** 0.2 + 0.07***
Condition: WITH ADDED OLEATE (0.75 + 0.06mM)
15 4 3.31 + 0.87 4.02 + 1.49 7.33 + 2.25 1.2 + 0.21
30 4 4.73 + 0.72 6.45 + 1.77 11.17 + 2.15 1.37 + 0.34
45 4 6.31 + 0.76 7.79 + 1.55 14.1 + 1.26 1.32 + 0.4
60 4 7.58 + 0.57 9.56 + 1.69 17.14 + 1.24 1.32 + 0.35
For experimental details see the legend of Table 5.1 and the 
methods section 2.9. The values are the mean + SEM. "Student's 
t test" was used for the statistical evaluation of the data. The 
p values are related to the results of control experiments (Table 
5.1), *p<0.05, **p<0.01, ***p<0.001.
The ratios of 30HBA/AcAc in the liver perfusates during
14
the time course of ketone body formation from [U- C] oleate are 
shown in Tables 5.9 to 5.13. In comparison with control values 
the ratio of 30HBA/AcAc was decreased by 50% (p<0.05) and 70%’ 
(p<0.05) in 12 and 48 hours starved rats. Whereas the ratios 
were increased by 27% (NS), 85% (p<0.01) and 56% (p<0.05) for
rats bearing the Walker 256 carcinosarcoma at day 6, 10 and 14
PI. In the case of rats bearing the R3230AC adenocarcinoma (day 
23 PI), no significant change was found for the 30HBA/AcAc ratio 
of the liver perfusate.
5.2.7 Glucose Release by the Perfused Liver During 
Ketogenesis
Glucose release by the perfused liver was also measured 
during ketone body formation from oleate in order to gauge 
aspects of the state of carbohydrate metabolism in the liver. 
The results are shown in Fig. 5.8. In the case of pair fed NTB, 
12 and 48 hours starved rats, glucose released into the perfusate 
was decreased by 25% (NS), 64% (p<0.01) and 70% (p<0.01) in 
comparison with control rats. During the early stages of Walker 
256 carcinosarcoma bearing, glucose release was increased by 20% 
(NS) and 24% (NS) at day 6 and 10 PI, but at the terminal stages 
(day 14 PI) of tumour growth, the glucose release by the perfused 
liver was decreased by 42% (p<0.05).
5.2.8 Concentration of Oleate in the Circulation
The plasma concentrations of free fatty acids were 
found to be elevated in starved and tumour bearing rats (Table 
3.3). Therefore, the livers of control, variously starved and
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Table 5.9: Ketone body formation from [U- C] oleate by the 
perfused livers of control (fed ad libitum) rats
14
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
__________________________________________  AcAc
d.p.m. g — i liver (w/w)
15 1952 + 109 3909 + 482 5662 + 524 1.91 + 0.25
30 2691 + 344 4760 + 881 7452 + 867 1.88 + 0.45
45 3464 + 311 5761 + 1760 9225 + 1748 1.-71 + 0.56
60 4253 4- 655 7210 + 1426 11462 + 1454 1.84 + 0.46
Livers were perfused with Krebs-Henseleit bicarbonate buffer (pH 
7.4, equilibrated with 95%02:5%C02 at 37°C) containing [U-14C] 
oleate (0.01Ci/mol) for 60 min. as described in section 2.9. 
2.0ml samples were taken at 15 min. intervals and mixed with an 
equal volume of 0.6% HCIO4 and left to stand in an ice bath for 5 
min. The protein precipitates were removed by centrifugation at 
5000xg for 10 min and the supernatant was neutralised with 
saturated KHCO3 solution. [U-1 4 C] acetoacetate and [U-1 4C] D-(- 
)-3-hydroxybutyrate were assayed as described in section 2.9.11. 
The values are the mean + SEM for four perfusions in each 
experimental group.
Table 5.10: Ketone body formation from [U- C] oleate by the 
perfused livers of »pair fed1 non-tumour bearing 
rats
14
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
__________________________________________  AcAc
d.p.m. g— i liver (w/w)
15 1641 + 680 4184 + 2070 5824 + 2123 2.6 + 0.51
30 2954 + 971 8275 + 4582* 11244 + 4164** 2.75 + 0.55
45 4754 + 1988 7488 + 2796 12242 + 4664* 1.87 + 0.62
60 5676 + 2564 11240 + 5119 16916 + 7636* 2.13 + 0.33
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for four rats 
in each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.11: Ketone body formation from [U- C] oleate by the 
perfused livers of 12_ hours starved rats
14
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
______________________________________________  AcAc
d.p.m. g — i liver (w/w)
15 1686 + 58 2057 + 168 3742 + 111 1.23 + 0.15
30 4512 + 574* 3700 + 191 8212 + 764 0.83 + 0.06*
45 6992 + 349 5018 + 83 12010 + 432 0.72 + 0.02*
60 9102 + 48 7254 + 66 16356 -1- 114* 0.8 + 0.01*
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for two 
rats in each experimental group. "Student's t test" was used for 
the statistical evaluation of the data. The p values are related 
to the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.12: Ketone body formation from [U- C] oleate by the 
perfused livers of 4_8 hours starved rats
14
Time
(min)
Acetoacetate 3-Hydroxy 
Butyrate
Total Ketone 
Bodies 3 0HBA 
AcAc
d.p.m . g- i liver (w/w)
15 4208 + 4.9** 4223 + 2064 8432 + 2069 1.0 + 0.49
30 11217 + 1544** 3044 + 388 14264 + 1159** 0.3 + 0.08**
45 16825 + 988** 7428 + 2485**24253 + 3473** 0.43 + 0.12**
60 26683 + 5550***8530 + 630 35213 + 4920***0 .34 + 0.09**
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for two 
rats in each experimental group. "Student's t test" was used for 
the statistical evaluation of the data. The p values are related 
to the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.13: Ketone body formation from [U- C] oleate by the 
perfused livers of rats bearing the Walker 256 
carcinosarcoma (day 6^ PI)
14
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
__________________________________________  AcAc
d.p.m. g — i liver (w/w)
15 1284 + 150 1452 + 283 2735 + 133* 1.17 + 0.36
30 1732 + 369 2008 + 288 3741 + 81* 1.25 + 0.43
45 2746 + 960 3248 + 369 5994 + 1329* 1.30 + 0.32
60 3690 + 1827 4084 + 430* 7774 + 1397* 1.54 + 0.88
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for two rats 
in each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.14: Ketone body formation from \\J- C] oleate by 
perfused livers of rats bearing the Walker 
carcinosarcoma (day 10 PI)
the
256
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
__________________________________________  AcAc
d.p.m. g— 1 liver (w/w)
15 599 + 183** 1610 + 397* 2209 + 579 2.75 + 0.18*
30 904 + 162** 3106 + 602 4010 + 764 3.42 + 0.06**
45 1195 + 260** 4566 + 927 5761 + 1187* 3.84 + 0.06**
60 1511 + 123** 5397 + 1236 6607 + 1059* 3.53 + 0.53**
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for two rats 
in each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.15: Ketone body formation from C] oleate by the 
perfused livers of rats bearing the Walker 256 
carcinosarcoma (day 14 PI)
14
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 3QHBA
__________________________________________  AcAc
d.p.m. g— i liver (w/w)
15 660 + 171** 1315 + 226** 1975 + 258 2.39 + 0.76
30 969 + 348** 2516 + 490* 3486 + 598* 3.65 + 1.47*
45 1282 + 135** 3368 + 783 4646 + 891* 2.57 + 0.46
60 1630 + 249** 4659 + 1087 6289 + 1280* 2.83 + 0.43*
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for four rats 
in each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Table 5.16: Ketone body formation from 
perfused livers of rats 
adenocarcinoma (day 23 PI)
r u -  c i
bearing
14
oleate by the 
the R3230AC
Time Acetoacetate 3-Hydroxy Total Ketone
(min) Butyrate Bodies 30HBA
__________________________________________  AcAc
d.p.m. g— 1 liver (w/w)
15 393 + 162** 1297 + 214 1690 + 131* 2.95 + 1.41*
30 1363 + 592 2522 + 638 3884 + 753 1.7 + 0.54
45 2494 + 500 2580 + 628* 5074 + 233* 1.26 + 0.5
60 2902 + 331* 5012 + 796 7914 + 543* 1.84 + 0.47
For experimental details see the legend of Table 5.9 and the 
methods section 2.9. The values are the mean + SEM for four rats 
in each experimental group. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments (Table 5.9), *p<0.05,
**p<0.01, ***p<0.001.
Figure 5.8: Glucose formation by livers during perfusion with 
oleate
Livers from rats, under the various experimental 
conditions, were perfused with Krebs-Henseleit 
bicarbonate buffer (pH 7.4, equilibrated with 
95%02 :5%CC>2 at 37 °C) as described in section 2.9. 
Glucose was assayed in neutralised perchloric 
acid extract of the perfusate by the 
hexokinase/glucose 6-phosphate dehydrogenase 
method (see section 2.7.6). Each point 
represents the mean value. The SEM are 
represented by the vertical lines.
•: Control (fed ad libitum) rats (n=4) 
a : "Pair fed" non-tumour bearing rats (n=6)
■: 12 hours starved rats (n=5) 
t : 48 hours starved rats (n=6)
o: Walker 256 carcinosarcoma bearing rats (day 
6 PI) (n=4)
a : Walker 256 carcinosarcoma bearing rats (day 
10 PI) (n=5)
□: Walker 256 carcinosarcoma bearing rats (day 
14 PI) (n=5)
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Table 5.17: Circulating concentration of oleate
n Concentration of oleate 
in the perfusate (mM)
Initial cone. 
t=0 min.
Final
t=60
cone. 
min.
Control (fed ad libitum) 4 0.75 + 0.07 0.70 + 0.09
"Pair fed"
(non-tumour bearing)
6 0.71 + 0.07 0.66 + 0.04
12 hours starved 6 0.72 + 0.18 0.70 + 0.18
48 hours starved 6 0.87 + 0.07 0.82 + 0.07
Walker 256 carcinosarcoma 
bearing (day 6 PI)
4 0.76 + 0.06 0.78 + 0.11
Walker 256 carcinosarcoma 
bearing (day 10 PI)
6 0.75 + 0.03 0.70 + 0.13
Walker 256 carcinosarcoma 
bearing (day 14 PI)
5 0.85 + 0.12 0.86 + 0.17
Livers from rats under the various experimental conditions, were 
perfused with Krebs-Henseleit bicarbonate buffer (pH 7.4, 
equilibrated with 95%02 :5%C02 at 37°C) for 60 min. as described 
in section 2.9. The concentration of oleate was maintained at 
elevated levels (0.75 + 0.06mM) by constant mechanical infusion 
of oleate solution (12mM) at a rate of 2.4umol/min as described 
in section 2.9.4. The concentration of oleate in the perfusate 
was assayed as described in section 2.9.5 and 2.7.8. The values 
are the mean + SEM; n=number of observations.
tumour bearing rats were perfused with elevated levels of oleate 
(0.75 + 0.06mM) in order to study the rate and extent of
ketogenesis. The circulating concentration of oleate in the 
perfusion fluid during the time course of ketogenesis was 
maintained at a steady state as described in section 2.9.4. 
Results are shown in Table 5.17. It was evident from the results 
that in all cases, the final concentration of oleate was not 
significantly different from the starting concentration 
indicating that impairment of long chain fatty acid uptake was 
unlikely.
5.2.9 Oxygen Consumption During the Course of Liver Perfusion
The oxygen consumption of the perfused liver was
measured in the presence and absence of oleate. Results are
shown in Table 5.18. In all cases, oxygen consumption was
greater during perfusion with oleate than in the absence of that
substrate. The variation in the degree of stimulation of oxygen
consumption in the presence of oleate by livers of rats under all
experimental situations may be related to the capacity of the
livers to oxidise oleate to CO (Fig. 5.7). In the presence of
2
oleate, the oxygen consumption was increased by 51% (p<0.01), 62% 
(p<0.01), 70% (p<0.01) and 40% (p<0.05) during the time course of 
liver perfusion of control (fed ad libitum), pair fed NTB, 12 and 
48 hours starved rats. The livers of rats bearing the Walker 256 
carcinosarcoma or R3230AC adenocarcinoma consumed less oxygen 
(not significantly different) in the absence of oleate when 
compared with the oxygen consumption by the liver of control 
rats. However for livers of tumour bearing animals perfused with
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Table 5.18: Oxygen consumption during the course of liver 
perfusion by control (fed ad libitum), variously 
starved rats and rats bearing the Walker 256 
carcinosarcoma or the R3230AC adenocarcinoma
Oxygen consumption 
umol g — l liver (w/w)
Absence of Oleate
oleate (0.75 + 0.06mM)
Control (fed ad libitum) 4
"Pair fed" 6
(non-tumour bearing)
12 hours starved 6
48 hours starved 6
Walker 256 carcinosarcoma 3
bearing (day 6 PI)
Walker 256 carcinosarcoma 4
bearing (day 10 PI)
Walker 256 carcinosarcoma 4
bearing (day 14 PI)
R3230AC adenocarcinoma 4
bearing (day 23 PI)
2.03 + 0.10 3.07 + 0.12
1.96 + 0.11 3.18 + 0.12**
1.75 + 0.11 2.97 + 0.20**
2.02 + 0.07 2.82 + 0.16*
1.73 + 0.32 2.42 + 0.32
1.69 + 0.20 2.53 + 0.17*
1.45 + 0.06 2.12 + 0.12*
1.76 + 0.07 3.25 + 0.12***
Livers from rats, under various experimental conditions, were 
perfused with or without oleate (0.75 + 0.06mM) as described in 
section 2.9. Oxygen consumption was measured from the difference 
between efferent and afferent oxygen concentration during the 
course of the perfusion (0-60 min.). The values are the mean + 
SEM; n=number of observations. "Student's t test" was used for 
the statistical evaluation of the data. The p values are related 
to the results of control experiments, *p<0.05, **p<0.01,
***p<0.001.
oleate oxygen consumption was increased by 40% (p<0.05), 50%
(p< 0.05) and 46% (p<0.05) in rats bearing the Walker 256 
carcinosarcoma at day 6, 10 and 14 PI and by 90% (pcO.001) in 
rats bearing the R3230AC adenocarcinoma (day 23 PI).
5.2.10 Free Fatty Acid and Triglyceride Composition of the
Perfused Liver
The FFA and TG content of the liver after 60 min. of
perfusion with oleate are shown in Table 5.19. FFA content did
not change significantly in the perfused livers of pair fed NTB, 
12 and 48 hour starved rats and rats bearing the R3230AC 
adenocarcinoma (day 23 PI), when compared to that of control
rats. FFA were increased by 282% (pcO.001), 111%(p<0.001) and
177% (p<0.001) in the livers of rats bearing the Walker 256
carcinosarcoma at day 6, 10 and 14 PI.
The TG content of the perfused livers of pair fed NTB 
rats was increased by 18% (NS), but decreased by 6% (NS) and 34% 
(p<0.01) in the perfused liver of 12 and 48 hours starved rats, 
in comparison with control rats. Whereas the triglyceride 
content was increased by 88% (p<0.001), 139% (p<0.001) and 89%
(pcO.001) in the perfused livers of rats bearing the Walker 256 
carcinosarcoma at day 6, 10 and 14 PI. An increase of 119%
(pcO.001) was also noted for the perfused livers of rats bearing 
the R3 2 3 0AC adenocarcinoma (day 2 3 PI) .
14
5.2.11 Distribution of [U- C] Oleate into Lipid Components
14
The distributions of incorporated [U- C] oleate into
lipid, neutral lipid and free fatty acid fractions were
14
measured in the liver after 60 min. of perfusion with [U- C]
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Table 5.19: Free fatty acid and triglyceride composition of 
the perfused livers of control (fed ad libitum) 
and variously starved rats and rats bearing the 
Walker 256 carcinosarcoma or R3 2 3 OAC 
adenocarcinoma
Free fatty acid Triglyceride
n ______________________________
umol g— 1 frozen liver powder
Control (fed ad libitum) 4 15.37 + 1.19 11.58 + 3.57
"Pair fed" 6 15.45 + 1.57 13.71 + 1.35
(non-tumour bearing)
12 hours starved 5 16.60 + 3.3 10.91 + 0.94
48 hours starved 6 15.36 + 3.02 7.69 + 1.38**
Walker 256 carcinosarcoma 4 58.76 + 11.4*** 21.86 + 4.67 ***
bearing (day 6 PI)
Walker 256 carcinosarcoma 6 32.48 + 11.4*** 27.71 + 2.8***
bearing (day 10 PI)
Walker 256 carcinosarcoma 6 42.65 + 11.4*** 21.84 + 1.76***
bearing (day 14 PI)
R3230AC adenocarcinoma 4 14.79 + 0.75 25.35 + 8.56***
bearing (day 23 PI)
Livers from rats, under the various experimental conditions were 
perfused as described in section 2.9. For other experimental 
details see the legend of Table 5.17. At the end of the perfusion 
and with pump still running approx. 2.Og of perfused liver (left 
lateral lobe) was removed and freeze clamped. The frozen liver 
was ground to a fine powder under liguid nitrogen. Lipids -from 
the specimen of liver powder were extracted in a mixture of 
chloroform and methanol (2:1 v/v) as described in section 2.9.8. 
Free fatty acids and triglycerides were separated from the total 
lipid extract using a column containing Florisil (5g; 60-100 mesh) 
and later assayed as described in section 2.7. The values are the 
mean + SEM; n=number of observations. The p values are related to 
the results of control experiments, *p<0.05, **p<0.01, ***p<0.001.
oleate and the results are shown in Table 5.20. Total hepatic 
lipids were reduced in semistarved and starved animals as shown 
by decreases of 29% (NS), 52% (p<0.05) and 68% (p<0.01) in pair 
fed NTB, 12 and 48 hours starved rats in comparison with control 
(fed ad libitum) rats. In contrast, the total lipid content was 
increased by 34%, 5% and 11% in the perfused liver of rats 
bearing the Walker 256 carcinosarcoma at day 6, 10 and 14 PI.
The ratio of neutral lipid to total lipid was approximately 
0.6 in the perfused livers of control (fed ad libitum) rats. 
This ratio was unchanged for the perfused liver of pair fed rats 
but was decreased to 0.43 and 0.37 in the perfused liver of 12 
and 48 hours starved rats. These starved animals only contained 
26% and 36% of the neutral lipid value of control rats. In the 
perfused liver of the Walker 256 carcinosarcoma bearing rats, the 
neutral lipid content was 75%, 73% and 80% of the total lipid 
content at day 6, 10 and 14 PI. These values were 29% (p<0.05), 
26% (p<0.05) and 38% (p<0.01) comparatively greater than the 
neutral lipid content of perfused livers of control rats. For 
the R3230AC adenocarcinoma bearing rats, the neutral lipids 
comprised 83% of the total lipids, which was 44% (p<0.01) greater 
than that of control rats.
It was found that the FFA content was increased by 28% 
(NS) and 4% (NS) in the livers of pair fed NTB and 48 hours 
starved rats, but decreased by 9% (NS) in 12 hours starved rats 
when compared to control rats. Perfused livers of Walker 256 
carcinosarcoma bearing animals contained 34% (NS), 279% (p<0.001) 
and 15% (NS) more fatty acid at day 6, 10 and 14 PI in comparison
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Table 5.20: The distribution of [U- C] oleate into total 
lipid, neutral lipid and free fatty acid fractions 
in the perfused livers of control (fed ad 
libitum), variously starved rats and rats bearing 
the Walker 256 carcinosarcoma or R3230AC 
adenocarcinoma
14
The livers were perfused as described in section 
2.9. For further details see the legend of Table 
5.17. A measured quantity of frozen liver powder 
was used to extract total lipids into chloroform- 
methanol (2:1 v/v) mixture as described in section 
2.9.8. One half of this extract was used to 
determine the distribution of radioactivity into 
total lipid. The remaining half was applied to a 
column containing Florisil (5g; 60-100 mesh) in 
order to separate the neutral lipid and free fatty 
acids from the total lipids (see section 2.9.9). 
The values are the mean + SEM. ’’Student's t test" 
was used for the statistical evaluation. The p 
values are related to the results of dontrol 
experiments, *p<0.05, **p<0.01, ***p<0.001.
R3230AC
adenocarcinom
a 
4 
280750 ± 6250 
235500 ± 
18413** 
83.54 ± 6.78** 
39774 ± 
3533**
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with control rats. In the R3230AC adenocarcinoma bearing rats
(day 23 PI) the accumulation of free fatty acid in the perfused
liver was 475% (pcO.OOl) of that of the control rats.
5.3 Discussion
Starvation is characterised by increased mobilisation
of FFA from peripheral adipose tissue and their accelerated
transport into the liver (Mayes and Feltz, 1967b). This
statement was testified by the elevated levels of FFA in the
plasma and livers of variously starved rats (Tables 3.3 and 3.4).
It is suggested that elevated levels of hepatic FFA in these
rats were responsible for the stimulated rates of endogenous
ketogenesis (Fig. 5.4). However, the livers of tumour bearing
animals in spite of elevated concentrations of FFA (Table 3.4),
exhibited depressed endogenous ketogenesis (Fig. 5.4). This
result showed the existence of an impaired ketogenic mechanism in
these animals. A similar pattern obtained when the livers of
variously starved and tumour bearing rats were perfused with
14
either unlabelled or [U- C] oleate, further confirming the 
initial findings of impaired ketogenesis in tumour bearing 
animals.
The increased ketogenesis (endogenous or from oleate) 
of starvation, as shown by the data from pair fed NTB, 12 and 48 
hours starved rats (Fig. 5.4-5.6) may in part be explained by the 
tissue levels of malonyl CoA (McGarry and Foster, 1980). Under 
the conditions adopted in this study lipogenesis from 
carbohydrate was expected to be suppressed because of the low 
hepatic glycogen levels (Krebs et al., 1966) and the decreased
165
release of glucose in the perfusion medium (Fig. 5.8) by the
livers of rats in those experimental groups. The classical
investigations of McGarry and Foster (1980) revealed that
decreased lipogenesis was characterised by low hepatic levels of
malonyl CoA which was hormonally maintained by a starvation
induced high plasma glucagon:insulin ratio (section 5.1.1.2).
Low levels of malonyl CoA in the liver of starved animals result
in enhanced transport of acyl CoA into the mitochondria, which in
turn results in an increased shunting of fatty acid into the
oxidative pathway and less into the esterification pathway. The
levels of malonyl CoA were not investigated in the present
investigation; however this connection is supported by the
stimulated ketogenesis which was associated with low levels of TG
14
(Table 5.19) and low incorporation of [U- C] oleate into neutral 
lipid fractions (Table 5.20) in the perfused livers of
experimental animals.
It has been established that the greater the entry of
fatty acids into the oxidative pathway, the more it is channelled
into ketogenesis and less into the citric acid cycle. Thus, the
total production of energy from substrate remains relatively
constant (Mayes and Feltz, 1967b). Furthermore, the complete
oxidation of fatty acid to CO via the citric acid cycle also
2
depends upon the availability of oxaloacetate (Demaugre et al., 
1978; Mooney and Lane, 1982; Nosadini et al., 1980; O'Donnel and 
Freedland, 1980; Siess et al., 1982), which in turn depends upon 
its synthesis via glycolytic conversion of glucose to pyruvate 
and its subsequent carboxylation by an anaplerotic mechanism 
(Mooney and Lane , 1982). The site for the regulation of
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oxaloacetate synthesis was found to be the glycolytic step of
PFK-I (Lane et al♦, 1979). Recent investiagtions have disclosed
that the modulator fru 2,6-P activates this enzyme (Hers and Van
2
Schaftingen, 1982; Pilkis et al., 1981a; Uyeda et al., 1981).
During starvation or diabetes the hepatic levels of fru 2,6-P
2
decreased to 10% of the levels found in the livers of normal fed
rats (Neely et al., 1981). The low levels of fru 2,6-P may be
2
expected to inhibit glycolysis and stimulate gluconeogenesis and
therefore, decrease production and increase utilisation of
oxaloacetate. The overall effects of these interactions is
increased ketogenesis and decreased CO production. Consistent
2
with this are the results shown in Fig. 5.6 and 5.7, which
clearly demonstrate the existence of such an inverse relationship
between ketogenesis and CO formation from fatty acid in starved
2
rats. Therefore, the results of the present investigation, which 
demonstrated an enhanced ketogenesis in starved rats (Figs. 5.4- 
5.7) occurring at the expense of fatty acid esterification and 
oxidation, verified the operation of the above regulatory network 
in these animals.
The rate of oxygen consumption during isolated liver 
perfusion with or without oleate was used as a measure of the 
performance of the liver during the perfusion. In all 
experimental conditions oxygen consumption was greater during 
perfusion with oleate than in the absence of this substrate 
(Table 5.18). The oxygen consumption by perfused livers of rats 
under the various experimental situations was attributed to the 
oxidation of oleate-derived acetyl CoA; since the variation in
167
the degree of oxygen consumption during perfusion of livers with
oleate was positively correlated (r = +0.72) to their capacities 
14
for CO production.
2
The ratio of 3-hydroxybutyrate/acetoacetate
(3 OHBA/AcAc) in the perfusate was lower during endogenous 
ketogenesis than during ketogenesis from oleate in the liver of 
control rats. Tumour bearing or various degrees of
starvation, as with pair fed NTB, 12 and 48 hours starved rats, 
caused a further decrease in the ratio 30HBA/AcAc during 
endogenous ketogenesis. The decline in hepatic 30HBA/AcAc ratio 
in response to starvation in rats was also seen by Debeer and 
coworkers (1974). The fall in the ketone body ratio indicated an
oxidised mitochondrial redox state in these livers (Krebs
‘14
et al., 1969). The addition of unlabelled or [U- C] oleate to
the perfusion medium resulted in elevated 30HBA/AcAc ratios in
all experimental groups. It has been reported that long chain
fatty acids are the only physiological substrates that can
maintain a high 30HBA/AcAc ratio in the liver (Krebs and Hems,
1970) because during fatty acid oxidation 3-hydroxy acyl CoA
dehydrogenase (EC 1.1.1.35) and 3-hydroxybutyrate dehydrogenase
+
enzyme systems share a common NAD /NADH pool (Willms et al., 
1979). It is suggested that a reduced mitochondrial redox state 
in starved rats during fatty acid oxidation further limited the 
availability of oxaloacetate (La Noue et al., 1972) and therefore 
the citric acid cycle (Debeer et al., 1974) thus favoured ketone
body formation. However, the ratios of 30HBA/AcAc in the 
experimental conditions reported here (starvation and tumour 
bearing) did not vary from the range reported for normal animals
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(Krebs et al., 1969). Since the 30HBA/AcAc ratio reflects the
+
intramitochondrial redox state of the NAD couple (Williamson et 
al., 1967), it may be concluded that the redox state of the
mitochondria was unimpaired in the presence of long chain fatty 
acid under these conditions.
The tumour bearing animals, in spite of their anorexic 
and semistarved state, were unable to regulate hepatic ketone 
body synthesis. This is evident from the low rates of both
endogenous ketogenesis (Fig. 5.4) and ketogenesis from labelled 
or unlabelled oleate (Figs. 5.5 and 5.6). The results 
demonstrated a clear deviation from the normal regulation of 
ketone body metabolism and also an impairment of fatty acid 
metabolism in tumour bearing animals. Thus, it is concluded that 
tumour growth at a site distant from the liver acted to inhibit 
the ability of the host liver to oxidise fatty acids (Fig. 5.7) 
and to synthesise ketone bodies (Figs. 5.4-5.6). This neoplasm- 
induced environment of stimulated fatty acid esterifiaction 
(Table 5.20) without any impairment of hepatic fatty acid uptake 
(Table 5.17) resulted in the accumulation of fatty acid in the 
liver ('fatty liver syndrome') (Table 5.19 and 5.20). These 
results suggested that the inhibition of fatty acid oxidation and 
ketone body formation occurred by a mechanism which involved the 
inhibition of the transport of fatty acyl CoA from the cytoplasm 
to the mitochondria and thus results in the diversion of fatty 
acid towards the esterification pathway.
As discussed in the introductory review (section 
5.1.1.2), ketone body synthesis is extensively regulated by a
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number of hormones. Thus it was noted that the increased fatty 
acid esterification and decreased ketone body synthesis were 
similar to the effects of vasopressin on fatty acid metabolism 
(Rofe and Williamson, 1983 a,b). Notably elevated levels of 
vasopressin in the plasma of tumour bearing animals are reported 
by this investigation (chapter seven) and have previously been 
reported for more than fifteen different cancer situations 
(section 1.2.2.1.4). It is therefore suggested that vasopressin 
may affect the activity of ACT-I, thereby impairing fatty acid 
entry into the mitochondria and hence fatty acid oxidation and 
ketone body synthesis. Moreover, it is suggested that the 
proposed decreased activity of ACT-I may be attributed to a 
specific retrodifferentiating effect (Herzfeld and Greengard, 
1972) on this enzyme by tumour growth. The activity of ACT-I in 
foetal liver is only 5-10% of the adult value (Lee and Fritz, 
1971). Herzfeld and Greengard (1972) demonstrated foetalistic
changes in the activity of several adult type enzymes (section 
5.1.2) associated with tumour bearing. The developmental pattern 
of ACT-I (Fig. 5.3) in foetal liver resembles that of hepatic 
alanine aminotransferase which also undergoes
retrodifferentiation (Fig. 3.5). It is suggested that ACT-I may 
be a member of the same enzyme cluster during early development 
of the foetal liver, as that of alanine aminotransferase and is 
therefore retrodifferentiated in the same manner. Furthermore, 
it was reported that the enzyme complement of the well 
differentiated Morris hepatomas 9121 and 7787 closely resembled 
normal liver (McGarry and Foster, 1969) whereas that of the 
poorly differentiated Hepatoma 7777 resembled the
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retrodifferentiated liver (Matthaei, 1979). Lack of appreciable 
activity of ACT-I in the poorly differentiated Hepatoma 7777 
(Fields et al., 1981) further supports the proposal that tumour 
growth may have induced a retrodifferentiating effect on this 
enzyme in the host liver.
This investigation thus concludes that the activity of 
ACT-I and transportation of acyl CoA from the cytoplasm to the 
mitochondria should be extensively investigated in order to 
acquire a clearer picture of the impaired nature of ketogenesis 
in tumour bearing subjects. This information would have valuable 
implications for understanding the metabolic derangements in 
cancer associated cachexia.
Hyperlipidaemia, in particular the elevation of serum 
TG rich very low density lipoprotein (VLDLP), occurs in tumour 
bearing animals and cancer patients (Lanza-Jacoby et al., 1984). 
There is also evidence of elevated plasma free fatty acid levels 
in tumour bearing animals (Mider et al., 1951) and cancer 
patients (Carter et al., 1975; Feldman and Carter, 1971; Mueller 
and Watkin, 1961). Elevated levels of TG and FFA have also been 
reported in the liver of tumour bearing animals (Thompson et al., 
1981). The results of the present investigation demonstrated 
that there are elevated levels of FFA and TG in the plasma (Table 
3.3) and the perfused liver (Table 5.19 and 5.20) of tumour 
bearing animals. These results further confirmed the observation 
of such abnormalities reported in cancer patients and tumour 
bearing animals. A defect in the clearance of free fatty acids 
from circulatory triglycerides due to decreased activity of
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adipose tissue lipoprotein lipase (LPL) was also suggested to be 
responsible for the development of hypertriglyceridaemia, 
hyperfattyacidaemia and the depletion of fat stores during the 
growth of neoplasms (Lanza-Jacoby et al., 1982; Thompson et al./ 
1981). It was seen that the activity of LPL declined during the 
early stages of tumour growth and remained low throughout the 
course of tumour bearing (Lanza-Jacoby et al., 1984). It is of 
interest to note that the biochemical alterations in fatty acid 
metabolism induced by tumour bearing show marked similarities to 
those produced by cachectin (tumour necrosis factor) and other 
related monokines (see section 7.1.2.1).
A healthy person responds to starvation by producing 
ketone bodies, which act as an energy source and regulate muscle 
proteolysis by inhibiting the oxidation of branched chain amino 
acids and thus conserve muscle bulk (section 1.2.2.1.6). This 
investigation disclosed that tumour bearing animals did not 
'respond' to their anorectic state as evidenced by the low 
ketogenic response and consequently were unable to prevent the 
loss of protein from muscle.
In view of current understanding of monokine actions in 
vivo (section 1.3), it is proposed that the release of cachectin 
by blood mononuclear phagocytic cells in response to tumour 
growth or by the tumour per se , promotes the induction of cancer 
cachexia via its capacity to suppress LPL activity in adipocytes 
and stimulate an inappropriate and extensive production of 
vasopressin. These pathabolic effects, result in the depletion 
of adipose tissue and loss of muscle mass, to such an extent that 
it jeopardises the survival of the cancer subject.
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CHAPTER SIX
THE METABOLISM OF THE BRANCHED CHAIN AMINO ACIDS
BY THE SKELETAL MUSCLE OF TUMOUR BEARING RATS
6.1 Introduction
The branched chain amino acids (BCAA) leucine, 
isoleucine and valine are unique among the nutritionally 
essential amino acids in that they are degraded to the greatest 
extent by the peripheral tissues, whereas the metabolism of all 
other amino acids is principally focussed on the liver 
(Bloomgarden et al., 1981; Ichihara et al., 1973; Shinnick and
Harper, 1976). Skeletal muscle is considered under most
conditions to be the prominent site for the oxidative degradation 
of BCAA. By contrast, muscle does not degrade any other 
essential or non-essential amino acids (Adibi, 1976; Davis and 
Lee, 1985; Goldberg and Tischler, 1981; Harper and Zapalowski, 
1981; Lund, 1981). BCAA are major constituents of muscle (35% of 
the indispensable amino acids) and of dietary proteins (they 
contribute 40% to the total amino acids that are required to be 
preformed by mammals) (Adibi, 1971; Harper et al., 1984). BCAA 
make up approximately 50% of the indispensable nutritional amino 
acids (Recommended dietary allowances, National Academy of 
Science, U.S.A., 1986) and hence deficiencies of BCAA usually do 
not occur for the well nourished human and animal (Harper et al., 
1983). The levels of plasma BCAA fluctuate more widely in 
response to dietary and pathological conditions than any of the 
other essential or nonessential amino acids (Adibi and Mercer, 
1973; Frame, 1958). Increased levels of BCAA were reported in 
the plasma of healthy subjects after starvation (Adibi, 1971,
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1976), after ingestion of a large amount of fat (Swenseid et al., 
1967) and in patients with massive obesity (Adibi, 1968; Felig et 
al., 1969). The plasma levels of BCAA were notably depressed in 
patients suffering from long term protein deprivation (Kwashiokor
syndrome) (Adibi et al. , 1973) .
The importance of BCAA as metabolic fuels during the
stressful situation of caloric deprivation (starvation) or
increased caloric need (severe exercise) has frequently been
demonstrated. The muscle oxidation of BCAA increased markedly in 
certain catabolic stress situations including starvation (Paul 
and Adibi, 1978, 1980; Zapalowski et al., 1981), diabetes (Buse 
et al., 1973; Meikle and Klain, 1972), exercise (Rennie et al., 
1981) , post-operative trauma (Blackburn et al. , 1981) ,- septic and 
injury stress (Blackburn et al., 1981; Freund et al., 1981), 
infection and inflammation (Moldawer et al., 1981) and neoplastic 
disease (Goodlad and Clark, 1980). Alterations in the metabolism 
of BCAA were also reported in liver cirrhosis and in renal 
disease (Adibi, 1980; Schauder et al., 1981; Walser, 1978). The 
increased oxidation of the BCAA resulted in a decline of the 
plasma levels of all three BCAA and was associated with the 
increased degradation of muscle protein (Paul and Adibi, 1980).
6.1.1 Regulation of BCAA Oxidation
The oxidation of BCAA takes place in almost every organ 
of the body, but the rates vary from organ to organ. Despite the 
importance of BCAA as metabolic fuels and their intrinsic roles 
in the regulation of metabolic processes (Adibi, 1980). The 
regulation of BCAA oxidation has not been extensively studied.
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The following sections briefly summarise the processes involved 
in the regulation of BCAA oxidation.
6.1.1.1 Substrate and Enzymatic Regulation
The initial step in the oxidative degradation of BCAA
is the transamination of BCAA to their corresponding branched
chain keto acids (BCKA) derivatives. This is a reversible
reaction catalysed by BCAA aminotransferase (BCAAT; EC 2.6.1.42).
The second step in the degradative process involves the
intramitochondrial oxidative decarboxylation of BCKA to their
branched chain acyl CoA ester, NADH and CO . This is essentially
2
an irreversible reaction catalysed by BCKA dehydrogenase (BCKDH; 
EC 1.2.4.4).
Ichihara et al., (1973) described three isoenzymes of
BCAAT in rat tissues. According to these investigations all 
tissues contained isoenzyme I, but isoenzyme II and III were only 
found in brain and liver respectively. Furthermore, isoenzymes I 
and III transaminated all three BCAA, whereas isoenzyme II was 
specific for leucine only. Moreover, isoenzyme III was found to 
be more active in foetal and cancerous tissues than in normal 
tissues and hence was regarded as a carcinoembryonic protein 
(Goto et al., 1977; Ichihara, 1975). BCAAT occurred in both the 
cytoplasm and the mitochondria, but the proportions of the two 
fractions varied from organ to organ (Kadowaki and Knox, 1982). 
Snell and Duff (1985) demonstrated by the use of a differential 
fractional extraction procedures that most of the BCAAT activity 
of rat muscle was located in the mitochondrial compartment.
Enzymological evidence indicated that a common BCKDH
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catalysed the oxidation of a -ketoisocaproate (KIC) , a -keto-3- 
methyl valerate (VIC) and a-ketoisovalerate (KIV), the BCKA 
derivatives derived from the deamination of leucine, isoleucine 
and valine respectively (Fig. 6.1) (Danner et al., 1979;
Heffelfinger et al., 1983; Parker and Randle, 1973; Pettit et
al., 1978).
The rates of BCAA and BCKA oxidation were expected to 
vary from organ to organ in view of the differences that were 
reported in the distribution of BCAAT and BCKDH activities in the 
various tissues of the body (Harper et al., 1984).
The activity of BCAAT in the various tissues of the
body is variously modulated in response to change in the dietary
proteins (Mimura et al♦, 1968). However, the fluctuation of
BCAAT activity and its role in the regulation of BCAA oxidation
under various catabolic situations is still unknown.. The
activity of BCKDH is highly regulated by multiple interactions of
various factors involving the levels of BCKA, mitochondrial
+
ratios of branched chain acyl CoA, NADH/NAD and ATP/ADP together 
with covalent modification through a reversible phosphorylation 
(inactivation) - dephosphorylation (activation) mechanism similar 
to that of pyruvate dehydrogenase (Bremer and Davis, 1978; 
Buffington et al., 1981; Parker and Randle, 1978; Pettit et al.,
1978; Randle et al., 1981). The BCKDH is a rate limiting enzyme 
for BCAA oxidation in muscle (Goldberg and Odessey, 1972; Van 
Hinsberg et al., 1979; Wagenmaker and Veerkamp, 1982). Its
activity increased during fasting (Goldberg and Chang, 1978), 
diabetes (Paul and Adibi, 1978) and tumour bearing (Goodlad and
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Figure 6.1: Catabolic pathway of valine, isoleucine and 
leucine
All three branched chain amino acids follow the 
same degradative pathway. Valine on degradation 
forms propionate which is converted to pyruvate, 
hence valine is gluconeogenic. Leucine on 
degradation is converted into acetoacetate and 
acetyl CoA and hence is ketogenic. Isoleucine on 
degradation forms acetyl CoA and propionyl CoA, 
hence it is both gluconeogenic and ketogenic. 
For further details see the text. The pathway is 
taken from Biochemistry (1981) L. Stryer, 2nd 
edn., Freeman Press.
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Clark, 1980). It was demonstrated that the medium chain fatty
acids and carnitine affected the activity of BCKDH by changing
+
the mitochondrial ratios of NADH/NAD and acetyl CoA/CoA
(Spydevold and Hokland, 1981). Consequently the mitochondrial
concentration of ATP maintained an equilibrium between active and
inactive forms of BCKDH (Odessey and Goldberg, 1972, 1979). Very
little is known about the factors which regulate the putative
kinase and phosphatase reactions of BCKDH. The kinase reaction
was apparently inhibited by BCKA whereas the phosphatase reaction
2+ 2 +
apparently required Mg and Ca suggesting that working muscle
2 +
by raising mitochondrial Ca may activate the BCKDH (Randle et 
al., 1981). However, very little is known about the regulation
of BCAA oxidation subsequent to decarboxylation. In fact, there 
is even an uncertainty about the complete oxidation of BCAA in 
muscle (Palmer et al., 1985b).
6.1.1.2 Hormonal Regulation
Unlike gluconeogenesis and ketogenesis, very little is
known about the hormonal regulation of BCAA oxidation.
The activity of BCKDH in adipose tissue appeared to be
regulated by insulin (Goodman, 1977; Frick and Goodman, 1980)
which activated the enzyme by decreasing the apparent Km (Frick
et al., 1981). Insulin secretion was stimulated by elevated
plasma levels of leucine (Milner, 1970), which in turn
substantially increased the rate of uptake of leucine by adipose
tissue (Goodman and Frick, 1981). Insulin in the presence of
14
glucose increased the incorporation of C-labelled leucine into
fatty acid and decreased its oxidation to CO in adipose tissue.
2
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However, in the absence of glucose, insulin did not direct the
internal flow of leucine carbon and virtually all of the leucine
taken up by adipose tissue appeared as CO (Goodman and Frick,
2
1981) .
Epinephrine caused a significant but transient 
depression of BCKA oxidation in the perfused rat liver (Buxton et 
a l ., 1982) but stimulated BCAA oxidation by the perfused heart 
from fed or starved rats unless glucose was added to the medium 
(Buse et a l ., 1973). It also stimulated the oxidation of BCAA by 
diaphragm from starved rats, but not from fed rats (Harper et 
a l ., 1984). Glucagon stimulated BCAA oxidation by the perfused 
heart of the starved rat, but had no effect when the animals were 
fed, however it did not affect the oxidation of BCAA by rat 
diaphragm (Harper et a l ., 1984). Goodman and coworkers (1978) 
observed that growth hormone increased leucine oxidation by 
adipose tissue preparations from hypophysectomised rats. Growth 
hormone treatment in the same animals resulted in a 40% increase 
in the BCAAT activity in liver and doubled the activity in the 
kidney (Shirai and Ichihara, 1971) . Cortisol increased the 
activity of leucine specific BCAAT-II of the liver by two to six 
fold in rats whereas BCAAT-I was unaltered (Ichihara et al., 
1967). Shirai and Ichihara (1971) reported a three fold increase 
in the kidney BCAAT in cortisol treated rats. A small rise in 
muscle BCAAT in cortisol treated rats has also been shown (Mimura 
et al., 1968).
The molecular mechanisms by which some hormones 
modulate the oxidation of BCAA and BCKA in the various tissues of 
the body is unknown.
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6 .1.2 BCAA Oxidation and the Glucose-Alanine Cycle
Skeletal muscle released large quantities of alanine 
and glutamine into the circulation in vivo in the postabsorptive 
state and after fasting (Felig et al., 1970; Felig, 1975; Marliss 
et al., 1971). Alanine contributed >30% of the total amino acids 
released by muscle during starvation, despite the fact that it 
accounted for only 7-10% of the component amino acids of muscle 
tissue (Kominz et al♦, 1954; Odessey et al., 1974). The origin 
and extent of alanine synthesis in muscle has been the subject of 
intense investigations in several laboratories (Chang and 
Goldberg, 1978 a,b; Garber et al., 1976 a,b; Harper and 
Zapalowski, 1981; Lee and Davis, 1979; Palmer et al., 1985b; 
Snell, 1980) but to date the issue is still in dispute.
Mallette et al., (1969a) and Felig et al., (1970) 
independently suggested that alanine carbon was derived from 
circulating glucose and the amino group originated from the 
catabolism of the muscle protein. They hypothesised the 
existence of the "glucose-alanine" cycle in which alanine 
released from muscle served as a precursor for gluconeogenesis in 
the liver and aided in the transport of the amino group from 
muscle to liver for disposal as urea (Fig. 4.2). On the other 
hand Garber et al., (1976 a,b) and Goldstein and Newsholme (1976) 
suggested a very different model for the origin of alanine 
carbons, in which most of the alanine was derived from other 
amino acids produced by the nett degradation of muscle 
protein (i.e., both the carbon and amino group were synthesised 
in the muscle). These workers reported that alanine production
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isoleucine, valine,was stimulated by aspartate, leucine,
threonine and serine (Garber et al., 1976b) or by glutamate and
isoleucine (Goldstein and Newsholme, 1976) and consequently
concluded that the carbon chains of these amino acids were used
in alanine synthesis. Their proposed pathway involved the
conversion of amino acid to oxaloacetate and then to pyruvate via
+
PEPCK and PK or NADP dependent malic enzyme (Fig. 6.2).
The de novo synthesis of alanine from BCAA was recently 
reviewed by Snell and Duff (1985). These workers demonstrated 
that the metabolism of BCAA in muscle mitochondria led to the 
nett production of citric acid cycle intermediates and provided 
pyruvate for the de novo synthesis of alanine (Snell, 1980; Snell 
and Duff, 1981, 1982). The glutamate produced by the
transamination of BCAA acted as the amino group donor for alanine 
formation via transamination with pyruvate (Snell and Duff, 
1977). This reaction was catalysed by alanine aminotransferase, 
which is predominantly located in the cytoplasm (De Rosa and 
Swick, 1975; Snell and Duff, 1985). The transportation of 
carbons from the mitochondria for alanine synthesis into the 
cytoplasm occured via aspartate and the cytoplasmic pyruvate for 
alanine synthesis was then generated in part by the action of the 
cytoplasmic aspartate aminotransferase, PEPCK and PK (Fig. 6.3). 
This metabolic route was confirmed from the demonstration that 
aminomethoxy butanoate (AMB), an inhibitor of aspartate 
aminotransferase (Cornell et al., 1984; Smith et al., 1977;
Snell, 1978) inhibited valine and glutamate-stimulated alanine 
release in incubations with hemidiaphragms from 48 hours starved 
rats (Fig. 6.3).
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Figure 6.2: The de novo synthesis of alanine in muscle
The diagram illustrates that the carbon for 
alanine synthesis may be derived from the
oxidative degradation of valine and isoleucine to 
form succinyl CoA (1), reactions of the
tricarboxylic acid cycle and interactions of 
phosphoenolpyruvate carboxykinase (PEPCK;2), 
pyruvate kinase (PK;3) or malic enzyme (5) and 
alanine aminotransferase (4). The de novo 
synthesis of alanine may be affected by the 
activities of lactate dehydrogenase (6), pyruvate 
dehydrogenase complex (7) or citrate synthase 
(8). Leucine cannot contribute carbon to alanine 
synthesis, as acetyl CoA derived from leucine is 
oxidized to CO2 . For further details see section 
6.1.3.
The diagram is taken (with authors permission) 
from Bioscience Reports (1985), 5, 1015-1033.
AlanineLactate * +
Leucine
IsoleucinePyruvate
Phosphoenolpyruvate
Citrate
Oxaloacetate
Malate Isocitrate
Fumarate
Valine
Isoleucine Succinyl-CoA 2-oxoglutarate
Figure 6.3: Mitochondrial-cytoplasmic interrelationship in 
the de novo synthesis of alanine in muscle
The diagram illustrates that the metabolism of 
valine in muscle mitochondria, leads to the 
production of citric acid cycle intermediates. 
The transport of carbon from the mitochondria for 
alanine synthesis in the cytoplasm occurs via 
aspartate. Cytoplasmic pyruvate for alanine 
synthesis is generated in part by the action of 
cytoplasmic aspartate aminotransferase (2), 
phosphoenolpyruvate carboxykinase (3) and 
pyruvate kinase (4). Other enzymes involved in 
this mitochondrial-cytoplasmic interrelationship 
are alanine aminotransferase (1), branched chain 
amino acid amino transferase (5), mitochondrial 
aspartate aminotransferase (6), enzymes for 
converting a-ketoisovalerate into succinyl CoA 
(7) (see Fig. 6.1) and enzymes of the citric acid 
cycle (8). The location of the action of the 
aspartate aminotransferase inhibitor, 2-amino-4- 
methoxy-trans-but-3-enoate (AMB), is indicated. 
The diagram is taken (with author's permission) 
from Biochem. J. (1985) 225, 737-743.
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On the other hand the "glucose-alanine" cycle was 
recently reinvestigated by Palmer et al., (1985b). These workers 
concluded that the BCAA oxidation in muscle was incomplete and 
the flux of amino acids from muscle was unlikely to be of major 
quantitative importance for the provision of the carbon skeleton 
of alanine either in vitro or in vivo. Furthermore, the hind 
limb perfusion of 48 hours starved rats under conditions in which 
there was no nett glycogenolysis, demonstrated that alanine 
release was not in quantities that were in large excess of its 
content in the muscle protein (Davis and Lee, 1985). Moreover, 
it was shown that amino acid catabolism in muscle in the absence 
of added carbohydrate was too slow to sustain the nett synthesis 
of the carbon skeleton of alanine (Lee and Davis, 1986). These 
conclusions were in accord with the original formulation of the 
"glucose-alanine" cycle.
It is clearly evident that the origin of alanine carbon 
in muscle is still a controversial matter. It is presently 
difficult to ascribe quantitative values for the contributions of 
glucose and BCAA to the formation of alanine. This may remain 
the situation until an extensive study is made of the regulation 
of BCAA under conditions of normal and pathabolic states.
6.1.3 Ketone Body Synthesis and the Regulation of BCAA
Oxidation
During starvation there are elevated levels of ketone 
bodies in the blood (Robinson and Williamson, 1980). These 
compounds acted not only to replace glucose as the major fuel of 
the central nervous system but also contributed to protein
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Conservation (Owen et al♦, 1967, 1969; Sherwin et al., 1975).
There is now considerable interest in the possible effects of 
ketone bodies in the regulation of -
(i) muscle proteolysis (Palaiologos and Felig, 1976).
(ii) release of alanine from the extra hepatic tissues 
(Sherwin et al., 1975; Smith and Aoki, 1981)
(iii) branched chain amino acid oxidation in muscle (Landaas, 
1977; Snell and Duff, 1982; Zapalowski et al., (1981)
A brief review on the effects of ketone bodies on muscle 
conservation and BCAA oxidation was presented in section 
1 .2 .2 .1 .6 .
The Williams hypothesis (1980) proposed that one of the 
key events in the initiation and maintenace of cachexia was the 
deregulation of BCAA oxidation in muscle because of the low 
circulating levels of ketone bodies in cancer subjects. The 
investigation reported in chapter three demonstrated low 
circulating levels of ketone bodies in tumour bearing animals. 
The study reported in this chapter was carried out in order to 
inquire into the state of BCAA oxidation in the skeletal muscle 
of tumour bearing animals. The results are discussed against the 
background of the hypothesis and with an open mind with respect 
to the role of their metabolism in cancer cachexia.
6.2 Results
6.2.1 Comparative Rates of Leucine Oxidation by the Walker
256 Carcinosarcoma and the Gastrocnemius Muscle of 
Control and Tumour Bearing Rats In Vitro
Table 6.1 shows the rates of leucine oxidation, the
activities of BCAAT and the BCKDH together with the protein
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Table 6.1: Comparative study of protein content and 
L-[i~l4C] leucine oxidation by the tumour and 
gastrocnemius muscle of control and Walker 256 
carcinosarcoma bearing rats
Tissue homogenate (1.0ml) was mixed with 2.0ml of 
reagent mixture (section 2.10.1.2) and incubated 
at 37°C in a metabolic shaker (60osci/min) for 40 
min. i'+COz production, BCAA aminotransferase and 
BCKA dehydrogenase activities were assayed as 
described in section 2.10.1.2. The concentration 
of protein was determined by Biuret's method. 
Total protein content of whole body skeletal 
muscle for control animals was obtained by 
assuming that skeletal muscle represents 45% of 
body weight (Young, 1970), whereas for tumour 
bearing animals control values were corrected for 
a reduction of 30% in skeletal muscle mass (Table 
3.8a). Nitrogen content was calculated by 
assuming that protein contained an average of 16% 
nitrogen (Krik, 1947). The values are the mean + 
SEM for five animals. "Student's t test" was 
used to evaluate the statistical significance of 
the data. The p values are related to results of 
control experiments, *p<0.05, **p<0.01,
***p<0.001
Table 6.1
Walker 256 carcinosarcoma 
bearing rats (day 10 PI)
Control rats 
(pair fed)
Muscle Tumour
BCAA aminotransferase 
(nmol/h/mg protein)
* * *
34.73 + 2.14 58.97 + 6.52
* *
17.99 + 3.77
* * *
BCKA dehydrogenase 0.27 + 0.12 1.80+0.09 0.48+0.11
(nmol/h/mg protein)
* * *
14C02 production 50.33 + 2.19 315.20 + 16.02 68.46 + 16.0
(nmol/h/g tissue)
*
Protein concentration 183.35 + 8.70 180.50 + 11.06 143.70 + 14.6
(mg/g tissue)
* * *
Total protein content 21.0 + 0.85 13.98 + 0.62 5.26 + 0.01
(g/whole body skeletal 
muscle or entire tumour)
* * *
Nitrogen content 3.35+0.14 2.23+0.10 0.85+0.01
(g/whole body skeletal 
muscle or entire tumour)
content of the Walker 256 carcinosarcoma and the gastrocnemius 
muscle of the control and tumour bearing rats.
The rate of leucine oxidation was increased 5-6 fold 
(pcO.OOl) in the gastrocnemius muscle of rats bearing the tumour 
in contrast with the rates of the muscle of control animals. The 
increased rate of leucine oxidation by the muscle of the tumour 
bearing animals was found to be associated with a 70% (pcO.OOl) 
increase in the activity of BCAAT and a 560% (pcO.OOl) increased 
BCKDH activity in the muscle. The protein concentration of the 
muscle of Walker 256 carcinosarcoma bearing rats did not change 
significantly in comparison with the values of the control 
animals. However, the tumour bearing rats exhibited a reduction 
of 30% in their muscle mass (Table 3.8a). The nett loss of 
protein due to the reduction of muscle mass in tumour bearing 
animals was calculated and extrapolated to the whole body 
skeletal muscle mass. The data represented a total loss of 6-7g 
of protein from the muscle bed of animals during the time course 
of Walker 256 carcinosarcoma bearing.
The rate of leucine oxidation by the Walker 256 
carcinosarcoma growing in the hind limb of the rat was not 
significantly different from the leucine oxidation rate by the 
muscle of control animals (Table 6.1). The BCAAT activity was 
reduced by 50% (p<0.001) in the tumour tissue while the BCKDH 
activity was increased by 77%. The protein concentration of the 
tumour tissue was used to calculate the total protein content of 
the entire tumour mass (day 10 PI). The results illustrate that 
the tumour contained approximately l/4-l/3rd of the total muscle 
nitrogen of the host body (Table 6.1).
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6.2.2 Whole Body Leucine Oxidation by Control and the Walker
256 Carcinosarcoma Bearing Rats In Vivo
The determination of the rate of leucine oxidation in
vivo was commenced immediately following the intravenous
14
administration of a bolus dose of L-[l- C] leucine (30 uCi/kg
body weight). The results were guantified and expressed as a
14
percentage of the dose of the administered L-[l- C] leucine
-1
oxidised min . The plot of the change in the rate of leucine
oxidation reached a constant value in 80-120 min. In the example
of the control animals, the rate of leucine oxidation increased
linearly during the first 20 min. of the experimental period
14
reaching a level where 0.2% of the totally administered L-[l- C]
leucine was being oxidised each min. The rate of leucine
oxidation was relatively constant for the next 20 min. after
which its rate steadily declined reaching a value where 0.05% of
14 -1
the total L-[l- C] leucine load was being oxidised min at the
end of the experimental time (120 min.). For the Walker 256
carcinosarcoma bearing animals the rate of leucine oxidation
increased during the first 30 min. of the experiment and reached
14
a level where 0.48% of the administered L-[l- C] leucine dose
-1
was being oxidised min . The rate of leucine oxidation then
declined gradually during the next 30 min. Thereafter, there was
a slow linear decline which approached a rate of 0.1% of the 
14 -1
total L-[l- C] leucine load oxidised min at the finish of the
experimental interval. These results show that the rate of
leucine oxidation was 2-3 fold higher in rats bearing the Walker
256 carcinosarcoma in comparison with data for the pair fed
control rats. This notable difference was most apparent during
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Figure 6.4: Rate of L-[1- C] leucine oxidation in vivo by 
control and Walker 256 carcinosarcoma bearing 
rats
14
A tracer dose of L-[l- C] leucine in saline (20u 
Ci/ml) was administered via intravenous injection 
into the lateral tail vein as a bolus dose of 30u 
Ci/kg body weight. The animals were then placed 
in a metabolic chamber (Fig. 2.6). The time 
course of leucine oxidation was monitored by 
continuous trapping of respiratory i^C02 for 2 
hours as described in section 2.10.2.2. The rate 
of leucine oxidation is expressed as a percentage 
of the dose of [1-14C] leucine oxidised/min. 
Each point represents the mean for three 
observations. The SEM are represented by the 
vertical lines.
•: Control (pair fed) rats
▲: Walker 256 carcinosarcoma bearing rats (day 
10 PI)
14
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the first 80 min. of the experiment.
14
6.2.3 Extent of L-[l- C] Leucine Oxidation by Control and
the Walker 256 Carcinosarcoma Bearing Rats In Vivo
14
The extent of L-[l- C] leucine oxidation in vivo was
determined by following the time course of the cumulative
14
percentage dose of the administered L-[l- C] leucine oxidised to 
14
CO for a period of two hours. The results are shown in Fig.
2
6.5. For both the control (pair fed) and tumour bearing animals
there was a lag period of 10 min. A similar lag period was also
reported for the achievement of a plateau in the specific
14
radioactivity of the plasma after a bolus injection of L-[l- C]
14
leucine in rats (Pompaselli et al., 1985). The CO production
2
by the control animals then increased linearly during the
following 55 min. of the experiment when approximately 10% of
14 14
totally administered L-[l- C] leucine had appeared as CO .
2
The extent of leucine oxidation continued to increase during the
next 35 min. of the experiment when a further 4% (approx.) of the
14
totally administered L-[l- C] leucine appeared as respiratory 
14
CO . Thereafter only a further 1.0% of the totally
2 14 14
administered C isotope was recovered as CO during the final
2
20 min. of the experiment. The data show that a total of 15 +
14
1.8% of the administered dose of L-[l- C] leucine was oxidised
by the control animals during the time course of the experiment.
14
The production of CO by animals bearing the Walker
2
256 carcinosarcoma (after a lag period of 10 min.) increased
linearly during the initial 40 min. of the experiment.
14
Approximately 14.0% of the administered L-[l- C] leucine was
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Figure 6.5: Extent of L-[l- C] leucine oxidation in vivo by 
control and Walker 256 carcinosarcoma bearing 
rats
14
The experimental conditions were similar to those 
described in the legend of Table 6.4. The extent 
of leucine oxidation is expressed as a cumulative 
% dose of L-[l-i4C] leucine oxidised. Each point 
represents the mean for three observations. The 
SEM are represented by the vertical lines.
•: Control (pair fed) rats
a : Walker 256 carcinosarcoma bearing rats (day 
10 PI)
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recovered as respiratory CO during this period. after which
2 14
there was a further recovery of 9.0% of L-[l- C] leucine as 
14CO in exhaled air during the following 40 min. and a final 
24.4% yield during the last 40 min. The data showed that a total
14
of 27.4 + 2.6% of the totally administered C isotope was
14
recovered as CO by the tumour bearing rats. These results
2
indicate that twice as much leucine was oxidised by the tumour 
bearing animals as by the pair fed controls.
14
6.3 Discussion
The depletion of muscle protein due to increased 
degradation and decreased synthesis was demonstrated as a common 
systemic effect of bearing a growing neoplasm (Clark and Goodlad, 
1971, 1975; Goodlad and Clark, 1973, 1980; Lundholm et al., 1976, 
Sherman et al., 1950). The rates of protein synthesis by rectus
and gastrocnemius muscle were found to be reduced by 25-40% in 
tumour bearing rats in comparison with the rates for the fed 
control rats (Kawamura et al., 1982). Lundholm et al., (1976)
showed that muscle fibres from cancer patients had a 50% 
increased rate of protein degradation when tested in vitro in 
comparison with muscle fibres from normal healthy subjects. The 
Williams hypothesis (1980) for the metabolic basis of cancer 
cachexia proposed that the excessive muscle protein degradation 
(Lundholm et al., 1976; Goodlad et al., 1981) may be associated
with the elevated oxidation of BCAA and the conversion of 
isoleucine and valine into the carbon chain of alanine.
The results reported here for leucine oxidation are 
consistent with postulate II of the hypothesis (section 1.2.2.1).
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These results indicate that there was a five fold increase in the
14
in vitro oxidation of L-[l- C] leucine by the gastrocnemius 
muscle of rats bearing the Walker 256 carcinosarcoma. Tumour 
bearing was also associated with the increased activity of BCKDH 
in muscle. BCKDH is a rate limiting enzyme for the oxidation of 
BCAA in skeletal muscle and its activity was increased three-five 
fold during fasting (Goldberg and Chang, 1978). An increased 
oxidation of BCAA associated with elevated levels of BCKDH 
activity has already been demonstrated for the diaphragm of rats 
bearing the Walker 256 carcinosarcoma (Goodlad and Clark, 1980).
The results shown in Table 6.1 were further confirmed 
by the study in vivo presented in section 6.2.3. The results
presented in Fig. 6.4 indicated that the rate of leucine
oxidation was 2-3 fold higher in tumour bearing animals in
comparison with the control rats. Furthermore, thei results of
Fig. 6.5 showed that the extent of the totally administered L-[l- 
14 14
C] leucine converted into respiratory CO by tumour bearing
2
rats was approximately two fold greater then that for control
animals. Thus these results show that the tumour bearing animals
had an enhanced capability to oxidise an administered load of L- 
14
[1- C] leucine. The enhanced oxidation of BCAA in the muscle of 
tumour bearing animals was associated with and may have caused 
the nett loss of 6-7g of whole body protein (section 6.2.1). 
This represents a loss of l/3rd of the total skeletal muscle of 
these animals.
Some investigations have demonstrated a reduced rate of 
protein synthesis in the muscle of tumour bearing subjects 
(Kawamura et al♦, 1982; Rennie et al., 1983). It is not known
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whether the muscle protein loss or the increased BCAA oxidation
has any effect on muscle protein synthesis. However, it is
suggested that the enhanced BCAA oxidation limits its
availability for the processes of protein synthesis in muscle.'
The synthesis of protein requires the full set of all 22
naturally occuring amino acids and therefore the low availability
of BCAA, which are the most abundant amino acids in muscle, could
result in the suppression of protein synthesis. Furthermore,
the results show (Table 6.1) that the amount of nitrogen
concentrated by the tumour is slightly less than the amount of
nitrogen lost by the skeletal muscle of tumour bearing animals.
It is thus suggested that most of the nitrogen lost from the host
skeletal muscle was accumulated in the tumour, whereas the
remaining nitrogen disappeared in the urine (Table 3.6). This
considerable accumulation of nitrogen in the tumour (over a
period of 10 days) supports the reports of a substantially high
rate of protein synthesis in this tissue. Kawamura and coworkers
(1982) determined that the fractional rate of protein synthesis
in the tumour was 6-8 fold higher than that of the skeletal
muscle of pair-fed NTB animals. It is thus suggested that the
tumour-induced stimulated protein breakdown (Goodlad et al.,
1981; Lundholm et al., 1980) and inhibited protein synthesis
(Kawamura et al., 1982; Rennie et al., 1983) in tumour bearing
subjects guaranteed a supply of amino acids for the nett
anabolism of protein in the tumour. The small quantitative
14
difference in the rate of L-[l- C] leucine oxidation for the in 
vitro and in vivo studies may be explained on the basis
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that L-[1-1^C] leucine and its deaminated product L-[1-^C]a-ketoisocaproate 
can be metabolised by various other organs of the body (Hutson et al., 1978)
14
thus the CO produced may be diluted with unlabelled 
2
free CO or it may enter into carboxylation reactions which 
2
involve the fixation of CO . Moreover, it was also shown that
2
neoplastic cells had an increased ability for amino acid uptake. 
The rate of uptake of amino acids by neoplastic tissues in vivo 
was reported to be 2-3 fold higher than that of skeletal muscle 
of tumour bearing mice (Christenson and Henderson, 1952). 
Therefore, in the intact tumour bearing animal there is less 
leucine available for oxidation.
The present investigation also showed that the enhanced 
oxidation of BCAA in the muscle of the tumour bearing animal was 
associated with elevated plasma levels of alanine (chapter 
three). This observation was consistent with the argument
proposing that the de novo synthesis of alanine arose from the 
catabolism of BCAA. However, the precise origin of muscle 
derived alanine carbon is still a matter of controversy (section 
6.1.3). A pathway does exist for the de novo synthesis of
alanine from BCAA in muscle (Snell and Duff, 1982), but its 
relative contribution to the development of hyperalaninaemia in 
tumour bearing subjects is unknown. Furthermore, the results of 
the investigation reported here do not favour the operation of 
the glucose-alanine cycle in cancer subjects. The results of
chapter four demonstrated a decreased ability by the tumour 
bearing animals to incorporate alanine carbon into glucose 
because of the notable suppression of the hepatic alanine 
aminotransferase (section 3.2.9). There is also no information 
about the contribution that glucose may make to the elevated
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plasma levels of alanine frequently seen in the tumour bearing
animals. This contribution is expected to be low because of the 
maintenance of the normal plasma glucose concentration in the 
tumour bearing animals. If it is assumed that there was an 
increase in the conversion of glucose to alanine by the muscle of 
tumour bearing animals, then the increased utilisation of glucose 
by the tumour (Reitzer et al., 1979) and its limited hepatic 
regeneration from alanine (section 3.2.9) coupled with decreased 
food intake due to anorexia should result in measurable 
hypoglycaemia. However, this does not appear to be the case 
since tumour bearing animals are normoglycaemic (Table 3.1). In 
the absence of data to the contrary, it is suggested that the 
contribution of the glucose-alanine cycle in animals bearing a 
neoplasm is either impaired or nonexistent.
It is concluded from the results of both the in vitro 
and in vivo investigations that the aspect of the Williams 
hypothesis dealing with enhanced branched chain amino acid 
oxidation by muscle in cachectic subjects has not been disproved 
and thus still stands. The hypothesis also proposed that the 
elevated oxidation of BCAA in cancer subjects may be attributed 
to their low circulatory levels of ketone bodies. The ability of 
the neoplasm to effect the host body synthesis of ketone bodies 
was demonstrated in this investigation (chapter five). These 
data have also been reported by others (Conyers et al., 1979 a,b; 
Mider et al., 1951; Williams et al♦, 1980). It was shown that 
ketone bodies inhibited the release of alanine from skeletal 
muscle (Palaiologos and Felig, 1976; Snell and Duff, 1982) and
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14 14 14
CO production from L-[l- C] leucine and L-[l- C] valine 
2
(Palmer et al., 1985a). These effects of ketone bodies have been 
attributed to their actions on muscle proteolysis (Palaiologos 
and Felig, 1976), on the availability of pyruvate transamination 
by inhibiting the glycolytic flux (Turinsky and Shangraw, 1981) 
and/or on BCAA uptake, transamination and decarboxylation in the 
muscle (Palmer et al., 1985a; Snell and Duff, 1982; Zapalowski et 
al., 1981). Thus the results of this investigation support the
proposal that low circulating levels of ketone bodies may provide 
the mechanism for the enhanced oxidation of BCAA in tumour 
bearing animals. It is suggested that the connection of these 
two metabolic events is a condition of the metabolism of BCAA in 
cancer cachexia.
191
CHAPTER SEVEN
INTERACTION OF TOXOHORMONES IN THE 
DEVELOPMENT OF CANCER CACHEXIA
7.1 Introduction
7.1.1 Vasopressin in Human Cancer
The inappropriate production of vasopressin 
(the antidiuretic hormone) is a well recognised phenomenon in 
patients with malignant disease (Table 1.2). The history of this 
syndrome goes back to 1938 when Winkler and Cranshaw reported for 
the first time, symptoms of hyponatraemia and renal salt loss in 
the case of a patient with bronchogenic carcinoma. Approximately 
20 years later Schwartz et al., (1957) reported two patients with
bronchogenic carcinoma exhibiting symptoms of hypotonicity of the 
extracellular fluid and hypertonicity of the urine as the result 
of an unexplained failure of renal sodium conservation. These 
patients had a normal glomerular filtration rate and normal renal 
and adrenal corticol functions. There was no clinical and/or 
laboratory evidence that significant amounts of fluid had shifted 
from the extracellular to the intracellular space. The chloride 
space was not changed, blood pressure had not declined and there 
were no symptoms of vascular collapse. The - asymptomatic 
hyponatraemia in these cancer patients was attributed to an 
inappropriate secretion of the antidiuretic hormone (ADH). 
Furthermore, in the absence of any other known stimulus for ADH 
secretion, it appeared that the neoplasm may be the site for 
conducting an ectopic and inappropriate ADH secretion (Schwartz 
et al., 1957). A large number of cancer patients were diagnosed
(soon after the report of Schwartz et al., 1957) with the
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TABLE 7.1: THE LEVELS OF V A S O P R E S S I N  IN THE NORMAL HUMAN TISSUES
The bio a s s a y  was carr ied out by comparing the anti diuretic  
acti vity of e x t r a c t e d  m ate rials and vaso pressin standards in 
wat e r  loaded rats. One unit of vasopressin activity was equal 
to 0.5mg of dry acetone powder of posterior p itu itary gland as 
r e c o m m e n d e d  by Wor l d  Health Orga nisation (Bangham and Musset, 
1958). DAP = Dry A c e t one Powder. * In rat tissues.
Specimens Bioassy R a d i o i mmunoa ssy Refe rences
piasma
i i
I I
i i
i i
< 1 .OuU/ml 
2 . 5 - 3 .OuU/ml
2 . 5 ± 0 .43 pg/ml 
2 . 80 ±0.40Pg/ ml*  
1-3 pg/ml
Hira ta et.al ., 1975 
DeSo usa and Delaere, 1965 
Gold et a l ., 1983 
Wood and Johnston, 1983 
Wils on and Foster, 1985
1 ung
i i
l l
i l
< 1 0 - 2 0 u U / m g D A P  
< 1 .OuU/mgDAP
<3uU/mgDAP
< 1 .Ong/mgDAP 
< 1 .OuU/mg w/w
Vorherr et a l ., 1968 
H a ll pike and Hughes, 1966 
Marks et a l ., 1968 
Utiger, 1966
1 i ver
l l
l l
< 1 0 - 2 0 u U / m g D A P  
< 1 .OuU/mgDAP
< 4 .OuU/mgDAP 
<1 .OuU/mg w/w
Vorherr et.al., 1968 
Hall p i k e  and Hughes, 1966 
Utiger, 1966
pancrease - <1.0 og/mgDAP Marks et a l . ,  1968
muscle - < 1 0Ong/mgDAP Marks et a l . ,  1968
kidney
i i
<1 .OuU/mgDAP
<1 .Ong/mg w/w
Hal l p i k e  and Hughes, 1966 
Utiger, 1966
lymphnode < 1 .OuU/mgDAP - Hal 1 pike and Hughes, 1966
pituitary
l l
l l
l l
8 5 ± 1 5 m U / m g D A P
40ng /mgDAP  
7 ,600 ,000uU/gland 
3 2 5 , O O O u U / g 1 and*
Vorherr et a l ., 1968 
Marks e t . a l ., 1968 
Utiger, 1966 
Utiger, 1966
uri ne
l l
l l
l l
40mU /24h  
3 5 . 5mU/24h
156 pg/ml 
20-40fmol/ml
H a ll pike and Hughes, 1966 
Ruch, 1967 
Kay and Ross, 1977 
Perks et a l . ,  1978
symptoms of an inappropriate secretion of the antidiuretic
hormone (SIADH) (Tables 7.1 and 7.2). In these patients, beside 
the symptoms mentioned above, clinical, laboratory and 
microscopic examinations revealed normal renal and adrenal 
functions (Greenberg et al., 1964) and at autopsy no pathological 
changes were found in the kidney and adrenal glands (Roberts, 
1959). Addison's disease was absent (Rees et al., 1960) and 
abdominal (Bower et al., 1964) and neurological (Bower et al., 
1964; Marks et al., 1968) examinations were also normal. 
Baseline urinary ketosteroids were within normal limits and a 
satisfactory response to ACTH stimulation was obtained (Grantham 
et al., 1965). There was no significant response to loss or gain 
of potassium from body fluids (Bartler and Schwartz, 1967). 
Tests for blood, ketone bodies and glucose in the urine were 
negative (Cassileth and Trotman, 1973). Hepatic (Falchuk, 1973) 
and cardiac functional tests (Falchuk, 1973; Marks et al., 1968) 
were also normal. Furthermore, patients suffering from cancer 
other than lung cancer had normal lungs (Marks et al., 1968). 
Many of these cancer patients were admitted to hospital in the 
terminal phase of their disease and metabolic abnormalities, if 
noted, were usually ascribed to cachexia (Kaye, 1966; Ross, 
1963) .
Bioassays of the primary tumours, the secondary 
metastasis, the patients' urine and plasma documented the 
presence of large quantities of antidiuretic material which was 
found to be indistinguishable from arginine vasopressin (AVP) 
(Table 7.3). There was no evidence for the presence of lysine
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Vasopressin (Barraclough et al♦/ 1966). Later this antidiuretic 
principle was proved to be arginine vasopressin by 
radioimmunoassay (Utiger, 1966) and the result was confirmed by a 
large number of other investigations (Table 7.2).
Recent enquiries revealed that levels of vasopressin 
were also increased in patients suffering from a variety of 
stress situations, such as haemorrhage (Errington and Silva, 
1972; Kasting et al., 1981), sepsis and septic shock (Wilson et 
al., 1981), diabetic stress and diabetic coma (Walsh et al., 
1979) and hypoxaemia and hypercapnia (Rose et al., 1984). 
Furthermore, endotoxin stimulated the elevation of vasopressin 
concentration in the plasma of freely behaving unanaesthetised 
rats, independent of any change in their plasma osmolality, 
systemic blood pressure, plasma volume, body temperature or 
plasma glucose (Kasting et al., 1985).
Moreover, prostaglandin E , a substance which is
2
released by activated macrophages and is present in elevated 
levels in the tumour bearing host (section 7.1.2.2) also 
stimulated the release of vasopressin from the posterior 
pituitary gland (Clifton and Wallin, 1985; Sklar and Schrier, 
1983) .
Although elevated levels of vasopressin were reported 
in a number of stress situations i.e., inflammation and tumour 
bearing, its role in these conditions is still obscure. Recent 
investigations have demonstrated that vasopressin, in addition to 
the maintenance of diuresis, also regulates a number of metabolic 
processes. It caused hyperglycaemia in the intact rat (Hems et 
al., 1975) and promoted glycogenolysis in rat liver slices
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(Heidenrich et al., 1963), the perfused liver (Hems and Whitton, 
1973) and isolated hepatocytes (Hems et al., 1978b). It also 
stimulated gluconeogenesis in both the perfused rat liver and 
isolated rat hepatocytes (Hems and Whitton, 1973; Hue et al., 
1978; Whitton et al., 1978). Vasopressin also has several unique 
effects on hepatic lipid metabolism. It inhibited ketogenesis 
from oleate (Rofe and Williamson, 1983a) and stimulated its 
esterification in isolated rat hepatocytes (Williamson et al., 
1980; Sugden et al., 1980b). Furthermore, vasopressin inhibited 
both lipogenesis by the perfused rat liver (Hems, 1977) and 
lipolysis in rat adipose tissue in vivo (Rofe and Williamson, 
1983b) .
Based on the elevated levels of vasopressin frequently 
encountered in cancer patients and its notable involvement in the 
regulation of intermediary metabolism, a role for vasopressin was 
proposed in the development of cachexia in cancer patients 
(Williams et al., 1980; Williams and Matthaei, 1981). The 
present investigation is directed to examine this aspect of the 
role of vasopressin (also see chapter one).
7.1.2 Roles of Intratumoural Macrophages in Cellular Immunity
and Intermediary Metabolism
7.1.2.1 Secretion of Cytotoxic Proteins/Peptides
The existence of macrophages within tumours has been 
recognised for the last 10 years (Evans, 1977, 1980, 1982; Key, 
1983; Moore and Moore, 1980; Russell et al., 1980). It was 
demonstrated that macrophages were either absent from or 
contributed up to 80% of the total tumour cell suspension.
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Poorly immunogenic and highly metastatic tumours had low
macrophage content (3-12%), while highly immunogenic and poorly
metastatic tumours tended to have high macrophage content (4 0-
54%) (Eccles and Alexander, 1974; Talmadge et al., 1981).
Similarly, progressively growing tumours had a high content of
macrophages, while their contribution was notably reduced in
regressing tumours (Berrera et al., 1985; Young et al., 1986).
In summary, most growing neoplasms were reported to contain
resident macrophages in the range of 20-30% of the total tumour
cell suspension (McBride, 1986).
It was demonstrated that following activation with
lipopolysaccharide, y -interferon, tumour cells or other
biological response modifiers, macrophages became cytotoxic to
neoplastic cells and inhibited tumour growth (Cohen et al., 1982;
Fernandez-Cruz et al., 1985; Fidler and Schroit, 1984; Pace et
al., 1981, 1985). Macrophage mediated cytotoxicity may be most
efficient when cell to cell contact is established but a number
of cytotoxic soluble factors have been isolated from macrophages
in vitro growth medium supernatant fractions. These include
arginase (Currie, 1978), C , a complement component (Ferluga et
3
al., 1978), H O (Nathan et al♦, 1979), serine proteinase (Adams
2 2
et al., 1980)- and a family of cytotoxins which are physically
related and are collectively called monokines (Wood et al. , 
1976). They are so called because they originate from (in)
mononuclear phagocytic cells. Another term frequently used for 
the macrophage cytotoxic soluble factors is interleukin-I (Aarden 
et al., 1980). This classification is based upon its property of 
enhancing the activity of lymphocytes. This term also serves to
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distinguish the compound from the other macrophage derived 
factors which stimulate the proliferation and maturation of 
lymphocytes (interleukin-II).
More recently, activated macrophages were shown to 
release another cytotoxin called "tumour necrosis factor" (TNF) 
which was isolated from the serum of endotoxin treated mice and 
rabbits previously infected with Bacillus Calmette-guerin (BCG) 
(Carswell et al., 1975; Mannel et al., 1981). TNF was so named 
because it displayed cytostatic and cytocidal activities against 
several transformed cell lines in culture, but was ineffective 
with normal cell cultures derived from human, rabbit, chicken and 
mouse sources (Carswell et al., 1975; Helson et al., 1975; 
Matthews, 1978; Matthews and Watkins, 1978; Ostrove and Gifford, 
1979; Ruff and Gifford, 1981 a,b).
Recent investigations demonstrated the secretion of 
another monokine "cachectin" (Beutler et al♦, 1985a). The 
synthesis and release of cachectin in vivo is elicited during an 
inflammatory response directed against bacterial infection, 
protozoan parasites or a growing neoplasm, but can be reproduced 
in vitro by treatment of macorphages with bacterial endotoxin 
(Aderka et al., 1985; Beutler et al., 1985a). Comparison of 
mouse cachectin and human TNF revealed strong homology. Thus the 
amino terminal sequence data and the results of comparative 
studies (see section 1.3) suggest that cachectin and TNF were 
identical proteins (Beutler et al., 1985b). This identity was 
confirmed by genetic sequence analysis (Caput et al., 1986; 
Fransen et al., 1985; Pennica et al., 1985).
197
Cachectin/TNF has a molecular weight and an isoelectric
point in the range of those described for interleukin-I, but
cachectin has no characteristic interleukin-I activity (thymocyte
proliferation) (Beutler et al., 1985a). However, recent
investigations have demonstrated that cachectin/TNF can induce
the production of interleukin-I by resident mice peritoneal
macrophages (Bachwich et al., 1986a). The addition of
cachectin/TNF to cultures of human synovial cells stimulated
collagenase and prostaglandin E (PGE ) production in a dose
2 2
dependent manner (Dayer et al., 1985). Moreover, the production
of interleukin-I was augmented by the indomethacin inhibition of
the cyclooxygenase pathway of arachidonic acid metabolism
(Bachwich et al., 1986b). These studies have therefore supported
the suggestion that PGE is an endogenous mediator of
2
interleukin-I production (Kunkel et al., 1986; Kunkel and
Chensue, 1985).
7.1.2.2 Secretion of Prostaglandin E
2
In addtion to the cytotoxic effects of intratumoural
macrophages (ITM) on tumour growth, their stimulatory effect on
neoplastic cell growth in vitro (Currie, 1981; Gabizon et al.,
1980; Keller, 1976) and in vivo (Evans, 1978 a,b, 1979; Kadhim
and Ress, 1984; Mantovani, 1978, 1981; Mantovani et al., 1980)
has also been demonstrated. The effect of ITM on tumour growth
stimulation was attributed to their capability of secreting
elevated levels of PGE (Balch et al., 1984; Braun et al., 1983;
2
Plescia et al., 1984; Young et al., 1986). PGE in turn
2
suppressed the immune responses of the host against the neoplasm
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by various interactions. It inhibited ß-lymphocyte proliferation
(Thompson et al., 1984) and T-lymphocyte mitogenesis (Goodwin et
al., 1977), cytotoxicity (Ting and Hargrove, 1982),
differentiation (Young and Hoover, 1986; Young and Dizer, 1983)
and proliferation (Walker et al., 1983). These alterations in
lymphocyte properties have devastating effects on the ability of
the host to regulate and destroy the growing neoplasm.
Furthermore, PGE , also encouraged the growth and spread of the
2
neoplasm by stimulating tumour angiogenesis (Auerbach, 1981;
BenEzra, 1978; Form and Auerbach, 1983; Muthukkaruppan et al.,
1982; Ziehe et al., 1982) and tumour cell migration (Young et
al. , 1986) . Other effects of PGE include osteolysis (Dowsett et
2
al., 1976; Galasko and Bennett, 1976; Voelkel et al., 1975),
hypercalcaemia (Seyberth et al., 1975) and muscle proteolysis
(Baracos et al., 1983).
Elevated levels of PGE were reported in a variety of
2
human and animal tumours (Table 7.4). PGE production by
2
neoplastic tissue was correlated with the extent of inflammation,
necrosis and the capacity of macrophages to enhance tumour cell
migration (Young et al., 1986). However, enhanced PGE formation
2
was not correlated with tumour size, tumour site or degree of 
differentiation (Honn et al., 1981). It was also shown that
oestrogen positive breast tumour tissue had greater PGE
2synthesising capacity than oestrogen negative tumours (Campbell 
et al., 1981; Watson and Chuah, 1985). Moreover, it was
demonstrated that the survival time after mastectomy was found to 
be correlated inversely with the amount of prostaglandin like 
material extractable from the human neoplasm (Bennette et al.,
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Table 7.4: Prostaglandin E in Animal and Human Tumours
2
Animal Tumours
Dimethyl benz(a) anthracene 
Mammary carcinoma (rat)
Tan et al., 1974
HDSMi fibrosarcoma (mouse) Tashjian et al., 1972
Lewis Lung carcinoma (mouse) Young and Henderson, 1982
Moloney Virus sarcoma (mouse) Humes et al., 1974
NC-Mammary adenocarinoma (mouse) Bennett et al., 1985
R3230AC adenocarcinoma (rat) Karmali and Marsh, 1985
Sarcoma-180 (mouse) Stein-Werblowsky, 1974
VX2-carcinoma (rabbit) Voelkel et al., 1975
Yoshida hepatoma (rat) Trevisani et al., 1980
Human Tumours
Basal cell carcinoma of skin Kragballe et al., 1985
Breast carcinoma Bennett et al., 1979a;
Kibbey, 1979; Rolland et 
al., 1980
Colonic carcinoma Bennett et al., 1977
Hodgkin's disease Goodwin et al., 1977
Ileal, jejunal and rectal carcinoma Bennett et al., 1977
Kaposi's sarcoma Bhana et al., 1971
Lung carcinoma Sandler et al., 1968
Lymphoma Sebahoun et al., 1985
Medullary carcinoma of thyroid Williams et al., 1968; 
Kaplan et al., 1973
Neuroblastoma Hamprecht et al., 1973
Papillary carcinoma of thyroid Williams et al., 1968
Renal cell carcinoma Zusman et al., 1974
Squamous cell carcinoma - head and neck Bennett et al., 1980 
Squamous cell carcinoma - skin Kragballe et al., 1985
1979a).
It is concluded from the above introductory review that
there is a macrophage-neoplastic cell interaction in tumour
bearing subjects. The result of this interaction is the release
of cellular mediators (toxohormones) by either the growing
neoplasm per se or by specific host tissues in response to the
existence of neoplastic cells. Three mediators namely,
cachectin, vasopressin and PGE are suspected of being
2
responsible for instigating communication between neoplastic and 
non-neoplastic tissues in situations where the neoplasm may 
either be remote from or adjacent to the affected organs or 
tissues. The network of communication established by these 
mediators induces specific and drastically altered effects on the 
metabolism of the host tumour.
The investigation reported in this chapter was aimed to 
examine the existence of these toxohormones in various tissue of 
cachectic tumour bearing animals, ideally to identify the 
toxohormones alluded to in the Williams hypothesis. The results 
are discussed with specific reference to their roles in the 
deranged host metabolism in the neoplastic state.
7.2 Results
7.2.1 Prefatory Statement
The presence of cachectin in various tissues of tumour 
bearing animals was not investigated because the procedures for 
isolation and characteristion of cachectin/TNF were developed 
during the period of late 1985 - early 1986. Towards the
completion of the major experimental programme of the author, the
200
limitation of time restricted the establishment of techniques
concerned with the isolation of cachectin/TNF from tumour bearing
animals. However cachectin/TNF has been isolated from the
peripheral blood mononuclear cells of cancer patients (see
section 7.1.2.1). Furthermore, the role of cachectin/TNF in
situations of endotoxicosis, inflammation and neoplastic states
have been recognised (see section 1.3). These studies indicate
that cachectin/TNF may have a role in the induction and
maintenance of cachexia in tumour bearing animals.
The following sections describe the investigations of
levels of AVP and PGE in various tissues of tumour bearing rats.
2
The results are compared with the data of control (fed ad
libitum) rats for the corresponding tissues. No other
investigations have reported that semistarvation results in the
increased production of AVP or PGE , therefore investigations on
2
the tissues of pair-fed-NTB animals were considered unnecessary.
7.2.2 Vasopressin Levels in the Tissues of Control and TumourBearing Animals
The levels of vasopressin in control and tumour bearing 
animals are given in Table 7.5. The results show that the plasma 
AVP levels were increased in rats bearing the Walker 256 
carcinosarcoma by 100% (NS), 195% (p<0.05) and 183% (p<0.01) at
day 6, 10 and 14 PI respectively, in comparison with the hormone
levels of control animals. The plasma concentrations of AVP were 
also increased in rats bearing the R3230AC adenocarcinoma by 
329%, 285% and 124% at day 10, 15 and 20 PI in comparison with 
controls. However, the increases in plasma AVP in this group of
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Table 7.5: Vasopressin levels in the plasma of control and 
tumour bearing rats
n Plasma AVP 
(pg/ml)
Control rats 
(fed ad libitum)
6 2.05 + 0.72
Walker 256 carcinosarcoma bearing rats
day 6 PI 2 4.10 + 0.05
day 10 PI 10 6.05 + 1.05*
day 14 PI 10 5.80 + 0.87**
R3230AC adenocarcinoma bearing rats
day 10 PI 3 8.80 + 5.50
day 15 PI 6 7.88 + 3.88
day 20 PI 2 4.60 + 1.00
Vasopressin from plasma was extracted as described in section 
2.11.3.1. The plasma extract was incubated with [125I]AVP and 
specific vasopressin antisera as described in section 2.11.4. 
Separation of AVP-antiAVP complex from the incubation mixture was 
achieved by precipitation with Goat anti rabbit gamma-globulin as 
described in section 2.11.4.3. The % [125I] AVP bound to 
antibody was calculated and the amounts of AVP in the plasma 
extracts were estimated using the calibration curve (Fig. 2.4). 
The values are the mean + SEM; n=number of observations. 
"Student's t test" was used for the statistical evaluation of the 
data. The p values are related to the results of control 
experiments, *p<0.05, **p<0.01.
Table 7.6: Vasopressin levels in the tissues of control and 
tumour bearing animals
Tissues Control rats 
(fed ad libitum)
Walker 256 
carcinosarcoma 
bearing rats
R3230AC 
adenocarcinoma 
bearing rats
Urine (pg/ml) 125 + 9.0 363 + 24.0*** 247 + 16.0***
(n=8) (n=7) (n=8)
Liver (pg/g w/w) ND ND ND
(n=8) (n—8) (n=8)
Tumour (pg/g w/w) - ND ND
(n=8) (n=8)
Vasopressin from the liver, tumour and urine was extracted as 
described in sections 2.11.3.2 and 2.11.3.3. For other 
experimental details see the legend of Table 7.5. The values are 
the mean + SEM; n=number of observations; ND=not detected. 
"Student's t test" was used for the statistical evaluation of the 
data. The p values are related to the results of control 
experiments, ***p<0.001.
tumour bearing animals were not statistically significant. The 
AVP concentrations in various tissue extracts of control and 
tumour bearing animals are shown in Table 7.6 The urinary
excretion of AVP was increased by 190% (p<0.001) and 98%
(p<0.001) in rats bearing the Walker 256 carcinosarcoma and
R3230AC adenocarcinoma (day 10 PI) respectively, in comparison 
with controls. AVP was not detected in the liver or tumour 
extracts.
7.2.3 Prostaglandin E 2 Levels in the Tissues of Control and 
Tumour Bearing Animals
The levels of PGE in the tissues of control and Walker
2
256 carcinosarcoma bearing animals (day 10 PI) are shown in Table
7.7. The levels of PGE were increased by 237% (p<0.001), 170%
2
(p<0.05) and by 2890% (NS) in the plasma, urine and muscle
respectively of rats bearing the Walker 256 carcinosarcoma in
comparison with the values for corresponding tissues of control
animals. Large quantities of PGE were measured (43ng/g w/w) in
2
the implanted Walker 256 carcinosarcoma.
7.3 Discussion
Results shown in Tables 7.5 and 7.6 demonstrated that 
high levels of AVP were found in the plasma and urine of tumour 
bearing animals. AVP was not detected in either the liver or 
tumour extracts. The total absence of AVP in the tumour tends to 
preclude its involvement as the source of AVP by ectopic 
production. Whereas in the liver, failure to measure AVP may be 
attributed to the fact that binding of AVP to its receptors 
involves the cleavage of the disulphide bonds which are a
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Table 7.7: Prostaglandin E 2 levels in the tissues of control 
and Walker 256 carcinosarcoma bearing rats (day 
10 PI)
Tissues n Control rats 
(fed ad libitum)
n Tumour bearing 
rats
Plasma (pg/ml) 7 260 + 13.0 10 877 + 92.0***
Urine (pg/ml) 4 5449 + 180 3 14711 + 4236*
Muscle (pg/g w/w) 2 48.3 + 6.3 6 1468 + 501
Tumour (pg/g w/w) - - 3 43302 + 1231
Prostaglandin E2 from tissue specimens was extracted as described 
in section 2.12.3.1. The extracted material was incubated with 
fixed amounts of [ 125I]PGE2 and specific PGE2 antisera as 
described in section 2.12.4. Separation of PGE2~antiPGE2 complex 
from the incubation mixture was achieved by its precipitation 
with 16% polyethylene glycol solution, as described in section 
2.12.4.3. The % [ 125I]PGE bound to antibody was calculated and 
the amounts of PGE2 in tissue extracts were estimated using the 
calibration curve (Fig. 2.5). The values are the mean + SEM; 
n=number of observations. "Student's t test" was used for the 
statistical evaluation of the data. The p values are related to 
the results of control experiments, *p<0.05, ***p<0.001.
necessary part of the mechanism of the RIA (Moore et al., 1977).
Elevated levels of AVP were demonstrated in patients
with a variety of neoplastic diseases (Table 1.2) and in a number
of stress situations (section 7.1.1). A rapid tumour growth rate
(Tables 3.4 a,b) and adrenal hypertrophy (Tables 3.10 a,b) were
notable; symptoms indicating that tumour bearing animals were
under physical and metabolic stress (Selye, • 1946; Tepperman et
al., 1943). Therefore, the results presented here verify
postulate IV of the Williams hypothesis, that the tumour bearing
animal may inappropriately and excessively secrete vasopressin in
response to the stress of tumour bearing. However, the results
of Table 7.5 showed that increased AVP levels in the plasma of
animals bearing the R3230AC adenocarcinoma were not statistically
significant in comparison with control values. These data should
not be misinterpreted, as the statistical significance of values
do not represent the biological significance of the data. The
statistically non-significant increase in the levels of plasma
AVP in R3230AC adenocarcinoma bearing rats may have strong
biological influences on the host organs. The same reasoning
applies for the statistically non-significant increase in the
PGE concentration in the muscle of Walker 256 carcinosarcoma 
2
bearing rats.
Another factor which may strongly stimulate the release
of vasopressin in tumour bearing is PGE (Clifton and Wallin,
2
1985; Sklar and Schrier, 1983). Elevated levels of PGE were
2
reported for a variety of human and animal tumours (Table 7.4).
The results shown in Table 7.7 further confirm these reports.
The presence of large quantities of PGE in the tumour (Table
2
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7.7) supports the proposal that it may be the tissue site of
synthesis. The synthesis of PGE by macrophages entrapped in the
2
tumour tissue was previously reported (Balch et al., 1984; Braun
et al., 1983; Plescia et al., 1984; Young et al./ 1986).
Furthermore, it was demonstrated that the production of PGE by
2
resident tumoural macrophages was stimulated by cachectin/TNF 
(see section 7.1.2.1).
The results of the investigation reported here are
consistent with the suggestion that cachectin, vasopressin and
PGE are (or are among) the cachexia inducing toxohormones of the 
2
neoplastic state. The interaction of these agents establishes a
network of communication between neoplastic and non-neoplastic
tissues and the signals through this channel induce profound
alterations in the host immunologic and metabolic processes. It
is therefore concluded from our current understanding of the
perturbed whole-body biochemistry in cancer cachexia and the
putative effects of these "toxohormones" on host metabolism, that
tumour growth may elicit an immune response which is
characterised by the production of activated macrophages, some of
which may reside in the neoplasm. Activated macrophages
synthesise and release cachectin which then stimulates the
production of vasopressin and PGE . Elevated levels of
2
vasopressin inhibit ketogenesis (chapter five) and as a result,
the regulation of muscle protein synthesis/degradation is also
impaired (chapter six). PGE further enhances these processes.
2
Moreover PGE suppresses the immune responses against the 
2
neoplasm (section 7.1.2.2). It is suggested that the combined
204
action of these two agents is the growth and spread of the 
tumour, in association with cachectin-induced body tissue 
wastage, muscle weakness, negative nitrogen balance and 
ultimately death of the host.
This study concludes that further investigation should 
be carried out to demonstrate the ability of tumour-derived 
macrophages to synthesise and release cachectin in vitro. 
Further investigation should also focus on the nature of the role 
played by cachectin which may be expected to engineer all of the 
above events. These investigations may provide useful measures 
to interrupt the communications between neoplastic and 
non-neoplastic tissues and thus a means for the management of the 
mechanism of cachexia.
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CHAPTER EIGHT
CONCLUSION
8.1 Metabolic Basis of Cancer Cachexia
The present investigation was commenced as an attempt 
at answering the question ’how does the presence of a malignant 
neoplasm induce a chronic wasting of the host?', a syndrome which 
is commonly known as cancer cachexia. This condition has been 
studied by various workers over the last fifty years. However 
all such studies have failed to provide a credible mechanism for 
the metabolic basis of cancer cachexia. A contemporary review of 
the various theories of cancer cachexia was presented in section 
1.2. Recently, after clinical and laboratory investigations 
Williams et al., (1980) introduced a number of observations into 
an assembly of events which were consistent with the clinical 
history of patients and tumour bearing animals with cancer 
cachexia and were conceptually used to formulate a mechanism for 
cachexia. The postulates of this hypothesis for the metabolic 
basis of cancer cachexia were discussed in section 1.2.2.1 and an 
integration of the events of these postulates was illustrated in 
Fig. 1.4. The hypothesis is based on the 
following observations -
1) Clinical medicine - It was observed that cancer 
subjects (Conyers et al., 1979 a,b; Mider et al., 1951; Williams 
et al., 1980) with extensive body wasting and anorexia were not 
notably ketotic. In addition, further starvation in these 
subjects resulted in a lower than normal ketonaemic response 
(Rich and Wright, 1979; Sauer and Dauchy, 1983).
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2) Enzymology - There was dramatic reduction in the
activity of alanine aminotransferase (EC 2.6.1.2) in the liver of 
animals bearing tumours at distant organ sites (Beaton et al., 
1957; Goodlad and Clark, 1962; Herzfeld and Greengard, 1972, 
1977; Williams et al., 1980).
3) Endocrinology - Elevated levels of vasopressin were 
found in a number of stress situations (Errington and Silva, 
1972; Kasting et al., 1981; Rose et al., 1984; Walsh et al., 
1979; Wilson et al., 1981), inflammation (Kasting et al., 1985) 
and tumour bearing (see Table 1.2).
4) Intermediary metabolism -
a) Vasopressin increased long chain fatty acid 
esterification and decreased hepatic ketogenesis in isolated 
hepatocytes and whole liver (Rofe and Williamson, 1983, a, b; 
Williamson et al., 1980) .
b) Protein synthesis and degradation in muscle 
was regulated by circulatory concentrations of ketone bodies 
(Owen et al., 1967, 1969; Palaiologos and Felig, 1976; Rudermann 
et al., 1974; Sherwin et al., 1975; Smith and Aoki, 1981; Snell 
and Duff, 1982).
c) It was noted that many cancer patients and 
tumour bearing animals were hyperalaninaemic (Chung and Bauer, 
1969; Clarke et al., 1978; DeWys, 1970; Kishi et al., 1982; Rofe 
et al♦, 1986; Shearer et al., 1984).
In the present investigations, attempts were made to 
study the postulates of the hypothesis. Research was primarily 
conducted on rats bearing the Walker 256 carcinosarcoma, a fast 
growing tumour and an established model for tumour induced
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cachexia and anorexia (Guaitani et al., 1982). A number of 
investigations were also carried out on rats bearing the R3230AC 
adenocarcinoma which is a moderate growing tumour and was 
previously shown to induce cachexia (Williams et al., 1980) . The 
advantages of these tumour models over existing animal tumour 
models were discussed in section 1.4. The present investigation 
demonstrated (section 3.3) that body wasting, anorexia and 
depletion of muscle and adipose tissue are no longer regarded as 
the general symptoms of cancer cachexia as these symptoms were 
partly reproduced by implanting an inert mass comparable in size 
to many experimental tumours (Morrison et al♦, 1984). It was 
concluded from the. present study that cancer cachexia is 
characterised by a wide variety of symptoms including body 
wasting, anorexia, depletion of tissue proteins and lipids, 
increases in the concentrations of alanine, lactate, pyruvate, 
free fatty acids and triglycerides and decreased circulating 
concentrations of ketone bodies. There is also whole body and 
specific organ water retention and enlargement of the liver, 
spleen and adrenal glands.
This study demonstrated a decreased rate and extent of 
glucose formation from physiological levels of alanine by livers 
of tumour bearing rats in comparison with control rats. It is 
suggested that this decreased rate and extent of gluconeogenesis 
from alanine may be due to an impaired mitochondrial function 
and/or less utilisation of alanine due to a change in 
mitochondrial permeability and/or suppression of hepatic alanine 
aminotransferase activity due to tumour induced
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retrodifferentiated changes and/or a combination of these
processes.
Snell (1975) demonstrated that neonatal rats (1-2 weeks 
old) possessed an increased ability to utilise pyruvate or 
lactate as substrates for glucose production but an impaired 
ability to utilise alanine. This was due to a deficiency in the 
enzymatic capacity to convert alanine to pyruvate because of a 
low activity of alanine aminotransferase in the neonatal rat 
liver (Snell, 1975, 1982). These observations are consistent
with the situation found in the livers of tumour bearing animals, 
presented in this study. Gluconeogenesis from lactate (Gold, 
1968, 1974; Holroyde et al., 1975; Shearer et al., 1983; Reichard 
et al., 1963; Waterhouse et al., 1979) and pyruvate (Shearer et
al., 1983) was increased in tumour bearing subjects. In
addition, the activity of alanine aminotransferase was lower in 
the host liver (Fig. 3.5; section 1.2.2.1.1). These observations 
further support the proposal that the livers of tumour bearing 
subjects resemble immature livers in enzyme profile and therefore 
appear to be retrodifferentiated. Moreover this property of 
reduced gluconeogenesis from alanine is also seen in the septic 
and traumatised rat (McCollum and Berry, 1973; McCollum 1981; 
Wannemacher et al., 1980; Wolfe and Burke, 1976; Wilmore et al.,
1980). McCollum (1980) demonstrated that endotoxin
(lipopolysaccharide antigen) stimulated Kupffer cells of the 
liver to release mediators which then inhibited the conversion of 
alanine into glucose. It is known that tumour growth in the body 
can elicit a host response with prominent involvement of 
macrophages and other mononuclear cells (Nathan et al., 1980).
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Furthermore, it has been demonstrated that a tumour may 
'communicate' with distant non-involved organs of the body, in 
particular the liver; it is therefore possible that the Kupffer 
cells of the liver release mediators to inhibit gluconeogenesis 
from alanine in parenchymal cells. Moreover a factor, cachectin, 
has been isolated from activated macrophages and its role in the 
development of cachexia was proposed (Beutler et al., 1985a), but 
its involvement in the suppression of gluconeogenesis is still 
obscure.
Deviations from normal fatty acid metabolism and an 
impaired regulation of ketone body synthesis were demonstrated in 
the liver of tumour bearing animals. The results, as discussed 
in section 5.2, showed that tumour bearing animals, in spite of 
their anorexic and semistarved state, were in a circumstance 
which was unable to force the liver to oxidise fatty acids and 
synthesise ketone bodies; rather stimulated fatty acid 
esterification was noted (Table 5.20) without any impairment in 
the hepatic uptake of fatty acid (Table 5.17). This resulted in 
the accumulation of fatty acid in the liver (Table 5.19, 5.20). 
These results suggested that the inhibition of fatty acid 
oxidation and ketone body formation occurred due to an inhibition 
of the transport of fatty acyl CoA from the cytoplasm to the 
mitochondria, an event which is regulated by ACT-I (McGarry and 
Foster, 1980) and thus resulted in the diversion of fatty acid 
towards the esterification pathways. The increased fatty acid 
esterification and decreased ketone body formation observed in 
the livers of tumour bearing rats were similar to the effects of
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Vasopressin on fatty acid metabolism (Rofe and Williamson, 1983, 
a, b). Elevated levels of vasopressin in the plasma and urine of 
tumour bearing animals were found in this investigation (chapter 
seven) and have already been reported in patients bearing fifteen 
different kinds of neoplasm (Table 1.2). It is therefore
suggested that vasopressin may have affected the activity of ACT- 
1, thus impairing fatty acid entry into the mitochondria and 
hence fatty acid oxidation and ketone body formation.
Furthermore it is also proposed that the decreased activity of 
ACT-I may be attributed to the specific retrodifferentiating 
effect on this enzyme by tumour growth. The retrodifferentiation 
changes in the liver are characterised by shifting enzyme 
activity or specific protein concentration towards the levels 
that are characteristic of foetal tissue. Herzfeld and Greengard 
(1972) demonstrated foetalistic changes in the actvities of 
several hepatic enzymes associated with tumour bearing. One 
example was alanine aminotransferase (Fig. 3.5). The
developmental pattern of alanine aminotransferase (Greengard, 
1970) and ACT-I (Lee and Fritz, 1971) suggests that these 
enzymes may have emerged from the same enzymatic cluster during 
early development and thus are retrodifferentiated in the same 
manner. To date no specific data are available on tumour induced 
retrodifferentiation of ACT-I. Relevant to this were
demonstrations that the enzyme complement of the well
differentiated Morris hepatomas 9121 and 7787 closely resembled 
normal liver (McGarry and Foster, 1969), whereas the enzyme 
profile of poorly differentiated hepatoma 7777 resembled the 
enzyme activities of the retrodifferentiated foetalistic liver
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(Matthaei, 1979). Moreover, the poorly differentiated hepatoma 
7777 exhibited no appreciable activity of ACT-I (Fields et al., 
1981); an observation supporting the present proposal that tumour 
growth may have induced a retrodifferentiating effect on the 
enzyme in host liver.
Elevated levels of triglycerides and free fatty acids 
in plasma (Table 3.3) and in the perfused liver (Table 5.19) of 
tumour bearing rats were also encountered in the present 
investigation. A defect in the clearance of fatty acids from 
circulating triglycerides due to decreased activity of adipose 
tissue LPL was also suggested as being responsible for the 
development of hypertriglyceridaemia, hyperfattyacidaemia and 
depleted fat stores during the growth of neoplasms (Lanza-Jacoby 
et al., 1984; Thompson et al., 1981). The activity of LPL
declined during the early stages of tumour growth and remained 
low during the course of tumour bearing (Lanza-Jacoby et al., 
1984) . It is of interest to note that cachectin/TNF is known to 
effect the levels of LPL and several other enzymes and proteins 
by acting at the transcriptional levels of protein synthesis in 
adipose tissue (Torti et al., 1985). Moreover, other monokines
(section 1.3) are also known to induce hypertriglyceridaemia 
(Spitzer and Spitzer, 1983) and hypoketonaemia (Neufeld et al., 
1977) . Thus it is concluded that the impaired fatty acid 
metabolism of tumour bearing subjects may be attributed to the 
release of cachectin/TNF or other closely related monokines.
The muscle tissue of tumour bearing animals exhibited 
enhanced branched chain amino acid oxidation and as a consequence
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had surrendered 6-7g of protein from the whole body skeletal
muscle sites - a notable loss. It is suggested that elevated
levels of vasopressin in tumour bearing rats resulted in reduced
ketone body formation from fatty acid and as a consequence of
this the regulation of muscle proteolysis and branched chain
amino acid oxidation was impaired (Palaiologos and Felig, 1976;
Palmer et al., 1985a; Smith and Aoki, 1981). It was of interest
to note that elevated levels of prostaglandin E had been
2
reported in a variety of human and animal tumours (Table 7.4) and
notable elevations were also found during the present
investigation (Table 7.7). Prostaglandin E itself enhanced
2
muscle protein degradation (Baracos et al., 1983; Rodemann and
Goldberg, 1982; Turinsky, 1986) and also stimulated the release
of vasopressin from the posterior pituitary gland (Clifton and
Wallin, 1985; Sklar and Schrier, 1983). It was therefore
suggested that the combined action of these two agents (AVP and
PGE ) may be the prime cause of the increased protein degradation 
2
leading to the negative nitrogen balance of the host. 
Exaggerated muscle proteolysis was associated with high levels of 
alanine in tumour bearing animals (Table 3.1). Because of the 
notably reduced incorporation of alanine into glucose by the 
liver of tumour bearing subjects (section 4.2.4), the muscle mass 
and its essential reserves of nitrogen were lost inter alia as 
hyperalanineuria (Table 3.6).
The overall conclusion of the investigations presented 
in this thesis is that the hypothesis (Williams et al., 1980) had 
correctly predicted major sequences of the metabolic changes that 
are frequently associated with many neoplastic situations.
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Furthermore the completed investigation has also led to the 
tentative identification of the toxohormones (section 7.3) which 
are suspected of initiating the above sequence of events and may 
thus initiate, if not mediate, the metabolism of tumour induced 
cachexia.
8.2 Current Concepts of the Mechanism of Cancer Cachexia
The hypothesis of the metabolic basis of cancer 
cachexia (Williams et al., 1980) proposed that certain 
unidentified agent(s) is(are) involved in the initiation of the 
induction of cachexia in cancer patients or tumour bearing 
animals. The present investigation revealed that vasopressin,
PGE and cachectin may be the cellular mediators (toxohormones).
2
Elevated levels of these substances have been demonstrated in 
cancer subjects (chapter seven). These mediators are suspected 
of being responsible for instigating a connection between the 
neoplastic and non-neoplastic tissues in situations where the 
neoplasm may be either remote or adjacent to the affected organs 
or tissues. The consequences of this communication are tumour 
induced specific and drastically altered effects on the 
metabolism of host tissues. Consistent with our current 
understanding of the perturbed whole-body biochemistry in cancer 
cachexia and the putative effects of "toxohormones" on host 
metabolism, it is concluded that (Fig. 8.1) tumour growth may 
elicit an immune response characterised by the production of 
activated macrophages, some of which may reside in the neoplasm. 
Activated macrophages synthesise and release cachectin (Aderka et 
al,, 1985) which inhibits the activity of adipose tissue LPL
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Figure 8.1: Schematic representation of the roles of 
toxohormones in the development of cancer 
cachexia
Proposed mechanism for the metabolic basis of cancer 
cachexia involving the secretion of a toxohormone "cachectin" 
from the activated macrophages entrapped in either the tumour or 
formed in host body macrophages in response to neoplastic growth. 
The release of cachectin directs the inappropriate and excessive 
production of prostaglandin E2 (PGE2) in muscle and vasopressin 
from the posterior pituatary gland. Cachectin also acts directly 
on adipocytes and suppresses the activity of lipoprotein lipase 
(LPL) which results in decreased hydrolysis of triglycerides (TG) 
present in the form of very low density lipoprotein (VLDLP). 
This results in the hypertriglyceridaemia of cancer cachexia.
Elevated levels of vasopressin inhibit the synthesis of 
ketone bodies (KB) and stimulate the esterification of free fatty 
acids (FA) and thus further contribute to the development of 
hypertriglyceridaemia.
Elevated levels of PGE 2 and low circulating levels of 
ketone bodies result in exaggerated muscle proteolysis and 
enhanced oxidation of branched chain amino acids promoting the 
synthesis and release of alanine (Ala) from the muscle bed.
Cachectin suppresses the hepatic utilization of alanine 
for glucose (Glc) formation leading to hyperalaninaemia which in 
turn results in occasional hyperalaninuria. The overall effect 
is cachectin induced muscle wasting, negative nitrogen balance 
and irreversible loss of muscle nitrogen in the urine.
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(Torti et al., 1985). The deficiency of LPL results in decreased
removal of TG from plasma into adipose tissue. This situation
leads to hypertriglyceridaemia representing an accumulation of
very low density lipoproteins (VLDLP) in plasma. It is further
suggested that cachectin may inhibit hepatic ketone body
formation by impairing the activity of the enzyme ACT-I. ACT-I
may also be inhibited by vasopressin. Elevated levels of
vasopressin may result as a consequence of the direct effects of
cachectin on the posterior pituitary gland, since it was
demonstrated that endotoxin stimulated increased levels of
vasopressin in rats (Kasting et al., 1985). Cachectin also
stimulated the production of prostaglandin E (Dayer et al.,
2
1985) which in turn enhanced the production of vasopressin from
the posterior pituitary gland (Clifton and Wallin, 1985; Sklar
and Schrier, 1983). The diminished rate of hepatic ketogenesis
diverts fatty acids into the fatty acid esterification pathway
further contributing to the development of hypertriglyceridaemia
and a 'fatty1 liver. Excessive breakdown of muscle protein,
which is characterised by elevated levels of plasma alanine
occurs either by the presence of prostaglandin E in muscle
2
(Baracos et al., 1983; Rodemann and Goldberg, 1982; Turinsky,
1986) or by low circulating levels of ketone bodies (Palaiologos
and Felig, 1976; Palmer et al., 1985a; Smith and Aoki, 1981) or 
by both. Alanine utilisation was diminished because of the
inhibition of gluconeogenesis, which is attributed to the
suppressed activity of alanine aminotransferase. This results in 
the excretion of alanine in the urine (Table 3.6). The end
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result of these processes is the growth and the spread of tumour 
in association with tumour-induced body wastage, negative 
nitrogen balance, anaemia and ultimately death,
8.3 The Clinical Management of Cachexia
Tumour bearing animals exhibiting the symptoms of 
cachexia are not notably ketotic, despite their anorectic and 
semistarved state (Conyers et al., 1979 a,b; Mider et al., 1951;
Williams et al., 1980). The regulation of muscle protein
metabolism by circulating concentrations of ketone bodies is well 
documented (section 1.2.2.1.6). Therefore, iatrogenic ketosis 
was proposed as a measure for preserving host protein reserves 
and regulating the host metabolism (Conyers et al., 1979 a,b; 
Williams and Matthaei, 1981). However, while it was demonstrated 
that induction of ketosis by intravenous administration of lipid 
to patients with cancer cachexia did not reduce the loss of body 
weight, the level of serum albumin was improved and urinary and 
serum urea concentrations were decreased, thus suggesting a 
reduction in endogenous protein catabolism (Conyers, 1979b). 
Furthermore, isocaloric consumption of a high protein, high fat 
but low carbohydrate diet prolonged the survival of MCA-sarcoma 
bearing rats (Demetrakopoulos and Rosenthal, 1982). It was also 
shown that dietary induced ketosis reduced by two thirds the 
number of B16 melanoma deposits in the lung of C57B4/6 mice 
(Magee et al., 1979). Moreover, starvation induced hypoglycaemia 
and streptozotocin induced diabetes had been shown to suppress 
the growth of Ehrlich ascites tumour in mice (Fung et al., 1985). 
To date, only one study has reported the failure of systemic
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ketosis to control cachexia and the growth of the Walker 256
carcinosarcoma (Fearon et al., 1985). This failure was
attributed to the inability of ketosis to suppress blood glucose 
levels in these tumour bearing rats. More recently, and with 
something of an 'about face', these investigators, using a 
different tumour system, demonstrated that feeding a diet with an 
increased proportion of medium chain triglycerides produced a 
marked reduction in tumour size and improved the body weight of 
mice bearing the MAC-16 adenocarcinoma (Tisdale and Brennan, 
1986).
It is therefore concluded from the above studies that 
the induction of systemic ketosis in the tumour bearing animals 
may well have a positive effect on tumour regression and host 
nitrogen balance and thus establish the foundation of a procedure 
for the clinical management of cachectic symptoms in cancer 
subj ects.
A striking feature of cancer cachexia is the elevated
levels of prostaglandin E in tumour bearing subjects (Table
2
7.4). The putative effects of PGE in cancer were discussed in
2
section 7.1.2.2. It was shown that inhibition of PGE synthesis
2
by aspirin like drugs or indomethacin reduced the tumour growth
in mice bearing the fibrosarcoma (Tashjian et al., 1973), Malony
virus sarcoma (Humes et al., 1974) and sarcoma 180 (Stein-
Werblowsky, 1974). Indomethacin also restricted the growth of
Yoshida hepatoma in vitro (Trevisani et al., 1980). Moreover,
Santoro et al., (1977) demonstrated that 16,16-dimethyl
prostaglandin E inhibited the growth of the B16 melanoma both in
2
vitro and in vivo. Flubiprofen, a nonsteroidal inhibitor of
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PGE , reduced the primary growth of the tumour and increased 
2
survival time in mice bearing the NC-mammary adenocarcinoma
(Bennett et al♦, 1979b; Leaper et al., 1979). Rats bearing the
R3230AC adenocarcinoma and immunised against PGE demonstrated a
2
decrease in tumour weight and volume in comparison to untreated
tumour bearing controls (Karmali and Marsh, 1985).
Administration of PGE immune serum or purified anti-PGE to mice
2 2 
bearing the Lewis lung carcinoma prevented the suppression of T-
lymphocyte function and enhanced the macrophage migration
properties (Young et al., 1986; Young and Dizer, 1983; Young and
Henderson, 1982) and the resulting restoration of host immunity
coincided with a reduced frequency of tumour establishment,
growth and metastasis (Lynch and Solomon, 1979; Young et al.,
1986; Young and Knies, 1984; Young and Hoover, 1986). It is
therefore concluded from the above studies that the inhibition of
PGE synthesis in tumour bearing subjects may also be introduced 
2
as a therapeutic measure for arresting tumour growth, improving 
the host immune response against neoplastic cells and prolonged 
survival time.
Cachexia is generally defined as a disease of body 
wasting and muscle weakness. It is known that muscle proteolysis 
is associated with increased branched chain amino acid oxidation 
(Paul and Adibi, 1980) and that exogenous BCAA normalised the 
plasma amino acid pattern by increasing protein synthesis and 
decreasing protein degradation (Fischer et al., 1976). A number
of studies in vivo have demonstrated that administration of an 
increased proportion of BCAA in amino acid infusion solutions
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resulted in improved protein conservation in laparotomized rats 
(Yoshimura et al., 1979), injured and infected rats (Blackburn et 
al., 1979), post-operative patients (Freund et al., 1979), tumour 
bearing rats (Kawamura et al., 1985; Landle et al., 1985) and
cancer patients (Tayek et al., 1986). The optimal ratios of BCAA 
to non-BCAA in the parenteral nutrition formula was demonstrated 
to be 45:55 (Bower et al., 1985; Gimman and Fischer, 1981) and
it was also shown that this nitrogen conserving property of BCAA 
could not be duplicated by the use of BCKA or isocaloric dextrose 
(Yoshimura et al., 1979). Yap and coworker (1974) reported a
positive correlation between albumin synthesis rates and serum 
concentrations of leucine, isoleucine, valine and tryptophan. It 
was further shown that infusion of a total parenteral nutrition 
formula enriched with BCAA to 50% of the total amino acids in 
rats bearing the fibrosarcoma, increased fractional rates of 
muscle protein synthesis, improved survival time and reduced the 
tumour growth (Kawamura et al., 1985). BCAA enriched formulae
also improved whole body leucine kinetics, fractional rates of 
albumin synthesis, leucine balance and thus had favourable 
influences on protein metabolism in patients with cancer cachexia 
(Tayek et al,, 1986). It is therefore proposed that such
improvements may delay the development of cancer cachexia and 
allow more time for improved nutritional support for patients 
receiving chemotherapy, radiotherapy and other stressful 
treatments. The procedure may be translated into treatment 
benefits not previously realised with total parenteral nutrition.
The individual therapeutic measures discussed above, 
have had occasional successful outcome, however the combined
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action of these therapeutic agents may induce much more
pronounced and consistent effects on the general improvement of
cancer patients. It is concluded from the present investigation
that therapeutic measures which involve the infusion of
intralipid to promote the synthesis of ketone bodies and branched
chain amino acid enriched total parenteral nutrition together
with PGE synthesis inhibitors and/or specific antibodies to 
2
protect against the drastic effects of cachectin, vasopressin,
and PGE may represent rational strategies to impart a total or 
2
chronic delay in the development of cachectic symptoms.
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APPENDIX
A: List of Computer Programmes
A Casio FX-702P personal computer was used 
programming the calculations.
Programme PI - Tumour Weight Determination
The programme is based on the following formula -
2
TW = (a/iT) ,b 
2
where -
TW = Tumour weight 
a = circumference of tumour 
b = length of tumour 
tt = 3.14
LIST
10 PRINT "TUMOUR WT."
20 INPUT "CIRCUMFERENCE^',A 
30 INPUT "LENGTH OF TUMOUR=",B 
40 C=((A/3.14)f2*B)/2 
50 PRINT "TUMOUR WT.=";C 
60 GOTO 20
Programme P2 - Metabolite Concentration
The programme is based on the following formula
C = E x V 
6.22 x v
where -
E = change in extinction at 340nm 
C = concentration (y mol/ml)
V = total volume of reaction mixture (ml) 
v = volume of sample (ml)
6.22 = extinction of lymol NADH at 340nm
LIST
10 PRINT "CONC. (ymol/ml) "
2 0 INPUT "TOTAL VOL.='\A 
30 INPUT "VOL. OF SAMPLE=",B 
40 INPUT "AE=",C 
50 D=(C*A)/(6.22*B)
60 PRINT "CONC.(ymol/ml)=";D 
70 GOTO 20
for
Programme P3 - Gluconeogenesis Studies
The programme is based on the following formula -
A x T x 1 (1)
B C 2
G (2)
T
where -
G
A
B
T
C
1/2
R
t
glucose formation (umol/g of liver wet wt.) 
radioactive counts in glucose (d.p.m./^i of perfusate) 
specific activity of alanine (d.p.m./limol of alanine) 
total volume of perfusate = 170ml 
weight of liver (g)
based on relationship that two molecules of alanine 
are required to form one molecule of glucose 
rate of gluconeogenesis from alanine (glucose 
formation/min) 
time of sampling
LIST
10 PRINT "GLUCONEOGENESIS"
20 INPUT "DPM=",A
30 INPUT "SPECIFIC ACTIVITY=",B
40 INPUT "LIVER WT.=",C
50 INPUT "TIME=",D
60 E=(A/B)*((170/(2*C))
70 F=E/D
80 PRINT "GLUCOSE/g w/w=";E 
90 PRINT "RATE=";F 
100 GOTO 20
Programme P5 Leucine Oxidation In Vitro
The programme is based on the following formula -
I = A 
B
x 60 x 1000 
40 C
(1)
G = I X D (2)
where -
I
A
B
C
G
D
60/40
1000
BCKDH activity (nmol/hr/mg of muscle protein) 
radioactivity of 14C02 (uCi/ml of homogenate) 
specific activity of L-[1-14C] leucine ( Ci/ mol) 
concentration of protein in muscle homogenate (mg/ml) 
rate of leucine oxidation (nmol/hr/g of tissue) 
concentration of protein in gastrocnemius or tumour 
muscle (mg/g)
ratio used for extrapolation of 40 min. incubation to 
60 min. incubation
used for conversion of umol into nmol
LIST
10 PRINT "LEUCINE OXIDATION IN VITRO"
20 INPUT "DPM=",A
30 INPUT "SPECIFIC ACTIVITY=",B
40 INPUT "PROTEIN/ml of HOMOGENATE=",C
50 INPUT "PROTEIN/g of TISSUE=",D
60 F = A/2.2£6*(1/B)*1500
70 I = F/C
80 G = I*D
90 PRINT "nmol/hr/mg PROTEIN=";I 
100 PRINT "nmol/hr/g TISSUE=";G 
110 G0T02 0
Programme P6 - Leucine Oxidation In Vivo
The programme is based on the following formula -
A (1)B
J x 100 (2)D
E (3)T
where -
G
A
B
E
R
J
D
T
specific activity of 14C02 in expired breath (d.p.m./u 
mol)
total radioactive counts in hyamine hydroxide solution 
(d.p.m.)
amount of CO2 trapped in hyamine hydroxide solution (u 
mol)
leucine oxidation (% dose of leucine oxidised at time 
t)rate of leucine oxidation (% dose of administered L- 
[1-14C] leucine oxidised/min)
total radioactive counts recovered as 14C02 (d.p.m.)
nett radioactive counts injected as [1-14C] leucine 
(d.p.m.)
time of sample collection (min.)
LIST
10 PRINT "LEUCINE OXIDATION IN VIVO" 
2 0 INPUT "NETT DPM INJECTED='\D 
30 INPUT "DPM HYAMINE=",A 
40 INPUT "DPM ETHANOLAMINE=",F 
50 INPUT "COLLECTION TIME='\C 
60 H=A*2.5 
70 I=F*4 
80 G=H/495 
90 J=H+I
100 E=(J/D)*100 •
110 R=E/T
120 PRINT "TOTAL DPM C02=";J 
130 PRINT "SPECIFIC ACTIVITY C02=";G 
140 PRINT "% DOSE OXIDISED=";E 
150 PRINT "% DOSE OXIDISED/MIN=";R 
160 GOTO 30
Programme P7 - Student's t Test
The programme is based on the following formula
(i) unpaired data (when nx f ny)
t = ____________  x - y________________
1. + (n, - 1)S2 + (ny - l)s;>
nx ny nx + ny ” 2
where -
x and sx = mean and standard deviation of x data 
y and sy = mean and standard deviation of y data 
nx + ny - 2 = degrees of freedom
(ii) paired data (when nx = )
where -
x and sx = 
y and Sy =
2n - *2 =
FOR UNPAIRED DATA 
LIST
10 PRINT "T TEST"
20 INPUT "X1=",X 
30 INPUT "X2=",Y 
40 INPUT "Nl=",A 
50 INPUT "N2 = '\B 
60 INPUT "SD1=",C 
70 INPUT "SD2=",D 
80 Q=A+B-2 
90 F=X-Y
100 E=SQR(((A-l)*C*2+(B-1)*D + 2)*(1/A+l/B)/ (A+B-2) 
110 T=F/E
120 PRINT "T VALUE=";T ;"df=";Q
FOR PAIRED DATA
LIST
10 PRINT "START?(Y/N)";
20 $=KEY$
30 IF $="N" THEN 100 
40 IF $="Y" THEN 20 
50 PRINT:BEEP 0 
60 CLEAR
70 PRINT "DATA1 OR 2?";
80 A$=KEY$
90 IF A$^"l" THEN
IF A$^"2" THEN 80
x - y
Sy 2 + Sy
mean and standard deviation of x data 
mean and standard deviation of y data 
degrees of freedom
100 B=B+1
110 PRINT:BEEP 1
120 PRINT "X DATA"?B;
130 INPUT X$:BEEP 1 
140 IF X$="E" THEN 
B=B-1:BEEP 0:
GOTO 240 
150 C=C+VAL(X$)
160 D=D+VAL(X$)+ 2 
170 IF A$="1" THEN 100 
180 PRINT "Y DATA";B;
190 INPUT Y
200 H=H+Y
210 I=I+Y*Y
22 0 M=M+VAL(X$) *Y
230 GOTO 100
240 E=C/B
250 F=SQR((B*D-C*C)/ (B*(B-l) ) )
260 G=SQR((B*D-C*C)/ (B*B) )
270 IF A$="1" THEN 340 
280 J=H/B
290 K=SQR((B*I-H*H)/(B*(B-1) ) )
300 L=SQR((B*I-H*H)/ (B*B))
310 0=(B*M-C*H)/ (B*D-C*C)
320 N=(H-0*C)/B
330 P=(B*M-C*H)/SQR((B*D-C*C)*(B*I-H*H) )
335 INPUT "ST1 OR 2",S$
336 IF S$="ST1" THEN 510
337 IF S$="ST2" THEN 610 
340 INPUT "INPUT(0-17)",Z
350 IF Z=0 THEN PRINT "END";:END
360 ON Z-15 GOTO 450,480
370 RESTORE
380 FOR W=1 TO Z
390 READ V$
400 NEXT W
410 PRINT V$;"=";A (Z)
420 DATAN, SUMX, SUMX2, MEANX, SDX, SDXN, SUMY
430 DATA SUMY2, MEANY, SDY, SDYN, SUMXY, LRA, LRB,
440 GOTO 340
450 INPUT "Y DATA",Y
460 PRINT "EOX=";((Y-N)/0
470 GOTO 340
480 INPUT "X DATA",X
490 PRINT "EOY="; N+X*0
500 GOTO 340
510 PRINT "T TEST1"
520 INPUT "TEST MEAN=",U 
530 T=(E-U)/F*SQRB 
540 Q=B-1
550 PRINT "T=";T;"df=";Q
560 GOTO 340
610 PRINT "T TEST2"
615 INPUT "TEST DIFF=",U 
620 R=(F^2+K^2)/B
COR
630 T=(E-J-U)/SQRR 
640 Q=2*B-2 
650 PRINT "T=";T;"df= 
660 GOTO 340
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